annual report active positive outlook life keep go dayoverview overview performance define remarkable output delivery sustain financial performance shareholder gskcom performance highlight group turnover core operating profit total operating profit return shareholder major medicine approve core earning share total earning share estimate return investment potential phase iii study start potential medicine phase iii datum access medicine index pharmaceutical company sign alltrial expect campaign research transparency cover story betty age picture chronic health important obstructive pulmonary disease copd try care lung capacity mean find everyday task difficult health tool medicine inhale oxygen allow good live normal life bettys mindset stay busy active week go rehab exercise class copd disease lung lead betty copd patient damage airway cause north carolina usa narrower make hard air million people world estimate copd patient like betty reason gsk invest respiratory research healthcare company past year research new medicine cautionary statement forwardlooke statement group report file furnish securities exchange commission sec include document write information release oral statement public future behalf group contain forwardlooke statement forwardlooke statement group current expectation forecast future event investor identify statement fact relate strictly historical current fact use word anticipate estimate expect intend project plan believe word term similar meaning connection discussion future operate financial performance particular include statement relate future action prospective product product approval future performance result current anticipate product sale effort expense outcome contingency legal proceeding financial result group undertake obligation update forwardlooke statement result new information future event forwardlooke statement involve inherent risk uncertainty group caution investor number important factor include document cause actual result differ materially contain forwardlooke statement factor include limit discuss risk factor page annual report number adjust measure report performance business measure define reconciliation core result total result set mission gsk mission content strategic report improve quality chairman statement ceo review human life enable business overview global context business model people feel strategic priority perform well live long risk management grow deliver simplify financial architecture responsible business financial review governance remuneration board corporate executive team chairman letter board report shareholder committee report remuneration committee chairmans annual statement annual report remuneration remuneration policy report financial statement director statement responsibility independent auditor report financial statement note financial statement financial statement glaxosmithkline plc prepare gaap investor information quarterly trend fiveyear record product development pipeline product competition intellectual property risk factor share capital share price dividend tax information shareholder annual general meeting law regulation shareholder service contact gsk annual report strategic report chairman statement chairman statement shareholder value significant change recent year evidence performance year sir andrew clear follow page audit risk committee group good progress oversee issue challenge face ceo company strategy management encourage creation return billion environment gsk achieve board believe business see strategic ambition responsible shareholder benefit significant change sustainable manner management team drive recent year deliver sustainable growth reduce doubt commercial success risk enhance return shareholder directly link operate responsible way meet change expectation notably strong performance society respect company continue organisation major adopt industryleade position range new product approval area include issue respiratory disease hiv cancer critical longerterm prospect announcement plan group achieve evolve way business interact time effectively manage healthcare professional pay sale staff cost base deliver improve estimate rate development particularly please return particularly encouraging worth note sir andrew way board strongly support ceo gsk market capitalisation commitment company grow approximately billion advance transparency clinical trial billion company datum welcome subsequent action return billion shareholder company field time billion dividend billion hope step advance share buyback medical science improve patient care allegation fraudulent behaviour risk management commitment certain employee business ethical behaviour china wholly contrary company board aim assure integrity value addition chinese government gsk business operation rigorous investigation commission process system year independent review chinese operation risk management key law firm rope gray board discussion implement appropriate action necessary conclusion investigation gsk annual report board gender diversity governance remuneration composition board mindful change outline priority diversity term gender new narrative remuneration length tenure business experience report regulation annual report develop emerge market adhere new reporting standard year gsk female representation board level particular year remuneration exceed original aspiration report comprise part start board firmly believe require shareholder approval group diverse balance experience insight forthcome agm detail set tom swanns letter shareholder perspective background board member good longterm report interest group shareholder board change composition prospect female number change board male closing board like thank year like thank sir crispin sir andrew executive team davis stand valuable commitment year contribution nearly year service group demonstrate ability april please han wijer deliver innovation constantly strive join board nonexecutive director substantial change confident extensive experience run global group continue identify grasp company prove great opportunity strengthen gsk value board discussion performance reward shareholder plan change create sustainable longterm value society chairmanship board committee tom swaan succeed sir crispin davis chairman remuneration committee judy lewent succeed tom chairman audit risk committee tom remaining member committee addition like thank sir deryck maughan agree remain board sir christopher gent additional year chairman succeed sir robert wilson senior independent director sir deryck considerable experience knowledge gsk business provide continuity balance finally sir robert wilson stand agm year exceptional service like thank longstanding commitment group gsk annual report strategic report ceo review ceo review year company performance define remarkable output organisation lead sector new past year make overall gsk account fda new fundamental change gsk deliver innovation drug approval medicine approval access product patient achieve fda approval return billion customer improve sustainable financial new molecular entity nme performance shareholder company shareholder see strong delivery conversion advanced pipeline priority approve product represent step strategy deliver sustainable organic year lead sector new growth value shareholder medicine approval return billion shareholder dividend share particular want note grow buyback helping generate good annual strength respiratory portfolio total shareholder return tsr performance advair flovent ventolin breo anoro formation gsk seven respiratory product latestage development confident ability grow sale earning line maintain leadership position area guidance turnover billion decade core earning share cer achieve trading result addition highlight approval despite unexpected challenge future pipeline opportunity remain extensive include significantly reduce sale nme phase iiiii chinese business clinical development expect phase iii readout nme continue action plan nme phase iii start key reform business model well meet area respiratory oncology expectation society particular take immunoinflammation industryleade position action improve global public health increase transparency importantly continue improve clinical datum modernise commercial financial efficiency estimate practice interaction customer internal rate return investment good progress exceptional delivery continue target longerterm basis productive period improve productivity output company history underpin strategy create major new medicine file profile flexibility price new start approve medicine meet need payer breo anoro respiratory disease government tafinlar mekinist melanoma skin cancer tivicay hiv expect regulatory decision albiglutide remain asset group half addition launch new injectable quadrivalent flu vaccine usa gsk annual report broadly base sale growth create great flexibility invest delight achieve significant term sale see broadlybased growth market new product milestone malaria vaccine candidate performance improve launch continue demonstrate potentially performance business sale improvement financial efficiency halve number malaria case young exclude divestment strengthen ability deliver earning child vaccine potential save vesicare see stabilisation share growth ahead sale live hundred thousand child european business report flat business remain highly cash generative africa plan file approval sale benefit restructure billion free cash flow commit make programme helping offset economic addition realise billion available notforprofit price pricing pressure region divestment leave net debt billion high priority remain committed investing end year continue focus valuesbase conduct employee continue growth important emerge cash protect credit profile past year focus market business sale region fund organic investment restructuring bring life value transparency year fourth quarter programme ongoing respect people integrity patient exclude china commitment grow dividend focus thoughtful share buyback bolton acquisition mean human level year take step increase whichever offer attractive return equity holding fastgrowe indian strong belief pharmaceutical consumer subsidiary companys value allegation change business model announce plan build new china behaviour individual manufacturing capacity country considerable progress disappointing investigation agenda operate responsibly matter authority china consumer healthcare sale grow exclude meet change expectation society continue cooperate fully divest brand growth region new commitment increase company commit learn transparency clinical research early lesson take appropriate action optimise reshaping year announce support relation outcome investigation portfolio alltrial campaign continue step optimise pharmaceutical company commit outlook focus portfolio publish detailed clinical study report look continued momentum divest anticoagulant medicine business target core earning product million industry launch online system share ep growth cer create new establish product portfolio enable researcher request access turnover growth cer old largely nonpromote anonymised patientlevel datum clinical exdivestment basis ep base brand aim find opportunity trial please company turnover billion range reduce complexity enhance profitability adopt approach guidance take account rollout new optimise value group product product potential competition announce plan evolve way generic old product lovaza complete significant divestment sell market product healthcare consumer healthcare business professional align activity close like thank sale drink brand lucozade ribena interest patient remove employee partner supplier suntory japan billion perception conflict interest specifically continue commitment support overall iconic brand particularly plan stop direct payment healthcare confident core focus innovative believe growth potential well professional speak engagement product development programme realise company exist category attendance medical conference investment couple change presence substantial drink distribution extend principle patient make business model position infrastructure emerge market programme globally decouple sale team company competitively long term remuneration prescription generation financial efficiency continue expand access medicine cash generation people live develop world operationally continue restructure sign groundbreaking simplify business reduce longterm fiveyear partnership save child cost base deliver incremental combine resource capability yearonyear saving million organisation help save life ongoing structural initiative million child live poor sir andrew witty countries africa chief executive officer gsk annual report strategic report business overview business overview sciencele global healthcare company research develop broad range innovative product primary area pharmaceutical vaccine consumer healthcare group turnover cer pharmaceutical vaccine consumer healthcare turnover group turnover group turnover group pharmaceutical business develop vaccine business large develop market range consumer make medicine treat broad range world produce paediatric healthcare product base scientific acute chronic disease portfolio adult vaccine range infectious innovation brand main patentprotected disease distribute category total wellness oral care offpatent medicine million dose country nutrition skin health include supply number wellknown brand develop country sensodyne panadol horlick sale therapy area sale category sale category respiratory paediatric vaccine total wellness antiviral include vaccine polio oral care diphtheria tetanus pertussis measle central nervous system nutrition mump rubella meningitis chicken cardiovascular urogenital pox pneumococcal disease skin health rotavirus infection metabolic adolescent adult travel antibacterial include vaccine flu oncology emesis pandemic seasonal human papilloma virus cervical cancer dermatology hepatitis typhoid meningitis rare disease acwy booster vaccine diphtheria tetanus pertussis polio immunoinflammation viiv healthcare hiv read read read gsk annual report global reach significant global commercial presence market network manufacturing site country large centre usa spain belgium china employee reshape business recent year well align strategic approach place allow well access market highgrowth potential include asia pacific latin america japan employees region employee region business sustain investment spend billion noncore item billion total usa usa search develop innovative medicine europe europe vaccine consumer product emap emap year see significant delivery japan japan latestage pipeline key medicine approve regulator usa dedicated research programme turnover region turnover region disease affect develop world healthcare company research new vaccine new medicine world health organization priority disease hivaid malaria tuberculosis core expenditure usa usa europe europe emap emap japan japan potential phase iii study start structured turnover segment core expenditure primary area business allocation commercial business structure pharmaceutical vaccine combination regional unit area focus europe pharmaceutical vaccine pharmaceutical vaccine operate emap pharmaceutical vaccine pharmaceutical geographical segment combine business consumer healthcare japan pharmaceutical vaccine vaccine business function global unit viiv healthcare consumer healthcare viiv healthcare specialist hiv company trading found pfizer join shionogi consumer healthcare read trading turnover include canada calculation core result noncore item puerto rico australasia central vaccine set tender sale contract manufacturing sale gsk annual report strategic report global context global context opportunity challenge despite continue macroeconomic market challenge world remain significant need medicine healthcare treatment global economic overview base imf assessment outlook regional pharmaceutical global economic growth continue global economic growth market sale affect fallout international high rate likely see financial crisis begin develop economy india asian performance slow region subsaharan africa figure originally predict international factor political turbulence monetary fund imf european union instability growth precede year middle east likely continue affect international business environment usa economy grow annual rate indicator suggest underlie global healthcare market recovery support rebound total global pharmaceutical market sale sale world pharmaceutical market housing market continue fall rise slightly billion cer year source ims datum unemployment rate peak september billion end despite previous year accord industry early announcement federal reserve information company im hold taper quantitative easing measure year emerge market asia pacific see large sale growth push eurozone economy remain weak proportion total sale region unemployment high labour market sale europe depressed growth year largely unchanged total stringent fiscal reform introduce north american pharmaceutical sale number eurozone country cause billion represent market social political tension therapeutic class sale japan government fiscal stimulus unchanged term position oncology monetary easing support private immunomodulatory represent total consumption investment appear sale growth central nervous system effect economy grow decline area year decline figure performance emerge market ims institute healthcare informatic region highly variable china growth predict annual spend prescription remain stable medicine grow slowly growth come second half year north america europe japan inward investment india grow spend emerge nation grow growth subdue economy overall result economic expansion middle east north africa latin america population change market russia compare currency pressure federal population growth reserve taper announcement evolve lifestyle figure current predict growth rate population growth increase prosperity emerge market global change lifestyle government response dynamic likely expand need medicine healthcare product future united nations forecast global population reach billion usa sale steady compare billion birth partly result rate decline europe japan likely patent expiry blockbuster offset sharp rise population medicine north particularly middle east american region remain southern asia pharmaceutical market total sale world output advanced economy emerge market develop country sale source weo update january imf gsk annual report figure total global sale medicine therapeutic class people live long partly result medical advance like vaccination oncologyimmunomodulatory prevent treat disease previously central nervous system cause significant number death alimentary tract metabolic people live long likely cardiovascular system develop disease age lead ale thir ray bin great demand medical treatment country rise population growth global sale cer economy experience improve economic outlook prosperity increase see trend sedentary lifestyle increase reference ims datum consumption food alcohol tobacco datum include vaccine sale correspond rise chronic non communicable disease ncds type diabetes heart disease disease europe disproportionately affect low overall performance well middleincome country nearly europe sale death ncds occur approximately austerity measure project global increase death fiscal issue country main driver continue slow emap ncds great growth region emerge market continue grow increase african eastern quickly sale mediterranean region sale diverse area predict continue grow strongly government globe pressure improve healthcare provision strong healthcare infrastructure absent people purchase medicine household develop country spend great proportion sale income healthcare counterpart develop market recent pharma future report estimate outofpocket cost high china india brazil economic growth emerge market likely mirror increased spending healthcare government individual demand medicine vaccine consumer healthcare product expect continue grow significantly fast region mature market year number nongovernmental organisation world health organization lead sale effort support region country prioritise introduce wide healthcare provision particular emphasis infant immunisation ultimately potential prevent million death figure price control regulatory pressure prescription medicine vaccine industry highly regulate individual government overall responsibility determine product market country case stateregulate system product price wide variation regional countryspecific law regulation medicine present challenge availability new product different japan market government mandatory price cut seek control cost reduce spending impose national healthcare budget particularly alternate year sale japan proportion spend medicine see approximately growth squeeze market continue supportive new medicine sale gsk annual report strategic report global context global context continue usa industry regulator legislation regulatory agency food create new resource need figure good chance drug administration fda approve requirement monitor report childhood new molecular entity manage safety issue expand accord world health approval mark year see debate proposal approval medicine market improve regulation conduct organization wide range number experimental medicine clinical trial aim boost clinical vaccine available contribute development review expedite research member states proposal prevention control breakthrough therapy designation near finalisation simplify vaccinepreventable infection programme result safety clincial trial process europe birth rate rise develop country innovation act act design come effect tremendous opportunity speed approval process offer child protection medicine intend treat life austerity programme restrict budget infection common childhood threaten condition enable continued create challenge healthcare preventable vaccine medicine reach patient soon system europe country global vaccine action plan figure expedite development pressure drug price remain high predict widen government range cost usa government price containment measure international access vaccine prevent control private sector purchase reference pricing squeeze efficiency million death pharmaceutical manufacturer drug budget end decade require federal law provide rebate government certain medicine overall access patient treatment order qualify reimbursement remain variable increase use manage healthcare programme entry scheme launch new product rebate share state significant reform pricing system federal government offset overall france sweden industrywide cost prescription drug provide stability agreement manage entire medicaid insurance programme low drug budget help extent figure expedite development income americans rebate increase furthermore country policy expand affordable care implement reduce shortage yrs act aca increase mean medicine patient additional cost pharmaceutical see payment prescription manufacturer allow medicaid product increase provide great access patient japan prescription medicine japanese regulator pharmaceutical expansion medicaid programme medical device agency pmda expedite review process new health insurance approve medicine contain new introduce food marketplace financial penalty active ingredient month certain americans choose purchase april september drug administration way speed availability insurance launch january april pmda produce roadmap cause great deal uncertainty medicine intend treat outlining desire strengthen insurance market lifethreatening condition partnership foreign regulatory agency recent review find reduce europe include fda ema agency number year require asia heighten spirit cooperation european medicine agency ema clinical testing candidate medicine speed regulatory approval improve regulate new medicine breakthrough therapy quality safety measure european union approve medicine designation average improve quality quantity research contain new active substance speed information year clinical testing compare novel medicine share globally approve compare approve europe year undergo approval biosimilar monoclonal government japan continue progress standard review antibodie mab number additional initiative likely affect prescription medicine industry pharmacovigilance risk assessment include goal committee prac introduce prescription fill generic medicine revise pharmacovigilance legislation march introduction health complete year operation technology assessment evaluate lead increase pharmaceutical medical device information available public regulator scrutiny safety medicine gsk annual report emerge market country india brazil argentina emerge market prescription introduce consider practice medicine regulate variety way restrict grant patent certain different country industry type invention commonly available present significant challenge develop country requirement additional marketspecific indication country consider documentation example market widespread use compulsory licensing china india russia vietnam nigeria essentially individual company require local clinical datum order seek use another patent meet regulatory requirement seek right holder consent pay patent owner set usually market authorisation application maa low fee license requirement continue evolve emerge market align closely patent expire medicine europe usa japan terms medicine subject competition format content generic product effect particularly acute western market government region include generic product rapidly capture indonesia china india look large share market generic expand population cover manufacturer typically incur significant governmentfunde health scheme cost able offer increase opportunity high product considerably low price volume tender impact price brand competitor specific tool method pressure generic competition country implement control health apply significantly vaccine spend vary government biological product product continue seek way manage healthcare patent exist active ingredient spending include spend medicine delivery device emerge market large emerge market know heritage brand exist medicine brazil russia china india patent value government attempt manage cost patient price control market authority look way control consumer healthcare help manage outofpocket spending development timeline consumer patient example india healthcare product significantly shorter introduce price control patent intellectual property protection nonpatente product international prescription medicine reference price remain frequent approach consumer healthcare product reduce pricing country like turkey subject national regulation comparable brazil australia china russia testing approval manufacturing expect introduce soon label marketing product high trend emerge market include standard technical appraisal frequently protectionist policy favour local involve lengthy review approval process cut red tape domestic supplier cause delay product launch new european proposal consumer healthcare product intellectual property patent cut clinical trial regulation protection great reliance brand loyalty simplify requirement trademark protection create value journey scientific breakthrough member states market develop approve new medicine vaccine country market take year incur significant challenging retailer consolidate cost ensure reasonable reward globalise strengthen expertise investment research negotiate power base pharmaceutical company rely protection intellectual property competition patent trademark regulatory datum protection register design copyright main consumer healthcare competitor domain registration include colgatepalmolive johnson johnson procter gamble reckitt benckiser unilever patent generally year term pfizer novartis file long development time medicine patent life significantly competition prescription product erode launch country come company research lose time restore make patentprotected medicine patent challenge indication treat similar disease expire court determine medicine principal researchbase patent invalid noninfringed pharmaceutical vaccine competitor unenforceable lead loss include abbvie amgen astrazeneca bayer protection innovation legal bristolmyer squibb eli lilly johnson jurisdiction significant litigation gsk johnson merck novartis novonordisk summarise note financial pfizer roche holding sanofi takeda reference statement legal proceeding addition locallyoperate fig gvap plan httpwwwwhointimmunizationglobal operate market intellectual company compete gsk certain vaccineactionplandovgvapenindexhtml property right particularly patent market fig fda review processapproval httpwww datum protection enforceable reuterscomarticleususafdajama idusbrer government seek control price increase access medicine population limit right gsk annual report strategic report business model business model create value continute adapt business model deliver sustainable performance innovation expand access mission people insight people critical ability achieve continuously investigate need challenge inspire mission mission rely knowledge patient consumer understand improve quality human life enable expertise ability innovate help ensure medicine product people feel well live long employee ask perform ethical meet requirement intend mission give purpose develop integrity strive create workplace address specific need innovative medicine product culture employee feel value market available available people need able ownership professional possible development maximise potential business model mission underpin number responsible business key factor broadly base balanced strategic priority business pharmaceutical vaccine value consumer healthcare core strategic priority grow value patient focus business model concept innovation diversify global business deliver transparency integrity respect access create value research product value simplify operate people heart decision manufacture innovative product model place focused integrating make accessible people design help produce value culture decisionmake need possible sustainable growth improve operational work meet quality financial performance reshape improve healthcare make affordable policy control require continue business well align strategic accessible people huge challenge review challenge practice approach substantially require combined effort ensure action meet exceed different company term geography expectation society product capability responsible business year ago strategic priority mission business model output improve quality benefit patient human life enable discover customer people develop innovative medicine feel well live long cash profit generation underpin manufacturing value make shipping shareholder value high standard product people world return strategic priority wide benefit commercialisation distribution society insight increase access product reinvestment gsk annual report meet challenge involve increase work take strategic decision industry healthcare professional university alongside external partner capture introduce flexible approach pricing healthcare funder include government scientific diversity exist academia reflect country wealth ability charity regulator need work research charity company pay poor country mind partnership share inherent risk include cap price develop collaboration key principle market level form alliance non process research grow business approach governmental organisation reduce price knowledge expertise create intellectual highvolume contract continue reform business model property business model ultimately rely example take industryleade environment appropriately protect develop market pioneer novel position improve global public health intellectual property provide reimbursement approach widen access pricing access strategy opportunity earn reasonable return new medicine price increase transparency clinical trial investment current treatment data modernise commercial deliver section grow section practice interaction customer manufacturing output ability consistently produce high quality discover develop new medicine product distribute deliver innovation maximise access long expensive uncertain process global network key business product generate value patient require highly selective model extensive manufacturing shareholder society widely invest resource primary goal organisation supply chain make develop innovative new medicine primary contribution product distribute product country offer significant improvement provide benefit patient consumer world exist treatment focus effort successful delivery generate profitable area science present new simplify section sustainable performance turn opportunity likely lead significant allow generate value return medical advance commercialisation distribution shareholder enable reinvest large researchbase company commercial success depend market business significant scale resource expertise presence customer understanding create value make direct bring search new focus expand access indirect economic social contribution medicine recent year challenge seek product widely country operate traditional hierarchical business accessible possible country wide benefit society include contribution model create small agile level income development tax employment enhance accountable earlystage group gsk presence market frequently wellbee local community group task seek requirement medicine global community initiative biological target involve disease available wide geographical create molecule biopharmaceutical spread help addition allow ultimately new medicine understand unique characteristic marketplace adapt business model address specific healthcare need requirement gsk annual report strategic report strategic priority strategic priority deliver strategy design deliver sustainable growth reduce risk improve longterm financial performance return shareholder aim progress grow create balanced total sale grow billion business product portfolio capable exclude divestment diversify deliver sustainable sale growth performance generate multiple centre business business geographie reflect business area pharmaceutical vaccine successful implementation strategy consumer healthcare deliver change organisation receive approval well able sustain major new product product pipeline product offer valuable new indication exist medicine improvement treatment patient vaccine value healthcare provider generate high volume phase iii underpin focus datum key asset pipeline improve productivity rate estimate return investment return increase simplify business continue change restructure programme shape transform operate track deliver total annual operating reduce complexity saving billion compare efficient deliver incremental model saving million free resource reinvest business make good progress transform manufacturing network supply chain enterprise wide process responsible responsible business central considerable strategy deliver success progress agenda operate responsibly business important achieve specifically take action increase ensure value embed transparency clinical research datum culture decisionmaking help well modernise commercial operation meet expectation society interaction customer progress drive access medicine poor country pass key milestone development potential vaccine malaria gsk annual report highlight prioritie financial architecture successful launch commercialisation new financial architecture product pipeline design support delivery group turnover continue invest key strategy enhance growth business include return shareholder emerge market vaccine focus key priority consumer healthcare deliver sustainable sale growth improve operate look opportunity leverage improve financial increase focus optimise group turnover outside usa europe efficiency converting value product portfolio read earning cash apply architecture consistently drive well consistent decision delivery phase iii data making company potential new medicine improve delivery key vaccine financial objective earning significant new product approval nme phase iii start share growth free cash flow generation continue focus increase return shareholder rate return reinveste bolton acquisition attractive return available potential medicine phase iiiii development implement financial read architecture help return billion shareholder dividend buyback cost saving delivery restructuring outlook programme target incremental saving rollout standardise core earning share growth enterprise platform delivery cer base integrate supply chain adjust divestment complete sale growth cer base day reduction work capital million adjust divestment read complete range guidance reflect transition expect file rtss malaria vaccine portfolio year candidate approval rollout new product face approve offer potential competition generic increase volume medicine forprofit price old product lovaza supply develop country implement change incentivise sale team work healthcare professional pharmaceutical company sign alltrial campaign research transparency read gsk annual report strategic report perform perform key indicator measure performance number key indicator remuneration executive base group turnover cash return shareholder report growth perform gsk return billion shareholder dividend share buyback important continue focus deliver dividend growth return free cash flow shareholder share buy back offer attractive return alternative investment core operating profit margina total operating profit margin report growth cer report growth cer report growth report growth perform perform core operating profit billion total operating profit billion ape eto snp aea rxt tpi aeg llc ooa hsl roo rra yta fia fst teg yst yed afl mng income low expenditure low expenditure important objective remain improve operate leverage margin indicate cost manage sale grow core earning sharea total earning share report growth cer report growth cer report growth report growth perform perform effective cost control delivery noncore item include gain financial efficiency enable disposal group lucozade group deliver core eps ribena business anticoagulant increase cer product million impact important noncore item year largely earning share portion offset profit allocate share key indicator performance return generate shareholder dnedivid yub skcab dnedivid yub skcab dnedivid report growth cer report growth perform turnover adjust disposal prior year drive growth usa japan emap important key objective strategy deliver sustainable broadlysource sale growth yub skcab gsk annual report new product approval usa new pharmaceutical vaccine product performanceb approval new product approval report growth cer perform perform exceptional year lead sale new product billion approval significant product grow represent usa help drive continue pharmaceutical vaccine turnover improvement estimate internal important rate return measure show delivery important sale year product launch measure show prior year roll basis organisation deliver new product create incentive improve drive growth group performance turnover major growth areasb free cash flowbc share total turnover report growth perform growth exclude legal settlement see continue pharmaceutical growth emerge market japan perform consumer healthcare free cash flow billion vaccine consumer healthcare growth increase billion primarily impact divestment reflect low tax legal payment important measure focus major growth important area vaccine consumer healthcare measure show cash generate emap japan dermatology available return shareholder highlight progress deliver reinvest business strategy create broadbase sale effectiveness convert earning growth resilient volatility cash effective work capital control investment discipline exclude divestment relative total shareholder returnbd use number adjust measure calculation free cash flow report performance describe business include core result reconciliation provide management calculation cer describe planning report purpose simay lan lyt cir ibc etl mco asp edit constituent pharma peer company core result exclude return index list number item total result definition core result find reconciliation core result total result provide remuneration executive link marked key indicator information executive pay policy find remuneration report glaxosmithkline total return glaxosmithkline pharma peer return index ftse total return index gsk annual report strategic report risk management risk management approach risk rigorous process system place help assure integrity business operation include identify manage risk impact business management risk important factor longterm success business figure governance structure risk management key focus board senior management sound risk management help address inherent risk business board responsible system corporate creating value shareholder director governance strategy risk management financial performance protect company asset maintain focus fundamental product quality safety sustainability audit risk responsible reviewing approve aim identify assess manage risk committee adequacy effectiveness risk level organisation employee management internal control expect accountability identify escalate encounter risk appropriately manage risk corporate support ceo manage management hierarchy focus make executive team business activity escalation simple rapid transparent approach allow balance level type risk exposure ability pursue strategic priority risk oversight authorise board assist compliance audit risk committee oversee hierarchy risk management risk management internal control governance show figure diagram council activity group summarise link role responsibility relationship different oversight management group figure provide business unit responsible identify assess representation process framework manage risk business risk management commit conduct business accordance applicable law regulation establish company risk management ensure appropriate internal control policy standard internal control compliance effective risk management implement company value underpin board approach risk management global risk management board responsible ensure risk adversely impact company appropriately manage oversight manage audit risk committee arc arc holistic view look financial result control operation business management risk consider new emerge risk information board responsibility include corporate governance section board arc set direction risk management policy corporate executive team cet responsibility identify approve monitoring enforce key policy concern risk control determine group conduct business gnirotinom rof ytilibatnuocca gnitnemelpmi rof ytilibisnopser figure governance structure risk management figure control framework nterprise oversight frau ein wte nro jul nction independent assurance value helps inde endent isi kness monitor uas bar uge eia vfe ecti sov disci epl fon management rodw lsar sten ose tos ync edt teu ats business party include regulatory blem ser nding activity train ivn yle fikns nnh gae itg ine gnt communication ath roe iati cie action improve internal control group gsk value key individual accountability gsk annual report line management accountability compliance business management accountability compliance audit assuranceeach year cet review risk face responsibility rocc ensure business unit global support group agree list significant area business robust process function maintain risk management risk refer principal risk require place identify risk assign clear accountability compliance board rmcb purpose particular attention group perspective monitor effectiveness internal control rmcbs identify specific operational include cause actual result mitigation plan process place legal compliance risk affect differ materially expect historical ensure business unit global support achievement business objective result summary principal risk set function escalate significant operational help ensure appropriate internal control description risk compliance issue internal external audit implement relevant cet member present risk factor page results investigation rocc accountable different part business onward arc timely manner present annual report rocc addition cet consider arc principal risk interact expect party uphold company compound impact high standard set global risk officer global ethic specific accountability assign establish appropriate governance help compliance team responsible support designate individual responsible ensure expectation meet effective integration risk management develop overall group approach business unit global support principal risk identify risk management business function audit assurance responsible particular exposure regard operational daytoday management risk independently assess adequacy work cet arc support rest business commit effectiveness management risk area risk oversight compliance council rocc responsible valuesbase business report outcomes rocc arc membership comprise senior executive management responsible embed group maintain independent reporting represent business unit global culture decision make line outside business management support function make gsk work principal risk principal risk list believe cause actual result differ materially expect historical result list order significance description risk definition context potential impact mitigating activity set page risk factor patient safety antibribery corruption failure appropriately collect review followup report adverse failure foster culture company bribery event potential source compromise corruption unacceptable adopt measure embe group ability conduct robust safety signal detection procedure prevent bribery corruption employee interpretation ensure appropriate decision take complementary worker party interaction respect riskbenefit profile group product investigate allegation bribery corruption remediate include completeness accuracy product label issue identify comply applicable abac legislation pursuit additional studiesanalyse appropriate research practice commercial practice scientific engagement failure protect inform patient involve human clinical failure engage commercial andor scientific activity trial research conduct objective ethical preclinical clinical trial consistent letter spirit legal industry company sound scientific principle guarantee integrity discovery requirement relate marketing communication preclinical clinical development datum manage human biological medicine associate therapeutic area appropriate interaction sample accord establish ethical standard regulatory healthcare professional hcp patient legitimate expectation treat animal ethically practice good animal transparent transfer value welfare appropriately disclose human subject research medicinal product ensure integrity regulatory filing datum publish product quality environment health safety sustainability failure ensure product quality manufacture failure ethically manage environment health safety distribution process result noncompliance sustainability consistent company objective policy good manufacturing practice gmp regulation relevant law regulation supply chain continuity intellectual property failure deliver continuous supply compliant finished product failure appropriately secure protect intellectual property right financial reporting disclosure information protection noncompliance financial reporting disclosure requirement risk group business activity critical sensitive computer change recognition income expense system information available need access authorise deliberately change corrupted tax treasury crisis continuity management failure comply tax law significant loss inability recover sustain critical operation follow treasury activity disruption respond crisis incident timely manner regardless cause gsk annual report strategic report grow grow continue pursue strategy generating sustain broadly base sale growth past year create regionally continue significant balanced business product portfolio investment highergrowth market capable deliver sustainable sale growth example asiapacific latin america japan reshape business believe position vaccine consumer reflect change market dynamic healthcare key pharmaceutical therapeutic enable successful launch multiple area include respiratory hiv provide new product approval receive significant competitive advantage year europe restructuring opportunity synergy improve efficiency focus resource growth opportunity continue challenging environment progress summary group turnover year report turnover grow billion exclude divestment report growth cer performance line guidance despite unexpected challenge generate multiple business geography reflect successful implementation strategy report growth see encourage return growth cer exclude pharmaceutical vaccine business divestment stabilisation european business report pharmaceutical vaccine sale grow emerge market region exclude china consumer healthcare business sale emerge market year progress sale exclude divestment year complete divestment drink brand lucozade ribena report growth anticoagulant drug arixtra fraxiparine cer form establish product portfolio largely nonpromote brand report separately group sale gsk annual report build business emerge market focus emerge market invest heavily brazil recent year economy expand quickly term healthcare sixth large pharmaceutical market world pharmaceutical vaccine sale business brazil increase contribute overall growth emerge market region year exclude china expand sale medicine vaccine brazil commit scientific research latin america trust science programme collaborate outstanding scientific group explore new way treat priority disease form collaboration paulo research foundation create new sustainable chemistry centre photo doctor hospital rio janeiro brazil doctor large population million south america public healthcare system offer coverage citizen reference im world review analyst httpwwwabpiorguk industryinfoknowledgehubglobalindustrypagesindustry marketaspx httpdataworldbankorgindicatorshmedphyszs httpwwwkantarhealthcomdocsebooksbrazilthegem oflatinamericapdf priority successful launch commercialisation new product pipeline key priority time continue invest target growth business emerge market vaccine consumer healthcare continue look opportunity drive synergy pharmaceutical vaccine consumer healthcare review product portfolio increase focus reduce complexity optimise value gsk annual report strategic report grow pharmaceutical vaccines usa business perform dynamic challenging environment good progress new product approval turnover marketplace cardiovascular urogenital sale fall usa undergo great largely end transformation healthcare system vesicare copromotion agreement group turnover acs cam hcp anl oca rht iwo tih htf yfo srt anb thh mre icn aee ctv igu ict msa ioe tli payer pharmaceutical industry vaccine sale increase significant opportunity primarily result increase infanrix healthcare stakeholder include government pediarix sale million report growth cer entity healthcare provider private boostrix sale million industry work address benefit competitor supply challenge rise cost age shortage fluarixflulaval sale population epidemic chronic strong million follow disease factor economic launch quadrivalent flu formulation uncertainty place great emphasis demand high quality care low operating profit cost well health outcome portfolio progress course approval performance receive fda breo ellipta anoro pharmaceutical vaccine turnover ellipta respiratory disease tafinlar operating profit tho iot ice eth roa mct tiof que din rii lefo flue ina lle table agreement exclude healthcare tivicay hiv overall gsk pharmaceutical turnover account fda new drug approval exclude vesicare vaccine achieve report growth cer turnover grow core operating profit approval fda new molecular entity nme company therapy area particularly approval breo ellipta anoro ellipta breakdown turnover strong performance respiratory oncology add strength respiratory portfolio growth vaccine supplement exist product cer seven latestage respiratory sale grow advair development confident ability respiratory billion estimate underlying growth maintain leadership position area antiviral advair volume decline decade offset positive impact price mix central nervous system flovent sale million number product await review cardiovascular line estimate underlying growth decision fda submit urogenital year ventolin sale grow million arzerra firstline treatment chronic metabolic launch breo ellipta begin lymphocytic leukaemia cll million sale record quarter submit fda application albiglutide antibacterial adult patient type diabete file oncology sale grow reflect oncology emesis new drug application nda fluticasone continue strong growth contribution furoate asthma umeclidinium bromide vaccine votrient million promacta umec patient copd include dermatology million benefit chronic bronchitis emphysema new indication thrombocytopenia rare disease associate hepatitis receive immunoinflammation arzerra sale grow million oncology performance reflect contribution totalling million tafinlar mekinist launch monotherapy treatment achieve strong initial uptake braf melanoma market gsk annual report development september fda publish draft guidance establish bioequivalence inhale medicine like advair contain fluticasone propionate salmeterol administer diskus propose generic version submit comment draft guidance fda identify date release final guideline generic applicant seek market entry lapse diskus patent protection august need send gsk paragraph certification november fda ease restriction patient access avandia rosiglitazone follow fda advisory committee review result rosiglitazone evaluate cardiovascular outcome regulation glycemia diabete record clinical trial continue significant improvement customer interaction follow change decouple work government pay number prescription provide bioterrorism protection issue sale representative follow announcement december change way interact healthcare anthrax likely agent raxibacumab contract late professional start process bioterrorist attack long line example work implement change usa centers disease control closely government expect place prevention cdc classify work government business start category biothreat texas university system establish initiative support health million biodefence pandemic follow year collaboration wellbee community market influenzavaccine manufacturing facility biomedical advanced research operate invest million texas development authority patient assistance programme award new contract provide novel approach drug development usa programmes inhalation anthrax treatment raxibacumab funding award design help underprivileged family department health human million develop new antibiotic usa access essential healthcare service hhs publicprivate agreement mark time hhs take portfolio provide dose approach fund drug development year value approximately private sector company million million realise proud help protect citizen bioterrorism form broad fiveyear base contract yrarbil otohp ecneicspisb semaj inillavac gsk annual report strategic report grow pharmaceutical vaccines europe europe restructuring improve business performance support new product approval turnover marketplace sale central nervous system product europe remain challenging environment fall generic competition government continue implement growth vaccine sale austerity measure drive primarily successful tender group turnover france germany introduce rotavirus vaccine rotarix boostrix announce cut freeze reduction diphtheria tetanus pertussis flat medicine budget course supplement launch nimenrix vaccine strain meningitis southern europe austerity measure report growth cer continue drive price reduction portfolio progress october spanish number new product receive government announce plan repay approval europe include relvar billion debt ellipta asthma copd tafinlar pharmaceutical industry advance metastatic melanoma introduction health technology fourstrain influenza vaccine assessment hta system impact additionally twodose schedule operating profit european marketplace government approve cancer vaccine cervarix htas guide decision allocation healthcare resource include year old girl synflorix approve immunisation pneumonia expenditure medicine assessment infant child approval grant criterion challenge operating profit view acceptable new indication exist product clo inm icp mat ar pta pfi ata ioin aty mad cfo ero iaic vit eis conjunction trastuzumab certain type breast cancer report growth cer performance european pharmaceutical vaccine development turnover billion flat compare restructure european breakdown turnover benefit recent business course restructure refocusing business growth reduce inefficiency ensure focus offset continue pricing pressure cer investment area growth generic competition number respiratory product potential reorganisation largely complete end antiviral pharmaceutical sale pharmaceutical year divest central nervous system billion vaccine grow anticoagulant product arixtra billion largely improve cardiovascular fraxiparine aspen group tender performance operating profit urogenital million transaction europe rise metabolic agree transfer manufacturing site therapy area respiratory sale france aspen antibacterial reflect increase competition december announce change oncology emesis market seretide sale way compensate global sale billion volume decrease vaccine employee work directly prescribe net impact price mix serevent dermatology flovent sale healthcare professional hcp remove individual sale target change rare disease respectively roll global sale force immunoinflammation oncology sale grow million announce change work lead sale votrient increase healthcare professional million continue build start process end direct market share market revolade payment healthcare professional receive approval use thrombocytopenia speak engagement attendance associate hepatitis end medical conference start sale year increase million tafinlar launch certain market achieve strong uptake early launch market gsk annual report openness offer early access innovative medicine commit ensure patient europe continue benefit innovative increase number patient benefit medicine access votrient achieve develop novel approach ensure reimbursement status cancer type sustainable manner region advanced kidney cancer softtissue sarcoma engage government healthcare professional regulator engage oncologist commit ensure patient ensure eligible patient appropriate medicine benefit europe able access tafinlar ahead soon available reimbursement cost launch kidney cancer initiative contribute product votrient agree growth oncology business provide headtohead datum year bring innovative medicine standard care year market help patient cancer result positive retain access medicine quickly price negative pay seek key partner oncology rebate reduce price result available positive agree retain original price european business support number initiative support health wellbeing science education local community major supporter wellchild national charity sick child implement science education programme work secondary school teacher help inspire young people continue study science technology engineering math stem subject help connection science learn classroom potential future career continue provide financial support barretstown camp ireland provide therapeutic recreation programme child illness family gsk annual report strategic report grow pharmaceutical vaccine emap emerge market asia pacific business deliver strong performance despite political unrest economic uncertainty market turnover marketplace pharmaceutical sale emap rise remain optimistic longterm billion exclude china prospect emerge market respiratory therapy area sale grow emap region continue major engine lead seretide million group turnover growth industry characterise veramyst grow million grow population increase gdp ventolin sale million demand middle class oncology sale grow million great spending healthcare lead strong growth votrient business fundamental region million promacta report growth cer strong expect remain million sale tykerb come year hycamtin decline million economic currency volatility continue million respectively cause shortterm uncertainty sale antibacterial grow country subdue growth million primarily attribute price pressure create increase sale augmentin government tightly manage healthcare million operating profit budget particularly brazil korea india sale antiviral fall decline performance zeffix hepsera emap pharmaceutical vaccine turnover vaccine sale grow billion operating profit grow billion adversely exclude china reflect strong affected ongoing investigation china tender performance cervarix vaccine supply issue exclude infanrixpediarix partially offset tough weh rin ina atic tina pin roe fis ina les exo stp ina gri init sin nin wai ned report growth cer emap technology transfer agreement boostrix india finalise joint venture focus regionally pharmaceutical vaccine early stage research development growth strong middle east breakdown turnover sixinone combination paediatric vaccine africa latin america help protect child polio growth southeast asia partially offset infectious disease cer decline korea india respiratory performance india affect portfolio progress government price control introduce antiviral addition file new pipeline product middle year continue central nervous system optimistic business prospect emap country implement catchup programme aim bring cardiovascular country demonstrate open offer establish product develop urogenital increase hold publiclyliste country programme indian pharmaceuticals subsidiary aim metabolic complete transaction receive approval product treat noncommunicable disease antibacterial china sale business respiratory antibiotic oncology oncology emesis china subject investigation vaccine government authority allegation development fraudulent behaviour concern dermatology follow announcement december disappoint allegation market emap business rare disease cooperate fully chinese authority started implement change way immunoinflammation compensate sale employee work directly prescribe healthcare professional hcp remove individual sale target change roll entire global sale force gsk annual report emap region continue expand leastdevelope market new formulation help low income estimate million people underserve healthcare provision develop country emerge market package actual medicine market access dcma unit manage look innovative way expand individual dose capsule allow commercial business world poor access product purchase quantity small country focus volume capsule time cut overall cost instance asthma patient emerge profit growth create medicine enable patient market low income pay new operating unit embrace country buy medicine quantity fit medicine directly subsaharan africa cash flow people pay weekly develop country step daily basis purchase new inhaler available market broad growth strategy africa medicine normally sell large philippine indonesia kenya nigeria remain fully committed support pack reach submit regulatory healthcare emerge market approval market ultimately response develop small despite challenge exist hope open access pack size inhal device country region believe patient currently unable afford costly produce ventolin rotacap use improve patient access medicine inhale respiratory medicine reengineere version establish vaccine patient benefit gsk inhaler technology key longerterm success times expensive produce business add commitment gavi alliance new agreement supply cervarix new gavi demonstration project significantly discount price extend synflorix vaccine supply agreement order protect additional million child world poor country partnership barclay seeks increase pneumococcal disease meningitis access affordable healthcare help pneumonia late commitment create improve economic condition add exist agreement supply growth combine skill gavi million dose synflorix expertise barclay help remove decade million dose financial barrier healthcare access rotarix year support small business development job creation start zambia drive improve access vaccine healthcare develop announce financial support country enter new million community health worker partnership save child campaign aim train health worker barclays bank alliance provide essential service poor save child longterm community subsaharan africa strategic global partnership aim help save life million child combine expertise resource influence group touch area business particular knowledge partnership gsk annual report strategic report grow pharmaceutical vaccine japan strong performance pharmaceutical product offset challenge environment vaccine business japan turnover marketplace portfolio progress japan remain world second large japanese business receive prescription medicine market usa regulatory approval arzerra vast majority resident cover chronic lymphocytic leukemia cll relvar group turnover social health insurance remainder ellipta asthma paxil posttraumatic receive public assistance demand stress disorder ptsd bring total highquality medical treatment remain high number approval approval receive xyzal april government announce plan january allergic rhinitis promotion use generic report growth cer medicine explicit goal increase focus reduce gap generic drug share market approval pipeline product accelerate generic launch japan usa europe category japan country receive regulatory approval relvar ellipta asthma performance launch take place early december pharmaceutical vaccine sale japan september trametinib dabrafenib operating profit grow billion growth dolutegravir mepolizumab churg pharmaceutical sale partially offset strauss syndrome grant orphan decline vaccine sale operate profit drug status subject priority review japan grow gsk orphan drug designation operate profit therapy area respiratory sale grow japan million adoair sale increase million strong development growth veramyst million japanese government review price report growth cer xyzal million relvar prescription medicine fund health ellipta launch december insurance year result average record sale million price cut revision april discussion breakdown turnover antiviral sale grow authority industry pricing government decision stockpile flu growth begin end year antiviral relenza cer september publish detail rare disease sale pulmonary respiratory payment healthcare professional arterial hypertension pah medicine volibris antiviral increase million keep new guideline transparency japan pharmaceutical central nervous system sale flolan fall impact manufacturer association price reduction cardiovascular launch generic epoprostenol continue support invest health urogenital manufacturer wellbee community market metabolic operate provide pharmaceutical product antibacterial perform strongly benign prostatic financial support area affect great east japan earthquake oncology emesis hyperplasia treatment avolve dutasteride addition support save child increase sale million vaccine partnership employee fundraising market leader january dermatology central nervous system cns medicine rare disease remain important therapy area antiepileptic lamictal perform strongly sale grow million generic competition lead decline sale antidepressant paxil vaccine sale primarily reflect impact cervarix suspension recommendation use hpv vaccine japan second half adverse comparison benefit final stage catchup hpv vaccination programme gsk annual report viiv healthcare viiv healthcare see important milestone approval launch dolutegravir new treatment hiv turnover marketplace key element international strategy currently million people live create local partnership generic hivaid world million manufacturer middle income country people die aidsrelated cause end confirm new group turnover death estimate relationship emcure launch generic close day maraviroc axentri india flat usa hiv market continue grow portfolio progress modest rate european marketplace strong viiv healthcare file investigational single despite austerity measure change healthcare report growth cer tablet regiman combine dolutegravir abacavir system associate pricing pressure lamivudine know dolutegravirtrii business outside region remain usa october important priority continue focus work experimental integrase inhibitor result establishment new middle gsk continue progress study east africa hub leastdevelope longacte injectable form drug lowincome subsaharan africa country set begin second quarter major market issue access operating profit development performance access medicine major focus viiv healthcare turnover flat viiv healthcare billion growth generate operating profit maintain commitment support epzicomkivexa selzentrycelsentri people hiv country maraviroc introduction newly approve tivicay dolutegravir company offer royaltyfree voluntary licence notforprofit pricing lowincome offset impact continue competition report growth cer old product operating profit grow leastdevelope country subsaharan africa people hiv live strong growth epzicom middleincome country kivexa million selzentry casebycase approach assess local breakdown turnover celsentri million epzicom need hiv medicine include kivexa perform particularly pipeline new breakthrough growth region business reflect increase tivicay cover access policy cer confidence marketplace enhance combivir position local guideline north announce voluntary licence medicine patent pool foundation improve epivir america europe access abacavir child live hiv epzicomkivexa highlight approval addition number community tivicay usa august physician selzentry initiative currently support response tivicay extremely trizivir positive product launch trajectory project world positive action positive action child fund pace well recent launch paediatric innovation seed fund hiv space tivicay record sale million viiv healthcare commit million fund grassroot regionally sale north america grow drive project usa address gap care good performance epzicom selzentry service people live risk launch tivicay europe hivaid sale decline arrival generic competition combivir offset strong growth continue support paediatric kivexa international region sale innovation seed fund focus decline increase generic competition project include mature portfolio balance strong collaboration clinton health access growth kivexa latin america japan initiative mylan pharmaceuticals russia partnership aim produce tastemasked dispersible medicine paediatric use november mylan file regulatory dossier prequalification regulatory approval procedure gsk annual report strategic report grow consumer healthcare consumer healthcare performance strong particularly oral care nutrition area boost renew focus core brand turnover marketplace skin health sale grow million global consumer healthcare marketplace lead abreva usa wide diverse individual regional level exclude noncore marketplace region present otc product divest sale group turnover challenge opportunity grow million lead strong develop economy europe asia contribution oral care brand alli north america competition intense abreva partially offset main market player strive gain market decline gastrointestinal product share innovation aggressive marketing increase competitor activity report growth cer increasingly premiumbrande competitor smoke control product drive market value offer consumer europe sale grow billion superior clearly differentiate product help strong growth product compete ownlabel offering respiratory health pain oral care sale growth slow slightly emerge market europe flat strong growth long term prospect remain strong drive sensodyne denture care brand emerge middle class great disposable offset decline aquafresh operating profit income increase gdp impact supply issue rest world market include india performance china latin america africa grow overall consumer healthcare turnover grow billion reflect growth operate profit billion exclude category market performance noncore otc brand divest india particularly strong sale half turnover grow india remain important market operating profit consumer healthcare business reinforce report growth cer grow investment publiclyliste consumer healthcare subsidiary bring consumer healthcare business hold share year structure category total breakdown turnover wellness oral care nutrition skin health development growth total wellness sale exclude noncore extend approach innovation cer otc brand divest launch shopper science lab half grow billion severe total wellness case study human performance cold flu season early help drive lab oral care growth respiratory brand nutrition offset reduction total wellness worldclass facility enrich sale china drive regulatory change ability well serve consumer skin health deepening understand influence increase oral care sale decision shelf improve billion drive growth sensodyne capability work elite performer toothpaste sensitivity acid erosion understand human performance apply denture care brand new product mass consumer continue strategy nutrition category grow emerge increase focus core portfolio market record increase family consumer healthcare brand particular nutrition horlick emphasis emerge market element increase consumer access india sale lucozade ribena geographic expansion bangladesh drink brand suntory beverage food ltd pakistan addition functional beverage japanese consumer good company grow emerge market billion complete sale europe end gsk annual report shopping habit shoppers gsk innovation limited use shopper science lab organisation explore habit behaviour understand technological innovation allow influence consumer choice deepen understanding flexibility facility allow analyse influence consumer decision different store layout shelf enhancement enable improve experience packaging display improve consumer ultimately increase shopper experience point purchase sale open high tech shopper collaborate research facility shopper science lab retail partner identify good joint value significant step creation opportunity large advanced investing facility ssl shopper insight collaboration facility allow gsk stay forefront europe fit cuttingedge science shopping give competitive technology include virtual insight advantage fastpace world engagement touch screen wall eyetracke consumer healthcare completely skin sensor monitor consumer keep aim emotional reaction mock retail well fastmove consumer healthcare pharmacy store company drive science value gsk annual report strategic report deliver deliver strategy increase productivity improve rate return underpinned change recent year organisation way work break traditional hierarchical underpinned focus business structure create small agile improve rate return autonomous team scientist believe change organisation increase level externalisation way work allow sustain research allow explore new area pipeline product offer valuable science share risk group improvement treatment patient rigorous allocate investment healthcare provider pharmaceutical vaccine consumer healthcare change process able decision early pipeline progression mean medicine significantly differentiate exist therapy progress progress summary new product approval usa receive approval significant new product include treatment new product approval respiratory disease asthma copd malignant melanoma skin cancer hiv new vaccine strain flu receive approval new indication exist vaccine cancer medicine gain significant approval generate high volume phase iii datum key asset pipeline unprecedented level latestage pipeline delivery company overall return pharmaceutical estimate internal rate return vaccine investment increase combination great innovation effective asset progression successful approval couple reduction estimate irr spend continue target internal rate return long term basis target gsk annual report treat hiv hivaid claim million life past year usa million people hiv improvement treatment year old hiv treatment usa expect live life expectancy approach general population establish viiv healthcare pfizer focus hiv treatment research longterm collaboration joint development novel medicine join shionogi viiv healthcare receive approval tivicay dolutegravir integrase inhibitor treatment hiv provide patient new treatment option parker picture learn hivpositive healthy mean possibly body good shape spend time people care parker age texas usa references world health organization hivaid fact sheet access httpwwwwhointmediacentrefactsheetsfsen access december center disease control prevention hiv united states glance access httpwwwcdcgovhiv statisticsbasicsataglancehtml access december samji cescon hogg modur althoff closing gap increase life expectancy treat hivpositive individual united states canada plo doijournalpone priority remain confident ability sustain pipeline delivery key focus delivery phase iii datum potential new medicine vaccine plan phase iii stage progression new product key area respiratory oncology vaccine drive improvement way work organisation continue priority increase level output maintain increase expenditure gsk annual report strategic report deliver pipeline progress new treatment option organisation perform exceptionally record number approval encourage evidence ability sustain output major new medicine file profile hivaid initial phase iii datum receive start approve breo viiv healthcare company establish darapladib chronic coronary heart disease anoro respiratory disease tafinlar pfizer focus hiv treatment therapeutic vaccine magea mekinist melanoma skin cancer research gain approval tivicay melanoma primary endpoint tivicay hiv expect regulatory usa europe tivicay oncedaily darapladib study coprimary decision albiglutide remain asset integrase inhibitor need endpoint magea study group half addition conjunction booster drug meet process analyse launch new injectable quadrivalent approve use treatment datum determine flu vaccine usa naive treatmentexperience patient patient subgroup benefit treatment phase iii study productive period company history overall gsk account vaccine mage lung cancer darapladib acute coronary syndrome read fda new drug approval year gain approval achieve new quadrivalent flu vaccine flulaval hand right partner company approval new molecular entity usa fluarix europe fourstrain asset ipx parkinson usa company vaccine provide add protection versus disease return impax pharmaceutical traditional trivalent vaccine delay anticipate regulatory respiratory approval launch date disappoint europe hpv vaccine cervarix receive respiratory breo ellipta oncedaily approval twodose schedule addition phase iii datum prompt return right combine steroid longacte beta exist dose european migalastat fabry disease amicus agonist approve usa medicines agency approve additional therapeutic vercirnon crohns disease treatment copd product indication pnuemonia synflorix chemocentryx drisapersen relvar ellipta approve infant child pneumonia continue duchenne muscular dystrophy prosensa treatment asthma japan relvar lead cause death decide pursue development ellipta receive marketing authorisation child tykerb head neck gastric europe copd asthma cancer study medicine indication fail meet primary endpoint new product copd anoro ellipta strong pipeline approve usa anoro ellipta promise progress remain confident capable oncedaily product reach number phase iii asset progress deliver strong sustainable pipeline market usa combine long regulatory filing year end potential new medicine act bronchodilator single inhaler new molecular entity nme relvarbreo anoro administer file submit usa europe phase iiiii clinical development novel inhaler device ellipta albiglutide treatment type diabete expect phase iii readout single tablet combination tivicay nme include magea darapladib oncology viivs kivexa treatment hiv arzerra mepolizumab severe asthma line treatment chronic lymphocytic phase iii study start oncology business strengthen leukemia cll umeclidinium long new asset number regulatory approval act muscuranic antagonist component new product tafinlar mekinist anoro copd approve usa use singly usa file fluticasone fuorate metastatic melanoma fdas steroid component relvarbreo accelerate approval process use monotherapy asthma europe combination oral target therapy submit votrient ovarian cancer accelerate approval contingent result phase iii trial expect regulatory decision europe design evaluate clinical benefit anoro ellipta incruse mekinist combination patient population mekinisttafinlar combination use tafinlar gain european approval important year malaria expect decision europe vaccine candidate phase iii datum show mekinist combination use month followup vaccine new indication exist product halve number malaria case portfolio tyverb revolade young child reduce approve regulator quarter number malaria case infant datum intend submit regulatory file europe asset gsk annual report significant new product approval relvarbreo ellipta anoro ellipta tivicay fluticasone furoatevilanterol umeclidinium vilanterol dolutegravir combination oncedaily inhale oncedaily dual bronchodilator integrase inhibitor approve corticosteroid longacte beta treat chronic obstructive pulmonary usa europe treatment agonist bronchodilator disease copd usa hiv combination antiretroviral therapy approve usa treat copd combine longacte europe treat asthma copd bronchodilator device integrase inhibitor japan treat asthma need conjunction new dry powder inhaler ellipta enable booster drug offer hour efficacy simultaneous delivery medicine daily dose approve patient new treatment million people usa receive new dry powder inhaler ellipta enable estimate affected copd hiv medicine simultaneous delivery medicine national heart lung blood institute globally million people live despite medical advance half hiv end asthma patient continue experience poor control significant symptom million people die aidsrelated european respiratory review illnesse worldwide people currently asthma lead cause death worldwide people live hiv copd international copd coalition tafinlar mekinist fluarixflulaval dabrafenib trametinib quadrivalent influenza vaccine pill metastatic melanoma approve firstinclass target treatment seasonal influenza vaccine usa europe melanoma approve usa protect different strain virus medicine target patient median age newly diagnose genetic mutation braf metastatic melanoma patient offer additional protection compare decade young patient traditional threestrain vaccine approximately half people cancer cancer network metastatic melanoma braf influenza public health mutation fdaapprove mek inhibitor problem cause severe illness patient braf death melanoma cause skin mutation cancerrelate death epidemic occur yearly autumn american cancer society number people worldwide winter diagnose melanoma usa estimate vaccination effective way death melanoma prevent infection national cancer institute patient worldwide metastatic melanoma expect survive year diagnosis malignant melanoma case class mek inhibitor seasonal influenza cause braf mutation lancet oncology death year worldwide gsk annual report strategic report deliver investment focus productivity remain committed improve productivity research development develop innovative new product great efficiency core expenditure primary goal discover rate return determine assess develop new medicine provide advance cost involve discover current treatment value develop late stage pipeline project patient payer profit newly approve medicine vaccine achieve people work regulatory approval available organisation core spend patient careful allocation billion year spend critical spend spread calculate estimate business pharmaceutical vaccine internal rate return irr consumer healthcare state longterm aim increase process pharmaceutical combination innovation vaccine long expensive uncertain effective asset progression successful difficult predict product approval reduction spend succeed fail important lead improvement current estimate pharmaceutical drive efficiency possible irr continue target vaccine offset risk key priority longerterm basis consumer healthcare continue implement improvement improvement estimate irr organisation increase important measure financial discipline level output maintain strategic progress improve increase expenditure economic research development level regulation approval underpin strategy create process consumer healthcare product flexibility pricing differ pharmaceutical new medicine vaccine research development times calculation irr incorporate actual short cost significantly predict sale figure base probability innovation consumer product base success medicine pipeline develop new product formulation account estimate meet customer need attributable cost estimate profit area decision margin capital investment work investment base capital requirement good opportunity calculation include product market science believe launch january december effective determine investment compound phase iib iii requirement basis fix proportion development process calculation sale base actual sale forecast sale adjust calculate rate return reflect expect failure rate broadly decline productivity issue line standard industry failure rate pharmaceutical industry cost base calculation face past decade result comprise estimate attributable important company cost actual project milestone provide great level transparency payment appropriate return organisation determine capital investment allocation gsk annual report pharmaceutical search new medicine pharmaceutical organisation restructure create research group agile autonomous outwardfacing believe structure key building strong pipeline innovative new medicine core pharmaceutical investment people employ earlystage research pharmaceutical business earlystage research drug discovery pharmaceutical core expenditure aim identify biological target involve billion decline compare development disease previous year view create small molecule biopharmaceutical context record number approval interact disease target gain strong pipeline output ultimately lead new medicine year believe evidence recent year transform strategy increase productivity pharmaceutical organisation aim work enhance efficiency productivity length time cost involve drug new approach key element discovery development essential break traditional hierarchical highly selective invest business model create small resource distribute expenditure agile earlystage group call early stage research latestage discovery performance unit dpus second discovery development focus area change process development scientific advance open progress experimental medicine facility central support new opportunity consider significantly differentiate exist likely lead significant medical advance therapie increase ensure evaluate experimental research external partner product key point development enable access new area science pathway confident share risk development put resource project believe dpu structure help maintain high probability succeed flexibility discovery research investment key centre usa focus promise scientific spain china announce opportunity plan significantly expand rejuvenate dpus dpu facility significantly scientist work pennsylvania usa ensure particular disease pathway area place maintain position science dpu responsible discovery leader attract new talent development potential new medicine early stage clinical trial completion phase lla timeline development stage pharmaceutical research drug discovery compound compound compound number patientssubject yrevocsiderp regulatory approval postmarkete preclinical clinical trial review launch surveillance phase phase phase iii approve new medicine year year year ind submit nda submit gsk annual report strategic report deliver pharmaceutical continue dpus give budget know commit medicine governance progress dpu business plan development decision typically governance structure aim regularly review discovery investment phase iia trial ensure clear accountability product board dib membership dib include compound test small number review oversight strategic issue senior commercial management human volunteer point devise overall budget management external individual expertise include instigate largerscale study human own executive team life science investment experience investigational medicine governance board determine understand payer perspective investigate efficacy safety investment lifecycle early chair president time work optimise commercialisation beginning dib continue active deal compound physical property describe early make collaborate external formulation produce portfolio investment board pib assess company individual academic efficiently sufficient quantity technical commercial investment case particular active venture manufacturing process case project progress development fund instrumental start research include develop new pib cochaire chairman venture fund year focus device deliver medicine president north america different area science region case study patientcentric design pharmaceutical include head nurture biotech ecosystem stage successful pharmaceutical region run competition goal use result study head global manufacturing increase understand nascent field submit regulatory file approval pib accountable investment bioelectronic view regulatory agency decision fund allocation form partnership academia responsibility guide investigational latestage pharma investment core discovery expenditure medicine later stage medicine discovery development million approximately development filing rest medicine biopharm oncology stiefel rare development team mdts small unit disease emerge market people allow investment decision latestage development holistic way ensure balance new molecular compound demonstrate diversity asset differ risk profile entity phase iiiii clinical development potential proof concept novelty opportunity development cost work decision potential reimburse payer advance latestage development nurture biotech ecosystem discovery research exciting innovative instrumental time consume high risk startup venture fund focus factor global different area science rare disease economic downturn result few bioelectronic region west coast investments earlystage life sciences usa company past year fund san diegobase number venture capital firm avalon ventures groundbreake stop invest altogether sector effort fund launch few investment average earlystage life science company invest fall company form fill gap ensure innovative collaboration announce december idea lose lack month fund financing take creative formally launch approach early research investment participation venture creation participation funding activity gain access broad number venture capital fund range early research programme include fund pharmaceutical case option buy company industry competitor demonstrate scientific promise gsk annual report project review pib certain key decision point commit medicine development commit phase iii commit file funding generally allocate key decision point typically year ahead pib carry annual latestage funding review investment project review adjust necessary prioritise individual late stage project incur annual expenditure total annual expenditure commercial accountability board cab responsible commercial alignment investment decision innovative market product portfolio govern transition portfolio commercial operation cab review individual asset commit launch milestone include endorsement commercial strategy global target asset cab approve investment phase iiibiv evidence generation conduct postlaunch review annual review reimbursement decision predict performance important governance board include scientific review board srb govern body accountable scientific patientcentric design assessment portfolio support investment decision make portfolio investment board pib srb key challenge design inhaler ellipta inhaler unusual debate review endorsement asthma copd treatment compound unified view scientific aspect delivery mechanism simple relvarbreo fluticasone furoate asset srb establish view reliable possible patient vilanterol anoro umeclidiminum overall scientific promise asset ensure effectively deliver dose vilanterol store separately development plan deliver asset cost medicine inhaler combine effectiveness clinical plan opportunity store compound risk likely product profile gsk forefront respiratory come contact dose gap evidence miss remain science launch ventolin administer actuate patient uncertain srb view formal year ago year unveil mean medicine position communicate pib new ellipta multidose dry powder inhaler need blend mark generation gsk important governance board require new formulation innovation inhalation device technology investment board tib develop new dual combination make investment decision new ellipta inhaler result separate storage especially platform technology licensing option year design development important combination base collaboration point entry planning involve testing medicine blend physical clinical trial new product supply tailor design base patient chemical interaction medicine nps board govern body experience design easy blend ellipta accountable technical feasibility patient use minimum number potential allow compound infrastructure assessment cover aspect step open inhale close store deliver potentially physical product supply chain new inhale respiratory enable new treatment combination medicine ellipta inhaler recently regulatory governance board launch single inhaler approve deliver relvarbreo lead chief regulatory anoro inhalation product officer operate focus enhance compliance company wide standard increase efficiency regulatory service align capability business need globally locally gsk annual report strategic report deliver vaccine prevention effort vaccine centre discover develop prophylactic therapeutic vaccine protect people infectious disease cancer chronic disorder effort vaccine focus research vaccine divide highlight development new prophylactic earlystage research laterstage therapeutic vaccine stringently development aim identify manage prioritise investment develop vaccine help body raise decision core investment immune response infective million organism newerstage research scientist work diseased cell scientist work new development new vaccine pharmaceutical resource vaccine currently vaccine require length time take discover development range disease develop new vaccine mean essential receive number approval new highly selective indication year page concentrate effort focus key approach vaccine area advance open new expand access new vaccine scientific opportunity consider vaccine development technologies acquisition year likely lead significant medical advance swissbase company okairos example purchase provide access discovery development novel vaccine platform technology discovery development new play important role development vaccine complex process typically new prophylactic vaccine take year new class therapeutic vaccine acquisition bring earlystage asset vaccine discovery begin identify new disease respiratory syncytial virus antigen specific structure hepatitis virus malaria tuberculosis ebola pathogen viruse bacteria parasite hiv cancer cell recognise immune system produce highlight result pathogen yeast bacteria mammalian largescale phase iii trial malaria vaccine cell genetically manipulate candidate rtss demonstrate purify formulate vaccine continue protect young child vaccine antigen create infant clinical malaria month bodys immune response vaccination vaccine research development cycle registration identify produce preclinical proof phase phase phase iii file post marketing antigen antigens test concept surveillance research include immunology preclinical development clinical development include post marketing surveillance transfer process manufacturing year year year year gsk annual report case formulation vaccine clinical lot involve mix antigen proprietary adjuvant system use adjuvant improve immune system response antigen contain vaccine innovate area adjuvant system year candidate vaccine usually combination antigen final composition vaccine antigen adjuvant change time traditionally vaccine prevent illness pioneer different approach design programme bodys immune system fight exist disease represent new treatment model therapeutic vaccine evaluate immunotherapeutic concept variety tumour type read phase iii datum investigational magea antigenspecific cancer immunotherapeutic melanoma science supply chain patient come trial meet coprimary endpoint continue trial second vaccine need keep constant initiative vaccine discovery coprimary endpoint assess result temperature partnership unveil october expect asset manufacture administration brazil fund development lung cancer phase iii coldchain know consider research biomedical technology datum indication read big challenge get potential overcome partnership collaboration vaccine people world significant longstanding barrier scientific partner funding body play particularly hot remote resource vaccine access develop country increasingly important role vaccine limited region overall partnership aim integrate research example collaborative key player vaccine development effort overcome challenge approach new research agreement biotechnology institution pharmaceutical sign early stage research partnership bill melinda gates foundation bmgf company nongovernment organisation bill melinda gates foundation aim accelerate advance vaccine ngo academia drive advance bmgf year million agreement potential transform vaccine potential support research see global health transform global health vaccine effort include lifecycle heat stable reduce need management vaccine market continuous refrigeration anticipate emerge pipeline increase value product bring extend reach adapt ensure meet need patient key decision point board overall view early vaccine development process commit advanced project chair senior governance research decide initiate research vice president discovery development programme commit candidate development vdcb recommendation progress consolidated organisation decide invest resource clinical project submit vib vaccine discovery development team development commit early clinical simplify infrastructure focus timely vib chair president vaccines development commit phase iii registration decision make enhance clarity board make final decision launch accountability continue inv project evaluate vdcb improve efficiency investment oversight key decision rest recommendation alongside public health operational transformation programme body vaccine development benefit business opportunity development commercial board vdcb vaccine cost risk project time overall continue emphasise investment board vib evolution portfolio vaccine importance project team vaccine leadership team responsible vdcb review research project daytoday progress research strategy advise scientific technical development include identify commercial feasibility develop new product skoorb nairdaivag gsk annual report strategic report deliver consumer healthcare product innovation ongoing commitment innovation create new scientifically differentiate product demonstrate contribution global sale product innovation portfolio critical sensodyne repair protect highlight continue grow consumer healthcare oral care innovation continue lead business focus create continual sensitive tooth category introduction pipeline new scientifically differentiate sensodyne repair protect usa product define consumer develop novel nonaqueous stannous healthcare category fluoride formulation oral care team new technology formulation able help consumer deal investment provide product meet need dentin hypersensitivity active ingredient consumer value expert sensodyne repair protect stannous reinforce leadership position particularly fluoride build repair layer area sensitive teeth family nutrition vulnerable area tooth help protect smoking cessation pain instability water oral health product commitment innovation reflect year address stability issue investment million core global sale innovative product incorporate product formulation consumer healthcare sensodyne repair protect provide prove increase overall effective lasting relief twinge sale come innovative product launch sensitivity offer everyday cavity protection recent year key contribution come fluoride niquitin strip womens horlick launch niquitin strip continue success range oral stopsmoke aid strip format horlick indian subcontinent design light smoker patent launch women horlick formula suspend nicotine polymer scientific formulation specifically meet systemwater soluble matrix combine unique nutritional need woman thin format enable dissolve region design include mouth approximately minute clinical daily requirement iron calcium study show effectiveness folate vital nutrient product relieve urge smoke second health drink woman allow consumer benefit fast india complete list macronutrient effective craving relief discrete format recommend world health launch product organization market study human performance gsk human performance lab scientific datum performance lead science facility focus apply result scientist apply research discovery research combine develop new product science expertise external advisor meet anticipate health need cuttingedge technology deepen wide population understand human performance work partnership individual organisation commit elite human performance professional athlete sport govern body sport team extreme explorer able improve understand body brain function drive improvement human performance gsk annual report pipeline progress late stage summary pipeline remain extensive total new molecular entity nme phase iiiii clinical development summary pharmaceutical vaccine phase iii development set comprehensive list medicine vaccine phase iii development available page therapeutic area compound indication phase iii file approve respiratory mepolizumab severe asthma eosinophilic granulomatosis polyangiitis relvarbreo ellipta copd mortality outcome vilanterol fluticasone furoate vilanterol copd fluticasone furoate asthma incruse ellipta umeclidinium copd hyperhidrosis anoro ellipta umeclidinium vilanterol copd relvarbreo ellipta asthma vilanterol fluticasone furoate relvarbreo ellipta copd vilanterol fluticasone furoate paediatric vaccine mmr measle mump rubella prophylaxis mosquirix malaria rtss malaria prophylaxis plasmodium falciparum nimenrix menacwytt neisseria meningitis groups disease prophylaxis vaccine zoster herpe zoster prophylaxis flu pre pandemic prepandemic pandemic influenza prophylaxis flu vaccine seasonal influenza prophylaxis antigenspecific cancer magea immunotherapeutic treatment melanoma immunotherapeutic magea immunotherapeutic treatment nonsmall cell lung cancer hiv dolutegravir abacavir hiv infection fix dose combination sulphate lamivudine tivicay dolutegravir hiv infection oncology arzerra ofatumumab chronic lymphocytic leukaemia use relapse patient arzerra ofatumumab diffuse large cell lymphoma relapse patient arzerra ofatumumab follicular lymphoma refractory relapse patient mekinist trametinib metastatic melanoma adjuvant therapy tafinlar dabrafenib tyverbtykerb lapatinib breast cancer neoadjuvant adjuvant therapy votrient pazopanib renal cell cancer adjuvant therapy arzerra ofatumumab chronic lymphocytic leukaemia line therapy votrient pazopanib ovarian cancer maintenance therapy mekinist trametinib metastatic melanoma mekinist trametinib metastatic melanoma tafinlar dabrafenib revoladepromacta hepatitis induce thrombocytopaenia eltrombopag tafinlar dabrafenib metastatic melanoma tyverbtykerb lapatinib metastatic breast cancer combination trastuzumab cardiovascular darapladib atherosclerosis diabetic macular oedema metabolic eperzan albiglutide type diabetes immunoinflammation benlysta belimumab systemic lupus erythematosus benlysta belimumab vasculitis sirukumab rheumatoid arthritis rare disease adenosine deaminase severe combine immune deficiency adascid mepolizumab eosinophilic granulomatosis polyangiitis severe asthma volibris ambrisentan chronic thromboembolic pulmonary hypertension infectious disease relenza zanamivir influenza dermatology toctino alitretinoin chronic hand eczema duac low dose acne vulgaris inlicence alliance relationship party use brand approve regulatory authority gsk annual report strategic report simplify simplify reduce complexity business remain central element strategy stop waste inefficiency reinvest saving business year implement invest new technology significant restructuring programme streamline different part business include manufacture supply chain transform global manufacturing finance network supply chain efficient well able respond need customer patient progress summary restructure annual saving undertake broad range restructure change programme begin onwards restructure saving simplify area business supply chain finance total ongoing restructure programme deliver annual saving billion expect deliver billion annual saving year year incremental saving ongoing structural programme million safety quality remain priority target manufacture supply organisation transform operation improve service end customer ensure safety sustainability work capital day operation create regional business centre globe bring support function order streamline standardise functional support work capital business day improvement adjust global erp system deployment significant divestment progress european intangible asset pharmaceutical revenue european impairment consumer healthcare revenue system creation establish product portfolio allow well allocate resource new portfolio medicine achieve reduction inefficiency realise opportunity reinvestment gsk annual report proximity production sale oral care product polident poligrip increase project grow significantly come year ongoing effort create streamlined flexible supply chain move manufacture active ingredient poligrip polident factory usa cork ireland ingredient travel mile road product manufacture dungarvan expect produce reduction poligrip cost good reduce carbon emission picture employee dungarvan site ireland production active ingredient cork dramatically increase speed response change customer demand reduce cost production delivery joe power site director cork priority continue restructure simplify business reduce longterm cost base manufacturing continue focus deliver product value optimal cost reduce pack presentation manufacturing defect waste fast track implementation integrate supply chain support enterprise resource planning erp order improve supply service level reduce stock out reduce cost supply chain core business service continue migrate service focus improve service efficiency effectiveness manage establish product portfolio reduce complexity enhance profitability optimise value group product gsk annual report strategic report simplify simplify operating model continue transform operating model reduce cost complexity improve efficiency transformation operating model site country manufacture simplification supply chain process remain key business strategy pharmaceutical consumer healthcare drive great efficiency area include enable standardise streamline product vaccine gms division logistic warehousing procurement important aspect business include responsible site employ portfolio simplification manufacturing supply chain people programme early stage supply pharmaceutical consumer reduce volatility improve restructuring programme continue healthcare product remain site responsiveness allow well inventory contribute support delivery employ staff run management deliver significant saving saving vaccine business million benefit pharmaceutical available reinveste priority supply chain growth business new product launch continue review network return shareholder seek opportunity optimise operation reduce complexity close small portfolio exist product restructure progress manufacturing site singapore usa discontinue unprofitable pack begin operational excellence mexico sell coleford site standardise pack presentation format restructure programme divestment lucozade improve operational efficiency programme remain track deliver ribena brand announce ensure patient customer need meet billion annual saving site leave network case study opposite year complete integration human reach target discontinuation programme come genome science manufacturing site year end remain target achieve close announce new major change usa acquire demiclen consumer reduction pack portfolio programme focus improve supply healthcare manufacturing facility slovakia fouryear period chain process build capability support growth manufacture restructure core business service european business programme invest manufacturing network early stage remain track year commitment total core business services cbs group deliver billion annual saving million announce set bring support restructure programme key centre india function include facility management produce annual saving billion implement improvement technological finance procurement centralise advance manufacturing process team streamline standardise addition programme begin operation aim increase productivity separate structural initiative supply chain progress free time business reshape longterm operating expense focus execution business strategy gm align organisationally liability produce reduction local market reduce number new model responsibility entire approximately million longterm global support staff pharmaceutical consumer healthcare employment cost restructure supply chain supplier invest global enterprise postemployment medical benefit delivery customer create fully resource planning erp system benefit million integrate supply chain play important role reduce cost restructure pension obligation improve service level reduce work consumer healthcare take ongoing structural initiative capital manufacturing supply chain business reform simplify deliver incremental commercial operation rollout erp supply chain model implement yearonyear saving million time budget endtoend chain deliver similar expect help million saving begin follow positive start offset mix pressure fund ongoing create great operating flexibility allow progress investment requirement deliver product customer enrol european pharmaceutical continue integration quickly efficiently vaccine market commercial erp human genome science business system european pharmaceutical transfer learning restructuring benefit revenue consumer pharmaceutical million healthcare revenue system manufacturing operation create supply chain structure align supplier complete advance deployment global manufacture supply delivery customer forecasting planning element global manufacturing supply erp system market latin america gms division focus deliver vaccine supply chain gsk business region forecast transformational plan enable implement endtoend transformation plan system datum manufacture supply new programme improve customer service standard enable consolidation product portfolio exist product reduce inventory leadtime reduction reporting business analysis consistently high quality improve forecast accuracy increase efficiency key priority implementation endtoend inventory management new sale operational planning process underway finalise end gsk annual report cut variation drive enhance productivity beginning conduct result able discontinue initiative particularly important audit identify manufacturing imigran pack format establish product portfolio epp group make migraine treatment expect cut epp comprise product imigran different pack achieve cost reduction brand generic business vary size quantity tablet change total supply medicine local product different pack format require unique discontinuing popular pack annual sale billion manufacturing process mean format resource ensure product long promote pack format great continue meet demand important operating cost cost complexity manufacture popular imigran pack process product simplify far possible allow focus bid reduce cost look reduction pack format new product launch product way simplify number pack format product overall great growth potential involved review imigran global initiative start pack listen patient find reduce number pack pack format like well discontinue pack format aim cut overall number pack format end accelerate deployment umbrella cbs improve forecasting planning process conduct number target programme group enable erp simplify business cost result reduction supply chain operate example introduction new cost reduce inventory level improve global platform run standard enterprise forecasting roll expect wide process reduce number complete mid individual business application see organisation decommission application key element cbs approach begin total creation regional multifunctional business service centre focus develop global category strategy deliver robust effective service begin standardise material market site region specification remove complexity open centre costa rica supply base usa complement start implement people kuala lumpur poland begin management element system globally operation global network end gsk agency foundation standardise continuously employees canada latin america improve support service offer system business unit centralise model improve process efficiency effectiveness free time business focus execution business strategy local market gsk annual report strategic report financial architecture financial architecture financial architecture design support execution strategy enhance return shareholder gsk financial architecture focus million contribution structural earning share key priority deliver sustainable benefit relate saving significant progress improve sale growth improve operate leverage longterm employment cost financial efficiency improve financial efficiency convert restructure postemployment medical continue share buyback programme enable earning cash benefit approximately million low deliver core eps financial architecture design restructure pension end eps guidance range ensure maximise return obligation sustainable sale growth remain focused managing cost expect deliver core eps continue simplify business allocate base effectively operational growth cer turnover growth resource efficiently flexibly excellence programme initiate cer exdivestment basis build leverage drive remain track deliver annual saving eps base turnover base earning share fast sale billion addition new billion turn convert earning cash major change programme announce reinvest business return track deliver pretax saving cash conversion shareholder return look billion business remain highly cashgenerative attractive continue balance cost saving continue focus improve apply architecture consistently continue investment business conversion earning cash drive well consistent support new launch pipeline great focus cash generation capital decision make company key driver future sale allocation particular focus work capital allocation decision growth increase contribution capital continue rigorously benchmarke cash flow pipeline sale onwards remain progress exclude distort impact return investment cfroi framework confident drive improvement disposal intangible writeoff core operate margin medium term reduce work capital conversion cycle sale growth day report sale grow billion financial efficiency cash basis deliver additional exclude impact product disposal despite pressure operate margin million saving despite renew growth sale grow business financial efficiency deliver business need start respiratory oncology vaccine viiv significant value year build inventory new launch healthcare consumer healthcare contribute positive leverage report develop endtoend supply chain account sale core earning share eps join manufacture commercial grow cer financial efficiency gain business increase visibility accountability expect deliver sale growth take advantage era low flexibility reduce inventory cer exclude product divest interest rate secure attractive required release cash longterm funding rate lose operate leverage flexibility overall reduce net funding return shareholder core operating profit flat cer cost percentage point free cash flow available invest report basis core operating margin maintain target credit rating business return shareholder decline percentage point preserve access shortterm consistent protect credit profile relate negative impact currency capital market priority cover dividend free operating margin benefit reduce cash flow requirement continue align tax strategy cost high royalty receipt offset available share buyback bolton future business profile expect upward pressure cost sale acquisition attractive implement number measure unwind cost manufacturing return available centralise pharmaceutical intellectual volume shortfall adverse mix impact property product inventory ownership decision allocate prepare launch new pipeline allow reduce cash flow rigorously benchmarke product group continue restructure core tax rate returnsbase framework base cfroi programme contribute incremental yearon ahead expectation comparison year saving million beginning year continue expect ongoing structural initiative return billion cash improvement tax rate especially shareholder pay billion dividend new product come ordinary dividend benefit newly introduce patent share addition buy billion box arrangement core tax share longterm programme rate expect start expect deliver continue dividend growth currently target share repurchase billion gsk annual report financial architecture drive improve return focus return sale growth eps return shareholder operate free cash leverage flow financial efficiency cash flow growth measurement report january group report establish product portfolio tail brand sale total billion billion exclude divestment separate segment set segment bring great focus optimise value particular profit cash group product realise attractive value effort consider divestment gsk annual report strategic report responsible business responsible business responsible business central strategy mission deliver success important achieve operating responsibly ensure value transparency clinical research embed culture decisionmake modernise commercial practice way help well meet expectation society interact customer pass significant milestone development continue bold step modify potential vaccine malaria business model specifically progress drive access medicine continue invest people poor country take action increase work hard reduce environmental footprint progress summary good progress announce plan evolve way sell forwardlooke commitment announce market product healthcare professional commitment report align company activitie area aim address unmet global interest patient health need align strategic priority value people begin rollout preventative healthcare health benefit partnership prevention increase volume medicine supply programme available employee develop country family worldwide achieve major milestone development launch new performance management system malaria vaccine candidate rtss lead well link employee reward value submit regulatory file vaccine available notforprofit price subsaharan africa planet form innovative new partnership save scope carbon emission child help save life million child operation grow slightly year decline company award global behaviour certification carbon trust water standard pharmaceutical company enable recognition yearonyear reduction external researcher access detailed anonymised operational water use globally patientlevel datum clinical trial new online system gsk annual report malaria milestone year malaria kill estimate people quarter death occur child malaria parasite endemic subsaharan africa plasmodium falciparum type malaria acute infection rapidly lifethreatene work partnership carry research vaccine fight malaria year achieve major milestone development world vaccine falciparum phase iii datum show vaccine halve number case young child aged month vaccination month vaccination base datum previous study plan submit regulatory application european medicine agency vaccine available early nahya picture paediatrician involve rtss malaria vaccine trial ifakara health institute tanzania hope malaria vaccine help child help reduce burden malaria disease ahya salim paediatrician research scientist tanzania africa reference world health organization fact sheet world malaria report december httpwwwwhointmalariamediaworldmalaria reportenindexhtml wellcome trust plasmodium falciparum httpmalariawellcomeacukdocwtdhtml priority continue challenge business model level ensure respond need patient meet wide expectation society year begin twoyear process end practice pay health care professional speak behalf help patient interest gsk annual report ssttrraatteeggiicc rreeppoorrtt rreessppoonnssiibbllee bbuussiinneessss responsible business approach conduct business important financial result achieve strive value heart decision meet exceed expectation society commercial success directly link improve access employ innovative significant contribution operate responsible way report funding mechanism use flexible pricing elimination lymphatic filariasis approach progress make approach base countrys wealth control soiltransmitte helminth intestinal area ability pay develop country worm donation albendazole market access dcma operating unit tablet ship million health seeks increase patient access tablet bring total donate behaviour medicine vaccine million billion tablet people develop country people research new treatment ldc define united nations planet disease sleep sickness dcma unit establish chagas disease visceral leishmaniasis develop longerterm volume medicine supply ldc commitment area increase million unit approximately malariarelate reflect global health need million death report year gsk align strategic priority commit tackle disease value transparency respect people price patent medicine invest million development integrity patient focus ldc cap quarter malaria vaccine candidate rtss include develop world price collaboration path malaria vaccine year report progress reinveste profit initiative support bill melinda commitment ldc local healthcare capacity gate foundation year clinical trial corporate responsibility report available building project country report datum vaccine gskcomresponsibility amount million intend submit regulatory follow page provide overview reinveste million application develop approach aim establish offpatent tafenoquine treatment relapse prevention vivax malaria product available develop country health catch programme remain committed support world programme seek approval health organization objective eradicate mission improve quality human medicine market polio completely provide vaccine life enable people feel well receive approval product unicef provide million live long main way dose oral polio vaccine global polio vaccine tiere pricing model develop new medicine vaccine eradication initiative year update consumer product increase access approach well align country ability product need innovative science create pay welloff country work regardless ability pay value closely gavi unicef improve time need generate return access vaccine organisation approach include strategy sustainable business invest purchase large volume vaccine open innovation disease research new treatment tomorrow world poor child benefit develop world seeks stimulate achieve evolve low price innovation enhance productivity business model implement novel research process research aim responsible approach approach flexible pricing structure transform approach intellectual pricing market important price accelerate innovation property external partnership reflect value medicine bring patient process open research finding mindful burden current open innovation model resource work new healthcare cost example price focus disease develop world way partner newly launch product explore way extend price currently available despite model solve significant health access healthcare positively differentiate profile example challenge traditional business commit improve access usa launch tafinlar braf model inadequate include antimicrobial patient need product irrespective inhibitor year price resistance noncommunicable disease ability pay focus product low exist braf inhibitor alzheimer disease affordability availability invest early join accelerate strong healthcare system develop disease develop world medicine partnership amp new country neglect tropical disease ntds like leprosy partnership national institutes intestinal worm affect billion people health nih pharmaceutical company world vulnerable community nonprofit organisation goal lead member london declaration amp transform current model gsk working bill melinda gate develop new diagnostic treatment foundation pharmaceutical challenge disease area data company control eliminate generate available broad biomedical ntds affect billion people community participate provide fund alzheimer pilot gsk annual report programme support believe share research context concern financial give finding positive negative disappointed allegation fraudulent stimulate innovation help build behaviour china business exist research aim take matter extremely seriously accelerate drugdevelopment process cooperate fully chinese authority produce new medicine patient take number action include commission independent report health wellbee international legal firm rope gray community extensive experience anticorruption commit improve health international risk wellbee community support programme improve healthcare commit learning lesson infrastructure enhance science health require result chinese education assist humanitarian relief investigation appropriate step necessary outcome gsk donate medicine value remain fully commit china support million cost million cash government healthcare reform health wellbee product donation worth million supply product patient education provide partner americare direct relief world health map international simplified policy underpin project hope humanitarian aid code conduct complete annual partner distribute donate medicine business certification programme ethical country include provide leadership certification require manager give supply antibiotic basic medicine designate employee certify affect conflict natural awareness understand compliance disaster include earthquake pakistan gsk value policy typhoon philippine designate employee complete tornadoes usa certification process gsk annual impact award continue support guide principle channel million business human right endorse outstanding healthcare charity united nations human rights council usa past year recognition principle undertake systemic assessment identify human right impact behaviour prioritise seven area examine gsk policy process aim interest patient update gsk human right statement consumer decision base finding assessment guide value transparency ccaasshh million respect people integrity patient focus research practice pprroodduucct andn din inkinkdi million policy guidance code time million conduct place people partner seek ensure research practice tmimaneagement million supplier meet high ethical standard patient safety management remain priority live value principle clinical trial conduct accordance ethical conduct priority gsk need good clinical practice gcp guideline operate integrity world employee complete training gcp interaction patient prescriber payer undertake role relate gsk government live value sponsor clinical research failure uphold high ethical standard gcprelate training activity impact company success conduct clinicalquality assurance assessment zero tolerance approach bribery corruption apply gsk addition conduct investigation party act behalf suspect irregularity take corrective company action appropriate independent regulatory authority perform inspection gsk site investigator conduct clinical trial gsk annual report strategic report responsible business responsible business continue build longstanding begin programme strengthen dedicated medical commitment clinical trial transparency modify nearly package line scientific capability appropriately lead facilitate research help manufacture site internationally allow engagement hcp improve advance medical science improve patient provide unique serial number nearly multichannel capability include use digital care launch online system enable stock keeping unit technology ensure appropriate product researcher request access detailed disease area information provide greatly value relationship anonymise patientlevel datum clinical hcp conveniently finally support supplier understand trial begin publish clinical study fair balanced objective medical education pressure cash flow financing face report csr medicine hcp provision independent small company follow change approve terminate development educational grant standard payment term supplier extend formation gsk usa offer review continue offer appropriate fee start commonly payment term small supplier identify hcp provide service gsk prescribed medicine support micro small medium size enterprise sponsor clinical research advisory activity alltrial campaign call report europe diverse supplier usa market research activity method result trial offer range supply chain finance essential provide insight specific earlystage research use number option supplier disease identification symptom method drug discovery work include diagnosis application clinical trial datum company take case research involve animal medication dosage administration opportunity plan use alternative animal effectively appropriately increase communication study animal research communicate benefit risk small supplier aware method demonstrate medicine help meet patient need support available effect potential new medicine living body test human sale marketing integrity people animal research commit act ethically practise good animal gsk important role play support people essential success welfare minimise number animal education healthcare professional hcps focus build individual capability number animal provide accurate information aim support empower decline low medicine help good good animal research include treatment decision patient research carry contractor mouse announce plan evolve way talent leadership development animal use non interact hcp align activity human primate interest patient aim attract retain talented people invest training implement new compensation development tailor individual manufacture supply system apply gsk sale need recognise potential efficient responsible manufacturing employee detail prescription product employee supply key gsk expect supplier prescribe healthcare professional uphold high standard set mean sale professional evaluate leader complete base code reward technical knowledge lead delivery programme help conduct quality service deliver middlelevel manager translate strategic support improve patient care overall ambition business meaningful conduct audits governance risk performance business replace action enrol leader management environmental health individual sale target lead business design safety sustainability issue subset develop capability manage supplier identify critical follow success action business function people supply chain usa decouple reward sale new management position launch representative number prescription gsk member pharmaceutical management essential teach basic issue focus instead demonstration supply chain initiative psci audits management skill value patient supplier labour practice year continue support environment health safety performance addition intend phase practice entrylevel student internship pay hcp speak behalf move endtoend supply chain operate industrial placement apprenticeship product disease area audience model pharmaceutical consumer graduate scheme increase prescribe influence prescribe healthcare product standardise graduate intake improve control entire supply chain work implement change aim recruit graduate effectively line local law year continue address regulation global business problem counterfeit effective coach global focus start measure initially adopt china reach leader country use serial number product package coach programme enable electronic monitoring purpose strengthen leadership capability patient safety gsk annual report pulse volunteer partnership programme give employee opportunity work fulltime month non profit organisation charity help address global healthcare challenge develop leadership skill employee volunteer organisation include save child new global partnership charity inclusion diversity focus enable gender diversity management senior role introduce targeted individual group coach sponsorship emerge diverse talent invite employee join dialogue session discuss address hide barrier hinder gender diversity end global workforce male female percentage woman management continue rise woman management position partnership save child help save million life svp director aim help save life million lifesave project manager child partnership reformulation chlorhexidine antiseptic total save child combine find corsodyl mouthwash capability ontheground gel umbilical cord cleansing prevent woman represent corporate expertise bring muchneede infection newborn executive team exceed medicine vaccine goal achieve female board register childfriendly world poor child train thousand representation female nonexecutive powderbase antibiotic drc help healthcare worker seek alleviate director board fight pneumonia big killer child malnutrition rank joint female ftse child intervention board report study womens new partnership build recommend representation board uks collaboration save child report commission lifesave company past year include commodity reinvestment programme employee gender number develop country team save child award million recognition africa malaria partnership male female total healthcare innovation originate board invest million develop world design reduce infant initiative encourage employee mortality award split management contribute million year fund organisation large total employee raise establish signature portion award friend sick programme demonstrate intervention children malawi development management senior manager define democratic republic congo drc lowcost device help newborn company act strategic report kenya joint paediatric board infant breathe director report regulation include person responsible planning directing look new repurpose product control activity company tackle cause newborn strategically significant company infant death board include director undertaking include consolidated account nerdlihc eht evassogob assile gsk annual report strategic report responsible business responsible business continue make sure people disability access career opportunity capture set standard talent global focus employee healthcare establish global disability council gsk agree priority area improve opportunity disabled people develop objective drive disability agenda forward put value practice monitor report progress offer competitive benefit package rich cultural diversity employee include preventive healthcare key strength help meet diverse employee family need patient healthcare provider partnership prevention country operate staff programme offer eligible employee base emerge market asia pacific family member access japan region represent preventive health service little cost total workforce nationality available employee represent corporate executive team gsk date benefit board place employee family monitor benchmark proportion member country ethnic minority workforce pilot run industry average national population focus encourage employee country usa exercise improve diet engage group represent diverse develop global physical fitness community programme launch engage people ceo member corporate executive team deliver live broadcast health safety wellbee energy performance programme help message employee update company progress strategy progressive healthcare company employee remain focused energised commitment believe help employee healthy productive end resilient productive priority bring employee country participate frequent global employee survey help mission life people energy resilience training understand performance employer take step address achieve goal zero harm employee employee assistance programme offer issue identify survey complete focus prevent incident advice information counselling focus training leader occur training activity confidential helpline website well coach support employee focus key risk driver safety available employee change well recognise individual machineryrelate incident contribution incident injury illness performance reward recognition rate hour incentivise behaviour consistent introduce interim survey work value priority way evaluate individual business unit function underreported working recognise reward performance cover employee result include datum number commercial announce new performance system show business operation business unit come effect system significant improvement team leader design ensure employee understand effectiveness priority area improvement work increase report near expect help base survey result miss incident well understand connect contribution delivery event occur share gsk employee enthusiastic knowledge business help strategy reward participant orange day volunteer prevent incident result senior people disincentivise programme give staff pay day report event unethical working practice clawback year purpose increase mechanism allow recover challenge employee world performancerelate pay work raise million expand network health year year save child safety coordinator sure safety commit support health programme track expand wellbee employee driver safety programme continent family year begin phase global preventive healthcare continue implement risk reduction initiative partnership prevention initiative improve process safety programme set standard manufacturing prevent employee healthcare event fire explosion release hazardous substance gsk annual report planet carbon emission tonne coe ensure continue deliver high quality product patient consumer scope emission future protect natural scope emission resource need today total scope emission carbon set ambitious target achieve carbonneutral value chain intensity ratio operational emission remain low sale revenue baseline engage employee supplier customer scope tonne coe sale address carbon emission value revenue million chain source raw material fte transport use disposal product scope tonne coefte carbon footprint analyse product target effective reduction scope scope carbon emission calculate accord greenhouse gas protocol corporate accounting reporting standard revise edition table certify scope carbon emission carbon trust carbon standard certifie make yearonyear overall reduction operation grow slightly emission associate operation transport apply recertification decline emission materially important carbon reduction strategy investment start deliver carbon emission reduction carbon emission name cdp performance instal equipment site table scope emission refer direct leadership indice global leader ware dismantle spend respiratory inhaler greenhouse gas emission include burn tackle carbon emission recycle component fuel energy emission sale force transparent reporting repeat survey supplier car emission manufacture meter packaging leaflet paper dose inhaler process emission water information help purchase manufacturing operation waste achieve reduction decision treatment scope emission include indirect water use previous year keep greenhouse gas emission consumption track meet target cut impact purchase electricity heat steam operational water use manage range important scope emission exclude raw baseline issue reduce environmental impact material increase map water usage value example use green chemistry value chain strong sale hfa chain identify production aim reduce use hazardous chemical propellantbase inhaler increase raw material use account process drug development scope emission estimate total water footprint replace low indirect emission include operation represent environmental impact scope embed carbon dioxide purchase raw material propellant company green chemistry performance unit release patient use dispose award global certification carbon establish research way meter dose inhaler business trusts water standard replace hazardous unsustainable chemical travel air logistic assessment carbon trust audit site well alternative usa india materially important emission support research sustainable chemistry emission use meter dose invest new centre excellence waste inhaler detail value chain green chemistry university carbon footprint performance datum publish generate waste nottingham pledge corporate responsibility report result business growth annual funding second centre reduce waste compare excellence sustainable chemistry important achievement include baseline total waste paulo brazil singapore well continue carbon reduction send landfill site fund research green sustainable award carbon trust year achieve zero waste landfill manufacturing partnership onyear overall reduction emission aim halve singapore economic development board operational waste compare collaborate launch tool help zero waste landfill company calculate carbon footprint tablet medicine distribute blister pack gsk annual report strategic report financial review financial review financial review summarise performance group year comparison result previous year financial review set balance sheet position group december group performance major restructuring cost charge work capital conversion cycle arrive operating profit include cost work capital conversion cycle financial review discusses operate arise operational excellence calculate number day sale financial performance group restructure programme initiate outstanding plus day inventory outstanding financial outlook financial resource expand day purchase outstanding compare result year major change restructure programme primarily result precede year initiate restructuring cost cer growth cer basis review follow acquisition human order illustrate underlying performance discuss result core basis genome sciences inc august practice discuss result total basis stiefel laboratory inc july term constant exchange rate cer growth rate include report reconciliation core result total growth represent growth calculate constant exchange rate cer result present exchange rate determine state cer growth result overseas company core result report align business discuss sterling remain unchanged performance report previous year cer use number adjust measure underlie trading performance represent growth constant exchange report performance business group primary growth driver rate represent growth actual measure management remove volatility inherent exchange rate plan reporting purpose noncore item discussion presentation core result report utilise restatement comparative investment analyst rate agency basis internal performance report information define measure core result present set note financial define ifrs comparable discuss financial review statement presentation financial similarly describe measure believe approach provide investor statement amendment ia company clear view underlie trading employee benefit implement core result report performance group believe year effect reduce approach group total operating profit core result exclude follow item result comparable majority million million total result amortisation peer use similar million comparative information impairment intangible asset exclude form underlie performance report restate accordingly computer software goodwill major discuss result precise restructuring cost include cost calculation differ financial review follow material acquisition legal charge present discuss total result net insurance recovery expense group settlement litigation government investigation operate free cash flow income royalty income disposal free cash flow net cash inflow associate product business operate activity capital expenditure acquisition accounting adjustment interest dividend pay non material acquisition control interest plus proceed tax effect item sale property plant equipment dividend receive joint venture associate undertaking free cash flow growth calculate sterling basis reconciliation present gsk annual report financial review group turnover segment group turnover business restate growth growth cer restate growth growth pharmaceutical vaccine cer pharmaceuticals europe vaccine emap pharmaceutical japan vaccines viiv healthcare consumer healthcare trading unallocate represent growth constant exchange rate represent pharmaceutical growth actual exchange rate vaccine total group turnover million consumer healthcare exclude impact disposal primarily conclusion vesicare copromotion agreement pharmaceutical vaccine turnover noncore otc brand divest turnover grow grow exclude impact conclusion vesicare pharmaceutical vaccine turnover grow exclude copromotion agreement pharmaceutical turnover disposal grow pharmaceutical turnover grow exclude vesicare grow sale respiratory exclude disposal grow growth japan product grow million lead growth advair emap partially offset continue pricing pressure performance include benefit favourable stocking generic competition europe viiv healthcare turnover pattern fourth quarter oncology product perform flat vaccine turnover grow despite adverse grow million lead strong performance comparison strong cervarix sale japan exclude votrient promacta initial impact launch cervarix japan vaccine sale grew reflect strong tafinlar mekinist monotherapie year gain growth infanrixpediarix boostrix partially offset impact generic competition lamictal benefit competitor supply issue fluarixflulaval number dermatology product increase benefit launch new quadrivalent formulation vaccine sale primarily result increase infanrix well performance business europe consumer pediarix boostrix sale benefit competitor healthcare turnover increase million exclude supply shortage fluarixflulaval sale strong follow noncore otc brand divest turnover grow launch quadrivalent flu formulation group turnover geographic region europe pharmaceutical vaccine turnover million flat compare benefit recent restructuring refocusing business offset continue pricing restate growth growth pressure generic competition number product cer pharmaceutical sale million seretide sale decline volume decline flat pricing oncology europe product particularly votrient promacta perform emap avodart growth product offset japan low sale number old product particularly impact continue pricing measure generic competition vaccine sale grow largely improve tender performance group sale outside usa europe account total turnover report growth adversely impact sale decline china gsk annual report strategic report financial review emap pharmaceutical vaccine turnover respiratory million adversely affect ongoing respiratory sale grow million investigation china pharmaceuticals million europe emap japan vaccines million china pharmaceutical seretideadvair sale million largely drive vaccine sale drive primarily decline strong performance flixotideflovent sale increase respiratory hepatitis product exclude china emap million ventolin sale grow million xyzal pharmaceutical vaccine sale grow drive sale exclusively japan grow million pharmaceutical growth middle eastafrica latin america reflect strong allergy season south east asia partially offset decline india korea respiratory sale grow advair vaccine sale million exclude million compare estimate underlying growth china reflect strong tender performance cervarix year volume decline offset positive infanrixpediarix partially offset tough comparison impact price mix flovent sale million estimate underlying growth year volume japan pharmaceutical vaccine turnover grow decrease offset positive impact price mix ventolin million growth pharmaceutical sale partially offset grow million estimate underlying growth decline vaccine sale strong growth respiratory drive improve price realisation half year product relenza avodart lamictal partly launch breo ellipta begin million sale offset generic competition paxil sale vaccine sale primarily record quarter reflect impact cervarix suspension european respiratory sale reflect increase recommendation use hpv vaccine japan competition market seretide sale second half adverse comparison million volume decrease net impact benefit final stage catchup hpv vaccination price mix serevent flovent sale programme respectively viiv healthcare turnover flat million growth respiratory sale emap grow exclude china lead generate epzicom selzentry introduction seretide grow million exclude china tivicay offset impact continue competition old seretide continue deliver strong growth emap product market veramyst grow million ventolin increase consumer healthcare turnover exclude noncore otc brand million divest grow growth category japan respiratory sale grow million strong growth europe primarily arise growth xyzal veramyst adoair sale grow specialist oral health include sensodyne denture care million relvar ellipta launch december restock alli stock rest record sale million world turnover grow strong growth india middle east latin america partly offset decline sale china drive antiviral impact shelve restriction contac mandatory decrease sale antiviral reflect decline zeffix price reduction fenbid report consumer healthcare turnover hepsera china partially offset tender shipment relenza grow million japan pharmaceutical turnover central nervous system cns seroxatpaxil sale fall million primarily generic restate growth growth competition japan europe requip sale fall cer million reflect generic competition europe respiratory lamictal sale fall million primarily result generic antiviral competition lamictal start central nervous system sale lamictal franchise fall million cardiovascular urogenital cardiovascular urogenital metabolic sale category fall primarily result impact antibacterial conclusion vesicare copromotion agreement oncology emesis exclude vesicare sale decline dermatology rare disease avodart franchise grow million growth sale duodartjalyn avodart sale grow million immunoinflammation pharmaceutical lovaza fall million result increase competition viiv healthcare hiv decline nonstatin dyslipidemia prescription market arixtra sale fall million gsk annual report metabolic rare disease increase metabolic product sale primarily reflect high volibris million mepron million sale prolia europe emap main driver growth category flolan sale fall million primarily result biennial price antibacterial reduction japan continued generic competition augmentin sale grow million strong growth europe emap reflect comparison supply interruption zinnat sale flat million immunoinflammation zinacef sale fall million benlysta turnover year million million total inmarket sale benlysta oncology emesis million oncology emesis sale grow million mark second consecutive year double digit percentage growth viiv healthcare hiv business sale strong performance viiv healthcare sale million flat sale votrient promacta arzerra contribution europe emap epzicom launch new metastatic melanoma product tafinlar kivexa sale increase million selzentry mekinist sales europe grow emap grow votrient million tivicay record sale million sale grow million promacta sale grow early stage launch start august million arzerra sale grow million tykerb tivicay approve europe january launch tyverb sale fall million increase competition plan market growth contribution hycamtin europe emap argatroban business offset decline mature portion continue adversely affect generic competition portfolio mainly combivir million continue strong growth contribution vaccine turnover votrient million promacta million benefit new indication growth growth thrombocytopenia associate hepatitis receive cer arzerra grow million performance vaccine sale reflect contribution totalling million tafinlar mekinist launch monotherapy treatment performance vaccine business improve end achieve strong uptake braf melanoma market year significant increase tender sale quarter month market january tafinlar increase vaccine sale principally attributable mekinist approve fda combination use growth infanrixpediarix fluarixflulaval boostrix largely offset decline cervarix japan reflect europe sale grow million lead sale votrient suspension recommendation use hpv vaccine increase million continue build japan adverse comparison strong cervarix market share market revolade receive approval europe sale benefit final stage hpv use thrombocytopenia associate hepatitis end vaccination catchup programme japan cervarix sale decline sale year increase million million exclude cervarix japan vaccine sale tafinlar launch certain market increase achieve strong uptake early launch market infanrixpediarix sale increase million growth emap sale grow million lead strong growth primarily reflect strong tender shipment europe emap votrient million promacta benefit competitor supply shortage million region tykerb million boostrix sale benefit competitor supply issue hycamtin million grow million dermatology sale hepatitis vaccine fall million primarily reflect sale decline million primarily result decline low sale result return compete vaccine million continue suffer market second half declines impact generic competition particularly bactroban duac europe china soriatane effect disposal number synflorix sale increase million help strong tail brand emap sale grow million tender sale middle eastafrica latin america reflect strong growth bactroban dermovate duac particularly middle eastafrica latin america european rotarix sale grow million strong growth middle sale grow million eastafrica europe partially offset impact increase competition japan fluarixflulaval sale increase million follow launch quadrivalent formulation gsk annual report strategic report financial review sale new pharmaceutical vaccine launch consumer healthcare turnover growth growth cer restate growth growth cer pharmaceutical total wellness arzerra oral care benlysta nutrition duodartjalyn skin health lamictal mekinist potigatrobalt prolia restate growth growth relvarbreo ellipta cer tafinlar usa tivicay europe votrient row xgeva dermatology consumer healthcare turnover grow year exclude noncore otc brand divest turnover grow vaccine reflect overall growth region synflorix nimenrix total wellness total wellness sale exclude noncore otc brand divest grow europe alli new product launch year report strong growth large stock inclusive sale new product million severe cold flu season early help grow year represent pharmaceutical drive growth respiratory brand include coldrex vaccine turnover sale new product beecham panadol cold flu growth partly offset million grow represent pharmaceutical reduction sale china contac new shelving vaccine turnover requirement fenbid advance mandatory price tafinlar mekinist metastatic melanoma approve reduction launch tivicay treatment hiv patient approve launch oral care tafinlar grant approval launch europe strong growth oral care sale lead growth specialist breo ellipta launch copd relvar oral health sensodyne sensitivity acid erosion ellipta grant approval europe copd asthma denture care brand aquafresh launch addition launch activity currently underway anoro ellipta approve nutrition treatment copd december nutrition sale grow strong growth rest world market lead horlick boost india key expansion market subcontinent lucozade grow ribena grow skin health skin health sale grew lead abreva regional performance exclude noncore otc product divest sale grew lead strong contribution oral care brand alli abreva partially offset decline gastrointestinal product reflect increase competitor activity smoking control product impact supply disruption europe sale grow help sale alli strong growth product respiratory health pain oral care sale europe flat strong growth sensodyne denture care brand offset decline aquafresh supply issue rest world market grow reflect growth category market particularly india partially offset reduction sale china mainly reduction sale contac fenbid gsk annual report core result table analyse core expenditure category use core reporting basis manage performance group definition core result set restate review group total result set page reconciliation total result core result present discovery development facility central support function cost sale pharmaceutical vaccine restate growth consumer healthcare turnover turnover cer core cost sale proportion pharmaceutical investment core cost sale turnover compare latestage portfolio decrease pharmaceutical net currency effect percentage point cost impact percentage point reduction cost sale percentage settlement early royalty agreement royalty income conclusion vesicare agreement cost sale royalty income million million include percentage increase percentage point reflect prior year royalty catchup adjustment record early expect impact unwind cost manufacturing volume core operating profit shortfall adverse mix impact prepare launch new pipeline product partially offset ongoing cost management well price realisation restructuring benefit restate growth sell general administration turnover turnover cer core operating profit restate growth core operate profit million flat cer term turnover increase core operate margin turnover turnover cer percentage point lower exclude currency sell general effect margin decline percentage point reflect administration negative impact expect increase cost sale partially core sga cost percentage sale flat offset high royalty income low expenditure net favourable yearonyear benefit group group continue restructure programme contribute restructure programme ongoing cost management effort incremental yearonyear saving million fund investment growth business preparation new ongoing structural initiative product launch contribution structural benefit approximately advertising promotion expense decrease sell million low total saving realise change distribution decrease general administration increase postretirement medical obligation approximately million group realise million saving research development cap future pensionable salary increase change basis future discretionary pension increase rpi cpi restate growth certain legacy plan turnover turnover cer research development core expenditure decline million turnover compare million turnover reflect completion number large trial phase ongoing project spend continue cost management remain focused deliver improve return investment sale contribution reduce attrition cost reduction important driver improve internal rate return expenditure determine percentage sale instead capital allocate strict return base criterion operation pharmaceutical broadly split discovery activity completion phase iia trial development work phase iib onwards gsk annual report strategic report financial review core operate profit business net finance cost restate growth finance income margin margin interest income cer fair value movement pharmaceutical vaccine pharmaceuticals finance expense vaccine interest expense consumer healthcare unwind discount liability remeasurement fair value movement corporate finance expense unallocated cost core operating profit core net finance expense million compare core operating profit segment million despite high average net debt level year largely drive continue share repurchase restate growth dividend shareholder reflect strategy improve fund profile group net debt december turnover turnover cer billion low december reflect receipt pharmaceutical billion disposal business intangible asset vaccine aspen share investment realise largely end usa year europe emap share tax profit associate joint venture japan share tax profit associate million viiv healthcare million principally arise group hold pharmaceutical aspen pharmacare trading core profit taxation unallocated pharmaceutical restate growth pharmaceutical vaccine turnover turnover cer core profit tax consumer healthcare taxation corporate tax core profit amount million include unallocated cost recognition credit reflect effective core tax core operate profit rate continue believe adequate provision liability likely arise period open agree tax authority ultimate liability matter vary amount provide dependent outcome agreement relevant tax authority litigation core earning share core eps increase cer term actual exchange rate dividend board declare interim dividend result dividend year pence pence increase dividend note financial statement dividend gsk annual report core result reconciliation december acquisition core intangible intangible major legal accounting total result amortisation impairment restructuring charge result turnover cost sale gross profit sell general administration research development royalty income operating income operating profit net finance cost profit disposal interest associate joint venture share tax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share weight average number share million core result reconciliation december restate acquisition core intangible intangible major legal accounting total result amortisation impairment restructuring charge result turnover cost sale gross profit sell general administration research development royalty income operating income operating profit net finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share weight average number share million gsk annual report strategic report financial review total result operate income operate income million million restate growth include profit disposal lucozade ribena business anticoagulant product million turnover turnover cer income include gain profit disposal noncore turnover otc brand million gain million arise cost sale revaluation preexisting collaboration hgs sell general viiv healthcareshionogi joint venture acquisition administration operate profit research development total operating profit million compare royalty income million noncore item result total net operating charge million million income intangible asset amortisation million million operating profit include million relate amortisation benlysta net finance cost intangible asset acquire hgs acquisition late profit disposal intangible asset impairment million million interest associate include writeoff asset partial impairment lovaza reflect reassessment group share tax expectation likelihood potential generic competition profit associate joint venture major restructuring charge million million profit taxation comprise million operational excellence programme million major change programme taxation million relate acquisition hgs total profit taxation year operational excellence programme initiate total profit attributable expansion expect cost approximately shareholder billion expect deliver annual pretax saving approximately billion end earning share earning ad major change programme focus opportunity simplify supply chain process build group capability manufacture restructure european pharmaceutical business cost sale programme expect cost billion noncash total cost sale turnover compare charge million expect deliver annual pretax increase primarily reflect expect impact saving billion unwind cost manufacturing volume shortfall adverse mix legal charge million million principally effect impact prepare launch new pipeline relate provision exist product liability matter product high amortisation impairment intangible asset partially offset ongoing cost management well price acquisition accounting credit net million realisation restructuring benefit million credit include item relate major acquisition business equity investment asset disposal oneoff require sell general administration regulatory charge certain adjust item total sga cost decrease turnover compare net credit include gain disposal lucozade ribena reflect low legal restructuring charge business anticoagulant product million net favourable yearonyear benefit group restructure net credit include gain profit disposal noncore otc programme ongoing cost management effort fund brand million gain million arise investment growth business preparation new revaluation preexisting collaboration hgs viiv product launch healthcareshionogi joint venture acquisition advertising promotion expense decrease sell net finance cost distribution fall general administration decrease primarily reflect low legal charge finance income research development interest finance income fair value movement total expenditure decline million turnover compare million turnover reflect completion number large trial phase ongoing project spend continue cost management finance expense partially offset high restructuring require regulatory interest expense charge unwind discount liability remeasurement fair value movement finance expense total net finance expense million compare million despite high average net debt level year reflect strategy improve fund profile group gsk annual report profit disposal interest associate critical accounting policy information pretax profit disposal interest associate judgement estimate give note financial million nil reflect disposal million statement key accounting judgement estimate ordinary share aspen pharmacare million relevant detailed note financial statement indicate relate follow area share tax profit associate joint venture turnover share tax profit associate million million principally arise group holding taxation note aspen pharmacare legal dispute note profit taxation impairment goodwill intangible asset take account net finance cost profit disposal interest note associate share profit associate profit pension postemployment benefit note taxation million compare million information judgement estimate area cer increase increase sterling term give note financial statement key accounting taxation judgement estimate turnover restate respect turnover accounting policy large business corporation tax statutory rate pharmaceutical vaccine market double taxation relief complex arrangement rebate discount allowance follow briefly describe nature arrangement existence pharmaceutical vaccine business overseas taxation current taxation arrangement certain indirect customer defer taxation customer able buy product wholesaler reduce price chargeback represent difference taxation total profit invoice price wholesaler indirect customer charge taxation total profit amount million contractual discount price accrual estimate chargeback represent effective tax rate calculate base term agreement historical reflect differ tax effect noncore item experience product growth rate include net defer tax charge million relate customer rebate offer key manage care group unwind deferred profit inventory exist inventory purchasing organisation gpo direct indirect produce prior restructure supply chain sell customer arrangement require customer achieve charge taxation total profit include defer certain performance target relate value product tax credit million primarily reflect continue purchase formulary status predetermine market share restructure supply chain compare predominantly non relative competitor accrual customer rebate cash defer tax charge million group estimate base specific term agreement balance sheet december include tax payable liability historical experience product growth rate million tax recoverable asset million medicaid programme stateadministere programme continue believe adequate provision provide assistance certain poor vulnerable patient liability likely arise period open medicaid drug rebate program establish agree tax authority ultimate liability matter reduce state federal expenditure prescription drug vary amount provide dependent patient protection affordable care act outcome agreement relevant tax authority litigation law participate provide rebate state accrual earning share medicaid rebate calculate base specific term relevant regulation patient protection affordable total earning share year compare care act noncore net credit total charge cash discount offer customer encourage prompt payment accrue time invoice critical accounting policy adjust subsequently reflect actual experience consolidated financial statement prepare accordance record accrual estimate sale return apply ifrs adopt use european union historical experience customer return amount invoice ifrs issue iasb follow accounting policy market relate information stock level approve board describe note financial wholesaler anticipate price increase competitor activity statement accounting principle policy require estimate assumption affect amount asset liability revenue expense report financial statement actual amount result differ estimate gsk annual report strategic report financial review reconciliation gross turnover net turnover legal dispute pharmaceutical vaccine business follow respect accounting policy legal dispute follow briefly describe process determine restate restate level provision necessary margin margin accordance requirement ias provision contingent liability contingent asset provide gross turnover anticipate settlement cost outflow resource consider probable reliable estimate market drive likely outcome dispute legal expense arise segment claim group involved government significant legal proceeding respect possible mandated state reliable estimate expect financial effect program result ultimate resolution proceeding cash discount case appropriate disclosure case include customer annual report provision return position change time prior year assurance loss result outcome legal adjustment proceeding exceed material item provision report group financial statement total deduction like pharmaceutical company face net turnover complex product liability antitrust patent litigation investigation operation conduct governmental market drive segment consist primarily manage care regulatory agency year general counsel medicare plan gsk negotiate contract pricing group head group legal function senior honour rebate chargeback mandate segment consist vice president head global litigation group primarily medicaid federal government program responsible litigation government investigation routinely receive government mandate pricing rebate chargeback brief chief executive officer chief financial officer total balance sheet accrual rebate discount allowance board director significant litigation pende return pharmaceutical vaccine business group governmental investigation group december december follow meeting appropriate detail status significant litigation government investigation review matter december december number claim notify information potential claim notify assessment validity claim progress settle claim recent settlement level potential manage care medicare reimbursement insurer gpo rebate meeting include assessment government state program sufficient information available able reliable cash discount estimate potential outcome dispute external customer return counsel assist litigation matter investigation assist briefing board senior management total follow discussion matter possible reliable estimate provision monthly process operate monitor inventory level require level provision legal dispute wholesaler abnormal movement process use gross review adjust appropriate sale volume prescription volume base party datum source information receive key wholesaler aim maintain inventory consistent level year year base pattern consumption basis pharmaceutical vaccine inventory level wholesaler distribution channel december estimate approximately week turnover calculation use party information accuracy totally verify believe sufficiently reliable purpose gsk annual report financial position resource property plant equipment business sciencebase technologyintensive highly regulate governmental authority allocate significant restate financial resource renewal maintenance property asset plant equipment minimise risk interruption production noncurrent asset achieve compliance regulatory standard number property plant equipment process use chemical hazardous material goodwill total cost property plant equipment december intangible asset million net book value million investment associate joint venture land building represent million plant investment equipment million asset construction million defer tax asset invest million new renewal property plant equipment mainly relate large number derivative financial instrument project renewal improvement expansion facility noncurrent asset worldwide site property mainly hold freehold new total noncurrent asset investment finance liquid resource december current asset contractual commitment future capital expenditure inventory million operating lease commitment million believe facility adequate current need current tax recoverable trade receivables observe stringent procedure use specialist skill manage derivative financial instrument environmental risk activity environmental issue liquid investment date operation modify discontinue report planet note cash cash equivalent financial statement legal proceeding asset hold sale total current asset goodwill total asset goodwill decrease year million december million decrease primarily reflect liability weaken overseas currency current liability shortterm borrowing intangible asset trade payable intangible asset include cost intangible acquire derivative financial instrument party computer software net book value current tax payable intangible asset december million shortterm provision million decrease reflect asset acquire total current liability acquisition okairos million capitalise development cost million million computer noncurrent liability software cost offset amortisation impairment longterm borrowing exist intangible million million respectively defer tax liability investment pension postemployment benefit hold investment include associate joint venture provision carry value december million derivative financial instrument million market value december noncurrent liabilitie million million large total noncurrent liability investment associate aspen pharmacare holding total liability limited book value december net asset million million investment theravance inc book value december million equity million year sell million share share capital aspen pharmacare holding limit represent share premium account interest million investment include equity stake retain earning company group research collaboration reserve provide access biotechnology development potential interest shareholder equity interest company arise business divestment noncontrolle interest total equity gsk annual report strategic report financial review derivative financial instrument asset net debt decrease million reflect receipt noncurrent current derivative financial instrument billion disposal lucozaderibena hold fair value million million majority anticoagulant product business intangible asset relate interest rate swap foreign exchange group investment aspen pharmacare holding limited contract designate nondesignated intercompany loan investment impact partly offset deposit accounting hedge consideration pay increase shareholding group indian consumer healthcare subsidiary inventory cost million acquire okarios million inventory million decrease million group strong cash generation enable financing share year decrease reflect impact disposal lucozade repurchase billion dividend payment billion ribena anticoagulant product business partly offset high vaccine stock stockbuilde new product launch movement net debt trade receivable trade receivables million increase net debt begin year reflect receivable aspen respect inventory manufacturing site form disposal increasedecrease cash bank overdraft anticoagulant product business partly offset weaken cash inflow liquid investment overseas currency net increase longterm loan net repayment shortterm loan derivative financial instrument liabilitie debt subsidiary undertaking acquire hold noncurrent current derivative financial exchange movement instrument fair value million million movement primarily relate foreign exchange contract designate net debt end year nondesignate intercompany loan deposit external debt legal provision accounting hedge total equity december total equity increase million trade payable december million increase arise principally trade payable amount million increase reduction pension deficit million reduction million reflect current year accrual postretirement provision million retain profit respect acquisition share group indian year exceed share repurchase partly offset liability pharmaceutical subsidiary million partly offset effect million arise open offer purchase share hold increase shareholding indian consumer healthcare noncontrolle interest group indian pharmaceutical subsidiary accrue weaken overseas subsidiary glaxosmithkline pharmaceutical limited currency summary movement equity set provision carry defer tax provision shortterm restate noncurrent provision million december million respect estimate future liability total equity beginning year million million relate legal prior year adjustment ia dispute provision legal dispute january restate indemnify disposal liability employee relate liability total comprehensive income year cost restructure programme extent balance dividend shareholder sheet date legal constructive obligation exist reliably estimate share issue change noncontrolle interest pension postemployment benefit forward contract relate noncontrolle account pension postemployment arrangement interest accordance ia deficit net surplus share purchase cancel hold allow deferred taxation million treasury share million pension arrangement million consideration receive share transfer million unfunded postemployment liability esop trust december scheme purchase insurance contract share acquire esop trust guarantee payment specify pensioner liability sharebase incentive plan contract value million december tax sharebase incentive plan net debt distribution noncontrolle interest total equity end year change noncontrolle interest year primarily arise cash cash equivalent liquid investment voluntary open offer acquire share gsk borrowing repayable year pharmaceutical ltd groups pharmaceutical subsidiary india borrowing repayable year net debt gsk annual report share purchase commitment respect loan future interest payable loan employee share ownership plan esop trust disclose take account effect derivative acquire million share glaxosmithkline plc enter number research collaboration develop million share hold trust satisfy future exercise new compound pharmaceutical company term option award group share option award arrangement include upfront fee equity investment scheme proportion share hold trust respect loan commitment fund specify level research award rule scheme require satisfy addition agree payment future exercise market purchase issue new milestone achieve share share hold trust match option agreement relate compound early award grant stage development potential obligation milestone december esop trust hold million payment continue number year compound million gsk share future exercise share option successfully development process generally close share award carry value million product marketing approval great possibility million deduct reserve market success amount show intangible asset value share million million represent maximum pay milestone million share repurchase cost achieve include billion relate externalise million note share capital share premium project discovery portfolio number new commitment account currently target repurchase licensing agreement include billion exact time future purchase arrangement adimab llc immunocore ltd morphosys share hold treasury share reach agreement trustee cancel determine company dependent pension scheme additional contribution year market condition factor december hold period include eliminate pension deficit identify million share treasury share million share december actuarial funding valuation deficit cost million million persist contribution payable follow deduct retain earning year depend level deficit table include share purchase period january commitment exclude normal ongoing annual funding february requirement approximately million information pension obligation note financial commitment contingent liability statement pension postemployment benefit financial commitment summarise note financial contingent liability statement commitment contingent liability obligation respect short longterm debt set follow table set contingent liability comprise note financial statement contingent liability discount bill performance guarantee letter credit note financial statement net debt item arise normal course business expect expire amount provide pension postretirement benefit set note financial statement pension total yrs yrs yrs postemployment benefit amount provide restructure programme legal environmental dispute set guarantee note financial statement provision contingent liability total contractual obligation commitment follow table set contractual obligation normal course business provide commitment december fall payment indemnification guarantee respect business disposal legal dispute subsequently arise provision total yrs yrs yrs outflow resource consider probable reliable estimate likely outcome dispute loan include note financial statement interest loan provision finance lease obligation provide outcome tax legal dispute finance lease charge outflow resource consider probable reliable estimate operating lease outflow december commitment dispute provision possible intangible asset reliable estimate potential outflow fund property plant equipment require settle dispute possibility investment outflow remote purchase commitment ultimate liability matter vary significantly pension amount provide dependent outcome litigation commitment proceeding negotiation relevant tax authority total discuss risk factor page note financial statement taxation legal proceeding gsk annual report strategic report financial review cash generation conversion investment appraisal summary consolidated cash flow set formal process assess potential investment proposal order ensure decision align overall strategy process include assessment cash flow return investment cfroi net present value npv net cash inflow operating activity internal rate return irr timeline project net cash inflowoutflow investing activity long term consider impact earning credit profile net cash outflow financing activity relevant increasedecrease cash bank overdraft discount rate perform financial analysis decide cash bank overdraft begin year internally allow determination extent investment increasedecrease cash bank overdraft cover cost capital specific investment discount rate exchange adjustment adjust account country risk weighting cash bank overdraft end year capital expenditure financial investment cash bank overdraft end year cash payment tangible intangible fix asset amount comprise million million disposal realise million million cash payment acquire cash cash equivalent equity investment million million overdraft year sale equity investment realise million million net cash inflow operating activity year future cash flow million million increase primarily reflect legal expect future operating cash flow sufficient fund settlement billion lower operate debt service cost satisfy normal level phase restructuring expenditure low tax payment capital expenditure meet obligation exist licensing pension contribution partially offset small reduction agreement meet expenditure arise major working capital compare give supply chain investment restructure programme precise time uncertain inventory launch preparation outline note financial statement major restructure free cash flow cost meet routine outflow include tax dividend free cash flow cash generate business subject risk factor discuss page meet obligation interest tax dividend pay time time additional demand finance noncontrolle interest capital expenditure property acquisition share repurchase access plant equipment intangible asset source liquidity short longterm capital market bank financial institution addition cash flow operation need free cash flow work capital free cash flow growth free cash flow million year increase work capital percentage turnover primarily reflect impact low tax payment special pension contribution partly offset small reduction work work capital conversion cycle day capital increase expenditure property plant equipment work capital programme continue progress pay dividend shareholder million spend improvement collection receivable million repurchase share effective management payable balance year reconciliation net cash inflow operating activity number initiative implement supply chain close equivalent ifrs measure free cash flow show support pharmaceutical vaccine consumer healthcare business provide strong endtoend accountability reconciliation free cash flow case programme early stage reduce volatility improve responsiveness allow well inventory management net impact inventory limit net cash inflow operating activity significant investment improve purchase property plant equipment service level prepare new product launch purchase intangible asset report work capital conversion cycle day distort disposal property plant equipment divestment year intangible asset interest pay impairment include denominator conversion interest receive cycle computation yearend conversion cycle dividend receive joint venture adjust factor day associate undertaking day respectively reduction day distribution noncontrolle interest free cash flow gsk annual report maturity profile gross debt maturity profile gross debt equivalent gbp bonds eur bond usd bond commercial paper bank borrowing lease treasury policy liquidity gsk report sterling pay dividend sterling profit december cash liquid investment hold role corporate treasury monitor manage external follow internal funding requirement financial risk support strategic objective gsk operate global basis primarily subsidiary company manage capital ensure bank balance deposit subsidiary able operate go concern optimise treasury treasury repo return shareholder appropriate balance debt equity treasury activity govern policy approve money market fund board director recently july treasury corporate debt instrument management group tmg meeting chair chief financial government security officer take place monthly basis review treasury activity member receive management information relate treasury cash liquid investment billion include amount hold activity viiv healthcare hold centrally december capital management net debt billion december table financial strategy support group strategic priority summarise cash gross debt effect hedge regularly review board manage capital structure group appropriate mix debt equity gsk financial architecture design support delivery cash liquid investment group strategy enhance return shareholder gross debt fix key priority deliver sustainable sale growth improve operating leverage improve financial efficiency convert float earning cash free cash flow generate noninterest bearing return shareholder reinveste bolton acquisition net debt attractive return available gsk continue gsk policy borrow centrally order meet anticipate apply strict financial returnsbase criterion cash funding requirement cash flow forecast funding flow return investment order allocate capital assess requirement monitor tmg monthly basis investment opportunity whilst protect credit profile strategy diversify liquidity source range business remain highly cash generative gsk facility maintain broad access funding market generate billion free cash flow addition realise gsk longterm credit rating remain unchanged billion divestment return total february current rating stable outlook billion shareholder billion dividend standard poor negative outlook moodys investor billion share repurchase net debt end service moodys shortterm credit rating year stand billion reduction billion compare standard poor moodys respectively previous year expect deliver continue dividend growth longterm share buyback programme target share repurchase billion depend market condition detail note financial statement financial instrument relate disclosure gsk annual report strategic report financial review treasury operation counterparty risk management objective treasury activity manage posttax net cost gsk set global counterparty limit banking income financial operation benefit earning use investment counterpartie base longterm credit rating variety financial instrument finance operation moodys standard poor corporate treasury usage derivative financial instrument manage market risk limit monitor daily corporate compliance officer operation derivative principally comprise forward foreign cco operate independently corporate treasury currency contract interest rate swap swap breach limit report cfo immediately borrowing liquid asset currency require group cco monitor credit rating counterpartie purpose manage exposure financial risk change change rating occur notifie corporate treasury foreign exchange rate interest rate change investment level authority limit appropriate addition relationship bank credit rating hold issue derivative speculative purpose review regularly report present annually tmg treasury policy specifically prohibit activity transaction approval financial instrument undertake manage risk arise underlie business activity speculation group report interest rate risk management gsk intend report core result performance gsk objective minimise effective net interest cost measure core result exclude divestment balance mix debt fix float interest rate time complete divestment include disposal policy interest rate risk management limit lucozade ribena anticoagulant product float interest payment prescribe percentage operate minor product summary restate core result exclude profit divestment set use interest rate swap redenominate bond core result float interest rate duration swap match core divest exclude duration principal instrument interest rate derivative result business divestment instrument account fair value hedge relevant liability turnover cost sale foreign exchange risk management sell general administration foreign currency transaction exposure arise internal external trade flow generally hedge group objective research development minimise exposure overseas operating subsidiary royalty income transaction risk match local currency income local operating profit currency cost possible internal trading transaction profit tax match centrally manage intercompany payment term profit tax reduce foreign currency risk foreign currency cash flow hedge selectively management corporate treasury profit attributable shareholder tmg possible manage cash surplus earning share penny borrowing requirement subsidiary company centrally reconciliation core result total result set forward contract hedge future repayment originate currency strategic report order reduce foreign currency translation exposure seek denominate borrowing currencie principal asset strategic report approve duly authorise cash flow primarily denominate dollars euros committee board director february sterling certain borrowing swap currency sign behalf require borrowing denominate swap foreign currency match investment overseas group asset treat hedge relevant asset forward contract major simon dingemans currency reduce exposure investment chief financial officer overseas group asset tmg review ratio borrowing february asset major currency monthly gsk annual report governance remuneration section board corporate executive team chairman letter board report shareholder committee report remuneration committee chairmans annual statement annual report remuneration remuneration policy report gsk annual report governance remuneration board board diversity experience international experience number director experience scientific global finance usa industry europe emap tenure composition nonexecutive executive year nonexecutive year year male board consider nonexecutive director female independent accordance corporate governance code sir christopher gent skill experience sir christopher year experience lead global chairman business track record deliver outstanding performance highly competitive industry appoint manage director nationality vodafone plc chief executive officer british retirement appointment date external appointment june chairman sir christopher nonexecutive director ferrari spa senior january adviser bain member british airways international committee membership business advisory board chairman nomination corporate responsibility committee member remuneration finance committee sir andrew witty skill experience sir andrew joined gsk work south africa chief executive officer usa singapore senior role appoint president gsk europe join gsk corporate executive team nationality british award public service medal government singapore august award public service star appointment date new year honour list award knighthood january chief service economy pharmaceutical industry executive officer serve lead nonexecutive board member department committee membership business innovation skill december member finance committee president european federation pharmaceutical industry association july external appointment sir andrew member prime minister business advisory group appoint business ambassador group january simon dingemans skills experience prior join gsk simon year experience chief financial officer investment banking warburg goldman sachs time advise broad range large corporate number nationality industry sector include pharmaceutical consumer healthcare british simon advise gsk decade appointment appointment date closely involve number gsk key strategic project include january chief establishment viiv healthcare financial officer april external appointment committee membership simon member corporate development council member finance committee national theatre deputy chairman group gsk annual report moncef slaoui skill experience moncef join gsk vaccine engineer chairman global development robust vaccine pipeline lead worldwide vaccine business development pharmaceutical product appointment lead give overall responsibility nationality gsk oncology business gsk vaccine moroccan belgian american global franchises phd molecular biology appointment date immunology universit libre bruxelle publish scientific paper presentation prior join gsk moncef professor immunology university mon belgium committee membership member finance committee external appointment moncef member phrma biotechnology industry organization board usa member advisory committee director national institutes health adviser qatar foundation member qatar biomedical research institute scientific advisory committee moncef advise president council advisor science technology member board agency science technology research astar january sir deryck maughan skill experience sir deryck wealth international corporate investment senior independent banking experience previously serve chairman chief nonexecutive director executive officer citigroup international salomon brothers inc serve vice chairman new york stock exchange nationality british external appointment appointment date sir deryck senior adviser partner kohlberg june senior kravis roberts nonexecutive director blackrock independent nonexecutive inc thomson reuters trustee british museum director new york university langone medical center director committee membership lincoln center member audit risk nomination remuneration finance committee professor sir roy anderson skill experience professor sir roy worldrenowne medical scientist advance independent nonexecutive knowledge infectious disease epidemiology currently professor director scientific expert infectious disease faculty medicine imperial college london fellow member policy advisory board royal nationality society fellow academy medical sciences royal british statistical society honorary fellow institute actuary appointment date foreign associate member institute medicine october national academy sciences french academy sciences professor sir roy background enable bring scientific experience committee membership board deliberation member nomination finance committee external appointment professor sir roy member international advisory board holdingham group trustee natural history museum london stephanie burn skill experience stephanie recognise global business leader serve independent nonexecutive chairman president ceo dow corning corporation director retirement end strong scientific background phd organic chemistry organosilicon specialty nationality staunch advocate science education officer american chairman american chemistry council appointment date external appointment february stephanie appoint nonexecutive director corning inc committee membership january appoint director board kellogg member corporate company february sit president export responsibility remuneration council stephanie officer society chemical industry finance committees america section past honorary president ukbased parent society gsk annual report governance remuneration board board continue stacey cartwright skill experience stacey charter accountant extensive experience global independent nonexecutive consumer business corporate finance serve executive director vice president chief financial officer burberry group plc july prior join burberry group plc stacey hold role nationality chief financial officer egg plc british work financerelated position granada appointment date group plc april external appointment committee membership stacey chief executive officer harvey nichols group member audit risk company role appoint february finance committee lynn elsenhans skills experience lynn wealth experience run global business independent nonexecutive significant knowledge global market gsk operate director serve chair president chief executive officer sunoco inc prior join sunoco president nationality chief executive officer lynn work royal dutch shell american join hold number senior role include appointment date executive vice president global manufacturing july external appointment committee membership lynn nonexecutive director baker hughes inc director member audit risk texas medical center director tee great houston corporate responsibility trustee united way great houston trustee finance committee rice university judy lewent skill experience judy extensive knowledge global pharmaceutical industry independent nonexecutive corporate finance join merck serve director chief financial officer retire judy previously serve nonexecutive director motorola inc dell inc nationality quaker oats company american external appointment appointment date judy nonexecutive director thermo fisher scientific inc april motorola solutions inc trustee rockefeller family trust committee membership chairperson audit committee rockefeller financial service life member massachusetts institute technology corporation chairman audit risk member american academy arts sciences judy committee member nonexecutive director purdue pharma inc napp pharmaceutical remuneration finance holding limit certain mundipharma international limited committees company daniel podolsky skill experience daniel worldrenowne researcher advanced knowledge independent nonexecutive underlie mechanism disease new therapy gastrointestinal director scientific expert disorder mallinckrodt professor medicine chief gastroenterology massachusetts general hospital harvard nationality medical school previously serve chief academic officer american partner healthcare system daniel current responsibility appointment date lead large academic medical centre relevant insight july healthcare delivery daniel bring scientific expertise board committee membership audit risk committee deliberation member audit risk external appointment corporate responsibility daniel president university texas southwestern medical finance committee center hold philip obryan montgomery distinguish presidential chair academic administration doris bryan wildenthal distinguish chair medical science member institute medicine national academy sciences member board southwestern medical foundation director antibe therapeutics inc member national academies sciences board army science technology gsk annual report tom swaan skill experience tom long distinguished career european banking independent nonexecutive industry member managing board chief director financial officer abn amro tom hold executive position dutch central bank nonexecutive director nationality financial service authority financial conduct authority dutch previously nonexecutive director appointment date kpmgs public interest committee vice chairman january supervisory board chairman audit committee royal ahold committee membership external appointment chairman remuneration tom chairman supervisory board vanlanschot bankiers committee member chairman board director zurich insurance group audit risk nomination member supervisory board royal dsm finance committee je ulrich skill experience jing managing director vice chairman asia pacific jpmorgan independent nonexecutive chase advise firm senior global client asset director class build relationship executive asias lead enterprise je prominent advisor large global nationality asset management company sovereign wealth fund multinational american corporation work line business jpmorgan chase appointment date foster great crossborder collaboration strengthen senior client july relationships asia pacific rest world committee membership jing managing director chair global market china member audit risk jpmorgan jing work finance committee deutsche bank manage director head great china equity previously hold financial position specialise asia pacific region clsa asia pacific markets emerge market investor corporation educate harvard stanford university external appointment je independent director ermenegildo zegna spa han wijer skill experience han broad range business economic political experience independent nonexecutive serve chief executive officer chairman akzo nobel director hans long distinguish career academia public service strategy consulting serve senior nationality vice president boston consulting group dutch external appointment appointment date han chairman supervisory board heineken april deputy chairman nonexecutive director royal dutch shell committee membership chairman supervisory board afc ajax member corporate responsibility remuneration finance committee sir robert wilson skill experience sir robert long distinguish career industry mainly independent nonexecutive rio tinto chief executive officer director executive chairman retirement october sir robert nonexecutive chairman group plc nationality january chairman economist british group nonexecutive director appointment date diageo boots november stand senior independent nonexecutive director committee membership member audit risk committee member corporate responsibility nomination external appointment finance committee sir robert senior adviser morgan stanley chairman riverstone energy limit chairman accenture global mining executive council gsk annual report governance remuneration corporate executive team corporate executive team sir andrew witty simon bicknell deirdre connelly roger connor chief executive officer senior vice president president north america president global governance ethic pharmaceutical manufacturing supply board assurance deirdre join gsk president roger president global simon appoint senior vice north america pharmaceuticals manufacturing supply gms president governance ethic february working appoint role assurance january eli lilly company year january work responsible risk management hold variety position year president designate gms compliance strategic auditing include president operations roger join gsk senior vice president global simon join company secretariat commercialisation womans astrazeneca work deputy company health senior vice president number role finance secretary glaxo wellcome human resource manufacturing strategy include appoint company secretary gsk site cork ireland glaxosmithkline plc deirdre native san juan puerto ware prior role combine position rico hold bachelor degree gms roger vice president role corporate compliance officer marketing economic office ceo corporate current appointment lycome college pennsylvania strategy february graduate harvard gain law degree simon university advance management hold degree mechanical qualified barrister programme manufacturing engineering member middle temple queen university belfast deirdre serve director master manufacturing leadership phrma board board macys cambridge university inc harvard university public charter accountant health policy council simon dingemans abbas hussain bill louv david redfern chief financial officer president europe japan senior vice president core chief strategy officer emap business service board david appoint chief strategy abbas appoint president bill appoint create lead officer responsible europe emap september core business services cbs proactive exploration new responsible japan april cbs integrate share business opportunity strategic march join company service global support planning leadership president emerge market function previously chief dermatology business addition asia pacific june information officer current role appoint chairman board viiv previously abbas spend year bill join company healthcare ltd april eli lilly hold position vice president medical datum include president europe sciences hold number previously senior vice vice president europe increasingly senior role president northern europe specific responsibility western responsibility manage gsk european midsize country africa bill bachelor science degree pharmaceutical business middle east areacommonwealth biology college william region prior senior vice independent state central mary master science president central eastern eastern europe region hold doctor philosophy degree europe david join company position sale marketing statistics university florida hold series finance australasia india role finance director european business abbas appoint viiv healthcare ltd board october aspen board david bachelor science december degree bristol university charter accountant bear madra india abbas degree medicinal chemistry pharmacology loughborough university gsk annual report moncef slaoui claire thomas phil thomson chairman global senior vice president senior vice president vaccine human resource global communication board claire appoint senior vice phil appoint senior vice president human resource president global communications responsible gsk august responsibility environmental sustainability strategy medium relation investor relation previously senior vice corporate responsibility internal president human resource communication product pharmaceutical international communication claire join company phil join glaxo wellcome appoint senior vice commercial trainee move president human resource pharmaceutical brand marketing pharmaceutical europe product communication successfully lead director medium function merger relation glaxo wellcome plc take position prior join company director investor relation gsk work ford motor company return corporate hold position human medium relation vice president resources phil earn degree english claire bachelor science history durham university degree economic management industrial relation university wale claire honour outstanding european woman achievement dan troy patrick vallance emma walmsley senior vice president president pharmaceuticals president consumer general counsel healthcare worldwide dan join company senior patrick appoint president emma assume role president vice president general counsel pharmaceutical january consumer healthcare worldwide september prior appointment october joining gsk senior vice president medicine president consumer previously partner discovery development healthcare europe washington law firm sidley austin llp represent mainly patrick joined company emmas leadership business pharmaceutical company trade head drug discovery new strategic direction association matter related focused organisation science well fast move food drug administration good chance lead consumer healthcare company drive fda government regulation new medicine create science value combine dan chief counsel small multidisciplinary team call good gsk scientific fda serve primary discovery performance unit knowledge speed liaison white house transform way marketing excellence fast department health human approach late stage clinical trial move consumer good world service design execution prior join gsk emma work dan graduate cornell prior join gsk patrick loreal year universitys school industrial clinical academic university college hold variety marketing general labor relation earn law london patrick member management role paris london degree columbia university board agency science new york school law technology research astar base shanghai general director genome manager consumer product research limited loreal china degree classic modern language oxford university gsk annual report governance remuneration corporate governance corporate governance letter shareholder dear shareholder new style remuneration report page comprise chairman board commit chairmans statement tom ensure gsk operate high swaan remuneration committee standard corporate governance chairman reflect committee believe governance structure underpin decision year outline ability deliver group strategy committee agenda grow diversified business deliver product value simplify operating annual report remuneration model set committee implement gsk remuneration policy new governance remuneration year way report change propose operate gsk policy light new provision financial reporting council update remuneration policy report set corporate governance code update gsk propose remuneration policy code commencement new apply year end remuneration reporting regulation annual general meeting review governance corporate reporting arrangement update code annual governance meeting available wwwfrcorguk year please chair respect principal area change governance meeting shareholder set update code take alongside judy lewent follow action chair audit risk committee sir deryck maughan senior independent year annual report disclose director sid meeting ahead time diversity policy able discuss broad range governance measurable diversity target please matter shareholder include board report relation gender management dynamic director diversity maintain female induction training development representation board arrangement succession planning july place gsk firmly whilst impart detail important ftse term female work undertake nominations board member representation corporate responsibility committee nhancement judy provide overview role audit risk committee report arc activity audit risk committee report page sir deryck share insight enhancement include discussion perspective board governance significant issue relate financial structure shareholder take statement committee consider role sid sir robert wilson address year arc report highlight shareholder follow page outline approach key area focus committee governance building work undertake year year annual report restructure new remuneration report corporate governance report year regulation come effect addition consolidate financial reporting year statutory disclosure shareholder participate member information section annual report investor group help develop page risk disclosure guidance aim assist quote previously appear corporate company understand practical governance report incorporate implementation new regulation expand risk management section introduction regulation page provide opportunity commend report fresh look present shareholder report director remuneration arrangement sir christopher gent chairman february gsk annual report board report shareholder oversight stewardship future action board board please report compliance requirement corporate governance code board responsible longterm success company corporate governance strategy risk management financial performance accountable shareholder ensure group appropriately manage governed deliver gsk strategy grow deliver simplify board programme board meet time board member attend schedule board meeting exception sir deryck maughan tom swaan hans wijer unable attend meeting prior business commitment convey view comment chairman matter discuss share director meet board agenda shape create time strategic discussion debate include deep dive review key issue business ensure focus consideration strategic priority agenda board meeting include follow business month strategy board oversight governance risk oversight january review extension operational excellence review financial review internal board review risk programme result outlook evaluation report internal review notice agm secretary report include control process reappointment auditor regulatory governance update march review emap performance strategy preparation agm update secretarys report include deep dive global franchise product regulatory governance update launch readiness review business development project annual global manufacturing preparation agm supply vaccine secretarys report business review include regulatory governance update july deep dive pipeline launch annual north america secretarys report include review talent leadership development pharmaceutical review regulatory governance update strategy review treasury funding pension review capital licensing strategy proposal review long range forecast october review output annual board annual business review review project cet strategy meet consumer healthcare transaction approve review group insurance strategy japan board review pension fund investment secretary report include hedge strategy regulatory governance update december deep dive china business secretary report include europe strategy update review regulatory governance update review approval plan year board member invite attend audit risk committee meeting risk matter routinely discuss board performance board identify certain action assist add value deliberation performance board action set action progressachievement external landscape board programme expand include briefing board member keen supplement understand external area moncef slaoui member senior team landscape teachin range topic therapeutic area board october visit gsk facility upper providence design phase iii trial pricing biopharmaceutical pharmacogenomic boardcet strategy meeting view hand emerge technology emerge technology manufacturing oversight strategy board programme adjust set aside time board wish spend time business unit strategy competitor deep dive business development review year analysis pricing regime acquisition strategy emerge issue iii board composition nomination committee continue focus longterm nominations committee task identify suitable recruitment nonexecutive director candidate replace board member retire year board please welcome new nonexecutive director han wijer provide experience run global organisation board deliberation action set gsk annual report discuss internally facilitate evaluation board activity senior independent director gsk annual report governance remuneration corporate governance board report shareholder oversight stewardship future action continue agms key highlight glance agm hold qeii conference centre agm hold qeii conference centre london london director attendance sir robert wilson stand board year billion vote cast resolution issue service share capital director stand reelection board sir crispin davis stand year service board believe director effective demonstrate director retire elect reelect commitment role board receive vote cast favour director formally evaluate chairman high vote favour elect reelect number standing reelection director low vote favour reduce require notice general meeting induction programme han wijer individually design facilitate chairman company secretary purpose orientate familiarise hans appoint board strategy grow deliver simplify industry organisation governance arrangement iii customise account experience geographical background business perspective committee serve key element onetoone induction briefing session site visit undertaken han set contactactivity induction content executive director gsk strategic financial priority cet member wide spectrum gsk business operation include pharmaceutical vaccine consumer healthcare business strategic development investor relation global communication strategie senior executive focus number core function finance tax treasury audit assurance risk management investor relation company secretary legal regulatory duty list company director corporate governance practice gsk site visit tour gm site upper merrion upper providence investor meeting meeting investor request induction training programme han continue focus internal management meeting attendance operational site visit order provide han good perspective management operate provide opportunity meet key talent gsk deepen understand key business issue board performance action point agree action point arise board evaluation review facilitate senior independent director sir deryck maughan progress disclose gsk annual report set strategy board look long term view year key strategic issue face company board meeting time spend routine matter manage enable strategicbusiness discussion priority whilst ensure critical area oversight maintain iii nnual boardcet meeting structure format session review ensure appropriately gear realise maximum value term strategic insight direction set china review appropriate action reviewed board implement necessary conclusion external investigation rope gray independent review gsk annual report leadership effectiveness senior independent director sir deryck maughan senior independent director sid board succeed sir robert wilson board meet time member attend sid sir deryck role act follows sound board sir christopher trust intermediary director available additional point contact number number shareholder responsibility include evaluation meeting hold whilst meeting performance chairman request chairman board member attend evaluate board committee collaboration sir christopher gent committee chairman year evaluation conduct sir andrew witty internally sid work chairman process simon dingemans selection new chairman appropriate chair moncef slaoui nominations committee agree recommendation professor sir roy anderson board chairmans successor stephanie burn sir deryck maintains understand issue concern stacey cartwright major shareholder meeting sir crispin davis report investor relation team lynn elsenhans judy lewent ceo sir deryck maughan sir andrew responsible management business daniel podolsky develop group strategic direction consideration approval board implement agree strategy tom swaan assist member corporate executive team cet jing ulrich meet time year require han wijers sir robert wilson short biography member cet give corporate executive team page addition schedule meeting board meet quorate basis occasion consider corporate transaction company secretary include authorise disposal lucozade ribena company secretary victoria whyte solicitor fellow brand china investigations institute charter secretary administrator victoria crispin davis retired board deputy secretary secretary remuneration an wijer appoint nonexecutive director committee act secretary board effect april board committee appointment company secretary january sir deryck maughan tom swaan hans wijer unable attend board meeting prior business company secretary support chairman designing commitment induction new director delivery corporate governance agenda particular planning agenda chairman annual cycle board committee meeting ensure information available board member timely basis sir christopher gents role chairman lead manage company secretary advise director board procedure business board provide direction focus corporate governance matter arrange non ensure clear structure effective operation executive director attend internal management meeting board committee set agenda board visit business operation enhance knowledge discussion promote effective constructive debate understand business support sound decisionmake process ensure board receive accurate timely clear information particular company secretary respond company performance consultation evolve global governance corporate reporting agenda behalf group engage sir christopher work closely sir andrew witty ensure shareholder ensure fully understand gsk governance strategy action agree board effectively remuneration arrangement implement provide support advice sir andrew respect executive responsibility manage group independence division responsibility chairman ceo agree board set governance section board consider nonexecutive director website independent character judgement free business relationship materially interfere exercise sir christopher responsible shareholder performance judgement chairman satisfied independence test group lead discussion development relation appointment board independence nonexecutive director serve nonexecutive director board year subject rigorous review particular board consider sir deryck maughan sir nonexecutive director provide strong independent element robert wilson serve board year board place constructively challenge continue demonstrate characteristic independence support management shape proposal strategy challenge management take rigorous debate whilst succession planning bring independent possessing outstanding knowledge company business affair judgement breadth skill experience gain senior level international business operation academia gsk annual report governance remuneration corporate governance corporate governance framework board coherent corporate governance framework clearly define responsibility accountability design safeguard enhance longterm shareholder value provide robust platform realise group strategy grow deliver simplify internal control risk management arrangement describe page integral gsk governance framework board chairman executive director independent nonexecutive director audit risk remuneration nomination chief executive committee committee committee officer corporate responsibility finance corporate administration corporate executive committee committee transaction committee team board committee order board operate effectively consideration key matter board committee establish board summary role board committee set table term reference committee available website report membership work undertake audit risk remuneration nomination corporate responsibility committee give page corporate corporate administration audit risk remuneration nomination responsibility finance transaction review review review review review review recommend recommend approve approve financial internal external issue report process board structure size potential annual report matter connection integrity overall executive composition impact form administration financial statement remuneration policy board gsk business convene group system internal board appointment oversight agm preliminary business certain control identification appropriate fee member quarterly result corporate transaction management chairman board committee reputation announcement risk external cet management internal audit determine approve monitor process term service certain major remuneration succession license capital propose executive director board cet transaction appointment member change external auditor cet group investment instrument responsible review counterparty limit initiate audit approve tender selection director external auditor remuneration report remuneration oversight work gsk annual report board induction business awareness training board diversity policy set detail induction programme han wijer present gender diversity gsk global workforce illustrate typical induction format new director responsible business ensure nonexecutive director develop maintain time allocation great insight understanding business invite nonexecutive director letter appointment set attend internal management meeting include meeting term condition directorship cet research development executive product executive scientific review board portfolio investment board sir christopher nonexecutive director expect commercial accountability board risk oversight devote time necessary proper performance compliance council meet employee informally dutie precise timing give vary year year visit group operation reception hold board depend company activity director expect meeting attend board meeting additional meeting require board keep uptodate legal regulatory governance expect attend meeting committee matter regular paper company secretary member audit risk committee meeting presentation internal external adviser open director furtherance risk compliance responsibility strategy session visit year board brief development operational site addition board member invite attend narrative executive remuneration reporting go concern risk cet meeting year attend certain research management board diversity impact review development executive operational meeting audit market market abuse insider trading shareholder engagement development corporate governance board chairmans evaluation include requirement september update board carry evaluation performance corporate governance code performance committee year facilitate board member undertake specific refresher training externally year progress board provision corporate integrity agreement cia outcomes evaluation internally facilitate deliver audit risk committee previous sid sir robert wilson report new board member induction programme action point arise evaluation board facilitate receive comprehensive training cia han wijer take current sid sir deryck maughan disclose training session induction feedback board evaluation summarise sir christopher meet director annually oneto board view board member effective basis discuss ongoing training development pharmaceutical industry undergo fundamental change requirement board work hard understand opportunity risk pose strategy supportive direction board composition articulate management team debate open robust seek build effective complementary board encourage contribute corporate responsibility capability appropriate scale complexity strategic ethic compliance take seriously good positioning business process board appointment lead balance core value company interest nomination committee describe page shareholder mindful need balance composition board openness sir andrew management team board committee refresh progressively time input view board member exemplary ability draw experience long serve director director attend management meeting visit site enhance tap new external perspective insight board competence recent appointee bring board deliberation board balanced term diversity experience nonexecutive director draw wide range industry desirability add experienced director background include pharmaceutical healthcare medical list environment acknowledge research academia retail financial service board committee strong engaged leader significant appropriate experience complex organisation global reach workload discharge play important role company considerable experience pharmaceutical industry governance recent appointee bring new approach group board discussions board diversity commit diversity boardroom similarly commit equal opportunity employee level organisation diversity inclusiveness workforce promote gsk believe key requirement effective board comprise range balance skill experience knowledge gender independence individual prepare challenge work team need back diversity personal attribute include character intellect sound judgement honesty courage gsk annual report governance remuneration corporate governance nonexecutive director lead sir deryck meet separately relation shareholder sir christopher present discuss performance consider leadership performance overall contribution work engage effectively shareholder regular high standard communication agm investor relation activity chairman board committee undertake separate announce financial result quarterly basis annual evaluation committee outcome evaluation result include annual report shareholder receive report discuss respective committee annual summary advise annual report board notice annual general meeting available website addition sir christopher meet nonexecutive director year sir andrew witty simon dingemans give independently executive director presentation institutional investor analyst medium year result available webcast accountability teleconference second quarter result hold webcast teleconference audience internal control framework result available website board recognise responsibility present fair balanced investor relation department office london understandable assessment group position prospect philadelphia act focal point communication investor sir andrew simon sir christopher maintain continuous board accountability review approve dialogue institutional shareholder performance plan effectiveness internal control operate group include objective programme regular meeting year financial operational compliance control risk management hold individual meeting investor internal control framework framework operation host approximately group meeting investor year continue operate date potential investor approval annual report framework process company secretary act focal point communication compliance law regulation reliability financial corporate governance matter small central reporting effectiveness efficiency operation corporate responsibility team coordinate strategy review framework assist identification evaluation policy development reporting specifically respect management principal risk require corporate matter team communicate socially responsible investor governance code code design manage stakeholder eliminate risk achieve business objective believe framework provide reasonable absolute sir christopher meet regularly institutional shareholder assurance material misstatement loss hear view discuss issue mutual importance communicate view member board audit risk committee committee receive report sid nonexecutive director available meet area significant risk group relate internal control shareholder follow consideration report committee report annually board effectiveness control remuneration committee chairman chairman head human resource hold annual meeting major board committee review assessment shareholder november discuss executive remuneration risk framework consider effectiveness system internal control operation group year addition chairman audit risk committee chair cover annual report date approval sid hold separate meeting major shareholder board board review focus company december major shareholders january subsidiary extend material associate undertaking governance matter joint venture investment consider risk briefing process place nonexecutive director company participation activity establish manage sir christopher focus sector specific issue procedure control place identify entity result general shareholder preference consolidated group result believe process follow board review remuneration report system internal control accord guidance internal remuneration report comprise remuneration committee control issue turnbull committee chairmans annual statement annual report remuneration accordance provision code remuneration policy report set page provide board responsible determine nature extent significant risk willing achieve strategic objective board provide oversight help ensure committee report group maintain sound risk management internal control system report audit risk nomination corporate responsibility committee describe activity review group risk management approach committee year set page discuss risk management section page management principal risk explain page gsk annual report audit risk committee report rope gray report directly gsk general counsel chair committee unfettered access law firm partner lead independent investigation addition time continue set aside committee meeting consider matter finally delight welcome je ulrich lynn elsenhans new member committee ongoing refreshment composition committee pleased contribution committee deliberation judy lewent audit risk committee chairman membership attendance dear shareholder membership committee appointment date attendance meeting set committee agenda include review integrity financial result appropriateness system attendance internal control business operation world meeting management risk focus consideration new member committee member emerge risk judy lewent chairman january april committees report include description work professor sir roy anderson undertaken committee year modify stacey cartwright april reflect new audit committee responsibility report requirement corporate governance code lynn elsenhans january code guidance audit committee issue financial sir deryck maughan january report council frc september particular daniel podolsky january committee report discuss significant issue tom swaan january committee consider address relation financial jing ulrich statement outline committee assisted board sir robert wilson december director make statement confirm rofessor sir roy anderson sir robert wilson stand gsk annual report account fair balanced member committee understandable tom swaan unable attend sir deryck maughan start committee board unable attend committee meeting prior business consider division work term risk commitment management agree board member invite attend entire committee meeting board continue addition schedule meeting committee meet cover risk specifically reserved review ensure quorate basis occasion review approve matter continuity consistency coverage oversight associate annual report account form preliminary quarterly result announcement complete year chair committee time enhance knowledge understanding board member invite attend committee meeting group meeting range senior executive discuss attendee include issue bring committee management attend cet regular attend risk oversight compliance council management meeting attendee attendee require connect network compliance officer chairman group rely oversee drive compliance gsk ceo cfo matter routine hold precommittee briefing meeting session management external auditor generally general counsel available director senior executive external audit financial controller partner wish discuss particular matter detail head audit assurance company secretary secretary please attend alongside chairman senior committee independent director annual governance meeting chairman research development hold major shareholder december major head governance ethic assurance shareholder january opportunity discuss chief medical officer area mutual importance relation work committee chief product quality officer event year bring evidence vigilance external auditor continuous improvement internal control risk management process system remain high priority committee allegation fraudulent behaviour business china currently investigation authority country separately commission independent review international law firm rope gray happen china gsk annual report governance remuneration corporate governance accordance code board determine stacey cartwright judy lewent tom swaan recent relevant financial experience board agree stacey judy tom appropriate qualification background audit committee financial expert define sarbanesoxley act determine independent mean securities exchange act amend addition judy lewent sir deryck maughan tom swaan members remuneration committee allow provide input committee review group performance oversight risk factor relevant remuneration matter work undertaken committee committee work largely recur structured programme activity agree conjunction committee chair management external auditor start financial year programme comprise standing item committee require consider meeting matter time coincide key event annual financial reporting cycle business event committee consider discuss decision relation number matter year significant set global internal control governance financial reporting compliance external auditor risk matter review integrity draft review global assurance review auditnonaudit consider emerge risk confirm compliance financial statement business unit expenditure review risk management corporate governance appropriateness assurance report consider auditor report framework compliance code accounting policy review litigation report finding endorse review risk discuss annual going concern assumption review internal control annual result approve addition new evaluation exercise ree oie approval framework perform evidencebased itg ing risk register plo anm mee ion confirm compliance assessment external operation committee annual report sarbanesoxley act auditor effectiveness review status clinical review term form quarterly external audit study transparency abac reference result announcement review audit process information protection consider approval assurance work risk consider new annual process confirm agree plan consider qualification report disclosure recommend expertise review progress requirement include independence auditor external independent new style audit report annual report fair review corporate balanced integrity agreement cia recommend abac investigation receive briefing understandable quarterly compliance appointment approval relation china number group tax treasury report undertake cia agm committee meeting arrangement train agree auditor review annual progress reinforce committee remuneration global enterprise resource independence approve audit plan planning system committee meet audit fee proposal implementation collectively separately set performance external auditor expectation auditor head audit assurance head governance consider initial result ethic assurance audit member management present review agree preapproval budget auditor provide nonaudit service respect financial reporting activity committee review recommend approval financial result announcement consider quarterly financial result announcement annual financial result contain annual report committee review significant issue judgement management determine result committee review paper prepare management set key area risk action undertake quantify effect relevant issue judgement management appropriate accounting require address issue financial statement gsk annual report significant issue consider relation financial statement year end december set follow table summary financial outcome appropriate addition committee external auditor discuss significant issue address committee year area particular audit focus describe independent auditor report page significant issue consider committee relation financial statement issue address committee go concern basis committee consider outcome management halfyearly review current forecast net debt preparation financial position financing facility option available group following review risk statement potential impact unforeseen event committee confirm application go concern basis preparation financial statement continue appropriate revenue recognition include committee review management approach time recognition revenue accrual return rebate rar accrual customer return rebate pharmaceutical vaccine accrual return rebate billion december committee review basis accrual concurred management judgement amount involved full description process operate pharmaceutical vaccine business determine level accrual necessary set critical accounting policy provision legal matter include committee receive detailed report actual potential litigation internal external recent government investigation legal counsel number detail update concern ongoing government investigation china extent china management outlined level provision consider necessary respect potential adverse determine litigation outcome area include respect china investigation possible determine provision necessary december provision legal matter billion set note financial statement provision provision tax issue committee consider current tax dispute area potential risk concur management judgement level tax contingency require december group balance sheet include tax payable liability billion impairment intangible asset committee review management process review testing goodwill intangible asset potential impairment committee accept management judgement intangible asset require writing result impairment charge million note financial statement intangible asset detail provision pension committee review significant assumption adopt management valuation postemployment obligation obligation group large pension postretirement healthcare scheme resultant net obligation amount calculate external actuary group net deficit december amount billion set note financial statement pension postemployment benefit effectiveness external auditor adhere independence policy include gsk policy evaluate effectiveness audit process prior make isa uki sec requirement recommendation reappointment external auditor deliver focus consistent audit approach globally committee review effectiveness performance reflect local risk materiality criterion agree conjunction management coordinate appropriately gsk audit assurance begin year audit function process committee consider feedback provide consistency advice level prior year external audit gather client satisfaction survey facilitate auditor client service review team audit partner rotation independent engagement team undertake audit work external auditor require rotate audit engagement survey seek feedback financial management team partner year previous audit partner step corporate business unit level cover key area position audit gsk financial statement robustness audit process quality delivery quality conclude people quality service review robust review process committee feedback note area improvement implement involvement ceo cfo select replacement follow year audit provide committee satisfied committee approve appointment new audit effectiveness external audit process recommend engagement partner effect financial year reappointment auditor forthcome agm commence january details current criterion judge effectiveness external auditor set audit firm tender deliver smoothrunne thorough efficiently execute audit committee keep review ongoing legislative proposal audit tender rotation competition provide accurate uptodate knowledge technical issues commission implement final timely basis proposal effectively supersede frc complyorexplain serve industry resource communicate good practice approach underpin code industry trend report apply company time year frc plan withdraw tender provision gsk annual report governance remuneration corporate governance pricewaterhousecooper llp remain place auditor auditnon audit service year comparison graph group inception december audit contract tender period performance review annually committee time review implication end previous audit partner year term committee consider appropriateness put place tender process include assess frc recent guidance subject level change currently underway inside group improvement auditor service include fee level propose auditor review conclude tender company interest time committee consequently approve appointment new audit partner committee agree issue review regularly annual appointment process nonaudit services sarbanesoxley act prohibits engagement external auditor provision certain service legal actuarial internal audit outsource financial information system design external auditor permit provide nonaudit services committee ensure auditor objectivity audit assurance service independence safeguard policy require preapproval service include tax regulatory compliance committee service total fee nonaudit work treasuryrelate service exceed audit fee special circumstance code conduct reporting line clear advantage company auditor undertake additional work service include audit number establish policy include auditrelated tax service preapproval detailed code conduct available governance section particular service category service subject website confidential reporting line report specific budget nonaudit service investigation unlawful conduct update version code competitive tender financial service provider line conduct publish january group procurement process skill experience fair balance understandable assessment external auditor suitable supplier nonaudit service consideration case request proposal key compliance requirement group financial submit relevant cet member cfo approval statement annual report account fair balanced understandable coordination review groupwide provision nonaudit service contribution annual report account follow establish document process perform parallel guideline set group policy engage formal process undertake external auditor external auditor provide nonaudit service include committee receive summary approach take ascertain skill experience external auditor management preparation gsk annual report suitable supplier nonaudit service account ensure meet requirement code ensure adequate safeguard place objectivity enable committee board confirm independence group audit threaten gsk annual report take fair balanced compromise understandable ensuring fee level exceed annual committee evaluation audit fee committee annual evaluation carry committee external auditor management report regularly chairman conclude committee continue operate committee extent service provide accordance effectively participation member executive preapproval fee services perform management attendee member comment favourably committee preapprove additional service caseby good level access committee chairman case basis fee pay company auditor associate set detail give note financial term enhancement committee deliberation statement operating profit agree heighten focus time management attention key risk area meeting assist committee possible accounting firm engage undertake overall effectiveness nonaudit services gsk annual report nomination committee report search process broad selection criterion generally focus achieve balance continental european british american emerge market experience individual expertise capability develop sector speciality mwm egon zhender specialise recruitment high calibre nonexecutive director engage ensure widest possible pool candidate available select mwm egon zhender provide recruitment consultancy service committee dossier potential nonexecutive appointee consider committee candidate shortlist interview merit objective criterion assess relevant qualification time commitment interview suitable candidate committee please recommend board han wijer potential nonexecutive director appoint board april board consider appointment achieve aim appoint sir christopher gent candidate experience run global company nomination committee chairman currently intend sir christopher gent step chairman end committee progress membership search successor membership nomination committee committee appointment date attendance meeting board committee change set board proactive approach refreshment board result orderly change composition board attendance committee recommendation committee set meeting member committee member sir christopher gent sir crispin davis stand reelection agm chairman year service sir robert wilson stand january december reelection agm year service give professor sir roy anderson october number recent appointment longstanding sir crispin davis july board member step board sir sir deryck maughan july deryck maughan agree stand reelection shareholder year stepping board tom swaan october agm chairman sir deryck conducting search sir robert wilson march chairmans successor sir deryck provide sir crispin davis retired board continuity balance composition board give tom swaan sir deryck maughan unable attend significant knowledge gsk business affair sir deryck committee meeting prior business commitment bring style role senior independent director succeed sir robert wilson closure agm attendee committee meeting include board confirm continue demonstrate characteristic independence carry role regular attend attendee attendee require board chief executive officer tom swaan succeed sir crispin davis chairman head human resource remuneration committee judy lewent succeed tom company secretary secretary swaan chairman audit risk committee january committee tom swaan member remuneration appropriate external adviser committee continue member audit risk committee judy member audit risk work committee committee april stephanie burn appoint remuneration committee main responsibility effect jing ulrich appoint audit main responsibility committee set risk committee effect date professor sir roy anderson sir robert wilson appointment new nonexecutive director step audit risk committee sir robert wilson committees particular area focus search appoint member corporate responsibility new nonexecutive director phase refreshment committee effect han wijers board progress appoint member remuneration corporate recruiting nonexecutive director committee evaluate responsibility committee effect october particular skill knowledge independence experience lynn elsenhans appoint member audit risk diversity include gender benefit balance board committee effect january appropriately appointment gsk annual report governance remuneration corporate governance board diversity corporate responsibility committee report committee responsible develop measurable objective support implementation board diversity policy include gender monitor progress achievement objective announce aspiration increase female representation board able report annual report encourage progress target board director woman stage continue refreshment board lynn elsenhans jing ulrich appoint new nonexecutive director july take cadre woman board please deliver early exceed target set maintain level female representation board level good representation woman management position illustrate gender diversity gsk global workforce continue support sir christopher gent effort increase pipeline woman senior position corporate responsibility committee chairman gsk support engagement executive search firm mwm egon zhender sign membership voluntary code conduct gender diversity good practice membership corporate responsibility committee committee appointment date attendance committee evaluation meeting set annual evaluation committee effectiveness undertaken committee chairman response share attendance committee conclude committee meeting member committee member continue operate effectively agree process committee identify new appointee improve sir christopher gent chairman january december stephanie burn december lynn elsenhans october daniel podolsky july hans wijers october sir robert wilson han wijer unable attend committee meeting prior business commitment attendee committee meeting include regular attend attendee attendee require chief executive officer chairman global vaccines general counsel head governance ethic assurance head global communication head global corporate responsibility company secretary executive independent external corporate responsibility adviser independent external corporate responsibility adviser augment gsk engagement stakeholder opinion sophia tickell appoint independent external adviser committee position hold previously march july tickell extensive experience pharmaceutical industry improve health system productivity sustainability energy supply distribution climate change policy shorttermism financial market gsk annual report cofounder director meteo direct people organisational change employee relation pharma future series aim align well societal inclusion diversity shareholder value hold number board advisory role leadership development approach performance management tickell attend meeting committee provide independent advice guidance corporate social employee health safety wellbeing responsibility matter chairman ceo volunteer main responsibility planet environmental performance supply chain main responsibility corporate responsibility committee set committee evaluation committee annual evaluation carry committee committee rolling agenda receive report chairman conclude committee continue operate member cet senior manager ensure progress effectively participation member executive meeting gsk corporate responsibility commitment management attendee set area focus review annual basis follow director report health innovate address currently unmet health need improve access product irrespective people purpose company act director live ability pay control eliminate disease report glaxosmithkline plc year end december affect world vulnerable people comprise page corporate governance report director responsibility statement page behaviour put interest patient consumer page investor information entitle drive value back robust company act board choose set policy strong compliance process strategic report matter require disclose people enable people thrive develop director report consider strategic importance individual deliver mission company follow planet grow business reduce isk management objective policy page environmental impact value chain ikely future development company committee review approve corporate strategic report responsibility report available reference esearch development activity page wwwgskcomresponsibility nclusion diversity work committee rovision information consultation employee committee focus attention issue page include arbon emission focus area specific topic consider director report draw present health investment include disease accordance reliance english company law develop world malaria open liability director connection report shall innovation strategy subject limitation restriction provide law director report approve duly authorise committee new partnership address access child mortality save children partnership board director february sign behalf behaviour patient incentive compensation program sell competency model embed valuesbase decision make organisation human right impact assessment sir christopher gent chairman conduct public disclosure clinical research transparency detail datum february trial result replacement refinement reduction use animal research development responsibility supply chain standard working practice diversity approach public policy interaction patient advocacy group gsk annual report governance remuneration director remuneration report director remuneration report chairman annual statement remove business committee review effort diversification measure sir andrew team improve performance share plan psp global public health increase transparency defer annual bonus plan clinical datum modernise gsk dabp matching award commercial practice interaction onwards business customer ongoing investigation diversification remain important authority china consider business mix appropriate committee sir andrew growth deliver board mindful impact issue additional focus reputation company specific measure remain result bonus award performance measure continue lower equal weighting change executive continue align effect increase proportion personal interest shareholder award base tsr adjust sir andrew elect year free cash flow new product defer maximum permit dear shareholder performance company dabp december extend time horizon hold twice value chairman gsk remuneration introduce additional twoyear gsk share require company share committee committee please hold period psp award ownership requirement present director remuneration report executive director seek remuneration executive relate onwards approval agm line performance annual bonus new remuneration reporting regime committee decide longterm incentive psp award dabp director remuneration report split appropriate award executive matching award describe annual separate report annual report director salary increase report remuneration page remuneration subject consistent average salary advisory shareholder vote agm budget employees agenda remuneration policy report business committee hold shareholder meeting subject bind vote furthermore committee decide november share update remuneration matter appropriate key decision change month proposal onwards increase annual longterm executive remuneration environment incentive opportunity executive committee continue continue evolve pace director executive remuneration arrangement new reporting regulation offer fresh review continue opportunity discuss remuneration performance pay regular dialogue shareholder practice policy shareholder group generate good tsr hold annual meeting gsk large proud track record listening performance formation investor later listen view view shareholder billion cash return feedback number decision year shareholder determine remuneration committee company keen relate executive remuneration ensure award committee view interest external view remuneration incentive arrangement remain appropriate executive team demonstrate strong matter particular consult gsk longterm interest delivery successful implementation widely remuneration policy shareholder key change group strategic priority particular shareholder feedback input highlight exceptional year productivity respond issue raise review design gsk deliver sale earning growth please receive support investor longterm incentive main line guidance lead industry consult objective simplification new product approval new commend report annual report respond concern previously raise product strengthen business remuneration remuneration policy investor result respiratory vaccine hiv oncology report shareholder approval review investor consultation importantly committee note agm year change way substantial future opportunity remain longterm incentive operate group total new molecular entity currently phase iiiii development action take streamline tom swaan increase focus group remuneration committee chairman noncore product asset february divest proceed billion ongoing organic structural initiative deliver incremental yearonyear saving million gsk annual report annual report remuneration total remuneration audit value earn annual longterm total salary benefit bonus incentive pension remuneration awards committee specific circumstance line state principle apply clawbackmalus determine appropriate total remuneration executive director set table moncef slaoui sir andrew witty simon dingemans chairman ceo cfo global vaccine total total total total total total salary benefit total fix pay pay performance annual bonus include defer value earn lti awards matching award defer annual bonus plan performance share plan total value earn lti award total pay performance pension total remuneration note certain expense incur normal course business consider taxable benefit table include figure restate detail provide analysis value ltis earn sir andrew witty simon dingemans moncef slaoui set page performance period simon dingemans award dabp end december early period remuneration record dabp simon dingemans year end december detail pension accrue date executive director receipt pension gsk give follow consideration committee reduction outstanding award vest level malus apply respect executive director follow section provide detail element total remuneration include intend implement policy gsk annual report governance remuneration director remuneration report comparator group pay performance salary committee use primary pay comparator group average salary increase budget employee consider executive pay executive director approximately usa crossindustry global pharmaceutical comparator group comparator group committee decide executive director salary anglo american france sanofi increase line increase sir andrew witty simon astrazeneca switzerland novartis dingemans moncef slaoui receive group roche holdings base salary increase bhp billiton astrazeneca table set base salary executive directors usa abbvie year british american tobacco amgen diageo bristolmyers squibb base salary reckitt benckiser eli lilly change rio tinto johnson johnson sir andrew witty royal dutch shell merck simon dingemans sab miller pfizer moncef slaoui tesco unilever benefit audit vodafone follow table show breakdown gross cash value amgen abbvie include remuneration benchmarking benefit receive executive director include tsr comparator group onwards financial service company remove sir andrew simon moncef witty dingemans slaoui new regulatory regime remuneration apply sector pay structure comparable sab miller add benefit group employee benefit global pharmaceutical comparator group basis travel tsr comparator group feature longterm incentive awards international assignment benefit primary pay comparator group executive director total benefit show table benefit restate primary pay comparator group global employee benefit director crossindustry pharmaceutical travel sir andrew witty international assignment simon dingemans benefit moncef slaoui total benefit review ceo remuneration committee employee benefit include healthcare car allowance personal financial reference pay group lead european company advice life assurancedeath service selection base size complexity travel expense include car travel family spouse partner cost associate accompany director gsk business summary total package competitive positioning ceo deem taxable benefit individual total remuneration benchmarke moncef slaoui second november order enable close vaccine business assume operational responsibility group secondment end december line senior gsk expatriate receive appropriate assignment expense include accommodation location allowance relocation specific financial advice tax equalisation benefit comprise expense incur ordinary course business deem taxable benefit individual include table restate significant change provision benefit propose detail refer policy report crossindustry global pharmaceutical european crossindustry group group group low quartile median median upper quartile current position benchmarking include salary expect value incentive base committee agree benchmarke methodology gsk annual report pay performance audit annual bonus majority annual bonus opportunity base formal review performance stretch financial target outcome adjust reflect individual performance apply individual performance multipli financial measure bonus threshold target maximum payable achievement target bonus threshold reflect stretch nature bonus target performance target annual bonus base follow performance measure actual target link company financial strategic plan committee believe target remain commercially sensitive target disclose financial performance personal performance sir andrew witty core group operating profit core group profit simon dingemans individual objective interest tax moncef slaoui vaccine performance detail policy report financial core group operating profit core group profit interest tax performance company performance term core group operating profit core group profit interest tax represent strong delivery group despite unexpected challenge reflect improve balance sale base reflect improvement european business effective cost control financial efficiency vaccine performance target year pipeline growth value exceed reflect productive period output company history major new product approve breo ellipta anoro ellipta tafinlar mekinist tivicay new injectable quadrivalent flu vaccine launch additional regulatory filing complete company pipeline remain extensive new molecular entity nme phase iiiii clinical development gsk remain track deliver target longterm rate return spend target year vaccine performance exceed reflect strong sale particular infanrixpediarix fluarix flulaval boostrix table set matter committee consider respect individual objective set executive director personal performance sir andrew witty sir andrew continue demonstrate strong leadership gsk remains challenge operate environment healthcare sir andrews remuneration reflect strong delivery group strategy area business subsequent realisation return shareholder gsk deliver sale earning growth core eps cer line market guidance sale growth generate multiple business geography reflect successful implementation group strategy source growth broadly year exceptional productivity gsk lead industry new product delivery major product approve additional regulatory filing complete productivity set backdrop continue improvement estimate rate return new product launch strengthen business respiratory vaccine hiv oncology group pipeline opportunity remain substantial total nme currently phase iiiii development phase iii start plan potential new product sir andrews leadership group generate good tsr performance formation gsk billion cash return shareholder fullyear dividend pence share repurchase billion sir andrew continue strengthen focus gsk core business area group divest noncore product asset proceed billion gsk increase shareholde indian consumer subsidiary ongoing organic structural initiative deliver incremental yearonyear saving million new efficiency result group strategic priority simplify business increasingly evident manufacture supply chain core business service sir andrew continue adopt industryleade position multiple corporate responsibility issue year gsk widely acknowledge take innovative step improve global public health develop country increase access transparency clinical datum modernise commercial practice interaction customer sir andrew request impact ongoing investigation chinese authority group subsidiary business china consider board evaluation performance gsk annual report governance remuneration director remuneration report performance target continue personal performance simon dingemans gsk deliver sale earning growth core eps cer line market guidance simon dingemans continue drive operate financial efficiency yearonyear cost saving million contribute overall performance increase core earning share constant currency basis simon drive delivery billion adjust free cash flow billion realise divestment give company flexibility need protect credit profile fund organic investment restructuring programme meet commitment grow dividend share buyback bolton acquisition continue achieve reduction effective core tax rate moncef slaoui moncef slaoui deliver year exceptional performance term approval filing pipeline detailed leadership vaccine business deliver solid sale growth despite adverse impact cervarix sale result suspension recommendation use hpv vaccine japan successfully establish new integrate way work part business create strong new product launch capability follow table show actual bonus earn compare opportunity opportunity level achieve bonus pay salary salary target maximum sir andrew witty simon dingemans moncef slaoui operation annual bonus plan change propose operation annual bonus plan inevitably target link directly financial strategic plan commercially sensitive committee consider appropriate disclose annual bonus target year detail performance achieve disclose annual report longterm incentive plan audit defer annual bonus plan matching award performance share plan level participation executive table show performance share plan psp award level director show table maximum executive director matching award grant respect deferral bonus total bonus defer award level award level matching share ad award award base salary base salary sir andrew witty share sir andrew witty shares simon dingemans share simon dingemans share moncef slaoui ad moncef slaoui ad vest matching award performance period end sir andrew wittys psp award subject december show page twoyear vest period year total performance condition matching award psp dabp matching awards subject performance defer annual bonus plan dabp continued employment performance share plan describe gsk annual report award performance period end december audit committee review performance psp dabp matching award grant executive director performance achieve year december actual vest level set table committee previously provide estimate vest award gsk annual report estimate base performance achieve time follow reflect performance achieve course performance period discretion exercise determine vest level commercial sensitivity target new product business diversification disclose time grant committee commit disclose time vest target show table performance vest measure relative weighting performance target performance achieve maximum award business business diversification measure base aggregate threeyear revenue diversification target vaccine consumer healthcare dermatology emerge market asia performance pacific japan vest schedule show aggregate sale period billion target vest maximum billion billion billion threshold billion new product new product performance measure base aggregate threeyear performance revenue target new product sale new product define product launch performance period precede year product launch year include vest schedule show aggregate sale period billion target vest maximum billion billion billion threshold billion adjust free adjust free cash flow afcf year billion line cash flow committee agree principle include adjustment number material performance distort item include legal settlement exchange rate movement special pension contribution afcf vest schedule disclose time grant threshold award vest achieve afcf billion achieve billion achieve billion maximum achieve billion straightline vest point relative tsr gsk tsr rank position comparator group pharmaceutical performance company gsk company vest schedule comparator group set awards total vest respect straightline vest apply point award performance period end december audit award grant executive director base performance year performance year portion award measure year december lapse gsk tsr rank position comparator group pharmaceutical company gsk company gsk annual report governance remuneration director remuneration report update performance ongoing awards committee review performance psp dabp matching award grant executive director follow table provide estimate vest take account performance date actual vest level determine base performance threeyear performance period indication regard prediction final vest level award performance period end december performance measure relative weighting performance update business business diversification performance award measure aggregate threeyear sale vaccine dermatology diversification consumer healthcare emerge market asia pacific japan threshold performance result vest maximum performance performance threshold result vest base aggregate sale base performance measure definition vest currently estimate maximum element new product new product sale performance measure aggregate threeyear sale new product launch threeyear performance performance period precede year threshold performance result vest maximum performance threshold result vest base aggregate sale new product base performance measure definition vest currently estimate threshold adjust free adjust free cash flow afcf vest schedule award disclose time grant cash flow threshold award vest achieve afcf billion achieve billion achieve performance billion maximum achieve billion straightline vest point base adjust free cash flow base performance measure definition vest currently estimate threshold relative tsr period january december gsk tsr rank position comparator group performance pharmaceutical company gsk company vest schedule comparator group set awards rank position remain level vest threshold current estimate potential total vest award vest award performance period end december audit performance measure relative weighting performance update business business diversification performance award measure aggregate threeyear sale vaccine consumer diversification healthcare emerge market asia pacific japan threshold performance result vest maximum performance performance threshold result vest good sale year business area base aggregate sale year base performance measure definition vest currently estimate maximum element new product new product sale performance measure aggregate threeyear sale new product launch threeyear performance performance period precede year threshold performance result vest maximum performance threshold result vest strong sale new product year gsk track deliver target longterm rate return spend base aggregate sale new product year base performance measure definition vest currently estimate adjusted free adjust free cash flow afcf vest schedule award disclose time grant cash flow threshold award vest achieve afcf billion achieve billion achieve performance billion maximum achieve billion straightline vest point base adjust free cash flow year performance measure definition vest currently estimate relative tsr period january december gsk tsr rank position comparator group performance pharmaceutical company gsk company vest schedule comparator group set awards rank position remain level vest threshold current estimate potential total vest award vest gsk annual report performance target award inevitably measure link directly strategy commercially sensitive particular committee consider appropriate disclose target new product performance grant result competitive harm target disclose gsk annual report end performance period detail extent meet committee provide update estimate vest target performance period performance target vest schedule set table award performance period end december performance measure relative weighting link strategy vest schedule new recognise importance future business performance product growth threshold vest performance revenue target base new product sale maximum incentivise well performance new product threshold define product launch performance period precede year performance period product launch year include measurement aggregate threeyear revenue target award new product sale reflect growth historic performance new product sale adjust free recognise importance effective work capital performance cash flow cash management target vest performance maximum billion billion billion threshold billion straightline vest point relative tsr focus delivery value shareholder tsr ranking performance relative tsr comparator group comprise comparator gsk global pharmaceutical company group vest relative tsr measure year maximum twelvemonth averaging period tsr measure local currency threshold median comparator group astrazeneca bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck novartis pfizer roche holding sanofi vest schedule base deliver vest median performance comparator group company median fall company threshold vest achieve median performance gsk annual report governance remuneration director remuneration report historical vest gsk ltis follow table show historical vest level companys longterm incentive plan defer annual bonus plan matching award performance share plan share option plan respect award executive defer annual bonus plan performance share plan share option plan vest vest vest vest vest total adjust free new business total year vest tsr cash flow product diversification vest eps grant performance period defer annual bonus plan award subject wholly tsr performance award subject performance measure psp award allemployee share plan payment past director audit executive director participate allemployee share julian heslop retire march outstanding balance plan include sharesave sharereward psp award performance period end december lapse performance criterion meet sharesave plan revenue customs approve plan open employee participant save month payment loss office audit net salary fix term year end payment loss office executive director saving period option buy gsk share discount market price set launch saving contract sir andrew witty simon dingemans share ownership requirement monthly contribution sharesave plan align interest executive shareholder sharereward plan revenue customs approve executive require build maintain significant holding plan open employee term participant share gsk time contribute month gross salary purchase executive require continue satisfy shareholde gsk share company match number gsk share requirement minimum month follow retirement buy month arrangement sir andrew witty company simon dingemans contribute month buy share sharereward plan current share ownership requirement sor set table dilution limit award plan incorporate dilution limit share ownership requirement consistent guideline provide association british ceo base salary insurer limit roll year period executive director base salary plan roll year period executive share plan cet member base salary estimate dilution exist award year december follow shareholding purpose sor february achievement sor base average share price working day precede date set follow gsk employee share plans executive share plan table audit holding sor purpose increase achievement february december shareholding sor sir andrew witty simon dingemans moncef slaoui outstanding share award subject performance criterion continue employment include shareholding purpose sor actual limit actual limit gsk annual report pension audit arrangement current executive director set table pension arrangement sir andrew witty sir andrew witty member glaxo wellcome define benefit pension plan accrual rate final pensionable salary plan close new entrant section plan sir andrew member provide normal retirement age maximum pension value rd pensionable salary april pensionable earning increase limit annum member include sir andrew simon dingemans simon dingemans member gsk pension plan pension contribution instead receive cash payment lieu pension base salary line gsk define contribution pension plan rate simon dingemans receive death service illhealth insurance provide pension plan include employee benefit moncef slaoui moncef slaoui member cash balance pension plan supplemental cash balance pension plan provide executive pension credit gsk make annual contribution moncef slaouis pension plan base salary plan provide cash sum retirement fund increase interest rate set annually advance base year treasury bond rate plan entitlement spouse pension pension increase moncef slaoui active member belgium fortis plan defer member plan define benefit plan lump sum payable normal retirement age company contribution plan moncef slaoui member gsk saving scheme open employee executive supplemental saving plan essp saving scheme open executive accrue benefit government limit impose gsk plan contribution plan invest range fund combine contribution rate plan core contribution plus match total base salary bonus bonus defer defer annual bonus plan follow table show breakdown pension value set sir andrew witty simon dingemans moncef slaoui pension remuneration value define benefit define benefit belgian define benefit employer cash contribution member contribution total pension remuneration value pension remuneration figure calculate accordance methodology set remuneration regulation calculate define benefit pension value difference accrue pension accrue pension increase inflation define benefit belgium define benefit multiply result negative value deem zero calculate total value amount translate euro dollar exchange rate sir andrew detail pension value set table accrue pension accrue pension pension remuneration sir andrew witty value fund unfunded total andrew join gsk predecessor company progress role increase seniority gsk appoint ceo time build pensionable service different tier glaxo wellcome pension plan current pension entitlement product service progression gsk moncef slaoui detail pension value set table accrue pension accrue pension pension remuneration moncef slaoui value fund unfunded belgium fund essp total moncef slaoui joined gsk predecessor company progress number senior role gsk appoint chairman research development june time build pensionable service belgium fortis plan cash balance plan supplemental pension plan annual employer cash contribution plan executive supplemental saving plan current pension entitlement product service progression gsk gsk annual report governance remuneration director remuneration report performance graph table percentage change remuneration ceo follow graph set performance company relative base salary benefit annual bonus ftse index pharmaceutical performance ceo sir andrew witty comparator group year period december employee graph prepared accordance remuneration regulation indication likely vest award reflect salary earn benefit receive annual bonus grant company incentive plan index earn respect compare wide select comparison purpose reflect index employee population salary increase include annual salary gsk constituent industry operate review additional change year promotion increase benefit employee reflect change benefit policy level year reflect change level benefit individual receive result change role promotion population consider relevant comparison closely reflect economic environment encounter ceo relative importance pay follow table set percentage change group dividend shareholder share buyback total employee pay change total employee pay dividend share buyback glaxosmithkline total return figure table set page glaxosmithkline pharma peers total return index dividend figure include supplemental dividend ftse total return index million pay dividend declare respect index comprise astrazeneca bristolmyers squibb eli lilly million million increase johnson johnson merck novartis pfizer roche holding sanofi timing share buyback influence market condition price remuneration table total employee pay group employee globally external appointment executive director ceo board encourage executive director hold external sir andrew witty directorship establish role ceo single figure broaden experience development help increase remuneration pool candidate nonexecutive director outside annual bonus award appointment consider nomination committee maximum ensure cause conflict interest vest lti award approve chairman behalf board company maximum policy remuneration earn appointment keep bonus amount include amount pay individual executive director operational efficiency bonus place year overall moncef slaoui receive relation maximum receivable subject limit base salary membership qatar biomedical research institute scientific respect psp award sir andrew advisory committee external appointment outstanding award share option grant receive remuneration sir andrew witty lapse include total vest simon dingemans hold external appointment percentage distort effect aggregate conditional remunerate share share option respect psp award sir andrew outstanding award share option grant lapse include total vest percentage distort effect aggregate conditional share share option respect threeyear element psp award respect fouryear element psp award threeyear element psp award dabp matching award respect fouryear element psp award psp award dabp matching award gsk annual report remuneration committee adviser committee committee access external advice require role committee year committee carry formal review independent role committee set company remuneration adviser committee result review committee policy gsk able recruit retain motivate decide reappoint deloitte llp provide independent advice executive remuneration policy regularly review executive remuneration committee chairman agree ensure consistent company scale scope protocols deloitte provide advice committee operation support business strategy growth plan satisfied advice receive deloitte helps drive creation shareholder value objective independent deloitte member remuneration consultant group term reference voluntarily operate code conduct relation committee term reference available executive remuneration consulting code conduct company website term reference review find wwwremunerationconsultantsgroupcom annually revise december light deloitte provide independent commentary matter well practice new remuneration regulation consideration committee provide update market practice legislative requirement deloitte fee advice governance provide committee fee board consider member committee charge time material basis deloitte llp provide independent nonexecutive director accordance consulting tax assurance service gsk year corporate governance code exception sir christopher committee satisfied compromise gent chairman company consider independent independence advice receive deloitte appointment tower watson provide additional market datum committee committee meet time schedule meeting member attending follow commitment shareholder attendance committee engage regular dialogue shareholder committee hold annual meeting gsk large investor discuss member meeting feedback remuneration policy particular committee member discuss significant change policy measure tom swaan assess performance chairman january stephanie burn shareholder vote remuneration matter sir christopher gent january vote judy lewent january total vote total vote total vote withhold sir deryck maughan july agm cast billion million han wijers october sir deryck maughan hans wijer unable attend committee meeting prior business commitment addition schedule meeting committee meet occasion consider remuneration matter review year include review longterm incentive design remuneration report new regulation committee meet quorate basis occasion approve formal grant longterm incentive awards employee corporate executive team committee meeting usually include close session member committee present individual invite attend committee meeting year executive committee attendee involve decision present discussion remuneration attendee committee meeting include regular attend attendee attendee require ceo cfo head human resource head reward secretary committee committee adviser deloitte llp gsk annual report governance remuneration director remuneration report principal activity matter address committee principal activity matter address set remuneration month overall incentive governance matter january approve executive remuneration review approve executive review draft remuneration report include salary ceo cfo bonus chairman global vaccine set bonus objective remuneration environment update february review lti performance outcomes approve remuneration report approve vest outstanding lti awards lti awards approve lti measure target award grant award executive director march remuneration environment update review shareholder feedback include consideration new reporting set committee agenda regulations july update new remuneration reporting review longterm incentive design review agm feedback external regulation include early draft performance measure comparator environment remuneration report group time horizons approve committee evaluation process cet remuneration review review independent adviser july grant interim lti awards executive august grant main share value plan award executive september review pay comparator group continuation review longterm review external remuneration incentive design performance measure environment comparator group time horizons october update executive pension update lti vest award review chairman fee arrangement review draft disclosure remuneration report november review term condition approve material annual investor policy meet november annual meeting investor december annual pay review review feedback shareholder approve executive director meeting salary review finding committee evaluation review draft remuneration report gsk annual report nonexecutive director letter appointment term engagement nonexecutive director chairman nonexecutive director set letter appointment available inspection company aim provide chairman nonexecutive company register office agm director fee competitive pay nonexecutive director initial appointment company equivalent size complexity subject limit subsequent reappointment subject election contain gsk article association periodic reelection shareholder nonexecutive director letter appointment review chairman fee contain provision notice period compensation sir christopher gent take role chairman january appointments terminate chairman fee increase january approximately sir follow table show date initial letter appointment christopher total fee deliver share nonexecutive director defer step board fee review nonexecutive director date letter appointment plan increase chairman sir christopher gent elect increase proportion fee deliver share professor sir roy anderson september january onwards stephanie burns february review nonexecutive director fee stacey cartwright march nonexecutive director fee increase january lynn elsenhans increase supplemental fee minimum judy lewent march fee continue deliver share defer sir deryck maughan nonexecutive director step board daniel podolsky july tom swaan december fee review plan increase je ulrich nonexecutive director fee apply january set hans wijers january sir robert wilson june annum standard annual cash retainer fee table audit set value fee benefit supplemental fee receive nonexecutive director form cash chairman audit risk committee share ad detail nonexecutive director senior independent director scientificmedical expert share allocation plan set chairman remuneration corporate responsibility committee nonexecutive director undertake intercontinental travel meeting meet christopher gent chairman corporate responsibility committee receive additional fee list restate benefit nonexecutive director fee fee emolument cash sharesad benefit total cash sharesad benefit total professor sir roy anderson stephanie burn stacey cartwright sir crispin davis lynn elsenhans sir christopher gent judy lewent sir deryck maughan daniel podolsky tom swaan jing ulrich han wijers sir robert wilson enefit primarily consist travel subsistence cost incur normal course business relation meeting board committee matter gskhoste event consider taxable table include figure restate overseasbased nonexecutive director include travel meeting onexecutive director pay gbp convert exchange rate set annually base average rate quarter year prior payment rate review move significantly year ames murdoch nonexecutive director receive fee benefit share build number year nonexecutive director share allocation plan release year detail crispin davis retired board han wijer join board april gsk annual report governance remuneration director remuneration report director interest share audit follow interest director company office december connect person show breakdown share plan interest december total director interest sharesad option unveste unvested unvested unvested february december january subject subject subject subject vest exercise performance performance performance performance exercise year executive director share sir andrew witty simon dingemans moncef slaoui ad moncef slaoui nonexecutive director share professor sir roy anderson stephanie burn stacey cartwright tom swaan sir christopher gent hans wijers sir robert wilson ads stephanie burn lynn elsenhans judy lewent sir deryck maughan daniel podolsky jing ulrich nveste share ad unvested option hold executive director subject performance reflect bonus deferral defer annual bonus plan sharesave awards gsk ad represent gsk share otal interest include share purchase glaxosmithkline sharereward plan share award sir andrew witty simon dingemans respectively plan balance share plan follow sharereward plan february december january sir andrew witty simon dingemans moncef slaoui participate sharereward plan otal interest include share ad result deferral bonus subsequent reinvestment dividend defer annual bonus plan total show table include bonus deferral exclude unvested matching award subject ongoing performance criterion amount represent gross share ad balance prior sale share ad satisfy tax liability defer annual bonus plan bonus deferral february december january sir andrew witty shares simon dingemans share moncef slaoui ad otal interest february include share ad vest performance element performance share plan award sell satisfy tax liability vest amount page detail moncef slaoui total interest include ad purchase plan executive supplemental saving plan essp ad award moncef slaouis connect person share value plan svp relevant balance follow moncef slaoui february december january retirement saving plan share value plan executive director moncef slaoui eligible receive award svp svp award show reflect holding moncef slaouis connect person employee gsk award subject threeyear vest period vest contingent continue employment gsk gain arise vest include moncef slaouis total remuneration figure year connect person grant ad august grant price face value moncef slaouis total interest share include psp award hold connected person employee gsk award subject performance criterion relevant employee cet december connect person hold ad award comprise award ad ad include dividend reinvestment gsk annual report sir andrew witty simon dingemans unvested option subject performance include holding respectively december sharesave plan participate term employee sharesave award grant sir andrew witty simon dingemans grant option plan december remainder unvested option subject performance relate bonus deferral structure nilcost option dabp executive director follow table provide detail vest unexercised option december share option plan sop gsk grant option plan executive director annual basis number share option date grant lapse date exercise price sir andrew witty moncef slaoui ad vest unexercised option totalling moncef slaoui represent ad option hold moncef slaouis connect person employee gsk follow table set detail option include nilcost option dabp annual investment plan exercise executive director simon dingemans exercise option year nilcost option dabp exercisable number share market gain exercise type award date grant option date exercise exercise price price exercise sir andrew witty sop dabp deferral dabp match moncef slaoui annual investment plan respect option sop sharesave plan remuneration receivable executive director calculate date option vest remuneration difference executive director require pay buy share ad total value share ad vest date executive director choose exercise option vest date subsequent increase decrease realise movement share ad price vest date date exercise increase decrease value result investment decision executive director record remuneration option vest executive director nonexecutive director total interest include share ad receive fee share allocation plan detail balance note dividend receive share ad plan convert share ad december han wijer join board april gsk annual report governance remuneration director remuneration report defer annual bonus plan matching award defer annual bonus plan dabp matching award annually executive director base individual mandatory deferral voluntary bonus election company match share ad oneforone depend company performance threeyear performance period performance condition vest level describe page report award ukbase executive director form nilcost option award vest ukbased executive director choose exercise award time year date grant awards usbased executive director conditional award share remuneration receivable respect matching share ad calculate share ad price date relevant award vest executive director choose exercise nilcost option vest date subsequent increase decrease realise movement share price vest date date exercise increase decrease value result investment decision record remuneration dividend reinveste nilcost option conditional award share executive director date vest follow table provide detail executive director respect dabp matching awards market price grant vest represent closing share price date performance period sir andrew witty share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant dividend reinveste vested lapse unvested february vest lapse february vest share number share market price vest gain remuneration remuneration performance period simon dingemans share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant dividend reinveste vested lapse unvested february gsk annual report defer annual bonus plan matching award continue performance period moncef slaoui ad market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant dividend reinveste vested lapse unvested february vest lapse february vest ad number ad market price vest gain remuneration performance share plan award performance share plan psp award executive director annual basis term psp number share ad vest determined follow end relevant performance period dependent gsk performance period performance condition vest level describe page dividend reinveste performance share ad award executive performance period date vest vest participant receive relevant number share participant defer receipt vested award remuneration receivable respect performance share calculate share ad price date relevant psp award vest psp award sir andrew witty year performance period deed award specify award subject year vest period year total year period additional performance criterion awards lapse sir andrew dismiss cause remuneration respect award consider realise follow determination remuneration committee vest level initial award remuneration recognise end threeyear performance period follow table provide detail executive director respect psp award market price grant vest represent closing share price date executive director performance period sir andrew witty share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant dividend reinveste vested lapse unvested february vest share number share market price vest gain remuneration remuneration gsk annual report governance remuneration director remuneration report performance share plan award continue performance period simon dingemans share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant dividend reinveste vested lapse unvested february vest share number share market price vest gain remuneration performance period moncef slaoui ad market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant dividend reinveste vested lapse unvested february vest share number ad market price vest gain remuneration remuneration gsk annual report share allocation plan nonexecutive director table set accumulate number share ad hold nonexecutive director december share allocation plan relation fee receive board member movement account year number share ad december dividend allocate december share allocation plan nonexecutive director footnote pay reinveste elect share professor sir roy anderson stacey cartwright sir crispin davis sir christopher gent james murdoch tom swaan sir robert wilson hans wijers ads stephanie burn lynn elsenhans judy lewent sir deryck maughan daniel podolsky jing ulrich crispin davis retired board elect receive share share allocation plan immediately retire board ames murdoch retired board elect receive share share allocation plan end quarter hans wijer join board april opening balance record date gsk annual report governance remuneration director remuneration report director senior management information provide compensation interest director senior management group group purpose group define nonexecutive executive director member corporate executive team company secretary financial year follow table set aggregate remuneration group period serve capacity remuneration total compensation pay aggregate increase accrue pension benefit net inflation aggregate payment define contribution scheme member group award share ad company share plan set table award dividend reinvestment award award share ad share ad defer annual bonus plan performance share plan defer investment awardsa share value planb notional share ad executive director eligible receive defer investment award participate share value plan february group follow interest share ad company holding issue executive share plan describe note financial statement employee share scheme interest february share ad note own represent issue share capital unexercised option defer annual bonus plan include share ad vest unexercised performance share plan include share ad vest defer defer investment award notional share ad share value plan gsk annual report remuneration policy report remuneration policy total remuneration executive director comprise follow element value earn salary benefit annual longterm pension total bonus incentive remuneration awards committee specific circumstance line state principle apply clawbackmalus determine appropriate future policy table company remuneration policy respect element outline table salary benefit international assignment policy purpose link strategy purpose link strategy purpose link strategy provide core reward role level set recruit retain high calibre gsk require executive director relocate individual execute business strategy order meet business requirement set level appropriate secure retain high calibre individual need deliver group operation operation strategic priority executive director eligible receive line policy employee operation benefit line policy employee secondment travel expense provide vary location include car executive overseas placement facilitate individual role experience performance allowance healthcare life assurancedeath relocation process provide continue independently source datum relevant service provide standard living assignment comparator group consider determine individual pension arrangement personal salary level international assignment allowance cover financial advice contractual postretirement relocation cost accommodation base salary increase typically effect benefit executive director eligible size family appropriate security location quarter year participate allemployee share scheme allowance relocationspecific tax financial sharesave sharereward plan salary normally pay currency advice school fee tax equalisation subject term executive director home country employee opportunity opportunity order recognise high business travel relocation benefit dependent number formal maximum limit requirement role executive director factor home host country family size ordinarily salary increase broadly line entitle car travel accompany duration assignment average increase wide gsk spousepartner business trip workforce benefit include expense incur ordinary possible provide typical value course business deem limit increase higher reflect taxable benefit individual change scope individual role performance measure responsibility experience salary adjustment benefit provision tailor reflect market reflect wide market condition practice geography executive geography individual operate director base different policy apply current future executive director base salary level set different country performance measure opportunity overall performance individual key formal maximum limit benefit cost consideration determine salary increase fluctuate depend change provider cost individual circumstance detail current benefit cost set annual report remuneration performance measure gsk annual report governance remuneration director remuneration report pension purpose link strategy opportunity pension arrangement provide competitive pension arrangement exist executive eligible benefit level retirement income director follow senior executive sir andrew witty member legacy cash balance pension plan operation glaxo wellcome define benefit plan supplemental cash balance pension plan pension arrangement structure accrual rate final pensionable salary include executive pension credit provide accordance plan operate annum april pensionable maximum contribution base salary country individual likely retire earning increase limit annum pension plan individual choose member include sir andrew witty member pension plan cash lieu gsk plan relevant pension contribution pay instead simon dingemans member gsk retirement saving plan executive pension plan pension contribution supplemental saving plan core new executive director instead receive cash payment contribution salary bonus entitle join define contribution salary lieu pension contribution match contribution salary pension plan receive cash payment moncef slaoui member cash bonus lieu pension contribution balance pension plan gsk plan global individual member gsk executive supplemental saving plan legacy define benefit plan define defer member belgium eligible appropriate equivalent contribution plan alternative pension plan fortis plan arrangement excess arrangement subsequently appoint usuk arrangement policy new external recruit board remain member plan performance measure salary contribution define contribution plan match contribution line policy member plan salary cash payment lieu pension contribution annual bonus purpose link strategy opportunity performance measure incentivise recognise execution threshold maximum bonus opportunity base financial target individual business strategy annual basis executive director follow performance objective reward achievement stretch annual base core group profit interest threshold maximum financial strategic business target tax executive director ceo bonus bonus delivery personal objective cfo balance base core group base base operating profit executive director salary salary operation balance base relevant business unit financial operational business target ceo performance set start year committee cfo individual performance objective bonus level determine committee multiplier base achievement chairman global base performance target vaccine individual performance target apply individual objective set start bonus award performance year committee performance financial operational target objective assess committee executive director require defer bonus earn share ad appropriate year defer additional bonus earn overall maximum deferral defer share vest end year performance period defer bonus share eligible dividend equivalent date vest committee apply judgement make appropriate adjustment individual annual bonus amount clawback andor malus provision apply describe gsk annual report defer annual bonus plan dabp performance share plan psp purpose link strategy opportunity performance measure incentivise recognise delivery dabp equally weight performance long term business priority financial growth maximum bonus deferral annual bonus measure increase shareholder value compare mandatory additional new product performance pharmaceutical company voluntary adjust free cash flow addition provide alignment maximum matching opportunity level shareholder interest retention element share share basis subject performance relative tsr encourage longterm shareholding criterion year vest threshold maximum discourage excessive risk take psp performance normal maximum award limit time comparator group currently comprise operation base salary annum maximum initial gsk global pharmaceutical dabp value performance share company vest median rise defer share match subject grant psp individual vest upper quartile performance achievement performance condition year detail unveste year matching award psp rule allow committee award page page conditional share nilcost option award salary eligible dividend equivalent respect exceptional circumstance performance period current award level executive psp director follow conditional award annually vest dependent achievement performance condition year salary award onwards vested award ceo hold year cfo year total prior release ceo psp award subject chairman global vaccine additional twoyear vest period award eligible dividend equivalent date vest performance target dabp psp set start performance period clawback andor malus provision apply describe clawback malus effect annual bonus payable executive director require defer minimum annual bonus dabp event trigger event significant misconduct way violation regulation law significant gsk policy code conduct company ability claw year annual defer bonus vest unvested ltis separate recoupment committee establish investigate relevant claim misconduct additionally continuity responsibility initiation adverse event emergence problem adverse event take account assess annual bonus award lti vest level year problem identify future period committee appropriate adjustment individual annual bonus grant vest level lti awards reflect thisment individual annual bonus amount gsk annual report governance remuneration director remuneration report longterm incentive measure committee select equally weight performance measure focus executive director longterm remuneration delivery gsk key strategic priority psp dabp award executive director base new product performance adjust free cash flow relative tsr addition set robust target committee implement number safeguard ensure target meet sustainable way performance reflect genuine achievement target represent delivery value shareholder performance measure impact acquisition divestment quantify adjust event major adjustment calculation performance measure disclose shareholder vest principal safeguard detailed measure chairman audit risk committee member member remuneration committee provide input audit risk committee review group performance oversight risk factor relevant remuneration decision rationale performance measure calculate follow vest schedule annual report remuneration performance measure rationale calculation methodology new recognise importance future business target base sale new product launch product growth performance period precede year performance key indicator assess performance aggregate threeyear revenue target reflect growth pharmaceutical industry strength company product historic performance pipeline new product performance measure recognise importance future business growth vest reduce insufficient progress include measure order incentivise performance performance period gsk target return drive development sale new product investment committee believe robust appropriate measure committee recognise time time reflect actual delivery pipeline launch appropriate company respond emerge pandemic excellence support gsk ethical responsibility value impact revenue include committee consider add shareholder value provide underlying performance sufficiently positive adjust free recognise importance effective work capital aggregate threeyear adjust free cash flow target cash flow cash management adjustment materially distort item performance use cash flow performance measure intend include exchange rate movement major legal taxation recognise importance effective work capital management settlement special pension contribution generate cash asset future valuecreate investment return shareholder relative tsr focus delivery value shareholder relative tsr measure year month performance committee recognise delivery value average period tsr measure local currency shareholder key priority relative total shareholder return peer group global pharmaceutical company select order closely align interest executive director investors committee regularly review composition tsr comparator group gsk annual report annual bonus measure annual bonus design drive achievement gsk annual financial strategic business target delivery personal objective majority annual bonus opportunity base formal review performance stretch financial target outcome adjust reflect individual performance apply individual performance multipli reason commercial sensitivity specific personal objective keep confidential financial performance individual performance committee believe important majority ceo ceo cfos financial target base core group operating profit individual performance objective sir andrew witty set small element base core group profit interest tax board january year board focus strategic priority reflect wide responsibility drive profitable investment develop group follow end associate joint ventures financial year board review performance generally set objective determine appropriate bonus payable bonus measure employee include moncef slaoui performance link pipeline performance robust governance structure establish ensure bonus payable fairly reflect executive director productivity performance ceo set individual objective executive director recognise moncef slaouis current dual responsibility global line company strategy make recommendation vaccine element bonus currently base vaccine committee performance objective performance consistent executive director element end year recommendation consider bonus currently base core group profit interest committee determine level bonus payable tax approach recruitment remuneration committee determine remuneration package new committee mindful sensitivity relate recruitment executive director casebycase basis depend package particular buying right relate role market operate experience previous employment signon payment seek total remuneration level set reference relevant pay minimise arrangement certain circumstance comparator group appropriate allow future enable recruitment exceptional talent committee development role determine arrangement good interest company shareholder arrangement expect new executive director participate short possible likeforlike basis forfeit award longterm incentive plan basis exist director arrangement vary depend plan exceptional circumstance committee reserve arrangement place previous employer flexibility set incentive limit new executive director form cash share subject additional exist limit performance condition explanation provide committee retain flexibility recognition high payment compensation previous remuneration level variable pay gsk global pharmaceutical competitor forfeit signon payment committee use flexibility remuneration arrangement newly appoint executive consider good interest company director disclose soon practicable investor furthermore use flexibility relation appointment external recruit award line principle future policy table subject performance follow policy principle apply role chairman condition nonexecutive director pension arrangement external appointment executive chairman director set remuneration policy table fee set level competitive pay company equivalent size complexity fee pay partly benefit provide line policy exist share executive director nonexecutive director require meet business need relocation support fee level new nonexecutive director set provide line company policy basis exist nonexecutive director company subject internal appointment entitlement exist local law regulation fee pay partly share remuneration element continue include pension entitlement event nonexecutive director different role outstanding award case responsibility appoint fee level benchmarke internal appointment require executive director set reference comparable role company equivalent size contractual term include termination provision complexity gsk annual report governance remuneration director remuneration report loss office payment policy follow table set contractual framework executive director term specifically relate termination set detail policy duration company policy fix term contract generally contract new appointment expire line contract applicable policy retirement age contract exist executive director expire date show notice period notice period termination employ company executive director calendar month mitigation ability impose month noncompete period nonsolicitation restriction executive director consider important company ability protect group intellectual property staff light committee believe appropriate provide mitigation contract termination employment event executive director employment company terminate follow policy payment apply element remuneration loss office payment policy termination termination notice month annual salary payable termination company prorate notice payment period work termination payment respect notice period extend contract expiry date bonus element normally include termination payment term contract seek balance commercial imperative good practice company enforce noncompete clause current ceo chairman global vaccine month ontarget bonus payable redundancy termination notice statutory redundancy pay apply general severance policy apply retirement death illhealth injury disability termination payment lti award psp dabp matching awards govern plan rule approve shareholder termination notice unvested awards lapse redundancy retirement generally award vest original timescale subject original performance condition award month forfeit death illhealth injury disability generally award vest follow end financial year normally take account performance date award prorate time event change control psp dabp matching awards vest take account performance date normally take account proportion performance period elapse alternatively award exchange new award annual bonus termination notice individual individual serve notice termination date fall december bonus forfeit termination notice company redundancy retirement death illhealth injury disability termination date fall financial year eligible prorate ontarget bonus employ december bonus payable base actual result dabp defer termination notice defer share vest date termination bonus award redundancy retirement death illhealth injury disability generally defer share vest end financial year termination date fall benefit generally benefit continue apply termination date termination notice company retirement executive line policy applicable senior executive chairman global vaccine eligible future date receive continue medical dental insurance terminationretirement termination mutual agreement certain circumstance good interest company board manage proactively succession planning development senior talent pipeline circumstance board agree executive departure mutual agreement order apply committee need satisfied executive demonstrate performance line expectation require contribute orderly succession complete year service group termination date case executive director treat good leaver purpose gsk longterm incentive plan termination date fall financial year eligible prorate ontarget bonus employ december bonus payable base actual result case ceo member define benefit pension scheme pension payable later termination date age actuarial reduction gsk annual report termination employment continue difference remuneration policy committee anticipate exercise discretion executive director employee provide psp dabp plan rule respect termination payment unforeseen circumstance set remuneration level executive director good interest company shareholder committee consider prevail market condition necessary exercise discretion explanation competitive environment comparison remuneration provide executive company similar size complexity international reach position relativity pay executive director leave company committee employment condition broad gsk workforce carry assessment individual performance conduct time role determine individual particular committee consider range base salary rise performance conduct contrary legitimate expectation workforce part gsk ceo cfo company committee reserve right apply chairman global vaccine employ consider appropriate mechanism clawback relevant comparison population reflect reduction lapse outstanding incentive awards malus closely economic environment encounter individual ensure termination payment good interest principle apply remuneration policy executive company shareholder director employee remuneration offer case termination cause payment unvested executive director policy strong emphasis award forfeit share defer dabp performancerelate pay offer employee vest date termination accrue salary group expense salary benefit include pension tailor local market service contract table set relevant date current executive annual bonus plan apply wide employee population director service contract available review base business individual performance company register office office hour combination performancerelate restrict share plan apply wide employee population date effective contract date expiry date note allemployee share plan available employee sir andrew contract amend include revenue customs approve sharesave witty remove sharereward plan entitlement bonus termination company conduct regular employee survey include feedback remuneration matter simon dingemans wide organisation align performance reward system value introduce new moncef contract replace performance system formally evaluate employee slaoui principally need remove entitlement bonus termination senior people disincentivise unethical working practice clawback mechanism allow recover performancerelate pay gsk annual report governance remuneration director remuneration report scenario future total remuneration ceo chart opposite provide illustration future total remuneration executive director respect remuneration opportunity grant policy range potential outcome provide executive director underlie assumption set scenario base salary benefit pension figure base actual amount receive respect ongoing policy executive director assume defer annual bonus maximum permit receive corresponding matching award dabp include value lti award fix expect maximum amount show value lti awards dabp psp base bonus opportunity relevant multiple cfo salary respectively include amount respect dividend reinveste factor change share price vest period fix pay performance annual bonus lti payable expect annual bonus assume target financial performance achieve performance executive director result individual performance multipli increase financial performance element bonus apply result assume bonus salary sir andrew witty simon dingemans moncef slaoui respectively fix expect maximum lti awards threshold level vest assume maximum chairman global vaccine assume annual bonus payable maximum level award dabp psp vest fix expect maximum longterm variable remuneration annual variable remuneration fix remuneration gsk annual report nonexecutive director remuneration policy element purpose link strategy overview chairmans fee provide inclusive flat rate fee formal maximum fee review annually set competitive pay reference review chairman performance independently company equivalent sourced market datum size complexity subject remuneration committee responsible evaluating make limit contain gsk article recommendation board fee payable chairman association chairman participate discussion respect fee fee pay combination cash andor gsk share ad detail gsk nonexecutive director share allocation plan basic fee formal maximum fee review annually set reference independently source market datum chairman ceo responsible evaluating make recommendation board fee payable company nonexecutive director minimum deliver form gsk share ad detail gsk nonexecutive director share allocation plan supplemental fee provide additional compensation additional fee committee chairman intercontinental travel senior nonexecutive director independent director current fee level set annual exclude chairman take report remuneration additional board responsibility undertake intercontinental travel meeting benefit facilitate execution travel subsistence cost nonexecutive director incur responsibility duty require normal course business relation meeting board committee role matter gskhoste event overseasbase nonexecutive director include travel meeting nonexecutive director time time accompany spouse partner meeting event cost associate meet company instance deem taxable treat benefit nonexecutive director nonexecutive enhance link nonexecutive director total fee exclude director share director shareholder gsk chairman pay form gsk share ad allocate share allocation plan require nonexecutive director ad account receive significant nonexecutive director opportunity invest fee form gsk share balance fee share ad account ad gsk share ad notionally award nonexecutive director allocate interest account set table include director interest table accumulate balance gsk share ad notional dividend accrue pay nonexecutive director leave board leave nonexecutive director receive gsk share ad cash equivalent value gsk share ad date leave date payment later letter nonexecutive director nonexecutive director subject annual election reelection appointment chairman term engagement normally serve long year date election set letter appointment shareholder general meeting set table chairman subject annual appointment shareholder serve long year date election shareholder general meeting gsk annual report governance remuneration director remuneration report operation scope remuneration policy basis preparation current remuneration policy policy set page director remuneration report prepare intend policy gsk executive accordance company act large nonexecutive director apply close company mediumsize company group account report annual general meeting submit amendment regulation regulation accordance committee approval shareholder committee regulation follow part annual report currently intends operate accordance policy prior remuneration subject audit total remuneration figure annual general meeting exception additional executive director include detail element twoyear hold period performance share plan award remuneration salary benefit annual bonus longterm incentive apply award onwards award pension nonexecutive director fee emolument receive year director interest share include interest committee write policy principally relation gsk share plan payment past director payment loss remuneration arrangement ceo cfo chairman global office share ownership requirement holding vaccine whilst take account possible recruitment opinion thereon express remain section replacement additional executive director director remuneration report subject audit operation policy committee intend policy operate page refer audit section period set entirety consideration seek change policy period director remuneration report approve believe appropriate longterm success board director sign behalf company consultation shareholder seek shareholder approval general meeting draft policy committee reserve right remuneration payment payment loss office include tom swaan exercise discretion available connection remuneration committee chairman payment notwithstanding line policy february set term payment agree policy come effect time relevant individual director company opinion committee payment consideration individual director company purpose payment include committee satisfy awards variable remuneration relation award share term payment agree time award grant committee minor amendment policy set report regulatory exchange control tax administrative purpose account change legislation obtain shareholder approval amendment statement consideration shareholder view committee engage regular dialogue shareholder hold annual meeting gsk large investor discuss feedback remuneration policy governance matter annual meeting hold november tom swaan committee chairman shared update remuneration matter month proposal onwards particular covered change performance condition apply longterm incentive introduction additional twoyear hold period performance share award year total apply executive director award onwards policy require disclose remuneration policy report gsk annual report financial statement section director statement responsibilitie independent auditor report financial statement note financial statement financial statement glaxosmithkline plc prepare gaap gsk annual report financial statement director statement responsibility director statement responsibility relation group financial statement director responsible prepare annual report disclosure information auditor remuneration report group financial statement director office date report accordance applicable law regulation confirm company law require director prepare financial far aware relevant audit information statement financial year law director company auditor unaware require prepare group financial statement accordance take step ought take international financial reporting standard ifrs adopt director aware relevant audit european union prepare group financial statement information establish company auditor aware director elect comply ifrs issue information international accounting standard board iasb company law director approve group financial statement confirmation give interpret accordance satisfied true fair view provision section company act state affair group profit loss group period go concern basis page contain information performance group prepare financial statement director require financial position cash flow net debt position borrow select suitable accounting policy apply facility information include treasury risk management consistently policy exposure market credit risk hedging activity judgement accounting estimate reasonable give note financial statement financial instrument prudent relate disclosure make enquiry director reasonable expectation group adequate resource state group financial statement comply ifrs continue operational existence foreseeable future adopt european union ifrs issue iasb reason continue adopt go concern basis prepare subject material departure disclose explain financial statement group financial statement director responsible keep adequate accounting internal control record sufficient explain companys board audit risk committee review transaction disclose reasonable accuracy time assessment risk internal control framework operate financial position group enable ensure gsk consider effectiveness system internal group financial statement remuneration report comply control operation group year cover report company act article ia regulation date approval board director responsible safeguarding asset group take reasonable step prevention corporate governance code detection fraud irregularity board consider glaxosmithkline plc apply principle provision corporate governance code maintain group financial statement year end december financial reporting council describe corporate comprise principal statement support note governance section page comply set financial statement page report provision board consider annual report take responsibility auditor relation group financial fair balanced understandable provide statement set independent auditor report page information necessary shareholder assess group performance business model strategy group financial statement year end december require financial conduct authority list rule include annual report publish auditor consider director statement compliance print form available website director relation point corporate governance code responsible maintenance integrity annual report specify review website accordance legislation govern preparation dissemination financial statement access annual report website available outside comparable annual report year end december legislation different comprising report director remuneration report current director name function list financial statement additional information investor corporate governance section annual report approve board director sign behalf confirm good knowledge group financial statement prepare accordance ifrs adopt ifrs issue iasb true fair view asset liability sir christopher gent financial position profit group chairman february strategic report risk section annual report include fair review development performance business position group description principal risk uncertainty face gsk annual report independent auditor report members glaxosmithkline plc opinion overview audit approach opinion group financial statement define materiality true fair view state group affair set certain threshold materiality help december group profit cash flow determine nature timing extent audit procedure year end evaluate effect misstatement individually financial statement properly prepared accordance international financial reporting standard ifrss adopt base professional judgement determine materiality european union group financial statement million represent profit taxation prepare accordance requirement company act article ias regulation agree audit risk committee report misstatement identify audit million opinion read context misstatement view warrant remainder report report qualitative reason separate opinion relation ifrss issue iasb overview scope audit explain note financial statement group group financial statement consolidation reporting unit addition apply ifrss adopt european union comprise group operate business centralise apply ifrss issue international accounting function standard board iasb establish overall approach group audit opinion group financial statement comply ifrss determine type work need perform issue iasb reporting unit group audit team component auditor pwc pwc network firm operate audit instruction work perform component group financial statement prepare auditor determine level involvement need glaxosmithkline plc comprise audit work reporting unit able conclude group balance sheet december sufficient appropriate audit evidence obtain basis opinion group financial statement group income statement statement comprehensive income year end identify reporting unit view require audit complete financial information size group statement change equity statement risk characteristic specific audit procedure certain specify cash flow year end balance transaction perform reporting note group financial statement include unit additional procedure perform group summary significant accounting policy explanatory level give evidence need opinion information group financial statement financial reporting framework apply area particular audit focus preparation comprise applicable law ifrss adopt prepare financial statement director number european union subjective judgement example respect significant accounting estimate involve make assumption audit financial statement involve consider future event inherently uncertain primarily conduct audit accordance international standard focus work area assess director audit ireland isas ireland audit involve judgement available evidence form judgement obtain evidence amount disclosure evaluate disclosure financial statement financial statement sufficient reasonable assurance financial statement free material misstatement audit test examine information sampling cause fraud error include assessment auditing technique extent consider necessary provide reasonable basis draw conclusion obtain accounting policy appropriate group audit evidence testing effectiveness control circumstance consistently apply adequately substantive procedure combination disclose consider follow area require reasonableness significant accounting estimate particular focus current year complete list director risk area focus identify audit discuss overall presentation financial statement area focus audit risk committee report matter consider significant issue addition read financial nonfinancial information relation financial statement set annual report identify material inconsistency audit group financial statement identify information apparently materially incorrect base materially inconsistent knowledge acquire course perform audit aware apparent material misstatement inconsistency consider implication report gsk annual report financial statement independent auditor report independent auditor report continued area focus scope audit address area focus rebate discount allowance return test calculation accrual validate assumption reference party pharmaceutical vaccine business datum assess judgement take reasonableness historical trend focus area rebate discount evaluate design operating effectiveness control rebate allowance return arrangement discount allowance return process pharmaceutical vaccine business complex establish appropriate accrual require significant judgement estimate director director determine accrual billion necessary december core business service evaluate design test operating effectiveness key control simplification operating model migration centralise processing environment test accuracy group continue rollout enterprise completeness datum migration new erp control process wide resource planning system erp addition managed direct centrally audit work perform component auditor financial transaction processing centralise bpos bsc perform oversight visit significant entity impact business process outsourcing location bpos change accounting service centralise business service centre bsc consequently year significant change finance function identify heighten risk control design operation impact period transition potential implication allege illegal act consider ongoing work independent investigator appoint follow allegation chinese authority company assess scope sufficient result illegal act group chinese business investigation date support director conclusion identify follow risk perform oversight visit china review approach testing result allege illegal act rise component auditor fine legal penalty event assess director determination possible reliably estimate allegation prove financial effect allegation time appropriately record measured financial statement assess reasonableness assumption trade forecast carry value asset group director support carry value asset chinese business chinese business supportable light perform additional audit test certain location outside china subsequent decline trading design evaluate practice allege china occur location potential impact future business group illegal act similar alleged occur china occur group refer note group financial statement fraud revenue recognition evaluate relevant system test internal control validity presume risk fraud revenue timing revenue recognise financial statement completeness recognition isas ireland accrual rebate discount allowance return test journal entry pressure management feel achieve post revenue account consolidation identify unusual irregular item plan result assess accounting material new agreement trading arrangement focus validity revenue recognise customer wholesaler oneoff transaction close yearend accrual perform yearend sale cutoff testing check revenue record rebate discount allowance return correct period calculation complex involve estimation risk management override internal assess overall control environment group include arrangement control staff whistleblow inappropriate action interview senior management isas ireland require consider group internal audit function examine significant accounting estimate risk judgement relevant financial statement evidence bias director represent risk material misstatement fraud test journal entry include consolidation entry addition audit work describe relation allege illegal act fraud revenue recognition gsk annual report go concern information annual report list rule require review director isas ireland require report statement set relation go concern opinion information annual report report perform review aterially inconsistent information audit note director statement director conclude group financial statement appropriate prepare group financial statement pparently materially incorrect base materially go concern basis accounting going concern inconsistent knowledge group acquire basis presume group adequate resource remain course perform audit operation director intend year date financial statement sign misleading audit conclude director use exception report arise responsibility go concern basis appropriate responsibility financial statement audit future event condition predict statement guarantee group responsibility director ability continue go concern explain fully statement director opinion matter prescribed responsibility director responsible preparation group financial statement company act satisfied true fair view opinion information give strategic report responsibility audit express opinion group director report financial year group financial financial statement accordance applicable law isas statement prepare consistent group financial ireland standard require comply statement auditing practice board ethical standard auditor report include opinion prepare matter require company member body accordance chapter report exception company act purpose give opinion accept assume adequacy information explanation receive responsibility purpose person company act require report report show hand come save opinion receive information expressly agree prior consent writing explanation require audit exception report arise responsibility matter report separately parent company financial director remuneration statement glaxosmithkline plc year end company act require report december information director opinion certain disclosure director remuneration remuneration report describe audit specify law exception company pass resolution accordance section report arise responsibility company act senior statutory auditor state corporate governance statement list rule require review corporate governance statement relate company compliance provision corporate governance code code report perform review pricewaterhousecooper llp annual report require code charter accountant statutory auditor provision director state consider annual london report take fair balanced understandable february provide information necessary member assess group performance business model strategy require code audit risk committee set significant issue consider relation financial statement address isa note ireland require report opinion maintenance integrity glaxosmithkline plc statement give director materially inconsistent website responsibility director work carry knowledge group acquire course auditor involve consideration perform audit matter accordingly auditor accept responsibility section annual report describe work change occur financial audit risk committee appropriately address matter statement initially present website communicate audit risk committee legislation united kingdom govern preparation exception report arise responsibility dissemination financial statement differ legislation jurisdiction gsk annual report financial statement consolidated income statement financial statement consolidate income statement year end december restate restate note turnover cost sale gross profit sell general administration research development royalty income operating income operate profit finance income finance expense profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year profit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny comparative information restate consistency presentation set note presentation financial statement consolidate statement comprehensive income year end december restate restate profit year item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reverse reclassification availableforsale investment fair value movement cash flow hedge defer tax fair value movement cash flow hedge reclassification cash flow hedge income statement share comprehensive incomeexpense associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest actuarial gainslosse define benefit plan defer tax actuarial movement define benefit plan comprehensive incomeexpense year total comprehensive income year total comprehensive income year attributable shareholder noncontrolle interest total comprehensive income year gsk annual report consolidate balance sheet december restate note noncurrent asset property plant equipment goodwill intangible asset investment associate joint venture investment defer tax asset derivative financial instrument noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables derivative financial instrument liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing trade payable derivative financial instrument current tax payable shortterm provision total current liability noncurrent liability longterm borrowing defer tax liability pension postemployment benefit provision derivative financial instrument noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity noncontrolle interest total equity financial statement page approve board february sign behalf sir christopher gent chairman gsk annual report financial statement consolidate statement change equity consolidated statement change equity year end december shareholder equity retain non total share share earning total control equity capital premium restate reserve restate interest restate january previously report prior year adjustment ias january restate profit year comprehensive expense year total comprehensive income year distribution noncontrolle interest dividend shareholder change noncontrolle interest forward contract relate noncontrolle interest ordinary share issue ordinary share purchase cancel hold treasury share ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive expense year total comprehensive income year distribution noncontrolle interest dividend shareholder change noncontrolle interest forward contract relate noncontrolle interest ordinary share issue ordinary share purchase cancel hold treasury share ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive incomeexpense year total comprehensive income year distribution noncontrolle interest dividend shareholder change noncontrolle interest ordinary share issue ordinary share purchase cancel hold treasury share ordinary share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december gsk annual report consolidate cash flow statement year end december restate restate note cash flow operating activity profit taxation year adjustment reconcile profit tax operating cash flow cash generate operation taxation pay net cash inflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment purchase intangible asset proceed sale intangible asset purchase equity investment proceed sale equity investment purchase business net cash acquire disposal business investment associate joint venture proceed disposal subsidiary interest associate decrease liquid investment interest receive dividend associate joint venture net cash inflowoutflow investing activity cash flow financing activity proceed share employee share option share acquire esop trust issue share capital purchase share cancellation hold treasury share purchase noncontrolle interest increase longterm loan increase shortterm loan repayment shortterm loan net repayment obligation finance lease interest pay dividend pay shareholder distribution noncontrolle interest finance cash flow net cash outflow financing activity increasedecrease cash bank overdraft cash bank overdraft begin year exchange adjustment increasedecrease cash bank overdraft cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent overdraft gsk annual report financial statement note financial statement note financial statement presentation financial statement implementation new accounting standard amendment ia employee benefit issue description business june implement gsk january glaxosmithkline major global healthcare group amendment eliminate ability defer recognition engage creation discovery development manufacture gain loss corridor method require remeasurement market pharmaceutical product include vaccine present comprehensive income require past overthecounter otc medicine healthrelate consumer service cost recognise income statement year product gsk principal pharmaceutical product include plan amendment defer portion relate medicine follow therapeutic area respiratory antiviral unvested benefit require return plan asset recognise central nervous system cardiovascular urogenital metabolic income statement calculate rate antibacterial oncology emesis dermatology rare disease discount rate apply pension obligation make immunoinflammation vaccine hiv minor accounting disclosure change revise standard increase pension charge compliance applicable law ifrs approximately million comparative period financial statement prepare accordance restate result pension charge increase company act article ias regulation million million international accounting standard ias international financial addition follow new amend accounting standard reporting standard ifrs relate interpretation adopt implement material impact european union current period financial statement compliance ifrs issue ifrs consolidated financial statement international accounting standard board ifrs joint arrangement composition financial statement ifrs disclosure interest entity consolidate financial statement draw sterling functional currency glaxosmithkline plc accordance ifrs fair value measurement ifrs accounting presentation financial statement comprise ia presentation item comprehensive income consolidate income statement ia investment associate joint venture consolidate statement comprehensive income ifrs disclosure offset financial asset financial consolidated balance sheet liability consolidate statement change equity group adopt early amendment ias impairment asset relation recoverable disclosure consolidate cash flow statement nonfinancial asset effect january note financial statement financial period composition group financial statement cover financial year january list subsidiary associate undertakings december comparative figure financial year opinion director principally affect profit january december appropriate net asset group give note principal group january december company parent company financial statement accounting principle policy financial statement parent company glaxosmithkline plc financial statement prepare historical prepared accordance gaap cost convention modify revaluation certain item accounting presentation company balance sheet present state accounting policy go concern basis accounting policy give financial statement prepare accordance accounting principle policy group accounting policy approve board describe note accounting principle policy information consolidation application accounting policy include area estimation judgement give note key accounting consolidated financial statement include judgement estimate asset liability result cash flow preparation financial statement conformity company subsidiary include esop trust generally accept accounting principle require management group share result net asset associate estimate assumption affect report amount joint venture asset liability disclosure contingent asset group share asset liability revenue expense liabilitie date financial statement report joint operation amount revenue expense report period actual result differ estimate financial statement entity consolidate december year gsk annual report accounting principle policy continue consolidation asset liability include related goodwill overseas subsidiary associate joint venture translate entity group power direct relevant sterling rate exchange rule balance sheet date activity affect return group generally result cash flow overseas subsidiary associate joint control financial operating policy account venture translate sterling average rate exchange subsidiary group ability exercise joint exchange adjustment arise open net asset control right net asset entity entity profit year retain overseas subsidiary associate account joint venture group ability joint venture translate sterling exchange difference exercise joint control arrangement right specify arise relate foreign currency borrowing hedge asset obligation specify liability arrangement group net investment operation take separate arrangement account joint operation component equity group ability exercise significant influence entity account associate result asset translate sterling asset liability result cash liability associate joint venture incorporate flow overseas subsidiary associate joint venture consolidate financial statement equity method report currency hyperinflationary economy accounting group right asset liabilitie revenue adjustment material reflect current price level expense joint operation include consolidated loss net monetary asset charge consolidated financial statement accordance right obligation income statement interest acquire entity consolidated date revenue group acquire control interest sell deconsolidate revenue recognise income statement good date control cease service supply available external customer transaction balance subsidiary eliminate order receive title risk loss pass customer profit tax take sale subsidiary reliable estimate relevant deduction relevant product sell customer outside group obligation fulfil earning process relevant proportion profit transaction joint venture regard complete joint operation associate defer product turnover represent net invoice value deduction discount sell party transaction noncontrolle interest allowance give accrual estimate future rebate record directly equity defer tax relief unrealise return methodology assumption estimate rebate intragroup profit account extent return monitor adjust regularly light consider recoverable contractual legal obligation historical trend past experience goodwill capitalise separate item case subsidiary project market condition market condition evaluate cost investment case joint venture wholesaler thirdparty analysis market research datum associate goodwill denominate currency operation internally generate information value add tax sale acquire taxis exclude revenue cost acquisition fair value net asset group copromote product counterparty acquire difference recognise directly income record sale group records share revenue statement promotion income turnover nature copromotion activity group record cost sale business combination pharmaceutical turnover include copromotion revenue business combination account acquisition million million million addition initial accounting method identifiable asset liability contingent eventbase milestone income exclude royalty income arise liability acquire measure fair value acquisition date development marketing collaboration group consideration transfer measure fair value include compound product party recognise turnover fair value contingent consideration milestone income million include turnover consideration transfer noncontrolle interest royalty income recognise accrual basis accordance exceed fair value net asset liability contingent term relevant licensing agreement liability acquire excess record goodwill cost acquisition charge income statement period expenditure incur expenditure recognise respect good service receive equity subsidiary acquire non supply accordance contractual term provision control interest recognise fair value non obligation exist future liability respect control interest share net asset subsidiary past event obligation reliably casebycase basis change group ownership percentage estimate manufacturing startup cost validation subsidiary account equity achievement normal production expense incur advertising promotion expenditure charge income foreign currency translation statement incur shipment cost intercompany transfer foreign currency transaction book functional currency charge cost sale distribution cost sale customer group company exchange rate ruling date include sell general administrative expenditure transaction foreign currency monetary asset liability restructure cost recognise provide retranslate functional currency rate exchange rule appropriate respect direct expenditure business balance sheet date exchange difference include reorganisation plan sufficiently detail income statement advance appropriate communication affect undertaken gsk annual report financial statement note financial statement accounting principle policy continue employee share plan incentive form share provide employee research development share option share award scheme research development expenditure charge income fair value option award calculate statement period incur development grant date blackschole option pricing model charge expenditure capitalise criterion recognise asset income statement relevant vesting period meet usually regulatory filing major group provide finance esop trust purchase company market approval consider highly probable property plant share open market meet obligation provide share equipment research development capitalise employee exercise option award cost run depreciate accordance group policy esop trust charge income statement share hold environmental expenditure esop trust deduct reserve transfer reserve retain earning vest environmental expenditure relate exist condition result period relate share option award reflect ultimate past current operation current future proceed receivable employee exercise benefit discernible charge income statement group recognise liability sitebysite basis reliably property plant equipment estimate liability include group portion total cost property plant equipment ppe state cost portion potentially responsible party cost purchase construction provision depreciation probable able satisfy respective impairment financing cost capitalise cost share cleanup obligation recovery reimbursement qualify asset construction record asset virtually certain depreciation calculate write cost residual value legal dispute ppe exclude freehold land straightline basis provision anticipated settlement cost legal expect useful life residual value life review dispute group outflow resource appropriate adjust annually normal expect useful consider probable reliable estimate likely live major category ppe outcome addition provision legal expense freehold building year arise claim receive dispute respect product leasehold land building lease term year liability claim relate certain product sufficient history plant machinery year claim settlement enable management equipment vehicle year reliable estimate provision require cover unasserted claim certain case incur report ibnr actuarial disposal ppe cost relate accumulate depreciation technique determine estimate impairment remove financial statement group involved legal proceeding respect net proceed take income statement possible reliable estimate expect financial effect result ultimate resolution lease proceeding case appropriate disclosure leasing agreement transfer group substantially case include provision cost benefit risk ownership asset treat finance associate claim group party lease asset purchase outright asset charge income statement incur include ppe computer software capital element leasing commitment show obligation finance pension postemployment benefit lease asset hold finance lease depreciate basis cost provide pension define benefit scheme consistent similar own asset lease term shorter calculate project unit credit method spread interest element lease rental include income period benefit expect derive statement lease operating lease rental cost employee service consistent advice qualified actuary charge income statement straightline basis pension obligation measure present value estimate lease term future cash flow discount rate reflect yield high quality corporate bond pension scheme asset measure goodwill fair value balance sheet date goodwill state cost impairment goodwill deem indefinite useful life test impairment cost postemployment liability calculate annually similar way define benefit pension scheme spread period benefit expect derive fair value interest acquire entitys asset employee service accordance advice qualified liability contingent liability exceed consideration pay actuary excess recognise immediately gain income statement actuarial gain loss effect change actuarial assumption recognise statement comprehensive income year arise group contribution define contribution plan charge income statement incur gsk annual report accounting principle policy continue availableforsale investment liquid investment investment classify available intangible asset forsale investment initially record fair value plus intangible asset state cost provision amortisation transaction cost remeasure subsequent reporting impairment date fair value unrealised gain loss availableforsale investment recognise directly comprehensive income licence patent knowhow marketing right separately impairment arise significant prolong decline fair acquire acquire business combination amortise value equity investment reduce carrying asset estimate useful life generally exceed year directly charge income statement straightline basis time available use estimate useful life determine amortisation charge disposal impairment investment gain loss account patent live applicable value defer comprehensive income obtain period nonexclusivity asset life review reclassify income statement dividend equity investment appropriate adjust annually contingent milestone recognise income statement group right payment recognise point contingent event receive payment establish equity investment record certain development cost incur group noncurrent asset expect sell associate acquire licence patent knowhow marketing year right write income statement incur purchase sale equity investment account criterion recognition internally generate intangible asset trade date purchase sale availableforsale meet usually regulatory filing major investment account settlement date market approval consider highly probable inventory acquire brand value independently fair value business acquire party brand inventory include financial statement low value substantial longterm brand cost include raw material direct labour direct cost contractual legal nature sell separately relate production overhead net realisable value cost rest business acquire brand amortise generally determine basis prelaunch inventory estimate useful life year hold asset high probability regulatory consider useful economic life indefinite approval product point provision carry value recoverable provision cost acquire develop computer software internal reverse point high probability regulatory approval use internet site external use capitalise intangible determine fix asset software site support significant business system expenditure lead creation trade receivables durable asset erp system software amortise seven trade receivables carry original invoice year computer software year provision doubtful debt provision evidence risk nonpayment take account age impairment noncurrent asset previous experience general economic condition trade carry value noncurrent asset review receivable determined uncollectable write firstly impairment standalone basis large cash provision available income statement generating unit indication asset impair additionally goodwill intangible asset indefinite subsequent recovery amount previously provide useful life intangible asset available use credit income statement longterm receivable test impairment annually provision impairment discount effect material charge income statement year concern trade payable impairment goodwill reverse impairment loss trade payable initially recognise fair value hold noncurrent asset reverse amortise cost equate nominal value longterm payable change estimate determine recoverable amount discount effect material extent revise recoverable amount exceed carry value exist net depreciation cash cash equivalent amortisation impairment recognise cash cash equivalent comprise cash hand current balance bank similar institution highly liquid investment investment associate joint venture joint operation maturity month readily convertible investment associate joint venture carry known amount cash insignificant risk change consolidate balance sheet group share net asset value date acquisition postacquisition retain profit loss goodwill arise acquisition borrowing group recognise right asset liabilitie revenue borrowing initially record proceed expense joint operation receive net transaction cost borrowing subsequently carry amortise cost difference proceed net transaction cost redemption recognise charge income statement period relevant borrowing gsk annual report financial statement note financial statement accounting principle policy continue key accounting judgement estimate prepare financial statement management require taxation estimate assumption affect amount current tax provide amount expect pay apply asset liability revenue expense report financial tax rate enact substantively enact statement actual amount result differ balance sheet date estimate follow consider key accounting defer tax provide liability method judgement estimate temporary difference arise tax basis asset liability carry amount financial statement turnover defer tax asset recognise extent probable revenue recognise title risk loss pass future taxable profit available customer reliable estimate relevant deduction temporary difference utilise defer tax provide relevant obligation fulfil temporary difference arise investment subsidiarie earning process regard complete associate joint venture time reversal gross turnover reduce rebate discount allowance temporary difference control probable product return give expect give vary temporary difference reverse foreseeable future product arrangement buy group arrangement defer tax provide rate tax enact purchasing organisation dependent submission substantively enact balance sheet date claim time initial recognition sale accrual time sale estimate rebate discount derivative financial instrument hedge allowance payable return base available derivative financial instrument manage exposure market information historical experience market risk principal derivative instrument gsk foreign currency swap interest rate swap forward foreign amount estimate fully reflect exchange contract group hold issue derivative final outcome amount subject change dependent financial instrument trade speculative purpose thing type buy group product sale mix derivative financial instrument classify heldfortrading carry balance sheet fair value derivative level accrual review adjust regularly light designate hedge instrument classify inception contractual legal obligation historical trend past experience cash flow hedge net investment hedge fair value hedge project market condition market condition evaluate wholesaler thirdparty analysis market research change fair value derivative designate cash flow datum internally generate information future event hedge recognise comprehensive income extent cause assumption accrual base change hedge effective ineffective portion recognise affect future result group profit loss immediately amount defer comprehensive income reclassify income statement hedge taxation item affect profit loss current tax provide amount expect pay net investment hedge account similar way cash defer tax provide temporary difference tax flow hedge basis asset liability carry amount rate enact substantively enact change fair value derivative designate fair value balance sheet date hedge record income statement change fair value hedge asset liability defer tax asset recognise extent probable future taxable profit available change fair value derivative instrument temporary difference utilise base management qualify hedge accounting recognise immediately assumption relate amount time future taxable income statement profit factor affect tax charge future year set discount note taxation change group effective tax rate change total tax charge year time effect money material balance discount approximately million current value appropriate rate interest unwind discount record finance income finance expense group open tax issue number revenue authority outflow fund believe probable reliable estimate outcome dispute management provide good estimate liability estimate account specific circumstance dispute relevant external advice inherently judgemental change substantially time new fact emerge dispute progress detail relate significant unresolved dispute set note taxation gsk continue believe adequate provision liability likely arise open assessment open issue exist ultimate liability matter vary amount provide dependent outcome negotiation relevant tax authority necessary litigation proceeding gsk annual report accounting judgement estimate pension postemployment benefit cost provide pension postemployment continue benefit charge income statement accordance ia employee benefit period benefit legal dispute derive employee service cost assess group provide anticipate settlement cost basis assumption select management outflow resource consider probable reliable estimate assumption include future earning pension increase likely outcome dispute legal discount rate expect longterm rate return asset expense arise claim group mortality rate disclose note pension estimate account specific circumstance postemployment benefit dispute relevant external advice inherently judgmental change substantially time new fact emerge expect longterm rate return bond determine dispute progress detail status uncertainty base portfolio mix indexlinke government involve significant unresolved dispute set note corporate bond equity risk premium add legal proceeding equity company director take legal advice discount rate derive rate corporate bond yield establish provision take account relevant country deep market corporate fact circumstance matter accordance bond government bond yield sensitivity analysis accounting requirement respect product liability claim provide note pension postemployment relate certain product sufficient history claim benefit reduction discount rate lead settlement enable management reliable estimate increase net pension deficit approximately million provision require cover unasserted claim group increase annual pension cost approximately involved legal proceeding respect million selection different assumption affect possible reliable estimate expect financial future result group effect result ultimate resolution proceeding case appropriate disclosure case include provision contingent liability quantify december provision legal dispute amount billion billion ultimate liability legal claim vary amount provide dependent outcome litigation proceeding investigation possible settlement negotiation position change time assurance loss result outcome legal proceeding exceed provision report group financial statement material goodwill intangible asset impairment goodwill deem indefinite life amortise annual impairment test cash generating unit goodwill allocate performed impairment test base established market multiple riskadjuste future cash flow discount appropriate interest rate assumption impairment test set note goodwill case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment relate goodwill impairment test intangible asset undertake event occur question carry value asset brand amortise subject annual impairment test valuation impairment test base established market multiple riskadjuste future cash flow estimate useful life asset limit discount appropriate interest rate set note intangible asset assumption relate future cash flow estimate useful life discount rate base business forecast inherently judgemental future event cause assumption impairment test change consequent adverse effect future result group gsk annual report financial statement note financial statement new accounting requirement exchange rate follow new amend accounting standard group use average exchange rate prevail issue iasb likely affect future annual report period translate result cash flow overseas current form expect material subsidiary joint venture associate undertaking impact result financial position group sterling period end rate translate net asset undertaking currency influence amendment ia offset financial asset financial translation relevant exchange rate liability issue december implement group january amendment provide additional guidance financial asset financial liability average rate offset ifrs financial instrument issue november euro amend time standard yen eventually replace ias cover classification measurement derecognition financial asset financial period end rate liability new hedge accounting model iasb intend expand ifrs add new requirement impairment euro complete replacement ia yen course date mandatory implementation set amendment ias define benefit plan employee contribution issue november implement group january amendment provide additional guidance treatment contribution define benefit plan employee party gsk annual report segment information group operate segment report base financial information provide chief executive officer responsibilitie corporate executive team cet individual member cet responsible geographic segment pharmaceutical vaccine business viiv healthcare consumer healthcare business respectively minor product reclassification pharmaceutical consumer healthcare segment effect january addition amendment ia employee benefit adopt note presentation financial statement detail comparative information restate accordingly investment essential sustainability pharmaceutical business segment report europe emerge markets asia pacific japan pharmaceutical vaccine operating profit exclude allocation globally fund central cost principally corporate function unallocate manufacturing cost group management reporting process allocate intragroup profit product sale market sale record profit analysis present basis trading unallocated pharmaceutical vaccine include canada puerto rico australasia central vaccine tender sale contract manufacturing sale cost vaccine central dermatology cost central manufacturing cost attribute segment pharmaceutical segment responsibility chairman research development report separate segment corporate unallocated cost represent cost corporate function restate restate turnover segment pharmaceutical vaccines usa europe emap japan viiv healthcare trading unallocated pharmaceutical vaccine turnover consumer healthcare turnover restate restate pharmaceutical vaccine turnover therapeutic area respiratory antiviral central nervous system cardiovascular urogenital metabolic antibacterial oncology emesis dermatology rare disease immunoinflammation pharmaceutical vaccine viiv healthcare hiv gsk annual report financial statement note financial statement segment information continue restate restate consumer healthcare turnover category total wellness oral care nutrition skin health pharmaceuticals viiv healthcare sale wholesaler approximately million million million million million million million million million respectively allocate finalcustomer discount wholesaler segment profit restate restate pharmaceutical vaccines usa europe emap japan viiv healthcare pharmaceutical trading unallocated cost pharmaceutical vaccine operate profit consumer healthcare operate profit segment profit corporate unallocated cost reconcile item segment profit operating profit operating profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year depreciation amortisation segment restate restate pharmaceutical vaccines usa europe emap japan viiv healthcare pharmaceutical trading unallocated cost pharmaceutical vaccine depreciation amortisation consumer healthcare depreciation amortisation segment depreciation amortisation corporate unallocated depreciation amortisation reconcile item segment depreciation amortisation total depreciation amortisation total depreciation amortisation gsk annual report segment information continue ppe intangible asset goodwill impairment segment restate restate pharmaceutical vaccines usa europe emap japan viiv healthcare pharmaceutical trading unallocated cost pharmaceutical vaccine impairment consumer healthcare impairment segment impairment corporate unallocated impairment reconcile item segment impairment total impairment total impairment ppe intangible asset impairment reversal segment restate restate pharmaceutical vaccines usa europe emap japan viiv healthcare pharmaceutical trading unallocated cost pharmaceutical vaccine impairment reversal consumer healthcare impairment reversal segment impairment reversal corporate unallocated impairment reversal reconcile item segment impairment reversal total impairment reversal total impairment reversal gsk annual report financial statement note financial statement segment information continue restate net asset segment pharmaceutical vaccines usa europe emap japan viiv healthcare pharmaceutical trading unallocated asset pharmaceutical vaccine net operating asset consumer healthcare net operating asset segment net operating asset corporate unallocated net operating asset net operating asset net debt investment associate joint venture derivative financial instrument current defer taxation asset hold sale net asset trade unallocated pharmaceutical consumer healthcare segment include asset centrally manage pharmaceutical vaccine consumer healthcare manufacturing operation depreciation total million million million recover standard cost product charge business geographical information regard group country domicile restate restate turnover location customer usa rest world external turnover turnover location subsidiary usa rest world turnover include intersegment turnover usa rest world intersegment turnover usa rest world external turnover gsk annual report segment information continue restate restate operate profit location usa rest world total operating profit restate net operating asset location usa rest world net operating asset restate noncurrent asset location usa rest world noncurrent asset noncurrent asset location exclude amount relate investment defer tax asset derivative financial instrument pension asset amount receivable insurance contract certain noncurrent receivables operating income impairment equity investment disposal equity investment disposal business asset legal settlement gain settlement preexisting collaboration acquisition hgs gain acquisition shionogiviiv healthcare joint venture fair value remeasurement contingent consideration recognise business combination fair value adjustment derivative financial instrument expenseincome disposal business asset legal settlement include gain disposal lucozade ribena business suntory million gain sale worldwide intellectual property right exclude certain emap market anticoagulant product business aspen group million fair value remeasurement contingent consideration recognise business combination arise principally contingent consideration payable acquisition shionogiviiv healthcare joint venture gsk annual report financial statement note financial statement operating profit restate restate follow item include operate profit employee cost note advertising distribution cost depreciation property plant equipment impairment property plant equipment net reversal amortisation intangible asset impairment intangible asset goodwill net reversal net foreign exchange loss inventory cost inventory include cost sale writedown inventory reversal prior year writedown inventory operate lease rental minimum lease payment contingent rent sublease payment fee payable company auditor associate relation group reversal prior year writedown inventory principally arise reassessment usage demand expectation prior inventory expiration include operate profit major restructuring charge million million million note major restructuring cost fee payable company auditor associate audit parent company consolidated financial statement audit company subsidiary auditrelate assurance service include attestation sarbanesoxley act audit auditrelated service taxation compliance taxation advice assurance service service addition fee pay respect gsk pension scheme audit service gsk annual report employee cost restate restate wage salary social security cost pension postemployment cost include augmentation note cost sharebase incentive plan severance cost integration restructuring activity group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance charge pension postemployment cost include credit million follow restructure postretirement medical obligation charge include credit million follow change policy relate discretionary pension increase certain pension scheme introduction limit future pensionable pay increase scheme set note pension postemployment benefit cost sharebase incentive plan analyse follow share value plan performance share plan share option plan plan average number person employ group include director year number number number manufacturing sell general administration research development average number group employee exclude temporary contract staff number group employee end financial year give financial record average number person employ glaxosmithkline plc nil nil compensation director senior management member cet aggregate follow wage salary social security cost pension postemployment cost cost sharebase incentive plan gsk annual report financial statement note financial statement major restructuring cost major restructuring cost charge arrive operating profit include restructure cost arise operational excellence programme initiate expand major change programme initiate follow acquisition human genome sciences inc hgs august follow acquisition stiefel laboratories inc july total restructuring cost million incur million incur operational excellence programme million major change programme follow area restructuring pharmaceutical business europe lead staff reduction sale force administration project rationalise core business service simplify eliminate process lead staff reduction support function transformation manufacture vaccine business deliver step change quality cost productivity rationalisation consumer healthcare business cost million incur restructure programme relate integration hgs remain cost million incur restructure programme relate integration stiefel business analysis cost charge operating profit programme follow increase provision major restructuring programme note provision reverse unused note impairment loss recognise noncash charge cash cost asset impairment million million million noncash charge total million million million noncash item principally accelerate depreciation asset life shorten result major restructuring programme charge settle cash include termination lease site closure cost consultancy project management fee finance income interest income arise cash cash equivalent availableforsale investment loan receivables realise gain liquid investment fair value adjustment derivative fair value profit loss derivative fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument ias gsk annual report finance expense interest expense arise financial liability amortise cost derivative fair value profit loss fair value hedge fair value movement derivative designate hedge instrument fair value adjustment hedge item fair value movement derivative fair value profit loss unwind discount provision movement amount owe noncontrolle interest finance expense derivative fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument ia interest expense arise derivative fair value profit loss relate swap interest expense associate joint venture december group hold significant associate aspen pharmacare holding limit aspen summarise income statement information respect aspen set turnover profit taxation comprehensive income total comprehensive income result aspen include summarise income statement information represent estimate earning aspen group year adjust transaction gsk aspen amount relate joint venture principally arise interest joint venture japan vaccine ltd daiichi sankyo ltd aggregate financial information respect associate undertaking joint venture set associate share turnover share tax profit share comprehensive income share total comprehensive income joint venture share turnover share tax loss share comprehensive income share total comprehensive income sale joint ventures associate gsk annual report financial statement note financial statement taxation restate restate taxation charge base profit year corporation tax statutory rate double taxation relief overseas taxation current taxation defer taxation defer tax credit arise predominantly result non cash item relate continue restructure supply chain intellectual property ownership reconciliation taxation rate group profit statutory rate taxation difference overseas taxation rate benefit intellectual property incentive credit intercompany stock profit impact sharebase payment reduction tax rate unrecognised loss permanent difference reassessment prior year estimate disposal associate tax unremitte earning restructure tax rate group operate country tax rate differ tax rate impact overseas taxis overall rate tax show group require ifrs create defer tax asset respect unrealise intercompany profit arise inventory hold group yearend apply tax rate country inventory hold tax rate country profit originally tax pay practice gaap result difference accounting treatment group tax rate current period intercompany profit ifrs reduce increase decrease arise change location workinprogress finished good restate restate tax item charge equity statement comprehensive income current taxation share base payment defer taxation sharebase payment define benefit plan fair value movement cash flow hedge fair value movement availableforsale investment total chargecredit equity statement comprehensive income item charge statement comprehensive income tax share base payment gsk annual report taxation continue issue relate taxation integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket give rise complexity delay negotiation revenue authority profit individual group company liable tax resolution issue ongoing requirement gsk group continue believe adequate provision liability likely arise period open agree tax authority ultimate liability matter vary amount provide dependent outcome agreement relevant tax authority litigation appropriate aggregate unremitte profit balance sheet date approximately billion billion legislation relate company distribution provide exemption tax repatriate profit subject certain exception provision defer tax liability million million respect withholding taxation arise distribution profit certain overseas subsidiary unprovide defer tax unremitted earning december estimate million million relate taxis payable repatriation levy overseas tax jurisdiction provision ground group able control timing reversal remain temporary difference probable reverse foreseeable future movement defer tax asset liability pension post manu share accelerate intra employment legal facture stock option net offset capital group benefit tax restruct valuation award temporary total allowance intangible profit restate loss dispute ure adjustment scheme difference country restate deferred tax asset previously report prior year adjustment ias defer tax asset january defer tax liability january january exchange adjustment creditcharge income statement credit equity charge comprehensive income acquisition transfer current tax december defer tax asset december defer tax liability december defer tax charge income relate change tax rate million million defer tax credit million defer tax credit defer tax movement arise origination reversal temporary difference net temporary difference mainly include accrue expense tax deduction available pay basis gsk annual report financial statement note financial statement taxation continue tax loss recognise unrecognised trading loss expire year year available indefinitely december defer tax asset addition group capital loss approximately billion respect defer tax asset recognise defer tax asset recognise probable future taxable profit available utilise loss factor affect tax charge future year global organisation factor affect future effective tax rate group mix profit different territory transfer pricing dispute tax authority location research development activity significant impact group effective tax rate change tax legislation territory group business operation impact group effective tax rate december government announce ongoing phase reduction main rate corporation tax main rate reduce effect april march reduction main rate corporation tax announce effect april defer tax movement reflect reduction tax rate effect april effect april substantively enact earning share restate restate penny penny penny basic earning share dilute earning share basic earning share calculate divide profit attributable shareholder weight average number share issue period deduct share hold esop trust treasury share trustee waive right dividend share hold esop trust diluted earning share calculate adjust weight average number share basic calculation assume conversion potentially dilutive share potentially dilutive share form employee share scheme exercise price average market price gsk share period performance condition attach scheme meet balance sheet date number share calculate basic diluted earning share reconcile weight average number share issue million million million basic dilution share option award diluted gsk annual report dividend dividend total dividend total dividend total share dividend share dividend share dividend paidpayable pence paidpayable pence paidpayable penny interim july july july second interim october october october interim january january january fourth interim april april april annual total supplemental april total ifrs interim dividend recognise financial statement pay declare gsk normally pay dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend second interim dividend amount recognise year follow dividend shareholder property plant equipment plant land equipment asset building vehicle construction total cost january exchange adjustment addition addition business combination capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december exchange adjustment addition addition business combination capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december gsk annual report financial statement note financial statement property plant equipment continue plant land equipment asset building vehicle construction total depreciation january exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december impairment january exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold sale impairment december exchange adjustment disposal writeoff impairment loss reversal impairment transfer fromto asset hold sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december net book value december group land building comprise freehold property million million property lease year million million property lease year million million include land building december lease asset cost million million accumulate depreciation million million impairment million million net book value million million include plant equipment vehicle december lease asset cost million million accumulate depreciation million million impairment million nil net book value million million lease agreement include renewal purchase option escalation clause impairment loss principally arise decision rationalise facility calculate base fair value cost disposal value use fair value cost disposal valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital wacc adjust appropriate relevant specific risk value use calculation impairment indicate pretax cash flow calculation expect materially different result test reperforme pretax cash flow pretax discount rate group wacc equivalent pretax discount rate approximately impairment loss charge cost sale million million million million sga million million include million million arise major restructuring programme reversal impairment arise subsequent review impaired asset condition gave rise original impairment deem long apply reversal credit cost sale carrying value december asset impairment charge reverse year million million gsk annual report goodwill cost january exchange adjustment addition business combination note transfer asset hold sale movement contingent consideration balance cost december net book value january net book value december movement contingent consideration balance mainly arise respect acquisition pfizer inc hiv business april carry value goodwill translate yearend exchange rate balance arise acquisition follow business cash generating unit stiefel laboratories inc europe emap human genome sciences inc europe emap japan pharmaceutical vaccines reliant pharmaceuticals inc pharmaceutical vaccine biomedical corporation europe emap japan pharmaceuticals vaccines sirtris pharmaceuticals inc europe emap japan pharmaceutical vaccines domantis limit europe emap japan pharmaceuticals vaccines glaxosmithkline japan pharmaceuticals vaccines cns inc consumer healthcare pfizer hiv business viiv healthcare maxinutrition group holdings limited consumer healthcare polfa poznan europe pharmaceutical vaccine certain business ucb emap pharmaceutical vaccine novamin technology inc consumer healthcare goodwill arise acquisition stiefel allocate europe emap cash generating unit impairment testing purpose benefit acquire business split cash generating unit goodwill arise acquisition human genome science biomedical sirtris pharmaceuticals domantis split europe emap japan pharmaceutical vaccine cash generating unit impairment testing purpose benefit acquire business split cash generating unit acquire business generate independent cash flow total goodwill allocate pharmaceutical vaccine amount million million amount allocate cash generating unit significant relative total balance gsk annual report financial statement note financial statement goodwill continue recoverable amount cash generating unit assess fair value cost disposal model value use model value use calculate net present value project riskadjuste posttax cash flow plus terminal value cash generating unit goodwill allocate initially posttax discount rate apply calculate net present value posttax cash flow discount rate base group wacc cash generating unit integrate operation large part group discount rate adjust appropriate specific country currency risk fair value cost disposal calculate similar discount cash flow approach posttax discount rate apply project riskadjuste posttax cash flow terminal value valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy detail relate discount cash flow model impairment test pharmaceutical vaccine consumer healthcare cash generating unit follow valuation basis high fair value cost disposal value use key assumption sale growth rate profit margin terminal growth rate discount rate taxation rate determination assumption growth rate internal forecast base internal external market information margin reflect past experience adjust expect change terminal growth rate base management estimate future longterm average growth rate discount rate base group wacc adjust appropriate taxation rate base appropriate rate region period specific project cash flow year terminal growth rate discount rate terminal growth rate discount rate pharmaceutical vaccines europe pharmaceutical vaccines emap pharmaceutical vaccine japan pharmaceuticals vaccines viiv healthcare pharmaceuticals vaccines consumer healthcare terminal growth rate exceed longterm project growth rate relevant market terminal growth rate fair value cost disposal calculation cash generating unit reflect impact future generic competition account new product launch pharmaceutical vaccine cash generating unit comprise collection small cash generating unit include asset indefinite live carry value million million consumer healthcare cash generating unit comprise collection small cash generating unit include brand indefinite live carry value billion billion detail indefinite life brand give note intangible asset case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment relate goodwill gsk annual report intangible asset computer licence amortise indefinite life software patent etc brand brand total cost january exchange adjustment capitalise internal development cost addition business combination capitalise borrowing cost addition disposal asset writeoff reclassification transfer fromto asset hold sale cost december exchange adjustment capitalise internal development cost addition business combination capitalise borrowing cost addition disposal asset writeoff transfer tofrom asset hold sale cost december amortisation january exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december impairment january exchange adjustment impairment loss disposal asset writeoff impairment december exchange adjustment impairment loss disposal asset writeoff impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december net book value computer software include million million internally generate cost charge impairment year include impairment lovaza reflect reassessment group expectation likelihood potential generic competition chemocentryx retigabine panmiraflair carry value december intangible asset impairment charge reversed year follow impairment reversal million million gsk annual report financial statement note financial statement intangible asset continue amortisation impairment loss net reversal charge income statement follow amortisation net impairment loss restate restate cost sale sell general administration research development licence patent etc include large number acquire licence patent knowhow agreement marketing right market use development net book value include million million internally generate cost note acquisition disposal give detail addition business combination year book value large individual item follow dolutegravir benlysta flulavalfluviral selzentry arzerra okairos technology platform lovaza duac toctino fraxiparine indefinite life brand comprise portfolio consumer healthcare product primarily acquire acquisition sterling winthrop inc block drug company inc cns inc number pharmaceutical brand acquisition stiefel laboratories inc book value major brand follow panadol sensodyne stiefel trade breathe right physiogel polident biotene corega poligrip brand consider indefinite life give strength durability brand level marketing support brand relatively similar stable profitable market sector similar risk profile size diversification market share mean risk marketrelated factor cause reduction live brand consider relatively low group aware material legal regulatory contractual competitive economic factor limit useful life accordingly amortise brand test annually impairment amortise intangible asset test indicator impairment arise testing apply fair value cost disposal methodology generally year posttax cash flow forecast terminal value calculation discount rate equal group posttax wacc adjust appropriate country currency specific risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy main assumption include future sale price volume growth product contribution future expenditure require maintain product marketability registration relevant jurisdiction assumption base past experience review management budget strategic planning cycle change market condition sale erosion competition terminal growth rate apply nil management estimate future longterm average growth rate relevant market case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment intangible asset gsk annual report investment associate joint venture joint joint ventures associates total ventures associates total january exchange adjustment addition disposal transfer investment distribution receive movement lossprofit tax recognise consolidated income statement december investment joint venture principally arise interest joint venture japan vaccine ltd daiichi sankyo ltd joint venture hold development commercial right exist preventative vaccine parent company supply vaccine include human papillomavirus hpv vaccine rotavirus vaccine seasonal flu vaccine mumps vaccine diphtheria pertussis dtp vaccine measle rubella vaccine mrv japan group hold significant associate december aspen pharmacare holding limit december group own million share aspen aspen list johannesburg stock exchange africa large pharmaceutical manufacturer major supplier brand generic pharmaceutical healthcare nutritional product southern african select international market investment market value million million group hold ownership interest voting control aspen group ability exercise significant influence shareholding nominate director active participation aspen board director year group dispose shareholding note summarise balance sheet information respect aspen set noncurrent asset current asset current liability noncurrent liability net asset summarise balance sheet information respect aspen base preliminary result information analyst forecast available december adjustment transaction gsk aspen reconciliation summarise financial information carry aspen investment set january profit year comprehensive income exchange adjustment dividend pay movement december interest associate undertaking goodwill carry value december gsk annual report financial statement note financial statement investment january exchange adjustment addition net fair value movement impairment loss transfer investment associate joint venture equity investment convert subsidiary acquisition business disposal december investment comprise noncurrent equity investment availableforsale investment record fair value balance sheet date investment trade active market fair value determine reference relevant stock exchange quote bid price investment fair value estimate management reference relevant available information include current market value similar instrument discount cash flow underlie net asset group hold number equity investment entity group enter research collaboration investment include list investment million million increase arise addition fair value adjustment addition year include investment theravance inc theravance million net fair value movement include increase value investment theravance million gsk own common stock theravance account equity investment voting restriction contain gsk governance agreement theravance prevent group exert significant influence disposal investment fair value movement reclassify equity income statement base average cost share acquire different time impairment loss record recognise income statement year operate income amount reclassify fair value reserve recognition impairment impairment initially result prolonged significant decline fair value equity investment acquisition cost subsequent decline fair value immediately take income statement investment include asset impair carrying value asset december calculate follow original cost cumulative impairment recognise income statement subsequent fair value increase carry value december noncurrent asset amount receivable insurance contract pension scheme surplus receivables inventory raw material consumable work progress finish good gsk annual report trade receivable trade receivables net provision bad doubtful debt prepay pension contribution prepayment accrue income interest receivable employee loan advance receivables trade receivable include million million provision bad doubtful debt million provision million state hospital authority greece ireland italy portugal spain trade receivables include million million associate joint venture receivables include million nil associate joint venture bad doubtful debt provision january exchange adjustment charge year subsequent recovery amount provide utilise december cash cash equivalent cash bank hand shortterm deposit increase cash cash equivalent reflect disposal proceed million largely receive end asset hold sale land building plant equipment vehicle intangible asset noncurrent asset transfer asset hold sale expect carry amount recover principally disposal sale consider likely hold low carrying fair value cost sell gsk annual report financial statement note financial statement trade payable trade payable wage salary social security payable defer income customer return rebate accrual accrual december payable include million respect maximum potential payable noncontrolle shareholder gsk pharmaceuticals ltd groups pharmaceutical subsidiary india voluntary open offer purchase additional share announce december purchase expect complete half december payable include million respect maximum potential payable noncontrolle shareholder gsk consumer healthcare ltd groups consumer healthcare subsidiary india note customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer include million million respect pharmaceutical vaccine accrual time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome subject change dependent thing type buy group product sale mix level accrual review adjust quarterly light historical experience actual rebate discount allowance give return change arrangement future event cause assumption accrual base change affect future result group trade payable include million million associate joint venture pension postemployment benefit restate restate pension postemployment cost pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme analyse fund define benefithybrid pension scheme unfunded define benefit pension scheme unfunded postretirement healthcare scheme define benefit scheme define contribution pension scheme net reduction postretirement healthcare scheme cost arise restructure postretirement medical obligation reduction pension scheme cost relate oneoff adjustment arise cap future pensionable salary increase change basis future discretionary pension increase rpi cpi certain legacy plan detail cost define benefit pension postretirement healthcare scheme charge income statement follows restate restate cost sale sell general administration research development gsk entity operate pension arrangement cover group material obligation provide pension retire employee arrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length service hybrid define benefit scheme include define contribution section gsk annual report pension postemployment benefit continue pension cost define benefit scheme accounting purpose calculate project unit method certain country pension benefit provide unfunded basis administer trustee company formal independent actuarial valuation group main plan undertake regularly normally year actuarial movement year recognise statement comprehensive income discount rate derive rate corporate bond yield country deep market corporate bond government bond yield discount rate select reflect term expect benefit payment project inflation rate pension increase longterm prediction base yield gap longterm indexlinke fix interest gilt mortality rate determine adjust sap standard mortality table reflect recent scheme experience rate project reflect improvement life expectancy line cmi projection longterm rate improvement year male females usa mortality rate calculate fully generational table project scale white collar adjustment average life expectancy assume individual age project apply individual age follow usa male female male female year year year year current project asset fund scheme generally hold separately administer trust specific asset proportion general fund insurance contract asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment group review investment strategy plan asset allocation plan adjust approximately return seek asset liability match asset target asset allocation plan update return seek asset liability match asset define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent employee entitle join define contribution scheme usa glaxo wellcome smithkline beecham define benefit scheme merge addition group operate number postretirement healthcare scheme principal usa group restructure postretirement medical obligation active retired member age current plan participant pay medical expense excess cover medicare prescription drug new arrangement participant instead eligible receive age health reimbursement account base year service subject inflation link maximum year retire age give option switch new arrangement impact change credit income statement million similar reduction postretirement obligation group change policy grant discretionary pension increase smithkline beecham define benefit scheme year group introduce limit define benefit scheme year rate pensionable pay increase group apply follow financial assumption assess define benefit liability usa rest world rate increase future earning discount rate expect pension increase cash balance creditconversion rate inflation rate gsk annual report financial statement note financial statement pension postemployment benefit continue amount record income statement statement comprehensive income year end december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service costcredit net interest cost expense remeasurement record statement comprehensive income postretirement pension benefit usa rest world group group restate restate restate restate restate amount charge operating profit current service cost past service creditcost net interest cost remeasurement record statement comprehensive income postretirement pension benefit usa rest world group group restate restate restate restate restate amount charge operating profit current service cost past service creditcost net interest cost gain loss settlement remeasurement record statement comprehensive income past service credit million include million relation restructure postretirement medical obligation past service credit million reflect adjustment million relate cap future pensionable salary increase change basis future discretionary pension increase rpi cpi certain legacy plan detail amount include past service cost include nil million million augmentation cost arise major restructuring programme note provision gsk annual report pension postemployment benefit continue summarise balance sheet presentation group define benefit pension scheme postretirement benefit set table restate restate recognise noncurrent asset pension scheme surplus recognise pension postemployment benefit pension scheme deficit postretirement benefit fair value asset liability define benefit pension scheme aggregate datum define benefit pension scheme group follow usa rest world group december equity list unlisted property unlisted corporate bond list unlisted government bond list asset list unlisted fair value asset present value scheme obligation recognise balance sheet include noncurrent asset include pension postemployment benefit actual return plan asset december scheme purchase insurance contract guarantee payment specify pensioner liability include asset present value scheme obligation table value million million million additional insurance contract purchase country include asset table value million million million october scheme enter repurchase agreement gain exposure indexlinke gilt relate loan include asset value million nil nil usa rest world goup restate restate restate restate december equity list property unlisted corporate bond list government bond list asset list unlisted fair value asset present value scheme obligation recognise balance sheet include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report financial statement note financial statement pension postemployment benefit continue usa rest world goup restate restate restate restate december equity list property list corporate bond list government bond list asset list unlisted fair value asset present value scheme obligation recognise balance sheet include noncurrent asset include pension postemployment benefit actual return plan asset postretirement pension benefit usa rest world group group restate restate restate restate restate movement fair value asset asset january exchange adjustment interest income remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment interest income remeasurement employer contribution scheme participant contribution benefit pay settlement curtailment asset december exchange adjustment interest income expense remeasurement employer contribution scheme participant contribution benefit pay asset december define benefit scheme include define contribution section account balance total million december million million group special funding contribution pension scheme total million million million nil million million million scheme gsk reach agreement trustee pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation base funding agreement follow valuation additional contribution expect million contribution base government bond yield curve approach select discount rate rate choose include allowance expect investment return reflect asset mix scheme employer contribution include special funding contribution estimate approximately million respect define benefit pension scheme million respect postretirement benefit gsk annual report pension postemployment benefit continue postretirement pension benefit usa rest world group group restate restate restate restate restate movement define benefit obligation obligation january exchange adjustment service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december exchange adjustment service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december exchange adjustment service cost past service cost interest cost movement remeasurement scheme participant contribution benefit pay obligation december define benefit scheme include define contribution section obligation total million december million million define benefit pension obligation analyse follows restate restate fund unfunded liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation grade postretirement healthcare scheme amend detail impact change oneoff reduction postretirement obligation million december postretirement healthcare scheme obligation million million million postretirement benefit unfunded gsk annual report financial statement note financial statement pension postemployment benefit continue movement net define benefit liability follow fair value present value net asset obligation total january restate exchange adjustment service cost past service cost interest incomecost settlement curtailment remeasurement return plan asset exclude amount include interest loss change financial assumption experience loss employer contribution scheme participant contribution benefit pay december exchange adjustment service cost past service cost interest incomecost settlement curtailment remeasurement return plan asset exclude amount include interest gain change demographic assumption loss change financial assumption experience loss employer contribution scheme participant contribution benefit pay december exchange adjustment service cost past service cost interest incomecost remeasurement return plan asset exclude amount include interest loss change demographic assumption loss change financial assumption experience loss employer contribution scheme participant contribution benefit pay expensesother movement december remeasurement include postretirement benefit detailed lossgain change demographic assumption gainloss change financial assumption experience gainslosse gsk annual report pension postemployment benefit continue define benefit pension obligation analyse membership category follow active retire defer postretirement benefit obligation analyse membership category follow active retired defer weight average duration define benefit obligation follow year year year pension benefit postretirement benefit sensitivity analysis effect change assumption benefit obligation annual define benefit pension post retirement cost revision ias decrease discount rate follow approximate effect increase annual pension cost decrease annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation year increase life expectancy follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation increase rate future healthcare inflation follow approximate effect increase annual postretirement benefit cost increase postretirement benefit obligation increase inflation follow approximate effect increase annual pension cost increase pension obligation gsk annual report financial statement note financial statement provision legal major employee restructure relate dispute programme provision provision total january exchange adjustment charge year reverse unused unwind discount utilise reclassification movement december settle year settle year december legal dispute nature group business number group involve substantial number legal matter subject negotiation litigation dispute include notification possible claim set year litigation proceeding include appeal note legal proceeding provision legal dispute procedure year reach resolution outof include amount relate product liability principally relate court settlement discussion protract avandia paxil poligrip antitrust principally relate group potential settlement discussion number wellbutrin flonase lamictal government investigation dispute amount provide base principally relate colorado investigation settlement current assessment progress dispute estimate avandiarelate investigation average wholesale price awp billion provide december nominal price investigation contract termination self settle year insurance environmental cleanup property rental december expect million charge year million million net reversal million provision legal dispute estimate insurance recovery primarily relate provision reimburse party insurer include product liability case paxil poligrip receivables balance note noncurrent asset product government investigation note trade receivables discussion legal issue note legal proceeding discount provision decrease nil million calculate riskadjuste project cash flow riskfree rate return movement include decrease nil million arise change discount rate year respect product liability claim relate certain product sufficient history claim settlement enable management reliable estimate provision require cover unasserted claim ultimate liability matter vary amount provide dependent outcome litigation proceeding investigation possible settlement negotiation gsk annual report provision continue major restructuring programme october group announce operational excellence programme improve effectiveness productivity operation note major restructuring cost addition group initiate major change restructure programme focus opportunity simplify supply chain process build group capability manufacture restructure european pharmaceutical business provision staff severance payment management formal decision eliminate certain position communicate group employee affect appropriate consultation procedure complete appropriate provision staff severance payment immediately pension augmentation arise staff redundancie nil million charge year transfer pension obligation provision show note pension postemployment benefit asset writedown recognise impairment property plant equipment note property plant equipment majority amount provide expect utilise year employee relate provision employee relate provision include obligation certain medical benefit disabled employee spouse usa december provision benefit amount million million employee benefit reflect variety provision severance cost jubilee awards longservice benefit provision include provision insurance provision million million onerous property lease provision million million number provision include vehicle insurance regulatory matter noncurrent liability accrual defer income payable increase payable primarily arise contingent consideration million relate acquisition share shionogiviiv healthcare joint venture previously hold shionogi ltd gsk annual report financial statement note financial statement contingent liability december contingent liability comprise guarantee discount bill item arise normal course business amount million million december nil nil financial asset pledge collateral contingent liability provision outcome tax legal dispute probable group suffer outflow fund possible reliable estimate outflow december dispute provision possible reliable estimate potential outflow fund require settle dispute possibility outflow remote description significant tax legal dispute group party set note taxation note legal proceeding net debt list exchange current asset liquid investment cash cash equivalent shortterm borrowing bank loan overdraft commercial paper obligation finance lease medium term note new york stock exchange medium term note london stock exchange longterm borrowing medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange european medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange obligation finance lease net debt gsk annual report net debt continue current asset longterm borrowing liquid investment classify availableforsale investment yearend gsk longterm borrowing billion december include treasury note billion billion billion fall government bond effective interest rate liquid investment year average effective preswap interest december approximately approximately rate note issue december approximately liquid investment balance december earn approximately interest float fix rate million longterm borrowing repayable year carry interest million respectively million million effective rate repayment date effective interest rate cash cash equivalent range december approximately approximately cash cash equivalent december earn pledge asset interest float fix rate million group pledge investment treasury note par million respectively million million value million million million million security irrevocable letter credit issue group gsk policy credit quality cash cash behalf respect group selfinsurance activity provision equivalent refer note financial instrument respect selfinsurance include provision legal relate disclosure dispute discuss note provision shortterm borrowing december million group cash balance hold escrow account connection group offer gsk billion billion commercial paper purchase share indian pharmaceutical subsidiary addition programme billion billion issue million million asset include note december billion billion gsk noncurrent asset form net debt billion year commit mediumterm facility pledge collateral future rental payment operate billion billion day commit facility lease arrangement enter human genome sciences inc facility place september prior acquisition group september respectively undrawn december liquid investment cash cash equivalent show table weight average interest rate current bank loan overdraft december weight average interest rate commercial paper borrowing december finance lease obligation rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total future rental payment future finance charge total finance lease obligation gsk annual report financial statement note financial statement share capital share premium account share ordinary share premium number share capital authorise december december december share capital issue fully pay january issue employee share scheme share capital cancel december issue employee share scheme share capital cancel december issue employee share scheme share capital cancel december december december number share issuable employee share scheme note number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme total million share purchase company cost million million share cancel monthly purchase share follow average share price exclude number share commission stamp duty march june july august september october november december total detail substantial shareholding refer gsk annual report movement equity retain earning reserve amount million december million million million million million relate joint venture associate undertaking cumulative translation exchange equity follow net translation exchange include total retain non translation earning fair value control exchange restate reserve interest restate january exchange movement overseas net asset reclassification exchange liquidation overseas subsidiary december exchange movement overseas net asset december exchange movement overseas net asset december analysis comprehensive income equity category follow non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reclassification fair value movement availableforsale investment reclassification cash flow hedge income statement fair value movement cash flow hedge defer tax fair value movement cash flow hedge share comprehensive income associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest actuarial gain define benefit plan defer tax actuarial movement define benefit plan comprehensive incomeexpense year retain non earning control total restate reserve interest restate item subsequently reclassify income statement exchange movement overseas net asset net investment hedge fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reclassification fair value movement availableforsale investment reclassification cash flow hedge income statement fair value movement cash flow hedge share comprehensive income associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest actuarial loss define benefit plan defer tax actuarial movement define benefit plan comprehensive expenseincome year gsk annual report financial statement note financial statement movement equity continued retain non earning control total restate reserve interest restate item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment reclassification cash flow hedge income statement share comprehensive expense associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest actuarial loss define benefit plan defer tax actuarial movement define benefit plan comprehensive expense year analysis reserve follow esop trust fair value cash flow share reserve hedge reserve reserve total january transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share purchase cancel ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust forward contract noncontrolle interest december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share purchase cancel ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust forward contract noncontrolle interest december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share purchase cancel ordinary share acquire esop trust writedown share hold esop trust december reserve include nondistributable merger premerger reserve amount million december million million reserve include capital redemption reserve create result share buyback programme amount million december million million gsk annual report relate party transaction gsk hold interest aspen pharmacare holding limit december gsk sell million share represent aspen share capital million gsk distribute million million product aspen extensive distribution network december balance gsk aspen million million balance payable gsk aspen million million december gsk complete sale worldwide intellectual property right exclude certain emap market anticoagulant product business aspen group relate inventory manufacturing site consideration million million defer receivable viiv healthcare shire canada joint venture dissolve gsk acquire net asset partnership subsidiary viiv healthcare ulc viiv canada own operate business partnership december gsk hold interest japan vaccine ltd jvc subsidiary glaxosmithkline joint venture daiichi sankyo ltd primarily responsible development marketing certain prophylactic vaccine japan gsk sell million vaccine product joint venture december balance gsk jvc million balance payable gsk jvc nil aggregate compensation director cet give note employee cost adjustment reconcile profit tax operating cash flow restate restate profit tax tax profit share tax profit associate joint venture finance income net finance expense depreciation amortisation intangible asset impairment asset write profit sale business profit sale intangible asset profit sale investment associate profit sale equity investment change work capital increasedecrease inventory decrease trade receivables increase receivables increase trade payable increase payable decrease pension provision sharebase incentive plan fair value adjustment cash generate operation gsk annual report financial statement note financial statement reconciliation net cash flow movement net debt net debt begin year increasedecrease cash bank overdraft cash inflow liquid investment net increase longterm loan net repayment ofincrease shortterm loan net repayment obligation finance lease net noncash fund subsidiary undertaking acquire exchange adjustment noncash movement movement net debt net debt end year january december exchange reclassification acquisition cash flow analysis change net debt liquid investment cash cash equivalent overdraft debt year commercial paper european medium term note debt year european medium term note net debt information significant change net debt note net debt gsk annual report acquisition disposal detail acquisition disposal significant subsidiary associate joint venture business give acquisition year gsk complete acquisition business cash include okairos european base biopharmaceutical company focus development specific vaccine technology prophylactic therapeutic field acquire total purchase price business million include million cash acquire million contingent consideration fair value book value adjustment fair value net asset acquire intangible property plant equipment inventory trade receivables asset include cash cash equivalent defer tax provision trade payable goodwill cash consideration pay contingent consideration total consideration acquisition beginning year estimate group turnover increase approximately million year okairo fully integrate gsk business practicable separately identify impact group profit year acquisition occur shortly end year material impact group profit year goodwill arise acquisition reflect potential business synergy value workforce acquire majority goodwill expect deductible income tax purpose result acquisition report europe emap japan trading unallocated pharmaceutical vaccine consumer healthcare operating segment transaction account acquisition accounting method acquisition cost expense total million contingent consideration january exchange adjustment addition remeasurement goodwill remeasurement income statement settlement december disposal lucozade ribena december gsk complete sale lucozade ribena business include manufacturing site relate inventory suntory beverage food ltd million cash recognise profit disposal operate income million lucozade ribena sale exclude retain market total million year end december cash consideration net asset sell inventory property plant equipment goodwill disposal cost profit disposal gsk annual report financial statement note financial statement acquisition disposal continue anticoagulant business december gsk complete sale anticoagulant business comprise worldwide intellectual property right exclude china india pakistan fraxiparine arixtra relate inventory manufacture site aspen group consideration million million receive cash million defer million defer consideration receivable relate inventory manufacture site receivable million consideration receivable relate inventory subject true final transfer inventory profit disposal million recognise operating income worldwide sale fraxiparine arixtra exclude retain market million year end december cash consideration cash consideration receivable net asset sell inventory property plant equipment intangible asset goodwill disposal cost total profit disposal deferral profit profit recognise year gsk hold investment aspen pharmacare holding limited aspen account investment associate million total profit disposal represent gsk continue interest shareholding aspen defer investment associate joint venture november gsk sell shareholding aspen represent issue share capital company million cash december gsk hold aspen continue recognise investment aspen associate cash consideration net book value share reclassification exchange comprehensive income reclassification fair value movement comprehensive income profit disposal business associate acquisition joint disposal venture total cash flow cash consideration pay cash cash equivalent acquire cash consideration pay net cash acquire total cash consideration payable net cash acquire contingent consideration cash consideration pay net cash acquire total cash proceed receivable cash proceed defer net cash proceed disposal gsk annual report acquisition disposal continue acquisition human genome sciences inc august gsk complete acquisition issue share capital human genome sciences inc hgs base biopharmaceutical company focus development protein antibody drug treatment immunoinflammation disease cash goodwill arise acquisition business reflect potential business synergy realisation value benlysta albiglutide darapladib asset simplify optimise commercial manufacturing operation complete ownership asset goodwill recognise expect deductible income tax purpose result acquire business report europe emap japan trading unallocated cost operate segment transaction account acquisition accounting method proforma turnover hgs business year million gsk record turnover million hgs product hgs product fully integrate gsk business practicable separately identify impact acquisition group profit year acquisition cost expense arise acquisition amount million fair value book value adjustment fair value net asset acquire intangible asset property plant equipment trade receivables asset include cash cash equivalent defer tax asset trade liability goodwill cash consideration pay gain settlement preexisting collaboration total consideration shionogiviiv healthcare joint venture october gsk acquire share shionogiviiv healthcare joint venture previously hold shionogi ltd asset acquire include investigational medicine dolutegravir early stage integrase inhibitor compound development total consideration comprise equity stake viiv healthcare gsk exist investment joint venture contingent consideration payable cash future defer tax asset loss settlement preexist relationship contingent consideration payable base percentage future sale performance compound develop joint venture market product total payable unlimited result acquire business report viiv healthcare transaction account acquisition accounting method acquisition cost expense arise acquisition amount million gsk annual report financial statement note financial statement acquisition disposal continue fair value book value adjustment fair value net asset acquire intangible asset defer tax provision negative goodwill consideration settle share viiv healthcare contingent consideration defer tax contingent consideration fair value investment joint venture convert subsidiary loss settlement preexist relationship total consideration acquisition gsk complete small acquisition cash total cash consideration pay million include million cash acquire fair value book value adjustment fair value net asset acquire intangible asset property plant equipment trade receivables asset include cash cash equivalent defer tax provision trade liability goodwill cash consideration pay contingent consideration fair value equity investment convert subsidiary gain settlement preexisting relationship total consideration acquisition beginning year estimate group turnover increase million year acquisition fully integrate gsk business practicable separately identify impact acquisition group profit year goodwill arise acquisition reflect potential business synergy sale growth increase gsk market presence follow acquisition market participant goodwill recognise expect deductible income tax purpose result acquisition report europe pharma research development reportable operating segment group recognise settlement gain million result measure fair value relationship exist prior acquisition date gain recognise operating income income statement acquisition cost expense arise acquisition total million gsk annual report acquisition disposal continue investment associate joint venture gsk cash contribution million shionogiviiv healthcare joint venture prior acquisition subsidiary cash investment million new joint venture group hold share gsk cash investment million associates human shionogi total associate genome viiv joint business joint science venture acquisition acquisition venture total cash flow cash consideration pay cash cash equivalent acquire cash consideration pay net cash acquire total cash consideration payable net cash acquire contingent consideration cash consideration pay net cash acquire acquisition year gsk complete subsidiary acquisition cash total purchase price million include million cash acquire fair value book value adjustment fair value net asset acquire intangible asset property plant equipment trade receivables asset include cash cash equivalent defer tax provision liability goodwill cash consideration pay fair value investment joint venture convert subsidiary total consideration acquisition beginning year estimate group turnover increase million year subsidiary fully integrate gsk business practicable separately identify impact acquisition group profit year goodwill arise acquisition reflect potential business synergy sale growth increase gsk market presence follow acquisition business addition goodwill million recognise respect fair value adjustment prior year acquisition goodwill recognise expect deductible income tax purpose result acquisition report europe emap japan trading unallocated pharmaceutical vaccine consumer healthcare operating segment group recognise loss million result remeasure fair value associate hold prior acquisition date loss report loss disposal interest associate income statement acquisition cost expense arise acquisition total million investment associate joint venture gsk cash contribution million joint venture group share cash investment associate total million transfer million equity investment associate group increase shareholding gsk annual report financial statement note financial statement acquisition disposal continue disposal gsk dispose subsidiary cash outflow disposal million net cash dispose february gsk dispose entire shareholding quest diagnostic inc clinical laboratory business list new york stock exchange sale comprise secondary public offering accompany repurchase share quest diagnostic generate profit disposal million tax associate joint acquisition venture total cash flow cash consideration pay cash cash equivalent acquire cash consideration pay net cash acquire total cash consideration payable net cash acquire defer consideration cash consideration pay net cash acquire net cash outflowproceed disposal net cash dispose noncontrolle interest group subgroup material noncontrolle interest viiv healthcare limited subsidiary viiv healthcare group focus research development worldwide commercialisation hiv medicine summarise financial information respect viiv healthcare group set turnover profit taxation comprehensive expense total comprehensive income total comprehensive incomeexpense year attributable noncontrolle interest dividend pay noncontrolle interest noncurrent asset current asset total asset current liability noncurrent liability total liability net asset noncontrolle interest attributable subgroup net cash inflow operating activity net cash outflow investing activity net cash outflow financing activity decreaseincrease cash bank overdraft year financial information relate viiv healthcare group standalone basis impact grouprelate adjustment acquisition noncontrolle interest february gsk increase shareholding glaxosmithkline consumer healthcare ltd india represent increase share hold price inr share million carrying noncontrolle interest acquire million december gsk announce voluntary open offer increase stake glaxosmithkline pharmaceutical limited pharmaceuticals subsidiary india represent maximum increase share hold share price inr share offer period begin february expect close march announcement offer oblige gsk complete purchase price offer risk reward ownership share deem pass gsk date carry noncontrolle interest deem acquire million obligation million pay noncontrolle shareholder record payable note december gsk annual report commitment contractual obligation commitment contract provide financial statement intangible asset property plant equipment investment purchase commitment pension commitment interest loan finance lease charge commitment related intangible asset include milestone payment dependent successful clinical development meeting specify sale target represent maximum pay milestone unlikely achieve amount riskadjuste discount number commitment licensing agreement include arrangement adimab llc immunicore ltd morphosys new arrangement offset reduced commitment prior year transaction include amendment agreement chemocentryx inc panmira pharmaceuticals llc gsk reach agreement trustee pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation table include commitment exclude normal ongoing annual funding requirement approximately million group commitment principally relate revenue payment licence alliance commitment respect future interest payable loan disclose take account effect interest rate swap commitment noncancellable operating lease disclose million million provide commitment group balance sheet commitment noncancellable operating lease rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total commitment noncancellable operating lease gsk annual report financial statement note financial statement inancial instrument relate disclosure liquidity risk gsk policy borrow centrally order meet anticipate gsk report sterling pay dividend sterling profit funding requirement cash flow forecast funding role corporate treasury monitor manage external requirement monitor tmg monthly basis internal funding requirement financial risk support strategy diversify liquidity source range strategic objective gsk operate global basis primarily facility maintain broad access funding market subsidiary company manage capital ensure subsidiary able operate go concern optimise december gsk billion borrowing repayable return shareholder appropriate balance debt year hold billion cash cash equivalent equity treasury activity govern policy approve liquid investment billion hold centrally board director recently july include disposal proceed receive end december gsk access shortterm finance billion treasury management group tmg meeting chair chief billion commercial paper programme billion financial officer take place monthly basis review treasury billion issue programme december activity member receive management information relate gsk billion year commit mediumterm activity internal audit review treasury internal control facility billion billion day commit facility environment regularly facility place september september gsk use variety financial instrument finance operation respectively undrawn december gsk derivative financial instrument manage market risk consider level committed facility adequate give operation derivative principally comprise forward current liquidity requirement foreign currency contract interest rate swap swap gsk billion european medium term note programme borrowing liquid asset currency require group december billion note issue purpose manage exposure financial risk change programme group shelf registration foreign exchange rate interest rate statement december billion billion gsk hold issue derivative speculative purpose note issue programme gsk longterm borrowing treasury policy specifically prohibit activity mature date transaction financial instrument undertake manage gsk longterm credit rating remain unchanged risk arise underlie business activity speculation february gsk current rating stable outlook standard poor negative outlook moodys investor capital management service moodys group shortterm credit rating gsk financial strategy support group strategic priority standard poor moodys respectively regularly review board gsk manage capital structure group appropriate mix debt equity market risk gsk financial architecture design support delivery group strategy enhance return shareholder interest rate risk management key priority deliver sustainable sale growth improve gsk objective minimise effective net interest cost operating leverage improve financial efficiency convert balance mix debt fix float interest rate time earning cash free cash flow generate policy interest rate risk management limit return shareholder reinveste bolton acquisition float interest payment prescribe percentage operate attractive return available gsk continue profit apply strict financial returnsbase criterion cash flow gsk use interest rate swap redenominate bond return investment order allocate capital assess float interest rate duration swap match investment opportunity whilst protect credit profile duration principal instrument interest rate derivative business remain highly cash generative gsk instrument account fair value hedge relevant generate billion free cash flow addition group liability realise billion divestment return total billion shareholder billion dividend billion share repurchase net debt end year billion reduction billion compare previous year gsk expect deliver continued dividend growth longterm share buyback programme target share repurchase billion depend market condition capital structure group consist net debt billion note net debt shareholder equity billion consolidated statement change equity total capital include provide noncontrolle interest billion billion gsk annual report inancial instrument relate disclosure corporate treasury usage limit monitor daily corporate compliance officer cco operate independently continue corporate treasury breach limit report cfo immediately cco monitor credit rating foreign exchange risk management counterpartie change rating occur notifie corporate foreign currency transaction exposure arise internal treasury change investment level external trade flow generally hedge group objective authority limit appropriate addition relationship bank minimise exposure overseas operating subsidiary credit rating review regularly report present annually transaction risk match local currency income local tmg approval currency cost possible gsk internal trading transaction match centrally intercompany payment term manage gsk actively manage exposure credit risk reduce surplus reduce foreign currency risk foreign currency cash flow cash balance possible treasury strategy hedge selectively management corporate treasury regionalise cash management concentrate cash centrally tmg possible gsk manage cash surplus possible gsk continue maintain conservative borrowing requirement subsidiary company centrally approach counterparty risk period table forward contract hedge future repayment set credit exposure counterpartie rate liquid originating currency order reduce foreign currency translation investment cash cash equivalent derivative gross exposure group seek denominate borrowing asset position derivative contract consider currency principal asset cash flow primarily purpose table isda agreement denominate dollar euro sterle certain borrowing risk net position counterparty table swap currency require borrowing set group financial asset liability offset basis denominate swap foreign currency match billion bank balance deposit invest aaaa investment group overseas asset treat hedge rate counterpartie december significantly high relevant asset forward contract major currency equivalent december result disposal reduce exposure group investment overseas proceed receive end december compare asset net investment hedge section note year significantly high bank balance detail tmg review ratio borrowing asset major deposit hold rate counterpartie whilst currency monthly significantly decrease rate counterpartie result gsk bank balance deposit hold citibank credit risk shift moodys upgrading citibank nas rating group consider maximum credit risk december million december million total million invest baabbb rate counterpartie group financial asset exception investment include bank balance deposit hdfc bank state bank comprise equity investment bear equity risk credit india bbva venezuela halk emirates bank counterpartie risk detail group total financial asset local cash management purpose local december gsk great concentration credit risk investment purpose gsk sole shareholder billion billion hsbc aaaa include disposal proceed receive end december million invest babb rate counterparty relate investment pakistan government treasury bill treasuryrelate credit risk million hold unrated bank islandsbanki gsk set global counterparty limit gsk banking cash management purpose iceland investment counterpartie base longterm credit rating moodys standard poor aaaa aaaa aabaabbbbaabbb baabbb babb total unrated bank balance deposit treasury treasury repo money market fund corporate debt instrument government security party financial derivative total aaaa aaaa aabaabbbbaabbb baabbb babb total unrated bank balance deposit treasury treasury repo money market fund corporate debt instrument government security party financial derivative total credit rating table assign moodys standard poor respectively opinion rating agency differ gsk assign low rating counterparty local rating agency datum source available rating convert global rating equivalent moodys standard poor publish conversion table gsk annual report financial statement note financial statement inancial instrument relate disclosure follow method assumption estimate fair value continue cash cash equivalent approximate carry gsk centrally manage cash reserve amount billion december available month exclude liquid investment base quote market price calculate billion centrally manage cash hold viiv healthcare base observable input case marketable security own subsidiary group invest centrally manage liquid base principal amount case nonmarketable asset bank deposit aaaaaa rate treasury security short repricing periods treasury repo money market fund bear credit exposure investment equity investment trade active market government aaaaa rate determine reference relevant stock exchange quote bid price equity investment determine reference wholesale retail credit risk current market value similar instrument reference outside usa customer account discount cash flow underlie net asset group trade receivable balance shortterm loan overdraft commercial paper approximate usa line pharmaceutical company group carry short maturity sell product small number wholesaler addition instrument hospital pharmacie physician group sale large wholesaler approximately longterm loan base quote market price case group pharmaceutical vaccine turnover december european medium term note fix rate group trade receivable borrowing level fair value measurement approximate wholesaler total million million group carry case float rate bank loan expose concentration credit risk respect loan wholesaler encounter financial contingent consideration business acquisition january difficulty materially adversely affect group financial base present value expect future cash flow result interest rate swap foreign exchange contract base group credit risk monitoring activity relate present value contractual cash flow market source data wholesaler include review quarterly financial information exchange rate interest rate balance sheet date standard poor credit rating development gsk internal receivables payable approximate carry risk rating establishment periodic review credit limit group believe credit risk provision companyowne life insurance policy base cash require excess normal provision bad doubtful debt surrender value note trade receivables lease obligation approximate carry fair value financial asset liability fair value investment gsk share table present carry amount fair december employee share ownership plan value group financial asset liability december esop trust held gsk share carry value million december million fair value million fair value financial asset liability include million base quote market price share represent price receive sell asset pay transfer purchase esop trust satisfy future exercise option liability orderly transaction market participant award employee incentive scheme carry value measurement date low cost expect proceed share recognise deduction reserve december gsk hold treasury share cost million million deduct retain earning gsk annual report financial instrument relate disclosure continue carry fair carry fair value value value value note cash cash equivalent availableforsale investment liquid investment government bond total liquid investment investment loan receivables trade receivables certain noncurrent asset scope ia financial asset fair value profit loss noncurrent asset scope ias derivative designate fair value profit loss ade derivative classify held trading ia ade total financial asset financial liability measure amortise cost borrowing exclude obligation finance lease bond designate hedge relationship bond bank loan overdraft commercial paper total borrowing exclude obligation finance lease obligation finance lease total borrowing trade payable provision certain noncurrent liability scope ias financial liability fair value profit loss trade payable provision certain noncurrent liability scope ia derivative designate fair value profit loss ade derivative classify held trading ia ade total financial liability net financial asset financial liability valuation methodology measure fair value table describe categorise trade receivables noncurrent asset trade payable provision noncurrent liability reconcile relevant note gsk annual report financial statement note financial statement financial instrument relate disclosure continue financial instrument hold fair value follow table categorise group financial asset liability hold fair value valuation methodology apply determine fair value possible quote price active market level price available asset liability classify level provide significant input valuation model base observable market datum significant input valuation model base observable market datum instrument classified level investment classify level table comprise equity investment unlisted entity group enter research collaboration investment emerge life science company noncurrent liability classify level comprise contingent consideration business acquisition level level level total december financial asset fair value availableforsale financial asset liquid investment investment financial asset fair value profit loss noncurrent asset derivative designate fair value profit loss derivative classify hold trading ia financial liability fair value financial liability fair value profit loss trade payable noncurrent liability derivative designate fair value profit loss derivative classify held trading ias level level level total december financial asset fair value availableforsale financial asset liquid investment investment financial asset fair value profit loss noncurrent asset derivative designate fair value profit loss derivative classify hold trading ia financial liability fair value financial liability fair value profit loss noncurrent liability derivative designate fair value profit loss derivative classify hold trading ia movement year financial instrument measure level valuation method present january net loss recognise income statement net gain recognise comprehensive income contingent consideration liability business acquire year equity investment convert subsidiary acquisition business equity investment addition equity investment disposal transfer level exchange december net loss million million attributable level financial instrument hold end year report operate income million million arise remeasurement contingent consideration liability principally contingent consideration payable acquisition shionogiviiv healthcare joint venture net gain million nil report sell general administration net gain nil million attributable level equity investment hold end year report comprehensive income fair value movement availableforsale investment gsk annual report financial instrument relate disclosure continue net liability position million million respect financial instrument measure level valuation method december include million million respect contingent consideration payable acquisition shionogiviiv healthcare joint venture consideration expect pay year vary line sale tivicay dolutegravir regulatory approval product obtain usa canada year european union january table show indicative basis income statement balance sheet sensitivity reasonably possible change key input valuation liability increasedecrease financial liability lossgain income statement change key input increase sale forecast decrease sale forecast increase market interest rate decrease market interest rate trade receivables noncurrent asset scope ias follow table reconcile financial instrument trade receivables noncurrent asset fall scope ia relevant balance sheet amount financial asset predominantly noninterest earn financial instrument noncurrent asset balance include companyowne life insurance policy asset include tax receivables pension surplus balance prepayment outside scope ias fair value fair value loan financial loan financial profit loss receivables instrument total profit loss receivables instrument total trade receivable note noncurrent asset note follow table show age financial asset past provision bad doubtful debt past day past day past day past day past day amount past great day provision bad doubtful debt total million million balance million million relate receivable state hospital authority greece ireland italy portugal spain total receivable state hospital authority country current past net provision million million trade payable provision noncurrent liability scope ias follow table reconcile financial instrument trade payable provision noncurrent liability fall scope ia relevant balance sheet amount financial liability predominantly noninterest bear accrue wage salary include financial liability liability include payment account tax social security payable provision arise contractual obligation deliver cash financial asset outside scope ia fair value fair value financial financial profit loss liability instrument total profit loss liability instrument total trade payable note provision note noncurrent liability note gsk annual report financial statement note financial statement financial instrument relate disclosure continue derivative financial instrument hedge programme follow table set fair value derivative hold gsk fair value fair value asset liability asset liabilitie fair value hedge interest rate swap principal million million net investment hedge foreign exchange contract principal million million cash flow hedge foreign exchange contract principal million million derivative designate fair value profit loss foreign exchange contract principal million million embed derivative derivative classify hold trading ia total derivative instrument analyse current noncurrent total foreign exchange contract classify held trading ia principal foreign exchange contract absolute total outstanding position balance sheet date group foreign exchange contract period month december group hold outstanding foreign exchange contract consist primarily foreign currency swap net liability fair value million million asset million liability december fair value million net liability million asset million liability million net liability fair value increase additional hedge intercompany loan deposit external debt legal provision designate accounting hedge fair value movement take income statement period offset exchange gain loss relate intercompany lending borrow external debt legal provision fair value hedge group designate series interest rate swap fair value hedge risk hedge variability fair value bond arise interest rate fluctuation gain loss fair value hedge disclose note finance expense carrying value bond designate hedge relationship include million million designate hedge item fair value hedge relationship net investment hedge year certain foreign exchange contract designate net investment hedge respect foreign currency translation risk arise consolidation group net investment european euro japanese yen foreign operation show table carry value bond designate hedge relationship include million million designate hedge instrument net investment hedge relationship cash flow hedge group enter forward foreign exchange contract designate cash flow hedge foreign exchange exposure arise euro dollar denominate coupon payment relate group european medium term note december group designate cash flow hedge foreign exchange exposure arise recognition liability denominate indian rupee group consolidate financial statement addition group carry balance reserve arise prehedge fluctuation longterm interest rate pricing bond issue year disclose note balance reclassify finance cost life bond gsk annual report financial instrument relate disclosure continue offset financial asset liability follow table set financial asset financial liability subject offset enforceable master netting arrangement similar agreement amount set financial asset liability group balance sheet set trade receivables trade payable derivative financial asset derivative financial liability amount offset balance sheet offset certain circumstance set gross net financial gross financial asset relate financial liability liability amount asset asset balance set liability set sheet balance sheet net december trade receivables derivative financial asset cash cash equivalent trade payable derivative financial liability bank loan overdraft gross net financial gross financial asset relate financial liability liability amount asset asset balance set liability set sheet balance sheet net december trade receivables derivative financial asset cash cash equivalent trade payable derivative financial liabilite bank loan overdraft gross financial asset liability set balance sheet primarily relate cash pooling arrangement bank amount meet criterion offset balance sheet settle net certain circumstance principally relate derivative transaction isda international swap derivative association agreement party option settle amount net basis event default party gsk annual report financial statement note financial statement financial instrument relate disclosure continue debt interest rate repricing table follow table set exposure group interest rate debt include commercial paper effect interest rate swap maturity analysis fix rate debt state contractual maturity float rate debt interest rate repricing date purpose table debt define class borrowing obligation finance lease effect effect interest interest debt rate swap total debt rate swap total float fix rate debt year year year year year year great year total original issuance profile fix rate interest float rate interest total interest bear noninterest bearing group hold interest rate swap designate fair value hedge convert million fix rate debt maturity year million maturity year float rate exposure sensitivity analysis foreign exchange interest rate sensitivity analysis prepare assumption net debt ratio fix float interest rate debt derivative portfolio proportion financial instrument foreign currency constant basis hedge designation december financial instrument affect market risk include cash cash equivalent borrowing trade receivables payable derivative financial instrument follow analysis intend illustrate sensitivity financial instrument change foreign exchange interest rate foreign exchange sensitivity table show indicative basis group sensitivity foreign exchange rate dollar euro yen financial instrument currency major foreign currency gsk financial instrument denominate gsk consider movement currency conclude cent yen movement rate sterling reasonable analysis financial instrument consider sensitive foreign exchange rate functional currency entity hold obligation finance lease intercompany loan fully hedge maturity certain nonderivative financial instrument net debt exclude present material exposure foreign exchange sensitivity group asset liability financial instrument include calculation movement income statement table relate primarily cash cash equivalent intercompany loan deposit intercompany trading balance hedge instrument legal provision trade receivables payable denominate functional currency entity hold whilst hedge instrument provide economic hedge relate remeasurement provision include calculation increase increase income income income statement impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currency cause follow decrease income million million million dollar euro yen exchange rate respectively million million nil gsk annual report financial instrument relate disclosure continue movement equity table relate hedge instrument foreign exchange derivative external debt designate net investment hedge hedge group asset denominate euro yen decrease decrease equity equity equity impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currency cause follow increase equity nil million million dollar euro yen exchange rate respectively nil million million table present group sensitivity foreign exchange rate base composition net debt show note adjust effect foreign exchange derivative net debt affect future foreign currency cash flow increase increase decrease decrease net debt net debt impact foreign exchange movement net debt cent appreciation dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currency follow impact net debt million million million dollar euro yen exchange rate respectively million million million interest rate sensitivity table show indicative basis group sensitivity interest rate float rate sterling dollar euro financial instrument issue debt bank borrowing cash cash equivalent liquid investment gsk consider movement interest rate year conclude basis point increase reasonable benchmark debt bank borrowing maturity year float rate calculation interest rate movement derivative financial instrument designate fair value hedge deem immaterial effect group income statement compensating amount carry value debt basis point movement interest rate deem material effect equity increase increase decrease decrease income income income statement impact interest rate movement basis point increase sterling interest rate basis point increase dollar interest rate basis point increase euro interest rate increase interest income high level indicative cash balance sheet date interest rate decrease basis point currently maximum increasedecrease income limit million nil million sterling dollar euro interest rate respectively million nil nil contractual cash flow nonderivative financial liability derivative instrument follow table provide analysis anticipate contractual cash flow include interest payable group nonderivative financial liability undiscounte basis impact interest rate swap exclude purpose table debt define class borrowing obligation finance lease interest calculate base debt hold december take account future issuance float rate interest estimate prevail interest rate balance sheet date cash flow foreign currency translate spot rate december contractual cash flow respect operating lease vacant space provision exclude table include commitment noncancellable operating lease table note commitment finance charge trade payable obligation obligation interest finance finance liability debt debt lease lease net debt total december year year year year year year great year gross contractual cash flow gsk annual report financial statement note financial statement financial instrument relate disclosure continue contractual cash flow nonderivative financial liability derivative instrument finance charge trade payable obligation obligation interest finance finance liability debt debt lease lease net debt total december year year year year year year great year gross contractual cash flow increase contractual cash flow nonderivative financial liability billion year result principally increase billion forecast future cash flow respect contingent consideration payable acquisition shionogiviiv healthcare joint venture table provide analysis anticipate contractual cash flow group derivative instrument exclude embed derivative equity option material undiscounted cash flow cash flow foreign currency translate spot rate december gross cash flow foreign exchange contract present purpose table practice group use standard settlement arrangement reduce liquidity requirement instrument amount receivable payable year increase compare december high level hedge intercompany loan external debt reflect increase principal amount show table receivables payable receivables payable year year gross contractual cash flow employee share scheme group operate share option scheme option grant employee acquire share ad glaxosmithkline plc grant price savingsrelate share option scheme share award scheme addition gsk operate performance share plan award grant employee acquire share ad glaxosmithkline plc cost subject achievement group specify performance target share value plan award grant employee acquire share ad glaxosmithkline plc cost year vest period grant restrict share award replace grant option employee cost scheme readily equate potential gain employee grant share option scheme normally exercisable year date grant grant restrict share share award normally exercisable end year vestingperformance period grant savingsrelate share option scheme normally exercisable year save grant share option scheme award performance share plan normally grant employee acquire share ad gsk plc circumstance settle cash option share option scheme grant market price ruling date grant accordance practice majority option savingsrelate share option scheme grant price market price ruling date grant share option award director cet subject performance criterion option pricing purpose value option award arrive share base payment charge blackschole option pricing model assumption model follow riskfree interest rate dividend yield volatility expect life savingsrelate share option share award scheme year year year weight average share price grant year share ad plan dividend reinveste gsk annual report employee share scheme continue volatility determine base year share price history appropriate fair value performance share plan grant account market condition expect life option determine base weighted average historic exercise option share option share option savingsrelate option outstanding scheme share scheme ad share option scheme weight weight weight weight weight weight number exercise fair number exercise fair number exercise fair price value price value price value january option grant option exercise option lapse december option grant option exercise option lapse december option grant option exercise option lapse december range exercise price option outstanding year end weight average market price exercise weight average remain contractual life year year year option outstanding share option share option savingsrelate december scheme share scheme ad share option scheme weighted late weight late weight late number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total option normally exercisable year date grant certain circumstance vest early set scheme rule change effective exercise price outstanding option year option exercisable share option share option savingsrelate scheme share scheme ad share option scheme weight weight weight number exercise number exercise number exercise price price price december december december gsk annual report financial statement note financial statement employee share scheme continue glaxosmithkline share award scheme performance share plan group operate performance share plan award grant director senior executive cost percentage award vest base performance group define measurement period dividend reinveste period award grant onwards director member cet performance condition base equally weight measure year performance period measure base achievement adjust free cash flow target second measure base relative tsr performance comparator group remain measure base businessspecific performance measure business diversification new product performance detail calculation measure remuneration report page award grant director member cet award base achievement adjust free cash flow target year measurement period remain award base relative tsr performance comparator group half tsr element award measure year half year award eligible employee performance condition consist part apply award performance condition compare gsk ep growth increase retail price index year measurement period second performance condition base strategic operational business measure year measurement period specific employee business area fair value award determine base closing share price day grant tsr performance element adjust likelihood condition meet assess time grant share weight ad weight number share ad issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december year share ad award dividend reinveste include share value plan group operate share value plan award grant form share certain employee cost award vest year performance criterion attach fair value award determine base closing share price day grant deduct expect future dividend yield duration award share weight ad weight number share ad issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december gsk annual report employee share scheme continue employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share open market finance provide group way loan contribution cost run esop trust charge income statement share hold esop trust deduct reserve hold value proceed receivable employee exercise deem permanent diminution value reflect transfer retain earning trust acquire hold share meet notional dividend reinveste deferred award smithkline beecham midterm incentive plan trustee waive right dividend share hold esop trust share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value gsk annual report financial statement note financial statement principal group company follow represent principal subsidiary associate glaxosmithkline group december detail give principal country operation location headquarters business sector business activity equity share capital entity wholly own group percentage interest show company incorporate principal country operation state europe location subsidiary sector activity england brentford glaxosmithkline holdings limited phch brentford glaxosmithkline service unlimited phch brentford glaxosmithkline mercury limit brentford glaxosmithkline finance plc phch brentford glaxosmithkline capital plc phch brentford smithkline beecham limited phch brentford wellcome limited phch brentford glaxo group limit brentford glaxo operation limit brentford glaxosmithkline export limit brentford glaxosmithkline research development limit brentford glaxosmithkline limit brentford setfirst limited phch brentford glaxosmithkline trading service limit brentford viiv healthcare limit brentford viiv healthcare limit austria vienna glaxosmithkline pharma gmbh belgium wavre glaxosmithkline pharmaceuticals rixensart glaxosmithkline biological czech republic prague glaxosmithkline sro phch france marly roi groupe glaxosmithkline sas marly roi laboratoire glaxosmithkline sas marly roi glaxo wellcome production sas marly roi glaxosmithkline sante grand public sas marly roi viiv healthcare sas amand les eaux glaxosmithkline biological sas germany buehl glaxosmithkline consumer healthcare gmbh munich glaxosmithkline gmbh greece athens glaxosmithkline aebe phch italy verona glaxosmithkline spa milan glaxosmithkline consumer healthcare spa netherlands zeist glaxosmithkline poland poznan glaxosmithkline pharmaceuticals poznan gsk service spz republic carrigaline smithkline beecham cork limit ireland dublin glaxosmithkline consumer healthcare ireland limited dublin glaxosmithkline ireland limit dungarvan stafford miller ireland limited dungarvan glaxosmithkline dungarvan limited sligo stiefel laboratory ireland limit romania brasov europharm hold phch buchar glaxosmithkline gsk srl russian moscow glaxosmithkline trading zao federation spain madrid glaxosmithkline switzerland muenchenbuchsee glaxosmithkline usa usa research triangle park stiefel laboratory inc marietta corixa corporation philadelphia glaxosmithkline llc phch pittsburgh glaxosmithkline consumer healthcare pittsburgh block drug company inc wilmington glaxosmithkline holdings americas inc phch wilmington glaxosmithkline capital inc phch research triangle park viiv healthcare company rockville human genome sciences inc gsk annual report principal group company continue america location subsidiary sector activity canada mississauga glaxosmithkline inc mississauga glaxosmithkline consumer healthcare inc laval biomedical corporation quebec mexico mexico city glaxosmithkline mexico phch asia pacific australia boronia glaxosmithkline australia pty ltd phch china beijing glaxosmithkline china investment ltd phch hong kong glaxosmithkline limited phch tianjin sinoamerican tianjin smith kline french laboratories ltd india mumbai glaxosmithkline pharmaceutical limit gurgaon glaxosmithkline consumer healthcare limited malaysia selangor glaxosmithkline consumer healthcare sdn bhd pakistan karachi glaxosmithkline pakistan limited phch philippines makati glaxosmithkline philippines inc phch singapore singapore glaxo wellcome manufacturing pte ltd singapore glaxosmithkline pte ltd phch south korea seoul glaxosmithkline korea limited thailand bangkok glaxosmithkline thailand limited phch japan japan tokyo glaxosmithkline phch latin america argentina buenos aires glaxosmithkline argentina phch brazil rio janeiro glaxosmithkline brasil limitada phch colombia bogota glaxosmithkline colombia phch venezuela caracas glaxosmithkline venezuela phch middle east africa egypt cairo glaxosmithkline sae phch nigeria lagos glaxosmithkline consumer nigeria plc phch south africa johannesburg glaxosmithkline south africa pty limited phch turkey istanbul glaxosmithkline ilaclari sanayi ticaret phch middle east africa location associate sector activity south africa johannesburg aspen pharmacare holding limited iii phch exempt provision section company amendment act ireland onsolidate subsidiary accordance section company act ground dominant influence iii equity account ground significant influence ncorporated ireland directly hold wholly own subsidiary glaxosmithkline plc key business sector pharmaceutical consumer healthcare business activity development export finance hold company insurance marketing production research service detail group subsidiary associate attach company annual return file registrar company glaxosmithkline capital inc glaxosmithkline capital plc whollyowne finance subsidiary company company fully unconditionally guarantee security issue glaxosmithkline capital inc glaxosmithkline capital plc gsk annual report financial statement note financial statement legal proceeding october district court issue ruling construe claim patent manner arzerra group involve significant legal administrative infringe patent genentech biogen idec stipulate proceeding principally product liability intellectual property tax judgment infringement file appeal claim antitrust governmental investigation related private construction issue united states court appeal litigation group make provision proceeding federal circuit december appeal hear regular basis summarise note accounting principle november court affirm district court claim policy note provision group construction give effect genentech stipulation patent involve significant legal proceeding respect infringe genentech file request rehear banc possible reliable estimate expect financial effect deny july end case result ultimate resolution proceeding avodartjalyn case appropriate disclosure case november banner pharmacaps inc banner notify include provision group file abbreviate new drug application respect legal proceeding describe anda market generic version avodart dutasteride provision group unable usa banner notification contain paragraph certification reliable estimate expect financial effect allege patent expire patent expiring stage group believe information patent cover compound dutasteride seek plaintiff know meaningful invalid infringe banner propose generic dutasteride respect legal proceeding number product group subsequently receive similar notice factor include limited stage proceeding anchen pharmaceutical anchen apotex apotex roxane entitlement party appeal decision clarity theory laboratorie roxanne watson laboratories inc watson liability damage govern law intellectual property claim mylan pharmaceuticals inc mylan variously challenging include challenge validity enforceability group patent patent patent product process assertion december anchen notify group file noninfringement patent loss case anda jalyn paragraph certification alleging result loss patent protection product issue patent invalid unenforceable infringe jalyn consequence loss significant decrease combination dutasteride tamsulosin cover sale product materially affect future result patent cover avodart subsequently group receive operation group similar notice impax laboratories inc impax watson legal expense incur provision relate legal claim challenge patent cover jalyn charge sell general administration cost provision group file suit anchen banner impax mylan roxanne take appropriate legal specialist advice watson united states district court district outflow resource consider probable reliable delaware infringement avodart jalyn patent estimate likely outcome dispute certain applicable case consolidate trial august product liability claim group provision group file separate suit apotex sufficient history claim settlement enable court infringement patent case management reliable estimate provision require consolidated original case generic cover unasserted claim december group defendant court order apotex aggregate provision legal dispute include tax case stay pende entry judgment banner matter describe note taxation billion case january group anchen settle ultimate liability legal claim vary amount provide litigation term allow anchen enter market dependent outcome litigation proceeding jalyn fourth quarter early certain investigation possible settlement negotiation circumstance group previously settle early patent group position change time challenge avodart teva pharmaceuticals teva term assurance loss result outcome allow teva launch generic dutasteride product legal proceeding exceed material fourth quarter early certain circumstance provision report group financial account tevas generic dutasteride product approve fda happen material adverse impact december result operation group reporting period trial consolidated case generic defendant judgment incur settlement enter hold january august district court significant matter describe upheld validity patent banner impax mylan roxanne intellectual property watson appeal decision favour group court appeal federal circuit august arzerra february federal circuit enter decision favour march genentech biogen idec file suit group affirm decision district court group united states district court southern district california allege group sale arzerra ofatumumab approve food drug administration fda treatment refractory chronic lymphocytic leukaemia cll induce contribute infringement patent claim treatment cll anticd monoclonal antibody group counterclaim patent invalid infringe gsk annual report benlysta separate component decision judge rule september court appeal refuse appeal eli lupin generic version trizivir infringe patent lilly company eli lilly assert human genome science trial teva stipulate generic version epzicom infringe inc hgs patent benlysta invalid patent district court enjoin teva launch ground lack necessary information require work generic epzicom product party appeal invention describe claim cover antibodie judgement antibody claim insufficiency argument high court february viiv healthcare receive notice lupin supreme court previously decide patent valid file anda contain paragraph certification epzicom ground supreme court refuse eli allege patent list orange book epzicom lilly petition appeal result litigation invalid unenforceable infringe patent relate end validity hgs patent affirm method treat hiv double combination expire court hemisulfate salt abacavir expire eli lilly separately request declaration high certain crystal form lamivudine expiring court supplementary protection certificate spc file lexiva hgs extend patent base future eli lilly marketing april ranbaxy laboratory limit ranbaxy notify authorisation antiblys antibody invalid viiv healthcare file paragraph certification allege litigation pende patent claim polymorphic form fosamprenavir calcium september court justice european union active ingredient lexiva invalid infringe patent cjeu hear argument question mean expire viiv healthcare sue patent protect basic patent hand guidance july mylan pharmaceuticals inc mylan notify viiv december cjeu answer question healthcare file anda lexiva paragraph eli lillys antibody protect hgs patent confirm certification assert patent claim active ingredient functional definition product spc seek expire polymorphic form active ingredient sufficient principle claim patent relate implicitly expire invalid unenforceable infringe mylan necessarily specifically active ingredient cover second generic company file anda lexiva spc high court implement guidance generic company challenge basic compound patent cjeu decide case hearing date set active ingredient august viiv healthcare outcome litigation effect group ability market benlysta licensor vertex pharmaceutical incorporate file patent infringement suit mylan patent claim active epzicomtrizivir ingredient patent claim polymorph united november group affiliate viiv healthcare states district court district delaware mylan subsequently receive notice teva pharmaceuticals usa inc teva file file declaratory judgment action viiv healthcare allege anda paragraph certification epzicom polymorph patent invalid infringe viiv healthcare combination lamivudine abacavir certification challenge stipulate noninfringement patent claim polymorph patent cover hemisulfate salt abacavir party file consent judgment december expire viiv healthcare sue teva patent polymorph patent trial schedule june viiv healthcare receive notice teva infringement basic active ingredient patent lexiva amend anda epzicom contain paragraph october ranbaxy file petition inter party review certification additional patent list orange book united states patent trademark office uspto allege allege patent invalid unenforceable infringe basic compound patent cover active ingredient invalid patent challenge new certification relate method march uspto grant petition inter party treat hiv combination expire certain review proceeding settle october term crystal form lamivudine expire august viiv confidential healthcare file suit teva combination patent united states district court district delaware lovaza march group receive notice teva pharmaceutical viiv healthcare receive notice lupin ltd usa inc teva par pharmaceuticals inc par apotex inc lupin file anda contain paragraph certification trizivir triple combination lamivudine azt abacavir apotex file andas paragraph certification alleging allege patent list orange book trizivir patent cover lovaza omegaacid ethyl ester invalid unenforceable infringe patent expire march invalid unenforceable infringe patent relate april group licensee patent method treat hiv triple combination expire marketing right usa puerto rico pronova hemisulfate salt abacavir expire certain biopharma norge pronova owner patent sue teva crystal form lamivudine expire june viiv par apotex united states district court district healthcare file suit lupin patent cover triple delaware group party suit combination united states district court district delaware district court consolidated discovery teva march pronova enter agreement apotex epzicom case viiv healthcare patent infringement suit settle patent litigation usa relate lovaza lupin relate trizivir case involve patent settlement grant apotex licence enter market cover combination lamivudine abacavir generic version lovaza quarter term settlement confidential december united states district court district delaware uphold validity patent expiry date march cover combination lamivudine abacavir epzicom triple combination lamivudine abacavir zidovudine trizivir gsk annual report financial statement note financial statement trial involve teva par hold march april february group reach agreement settle district court hold patent valid infringe substantial majority federal state case pende september court appeal federal circuit fourteen purport class action avandia pende canada rule pronova patent litigation lovaza group reach agreement principle resolve reverse district court rule court find assert single purport consumer class action israel claim pronovas patent invalid remand approve court group notify individual case district court order enter judgment favour claim lawyer represent claimant anda filer patent litigation application high court overall litigation expire early court find unnecessary subject group litigation order court list reach issue patent october pronova application hearing date june file combine petition panel rehear rehear banc number purport class action seek economic court appeal federal circuit court deny damage behalf party payer consumer assert petition january affirm claim arise state federal law include september decision federal circuit court racketeer influence corrupt organization act rico state pronova group receive paragraph notice unfair trade practice andor consumer protection law addition endo pharmaceuticals endo sandoz inc sandoz stride subrogation action initiate united health group inc arcolab ltd strides trygg pharma trygg advise humana medical plan humana bring submit abbreviate application fda generic group putative class action bring mdl court form lovaza pronova choose assert patent endo humana concerns medicare advantage claim briefing sandoz stride trygg await rule litigation action threshold class certification issue remain pende teva par court appeal federal circuit state court action concern nonmedicare group aware fda approve generic advantage claim action stay midjune copy lovaza date determine private lien resolution program resolve claim veramyst november group receive notice sandoz inc paxilseroxat paxil file anda paragraph certification veramyst group receive numerous lawsuit claim allege fluticasone furoate nasal spray challenge patent list use paxil paroxetine cause variety injury orange book veramyst invalid unenforceable lawsuit recent year allege use paxil infringe patent expire december pregnancy result birth child birth defect group file suit sandoz united states district health issue lawsuit claim allege patient court district delaware patent stay take paxil commit attempt commit suicide act fda approval sandozs generic product place violence patient suffer symptom discontinue early court decision adverse group trial treatment paxil schedule begin december pregnancy august group sandoz settle litigation term allow sandoz enter market generic competitor group reach agreement settle substantial veramyst quarter early certain majority claim relate paxil use pregnancy circumstance february number claim relate use pregnancy pende include schedule trial product liability philadelphia state court mass tort program mtp matter preclinical clinical trial conduct development dismiss payment united states potential product determine safety efficacy court appeal circuit rule june product use human follow approval regulatory glaxosmithkline llc delaware citizen purpose diversity body notwithstanding effort drug vaccine jurisdiction federal court result rule introduce marketplace unanticipated safety issue group seek remove federal court numerous case claim evident group recently file philadelphia mtp certain case set currently defendant number product liability lawsuit relate trial mtp november thomasswindle group pharmaceutical vaccine consumer healthcare matter pennsylvania superior court uphold summary judgment product significant matter describe favour group base expiration statute group able reliable estimate expect limitation december plaintiff case financial effect matter discuss category petitioned allowance appeal pennsylvania supreme include provision matter provision legal court group plan oppose petition allowance dispute note note provision appeal currently trial schedule propose certify class action canada avandia bartram action certify british columbia group name product liability lawsuit behalf national class action relate cardiovascular defect appeal individual assert personal injury claim arise use certification decision dismiss october avandia federal case file group party proceed commence discovery multidistrict litigation proceed pende united states district court eastern district pennsylvania mdl court case file number state court gsk annual report singh action alberta propose national class action february vast majority individual case previously seek certify class relate birth defect generally pende mdl mtp dismiss few certification motion likely schedule time active case mdl active case mtp inactive propose national class action british pende group schedule trial columbia hold abeyance november individual lawsuit purport proceeding forward certification class action assert consumer fraud claim file canada individual lawsuit resolve act violence class action dismiss leave putative class action february pende matter include remain pende canada file unfiled claim lawsuit appeal pende united states court turkey group voluntarily withdraw appeal ninth circuit pende florida zinccontaine formulation super poligrip market early second district court appeal concern allegation patient take paxil commit attempt commit suicide act violence sale marketing regulation group able reliable estimate expect discontinuation financial effect matter discuss category late public funding withdraw include provision matter provision legal claimant receive funding pursue litigation allege dispute note matter group paxilseroxat cause suffer withdrawal reaction provision note note provision dependency majority claimant discontinue claim june group inform legal aid china investigation agency laa legal services commission june number group pharmaceutical office consider discharge public funding certificate china visit government authority people follow recommendation special case review panel republic china prc july ministry public case poor prospect success remain claim security china release statement confirm ongoing police prosecute pende outcome laas decision investigation allege economic crime gsk china prc act government agency continue poligrip investigation allege crime violation law gsk china begin number product liability lawsuit claim operation group take allegation seriously file group state federal court continue cooperate fully chinese authority usa include purport class action allege zinc investigation super poligrip cause copper depletion permanent neurologic injury federal case consolidate denture cream group inform department justice adhesive multidistrict litigation mdl united states district securities exchange commission fraud court southern district florida establish office investigation possible time june group procter gamble defendant reliable estimate financial effect result litigation include mdl purport class matter action assert economic loss claim state consumer colorado investigation protection law claim medical monitoring original july group announce reach putative class action dismiss putative agreement united states government multiple state class action file puerto rico remove federal district columbia conclude group significant court transfer mdl remain pende ongoing united states federal government investigation specifically february current exception state court case united states department justice investigation pennsylvania state court case small claim court group sale marketing practice relate large tennessee state court case consolidated selling product begin february department philadelphia state court mass tort program mtp justice investigation possible inappropriate use nominal price exception medicaid rebate program iii department justice investigation development marketing avandia settlement payment billion settlement resolve criminal civil liability relate investigation payment cover group exist provision fund exist cash resource date state district columbia agree join federal settlement agreement receive portion share settlement payment agreement gsk annual report financial statement note financial statement group notify consortium state attorney cidra thirdparty payer litigation general investigate conduct underlie july number major healthcare insurer file suit nonavandia federal state sale marketing settlement group philadelphia pennsylvania county court determine company violate state unfair deceptive trade common plea seek compensation reimbursement practice statute state know participate medicine manufacture group cidra plant investigation puerto rico insurer claim group knowingly illegally market sell adulterate drug manufacture avandiarelated matter condition noncompliant cgmp thirdparty note july group reach agreement insurer unlawfully induce pay government number state district columbia resolve federal government avandia investigation suit allege federal state law cause settlement resolve claim federalstate medicaid programs action august group removed case november group agree pay million settle united states district court eastern district pennsylvania claim state district columbia state move dismiss complaint oral argument motion consumer protection law marketing promotion dismiss hold february motion currently avandia consideration district court manufacturing issue group plant cidra subject federal state group agree pay million resolve individual claim group resolve federal government lawsuit file attorney general office kentucky louisiana group compliance obligation maryland mississippi new mexico south carolina utah west corporate integrity agreement government virginia assert statutory common law claim relate development marketing avandia regard paxilseroxat state louisiana group product states group settle lawsuit file new york state participate federal government settlement attorney general office allege group fail disclose group defend action county santa clara data use paxil child adolescent california bring californias consumer protection group class settlement lawsuit bring law seek civil penalty restitution pretrial activity consumer thirdparty payer respectively economic schedule occur case proceed trial damage allegedly result prescription paxil children mdl court send case california federal court adolescent group deny liability settlement bench trial plaintiff voluntarily dismiss similar purport class action file behalf governmental entity pay prescription native american group cherokee nation oklahoma paxil minor remain similar purport class action mississippi band choctaw indians file lawsuit canada seek economic damage behalf individual respective tribal court allege common law claim include fraud purchase paxil use patient age negligence breach warranty unjust enrichment cherokee certification application purport class action nation matter relate sale marketing avandia adjourn permit filing evidence likely choctaw complaint relate avandia group product resume average wholesale price secdoj fcpa enquiry number state respective attorney general securities exchange commission sec counties new york state file civil lawsuit state department justice doj initiate industrywide enquiry federal court group pharmaceutical pharmaceutical company engaged company claim damage restitution average violation foreign corrupt practice act fcpa relate wholesale price awp andor wholesale acquisition cost wac sale pharmaceutical include argentina brazil canada price report pharmaceutical product cover states china germany italy poland russia saudi arabia group medicaid programmes case allege group report company ask respond enquiry caused report false awp wac price turn cooperate sec doj group inform allegedly cause state medicaid agency reimburse provider doj sec investigation china operation money cover medicine agency intend chinese government initiate state seek recovery behalf state payer case behalf instate patient consumer group antitrustcompetition resolve awp claim state medicaid programme group able reliable estimate expect states group settlement agreement financial effect matter discuss category federal government announce september multiple include provision matter provision legal additional settlement litigation concern awp issue dispute note matter group continue state illinois wisconsin provision note note provision hiv division enquiry july group receive subpoena eastern district new york attorney office sale marketing practice hiv product educational programme grant payment physician drug treat hivinfecte adult september group advise government conclude investigation decline intervene qui tam lawsuit file united states district court eastern district new york suit dismiss matter conclude gsk annual report sector enquiry flonase european commission launch enquiry purport direct indirect purchaser class action file investigate possible anticompetitive condition pharmaceutical united states district court eastern district sector final report pharmaceutical sector inquiry pennsylvania allege group illegally maintain monopoly power publish july announce final report market flonase charge plaintiffs supracompetitive commission decide continue monitor patent settlement price additionally suit file roxane laboratories inc agreement originator generic company relate generic competitor seek lose profit group allege market result group provide input report action unlawfully delay roxane entry market publish february predicate allegation filing group group receive questionnaire relate patent settlement allegedly sham citizen petition subsequent litigation group respond commission february december group reach agreement settle provision matter litigation direct purchaser payment million enquiry tyverb combivir agreement settle indirect purchaser class indirect purchaser payment million december group viiv healthcare receive request information european commission court approve class action settlement application direct pharmacy distribution group product matter conclude tyverb viiv healthcare product combivir group viiv lamictal healthcare provide request information provision matter purport direct indirect purchaser class action file united states district court district new jersey allege office fair trading competition act investigation group teva pharmaceuticals unlawfully conspire august office fair trading oft launch delay generic competition lamictal result formal investigation group pharmaceutical overcharge separate count accuse group monopolise company potential infringement competition act market district court recently deny motion investigation focus litigation settlement purport direct purchaser class reconsideration order group potential supplier generic paroxetine formulation grant gsk motion dismiss december plaintiff enter object effect file notice appeal united states court appeal prevention restriction distortion competition circuit group plan purport group infringe dominant position make payment indirect purchaser class dismiss follow outcome potential supplier generic paroxetine aim restrict direct purchaser case development generic competition group nevada vaccine antitrust litigation terminate agreement issue oft investigation cover issue investigate european vaccine center forprofit vaccination centre las vegas commission respect paroxetine european nevada allege group vendor engage union european commission price discrimination provide lowerpriced vaccine product pharmaceutical sector enquiry march commission southern nevada health district entity entitle announce formally conclude enquiry lowerpriced pharmaceutical product federal action march oft decide focus investigation healthcare program allegedly create competitive disadvantage potential anticompetitive aspect paroxetine settlement result antitrust injury vaccine center complaint agreement drop investigation relation potential allege violation sherman act robinsonpatman act abuse dominance february oft decide claim nevada state law group respond reopen dominance aspect matter complaint trial date set group cooperate oft investigation wellbutrin outset april oft issue statement december january february lawsuit objection set decision oft propose purport class action file allow affected party representation united states district court eastern district pennsylvania propose decision oft core theory harm group behalf direct indirect purchaser transfer value originator company potential competitor wellbutrin complaint allege violation antitrust law return restriction potential competitor enter sham litigation fraud patent office group market necessarily restrict competition delay true obtaining enforce patent cover wellbutrin generic competition accompany price reduction complaint follow introduction generic competition include situation value transfer context wellbutrin april district appellate court ruling settle patent litigation oft states generic manufacturer infringe group patent propose fine gsk detail provide fine calculate august gsk submit response november district court approve group rebut ofts argument october settlement certify class direct purchaser gsk present case oft oral hearing settlement conclude january group hearing gsk respond write followup question reach agreement principle settle claim indirect oft indicate decide proceed purchaser million district court approve case final decision likely issue october settlement matter conclude oft decision appeal competition appeal tribunal provision matter gsk annual report financial statement note financial statement wellbutrin addition private litigant suit december action file biovail corporation biovail sec file formal complaint stiefel charles stiefel group united states district court eastern district united states district court district florida allege pennsylvania purport class direct indirect purchaser stiefel principal violate federal security law induce allege unlawful monopolisation antitrust violation stiefel employee sell share employee stock plan relate enforcement biovail wellbutrin patent company greatly undervalue price disclose file biovail citizen petition direct indirect employee company sell matter purchaser class certify district court grant likewise stay pende rule finnerty appeal group motion partial summary judgment primarily immunity group provision stiefel litigation ground november district court grant benlysta security litigation group motion stay proceeding limited november class action suit file united ongoing discovery light supreme courts state district court district maryland allege human grant petition ftc watson reverse payment patent genome sciences inc hgs certain individual officer litigation case director group statement clinical trial december district court hold hearing benlysta fail disclose suicide trial participant connection remain issue case possible withholding information defendant cause hgs antitrust liability arise settlement underlie patent stock artificially inflate harm purchase hgs infringement litigation court recently order party stock inflate price submit plan additional discovery proceeding november second action file federal remain issue court case combine group commercial corporate hgs file motion dismiss suit oral argument hear september march court rule favour group able reliable estimate expect gsk hgs motion matter conclude financial effect matter discuss category include provision respect matter provision environmental matter legal dispute set note provision group notify potential responsibility relate provision follow matter past operation past waste disposal practice certain site indicate primarily usa matter subject securitieserisa class action litigation include proceeding initiate federal state government waste disposal site remediation cost tort stiefel action bring private party july class action suit bring behalf current group advise responsible party employee stiefel laboratories inc stiefel file approximately site appear national priority united states district court southern district florida list create comprehensive environmental response complaint allege stiefel officer director violate compensation liability act superfund proceeding employee retirement income security act erisa federal seek require operator hazardous waste facility state security law induce stiefel employee sell transporter waste site generator hazardous share employee stock plan stiefel greatly waste dispose site clean site reimburse undervalue price disclose employee stiefel government cleanup cost instance sell group july district group involve allege generator hazardous waste court deny plaintiff motion class certification october district court grant defendant motion summary superfund provide defendant jointly judgment dismiss remain plaintiff severally liable clean cost proceeding frequently litigation trial claim plaintiff timothy finnerty took resolve basis nature quantity waste dispose place resulted million jury verdict favour generator site group proportionate liability finnerty securities claim group appeal cleanup cost substantially determine verdict oral argument appeal schedule february site refer separately group settle finnertys erisa claim group potential liability vary greatly site site additionally stiefel complete defence verdict fry case cost investigation study remediation site try federal court florida october remain case time significant group routinely accrue amount related florida martinolich stay pende outcome share liability matter finnerty appeal addition finnerty matter appeal eleventh circuit bacon summary judgment grant plaintiff favour mackay summary judgment grant stiefel favour discovery continue georgia new york suit lawsuit involve claim similar bring finnerty gsk annual report financial statement glaxosmithkline plc prepare gaap director statement responsibility disclosure information auditor relation company financial statement director office date report confirm director responsible prepare parent company far aware relevant audit information glaxosmithkline plc financial statement remuneration company auditor unaware report accordance applicable law regulation take step ought take company law require director prepare financial director aware relevant audit statement financial year law director information establish company auditor aware elect prepare parent company financial statement information accordance united kingdom accounting standard applicable law united kingdom generally accept accounting confirmation give interpret accordance practice company law director approve provision section company act parent company financial statement satisfied going concern basis true fair view state affair company period make enquiry director reasonable expectation company adequate resource continue operational prepare financial statement director require existence foreseeable future reason continue select suitable accounting policy apply adopt go concern basis prepare financial statement consistently corporate governance code judgement accounting estimate reasonable board consider glaxosmithkline plc apply principle prudent provision corporate governance code maintain state regard parent company financial statement financial reporting council describe corporate applicable accounting standard follow subject governance section page comply material departure disclose explain parent provision board consider annual report take company financial statement fair balanced understandable provide director responsible keep adequate accounting information necessary shareholder assess group record sufficient explain company performance business strategy transaction disclose reasonable accuracy time require financial conduct authority list rule financial position company enable ensure auditor consider director statement compliance parent company financial statement remuneration report relation point corporate governance code comply company act responsible specified review safeguard asset company take reasonable step prevention detection fraud irregularity parent company financial statement year end sir christopher gent december comprise balance sheet year end chairman december support note set page february report responsibility auditor relation parent company financial statement set independent auditor report financial statement year end december include annual report publish print form available website director responsible maintenance integrity annual report website accordance legislation govern preparation dissemination financial statement access website available outside comparable legislation different strategic report risk section annual report include fair review development performance business position company group take description principal risk uncertainty face gsk annual report financial statement glaxosmithkline plc prepare gaap independent auditor report members glaxosmithkline plc report parent company financial statement matter require report exception opinion adequacy accounting record information explanation receive opinion parent company financial statement define company act require report opinion true fair view state parent company affair december receive information explanation require audit ave properly prepare accordance united kingdom generally accept accounting practice adequate accounting record keep parent company return adequate audit receive ave prepare accordance requirement branch visit company act parent company financial statement opinion read context director remuneration report audit remainder report agreement accounting record return audit exception report arise responsibility parent company financial statement prepare director remuneration glaxosmithkline plc comprise company act require report parent company balance sheet december opinion certain disclosure director remuneration note parent company financial statement specify law exception include summary significant accounting policy report arise responsibility explanatory information information annual report financial reporting framework apply isas ireland require report preparation comprise applicable law united kingdom opinion information annual report accounting standard united kingdom generally accept aterially inconsistent information audit parent accounting practice company financial statement apply financial reporting framework director pparently materially incorrect base materially inconsistent number subjective judgement example respect knowledge parent company acquire course significant accounting estimate make estimate perform audit assumption consider future event mislead audit financial statement involve exception report arise responsibility conduct audit accordance international standard audit ireland isas ireland audit involve responsibility financial statement audit obtain evidence amount disclosure financial statement sufficient reasonable assurance financial responsibility director statement free material misstatement caused explain fully director statement responsibility fraud error include assessment set director responsible preparation parent company financial statement satisfied hether accounting policy appropriate parent true fair view company circumstance consistently apply adequately disclose responsibility audit express opinion parent company financial statement accordance applicable law reasonableness significant accounting estimate isa ireland standard require comply director auditing practice board ethical standard auditor overall presentation financial statement report include opinion prepare addition read financial nonfinancial information company member body accordance chapter annual report identify material inconsistency company act purpose audit parent company financial statement identify give opinion accept assume responsibility information apparently materially incorrect base purpose person report materially inconsistent knowledge acquire show hand come save expressly course perform audit aware apparent agree prior consent writing material misstatement inconsistency consider implication report matter report separately group financial statement opinion matter prescribed company act glaxosmithkline plc year end december opinion company pass resolution accordance section information give strategic report director company act senior statutory auditor report financial year parent company state financial statement prepare consistent parent company financial statement pricewaterhousecooper llp director remuneration report audit charter accountant statutory auditor properly prepare accordance company act london february gsk annual report company balance sheet gaap december note fix asset investment debtor cash bank current asset creditor amount year net current asset net asset capital reserve call share capital share premium account reserve profit loss account equity shareholder fund financial statement page approve board february sign behalf sir christopher gent chairman glaxosmithkline plc register number gsk annual report financial statement glaxosmithkline plc prepare gaap note company balance sheet gaap expenditure expenditure recognise respect good service receive presentation financial statement supply accordance contractual term provision obligation exist future liability respect description business past event obligation reliably glaxosmithkline plc parent company gsk major global estimate healthcare group engage creation discovery development manufacture marketing pharmaceutical investment subsidiary company product include vaccine overthecounter otc medicine investment subsidiary company hold cost healthrelate consumer product provision impairment preparation financial statement impairment investment financial statement prepare going concern carry value investment review impairment basis draw accordance generally accept indication investment impair accounting practice gaap accounting provision result impairment review charge presentation december comparative figure income statement year concern december appropriate comparative figure reclassify ensure consistent presentation current year share base payment information issuance company subsidiary grant permit section company act profit company share represent additional capital contribution loss account company present annual company subsidiary additional investment report subsidiarie result correspond increase shareholder company include group account glaxosmithkline equity additional capital contribution base fair value plc publicly available advantage take grant issue allocate underlying grant vest period exemption provide frs cash flow statement revise taxation prepare cash flow statement exemption provide frs relate party disclosure disclose related party current tax provide amount expect pay applying transaction group tax rate enact substantially enact balance sheet date accounting convention standard company account taxation defer accelerate balance sheet prepare historical cost reason timing difference originate convention complie applicable accounting standard reverse balance sheet date defer tax asset recognise extent consider recoverable accounting principle policy future taxable profit preparation balance sheet conformity generally accept accounting principle require management defer tax measure average tax rate expect estimate assumption affect report amount apply period time difference expect asset liability disclosure contingent asset reverse defer tax liability asset discount liability date balance sheet actual amount differ estimate financial guarantee liability relate guarantee issue company behalf balance sheet prepare accordance subsidiary initially recognise fair value amortise company accounting policy approve board describe life guarantee note perate profit accounting policy fee relate audit foreign currency transaction company charge operating profit foreign currency transaction record exchange rate ruling date transaction forward rate hedge dividend forward exchange contract foreign currency asset liability director declare interim dividend result dividend translate rate exchange rule balance sheet date year pence pence increase dividend forward rate detail note group financial statement dividend dividend pay receive dividend pay receive include account period relate dividend actually pay receive gsk annual report note company balance sheet gaap continue fix asset investment share glaxosmithkline service unlimited share glaxosmithkline holding limited share glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relate share base payment debtor amount year corporation tax recoverable amount owe group undertaking amount year amount owe group undertaking creditor amount year bank overdraft amount owe group undertaking creditor company guarantee debt issue subsidiary company receive annual fee subsidiary aggregate company outstanding guarantee billion debt instrument amount subsidiary company relation guarantee fee recover life bond disclose debtor note gsk annual report financial statement glaxosmithkline plc prepare gaap note company balance sheet gaap continue share capital share premium account share ordinary share premium number share capital authorise december december share capital issue fully pay january issue employee share scheme share capital cancel december issue employee share scheme share capital cancel december december december number share issuable outstanding option number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme total million share purchase company cost million million share cancel company expect share repurchase billion exact time purchase share hold treasury share cancel determined company dependent market condition factor share purchase period january february reserve profit reserve loss account total january profit attributable shareholder dividend shareholder share purchase cancel hold treasury share capital contribution relate share base payment december profit attributable shareholder dividend shareholder share purchase cancel hold treasury share capital contribution relate share base payment december loss glaxosmithkline plc year million million profit dividend million million give retain loss million million profit cost share purchase cancel hold treasury share million profit loss account reserve december stand million million million unrealised million gsk annual report investor information section quarterly trend year record product development pipeline product competition intellectual property risk factor share capital share price dividend tax information shareholder annual general meeting law regulation shareholder service contact glossary term index gsk annual report investor information financial record financial record quarterly trend unaudite analysis group result provide quarter sterle financial year income statement total month cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare total turnover cost sale sell general administration research development royalty income operating income operating profit net finance cost profit disposal interest associate joint venture share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny income statement core total turnover cost sale sell general administration research development royalty income operating profit net finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny calculation core result describe gsk annual report quarterly trend unaudite analysis group result provide quarter sterle financial year income statement total month cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare total turnover cost sale sell general administration research development royalty income operating income operating profit net finance cost profit disposal interest associate joint venture share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny income statement core total turnover cost sale sell general administration research development royalty income operating profit net finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny calculation core result describe gsk annual report investor information financial record pharmaceutical vaccine turnover therapeutic area total usa europe emap rest world therapeutic area restate growth growth growth growth growth major product cer cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antiviral hepsera valtrex zovirax zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza metabolic antibacterials augmentin oncology emesis arzerra promacta tyverbtykerb votrient dermatology bactroban duac rare disease flolan volibris immuno inflammation benlysta pharmaceutical vaccine boostrix cervarix fluarix flulaval hepatitis infanrix pediarix rotarix synflorix viiv healthcare hiv cer represent growth constant exchange rate represent growth actual exchange rate gsk annual report pharmaceutical vaccine turnover therapeutic area total usa europe emap rest world therapeutic area restate growth growth growth growth growth major product cer cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antiviral hepsera valtrex zovirax zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare metabolic avandia product antibacterial augmentin oncology emesis arzerra promacta tyverbtykerb votrient dermatology bactroban duac rare disease flolan volibris immuno inflammation benlysta pharmaceutical vaccine boostrix cervarix fluarix flulaval hepatitis infanrix pediarix nimenrix rotarix synflorix viiv healthcare hiv cer represent growth constant exchange rate represent growth actual exchange rate gsk annual report investor information financial record viiv healthcare turnover total usa europe emap rest world therapeutic area restate growth growth growth growth growth major product cer cer cer cer cer combivir epivir epzicomkivexa selzentry trizivir total usa europe emap rest world therapeutic area restate growth growth growth growth growth major product cer cer cer cer cer combivir epivir epzicomkivexa lexiva selzentry trizivir year record record financial performance provide analysed accordance current reporting practice information include year record prepare accordance ifrs adopt european union ifrs issue international accounting standard board restate restate restate restate turnover division pharmaceutical vaccine pharmaceutical vaccine consumer healthcare group turnover geographic region usa europe emap japan group turnover segment usa europe emap japan viiv healthcare hiv trading unallocated pharmaceutical pharmaceutical vaccine consumer healthcare gsk annual report year record continue restate restate restate restate pharmaceutical vaccine turnover therapeutic area respiratory antiviral central nervous system cardiovascular urogenital metabolic antibacterial oncology emesis dermatology rare disease immunoinflammation pharmaceutical vaccine viiv healthcare hiv consumer healthcare turnover total wellness oral care nutrition skin health restate restate restate restate financial result total turnover operate profit profit taxation profit taxation pence pence pence pence pence basic earning share dilute earning share restate restate financial result core turnover operate profit profit taxation profit taxation pence pence pence core earning share core dilute earning share million million million million million weight average number share issue basic dilute restate restate restate restate return capital employ return capital employ calculated total profit taxation percentage average net asset year gsk annual report investor information financial record year record continue restate restate restate restate balance sheet noncurrent asset current asset total asset current liability noncurrent liability total liability net asset shareholder equity noncontrolle interest total equity number employee usa europe emap japan manufacturing sell administration research development geographic distribution employee table base location gsk subsidiary company number employee number permanent employ staff end financial period exclude employee employ manage gsk contract basis exchange rate guide holder ad follow table set period indicate information exchange rate dollar sterling report bank england buy rate average average rate year calculate average buy rate day year feb jan dec nov oct sep high low buying rate february gsk annual report pipeline product competition pharmaceutical vaccine product development pipeline key inlicence alliance relationship party month submission phase evaluation clinical pharmacology usually conduct volunteer month regulatory approval maa phase determination dose initial evaluation efficacy conduct approval letter small number patient bla biological licence application phase iii large comparative study compound versus placebo andor establish maa marketing authorisation application europe treatment patient establish clinical benefit safety nda new drug application usa month positive opinion maa ndabla regulatory review milestone show table achieve future filing date include list achieve regulatory review milestone compound type indication phase maa ndabla respiratory phosphoinositide kinase inhibitor idiopathic pulmonary fibrosis soluble epoxide hydrolase inhibitor copd phosphoinositide kinase inhibitor asthma copd cathepsin inhibitor bronchiectasis tumour necrosis factor receptor domain antibody acute lung injury danirixin cxcr chemokine receptor antagonist copd fluticasone furoate glucocorticoid agonist longacting beta agonist copd vilanterol muscarinic acetylcholine antagonist umeclidinium muscarinic acetylcholine antagonist beta agonist copd tolllike receptor agonist asthma sodium channel blocker cough recombinant human angiotensin convert enzyme acute lung injury fluticasone furoate glucocorticoid agonist muscarinic acetylcholine asthma umeclidinium antagonist losmapimod kinase inhibitor oral copd acute coronary syndrome mepolizumab monoclonal antibody nasal polyposis mepolizumab monoclonal antibody severe asthma eosinophilic granulomatosis iii polyangiitis relvarbreo ellipta longacte beta agonist glucocorticoid agonist copd mortality outcomes iii vilanterol fluticasone furoate vilanterol longacte beta agonist copd iii fluticasone furoate glucocorticoid agonist asthma submit oct incruse ellipta muscarinic acetylcholine antagonist copd hyperhidrosis submit feb apr umeclidinium anoro ellipta muscarinic acetylcholine antagonist longacte copd approve feb dec umeclidinium beta agonist vilanterol relvarbreo ellipta longacte beta agonist glucocorticoid agonist asthma approve nov vilanterol fluticasone furoate relvarbreo ellipta longacte beta agonist glucocorticoid agonist copd approve nov amay vilanterol fluticasone furoate paediatric vaccine rsv recombinant respiratory syncytial virus prophylaxis maternal immunisation rsv recombinant viral vector respiratory syncytial virus prophylaxis pneumoniae recombinant conjugate streptococcus pneumoniae disease prophylaxis generation mmr live attenuate measle mump rubella prophylaxis iii nov mosquirix recombinant malaria prophylaxis plasmodium falciparum iii malaria rtss nimenrix conjugate neisseria meningitis group approve apr menacwytt disease prophylaxis vaccine hiv recombinant hiv disease prophylaxis nthi recombinant nontypeable haemophilus influenzae prophylaxis hepatitis recombinant viral vector hepatitis virus prophylaxis hiv recombinant hiv disease immunotherapy tuberculosis recombinant tuberculosis prophylaxis zoster recombinant herpe zoster prophylaxis iii flu pre pandemic inactivated split monovalent quebec prepandemic pandemic influenza prophylaxis approve nov flu vaccine inactivate split quadrivalent seasonal influenza prophylaxis approve feb dec use brand approve regulatory authority gsk annual report investor information pipeline product competition pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound type indication phase maa ndabla antigenspecific cancer immunotherapeutic prame recombinant treatment resectable nonsmall cell lung cancer immunotherapeutic magea recombinant treatment bladder cancer immunotherapeutic immunotherapeutic recombinant treatment breast cancer magea recombinant treatment melanoma iii immunotherapeutic magea recombinant treatment nonsmall cell lung cancer iii immunotherapeutic hiv viiv healthcare hiv integrase inhibitor longacte hiv infections parenteral formulation dolutegravir abacavir hiv integrase inhibitor reverse hiv infection fix dose combination submit soct soct sulphate lamivudine transcriptase inhibitor fix dose combination tivicay dolutegravir hiv integrase inhibitor hiv infection approve jan aug oncology bromodomain inhibitor nut gene midline carcinoma trametinib akt protein kinase inhibitor cancer mek inhibitor focal adhesion kinase inhibitor cancer phosphatidylinositol kinase inhibitor cancer erbb monoclonal antibody cancer fibroblast growth factor ligand trap cancer afuresertib akt protein kinase inhibitor multiple myeloma votrient pazopanib multikinase angiogenesis inhibitor renal cell cancer monoclonal antibody afuresertib akt protein kinase inhibitor ovarian cancer foretinib mesenchymalepithelial transition factor nonsmall cell lung cancer cmet kinase inhibitor mekinist trametinib mek inhibitor braf protein kinase colorectal cancer tafinlar dabrafenib inhibitor human antiegfr panitumumab monoclonal antibody revoladepromacta thrombopoietin receptor agonist acute myeloid leukaemia eltrombopag revoladepromacta thrombopoietin receptor agonist aplastic anaemia eltrombopag revoladepromacta thrombopoietin receptor agonist myelodysplastic syndromes eltrombopag tafinlar dabrafenib braf protein kinase inhibitor nonsmall cell lung cancer arzerra ofatumumab human monoclonal antibody chronic lymphocytic leukaemia use relapse patient iii arzerra ofatumumab human monoclonal antibody diffuse large cell lymphoma relapse patient iii arzerra ofatumumab human monoclonal antibody follicular lymphoma refractory relapse patient iii mekinist trametinib mek inhibitor braf protein kinase metastatic melanoma adjuvant therapy iii tafinlar dabrafenib inhibitor tyverbtykerb lapatinib human epidermal growth factor receptor breast cancer neoadjuvant adjuvant therapy iii epidermal growth factor receptor egfr dual kinase inhibitor votrient pazopanib multikinase angiogenesis inhibitor renal cell cancer adjuvant therapy iii arzerra ofatumumab human monoclonal antibody chronic lymphocytic leukaemia line therapy submit oct oct votrient pazopanib multikinase angiogenesis inhibitor ovarian cancer maintenance therapy submit aug mekinist trametinib mek inhibitor metastatic melanoma approve feb mekinist trametinib mek inhibitor braf protein kinase metastatic melanoma approve feb ajan tafinlar dabrafenib inhibitor revoladepromacta thrombopoietin receptor agonist hepatitis induce thrombocytopaenia approve sep nov eltrombopag tafinlar dabrafenib braf protein kinase inhibitor metastatic melanoma approve aaug amay tyverbtykerb lapatinib egfr dual kinase inhibitor metastatic breast cancer combination trastuzumabapprove jul gsk annual report pharmaceutical vaccine product development pipeline continued achieve regulatory review milestone compound type indication phase maa ndabla cardiovascular metabolic prolyl hydroxylase inhibitor topical wound healing selective androgen receptor modulator heart failure prolyl hydroxylase inhibitor anaemia associated chronic renal disease perioperative risk reduction ileal bile acid transport inhibitor type diabetes camicinal motilin receptor agonist delay gastric empty losmapimod kinase inhibitor acute coronary syndrome copd retosiban oxytocin antagonist threaten preterm labour darapladib lppla inhibitor atherosclerosis diabetic macular oedema iii eperzan albiglutide glp agonist type diabete submit jan jan immunoinflammation janus kinase jak inhibitor ulcerative colitis receptor monoclonal antibody autoimmune disease macrophage target histone deacetylase rheumatoid arthritis inhibitor janus kinase jak inhibitor systemic lupus erythematosus psoriasis mor granulocyte macrophage colony rheumatoid arthritis stimulate factor monoclonal antibody belimumab lymphocyte stimulator monoclonal transplant rejection myaesthenia gravis antibody benlysta belimumab lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody benlysta belimumab lymphocyte stimulator monoclonal vasculitis iii antibody sirukumab human monoclonal antibody rheumatoid arthritis iii rare disease sap monoclonal antibody amyloidosis exvivo stem cell gene therapy metachromatic leukodystrophy exvivo stem cell gene therapy wiscottaldrich syndrome ozanezumab neurite outgrowth inhibitor nogoa amyotrophic lateral sclerosis monoclonal antibody exvivo stem cell gene therapy adenosine deaminase severe combine immune iii deficiency adascid mepolizumab monoclonal antibody eosinophilic granulomatosis polyangiitis iii severe asthma volibris ambrisentan endothelin antagonist chronic thromboembolic pulmonary hypertension iii infectious disease antiviral maturation inhibitor hiv infections nsb polymerase inhibitor hepatitis polypeptide deformylase inhibitor bacterial infection type topoisomerase inhibitor bacterial infection tafenoquine aminoquinoline plasmodium vivax malaria relenza zanamivir neuraminidase inhibitor influenza iii neuroscience lppla inhibitor alzheimer disease receptor antagonist multiple sclerosis myelinassociate glycoprotein monoclonal stroke antibody belimumab lymphocyte stimulator monoclonal myaesthenia gravis transplant rejection antibody ofatumumab human monoclonal antibody multiple sclerosis pemphigus vulgaris rilapladib lppla inhibitor alzheimer disease gsk annual report investor information pipeline product competition pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound type indication phase maa ndabla ophthalmology beta amyloid monoclonal antibody geographic retinal atrophy darapladib lppla inhibitor diabetic macular oedema atherosclerosis dermatology stearoyl coa desaturase inhibitor topical acne vulgaris umeclidinium muscarinic acetylcholine antagonist topical hyperhidrosis copd janus kinase jak inhibitor psoriasis lupus nonsteroidal antiinflammatory atopic dermatitis psoriasis ofatumumab human monoclonal antibody pemphigus vulgaris multiple sclerosis toctino alitretinoin retinoic acid receptor modulator chronic hand eczema iii duac low dose clindamycinbenzoyl peroxide gel acne vulgaris approve mar brand name appear italic trademark own andor license glaxosmithkline associate company optionbase alliance party include asset phase phase development company disease area phase cancer research cancer dynavax technology cutaneous systemic lupus erythematosus isis pharmaceutical transthyretinmediate amyloidosis iiiii hepatitis oncome pharmaceutical oncology iii shionogi bacterial infection asset gsk annual report pharmaceutical product competition intellectual property major patent expiry date product compound indication competitor brands usa respiratory anoro ellipta umeclidinium bromide copd spiriva onbrez nce nce vilanterol terfenatate device device avamysveramyst fluticasone furoate rhinitis nasonex flixotideflovent fluticasone propionate asthmacopd qvar singulair expire diskus device diskus device hfadevice hfadevice formulation formulation relvarbreo fluticasone furoate asthmacopd symbicort foster ellipta vilanterol terfenatate copd flutiform dulera nce nce device device seretideadvair salmeterol xinafoate asthmacopd symbicort foster expire fluticasone propionate flutiform dulera diskus device diskus device hfadevice hfadevice formulation formulation serevent salmeterol xinafoate asthmacopd foradil spiriva expire onbrez disku device diskus device hfadevice formulation ventolin hfa albuterol sulphate asthmacopd generic company hfadevice hfadevice formulation formulation antiviral relenza zanamivir influenza tamiflu expire valtrex valaciclovir genital herpe coldsore famvir expire expire shingles zeffixepivirhbv lamivudine chronic hepatitis hepsera expire use use central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expire expire imigranimitrex sumatriptan migraine zomig maxalt relpax expire expire requip ropinirole parkinson disease mirapex expired expire seroxatpaxil paroxetine depression effexor cymbalta expire expire anxiety disorder lexapro cardiovascular urogenital avodart dutasteride benign prostatic hyperplasia proscar flomax finasteride coreg carvedilol phosphate mildtosevere heart failure toprol hypertension leave ventricular formulation dysfunction post lovaza omega acid ethyl ester high triglyceride tricor expire risk factor detail uncertainty time followon competition generic competition possible note financial statement legal proceeding gsk annual report investor information pipeline product competition pharmaceutical product competition intellectual property continue major patent expiry date product compound indication competitor brands usa antibacterials augmentin amoxicillinclavulanate common bacterial generic product expire potassium infection oncology arzerra ofatumumab refractory chronic mabtherarituxan lymphocytic leukaemia imbruvica mekinist trametinib metastatic melanoma yervoy zelboraf promacta eltrombopag idiopathic thrombocytopenic nplate revolade purpura hepatitis mabtherarituxan associate thrombocytopenia tafinlar dabrafenib mesylate metastatic melanoma yervoy zelboraf grant tykerbtyverb lapatanib advanced metastatic herceptin breast cancer kadcyla positive patient votrient pazopanib soft tissue sarcoma yondelis sutent metastatic renal cell nexavar afinitor carcinoma rare disease volibris ambrisentan pulmonary hypertension tracleer revatio immunoinflammation benlysta belimumab systemic lupus erythematosus vaccines boostrix diphtheria tetanus acellular booster vaccination adacel pertussis infanrixpediarix diphtheria tetanus pertussis diphtheria tetanus pertussis pentacel pediacel polio hepatitis polio hepatitis pentaxim pentavac haemophilus influenzae haemophilus influenzae hexaxim type type cervarix hpv virus like human papilloma virus gardasil silgard particle vlp type adjuvant mpl aluminium hydroxide fluarix split inactivated influenza seasonal influenza vaxigrip mutagrip virus subtype fluzone influvac subtype antigen aggripal fluad intenza flumist fluarix tetra split inactivated influenza seasonal influenza intenza flumist qiv virus subtype vaxigrip qiv subtype antigen fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza vaxigrip mutagrip virus subtype fluzone influvac subtype antigen aggripal fluad intenza flumist pandemrix derive split inactivated ahnv influenza focetria celvapan influenza virus antigen prophylaxis adjuvant prepandrix derive split inactivated pandemic aflunov vepacel influenza virus antigen influenza prophylaxis adjuvant synflorix conjugate pneumococcal invasive pneumococcal prevenar prevnar polysaccharide disease pneumonia acute otitis medium gsk annual report pharmaceutical product competition intellectual property continue major patent expiry date product compound indication competitor brands usa hiv combivir lamivudine zidovudine hivaids truvada atripla expire expire stribild combination combination compleraeviplera epivir lamivudine hivaids truvada atripla expire expire stribild compleraeviplera epzicomkivexa lamivudine abacavir hivaids truvada atripla stribild combination combination compleraeviplera lexiva fosamprenavir hivaids prezista kaletra reyataz selzentry maraviroc hivaids isentress intelence prezista tivicay dolutegravir hivaid isentress prezista reyataz kaletra trizivir lamivudine zidovudine hivaids truvada atripla abacavir stribild combination combination compleraeviplera generic competition commence consumer healthcare product competition brand product application market competition total wellness panadol tablet caplet infant drop paracetamolbase treatment global usa reckittbenckiser nurofen headache joint pain fever cold symptom nicoderm gum patch mini lozenge treatment nicotine global novartis nicotinell niquitin original lozenge withdrawal aid johnson johnsons nicabate quit smoking nicorette europe nicorette retailer brand eno effervescent rapid relief antacid global hypermarcas estomazil tum chewable tablet pfizer gelusil sanofis rolaids johnson johnsons mylanta oral care sensodyne toothpaste toothbrushes prevention dental global colgatepalmolive mouthwashe sensitivity colgate pro relief polident denture adhesive denture improve comfort global procter gamble fixodent poligrip cleanser fit denture reckittbenckiser kukident corega clean denture steradent aquafresh toothpastes toothbrushe prevention carie gum global colgatepalmolive colgate mouthwash disease bad breath procter gamble crest oralb parodontax toothpaste mouthwash help stop bleed gum global colgatepalmolivess gum health colgate progum nutrition horlick malt milkbase drink nutrition ireland india mondelezs bournvita food nestle milo maxinutrition sport nutrition protein nutrition myprotein powder bar optimum nutrition skin health physiogel moisturise cream face body care dry germany france italy loreal roche posay lotion cleanser sensitive irritated skin poland spain beiersdorf eucerin pierre fabres avene oilatum emollient bath cream soothe treatment eczema poland reckittbenckisers shampoo dry skin condition market sanofis emolium gsk annual report investor information principal risk uncertaintie principal risk uncertaintie risk factor principal risk discuss risk uncertainty rule regulation change governmental relevant business financial condition result operation interpretation rule regulation evolve nature affect performance ability achieve objective particular risk alter change certain regulatory regime factor believe cause actual healthcare system substantial change result differ materially expect historical result failure comply applicable law regulation materially adversely affect financial result operate global basis industry highly competitive highly regulate competitor similarly business expose litigation government significant product innovation technical advance investigation include limited product liability litigation intensify price competition light competitive environment antitrust litigation sale marketing litigation litigation continue development commercially viable new product government investigation include related provision development additional use exist product critical unfavourable outcome increase relate cost ability maintain increase overall sale insurance premium materially adversely affect financial result detail status uncertainty develop new pharmaceutical vaccine product costly involve significant unresolved dispute potential litigation lengthy uncertain process product candidate set note legal proceeding fail stage include significant group economic human resource invest competitor product regulation require discussion mitigating activity company pricing strategy failure develop commercially take address principal risk uncertainty summary successful product develop additional use exist mitigation activity accompany principal risk represent product materially adversely affect financial result main action take manage principal risk principal risk factor uncertaintie list order adapt comply broad range law significance regulation requirement apply research development manufacturing testing approval distribution sale marketing pharmaceutical vaccine consumer healthcare product affect cost product development time require reach market uncertainty successfully patient safety strategic priority deliver product value grow diversified global company risk definition failure appropriately collect review follow report adverse event chief medical officer cmo responsible medical governance potential source compromise ability conduct group global policy policy safeguard human robust safety signal detection interpretation ensure subject clinical trial patient product appropriate decision take respect riskbenefit profile paramount importance cmo authoritative role evaluate product include completeness accuracy product label address matter human safety individual medical officer pursuit additional studiesanalyse appropriate group substantial global safety pharmacovigilance track adverse issue report product course clinical study risk impact group product approve marketing group extensive impact risk include potential harm patient reputational postmarkete surveillance signal detection system information damage product liability claim litigation governmental possible effect medicine receive source include investigation regulatory action fine penalty loss unsolicited report health professional patient regulatory product authorisation authority medical scientific literature medium policy employee require report immediately issue relate safety context quality medicine country manager responsible monitoring exception tracking training help assure collection preclinical clinical trial conduct development safety information report information relevant central safety investigational pharmaceutical vaccine consumer healthcare product department accordance group policy legal requirement determine safety efficacy product use human notwithstanding effort determine safety product information change benefitrisk profile group appropriate preclinical clinical trial unanticipate effect medicine result certain action characterise communicate evident product widely introduce minimise risk propose action discuss regulatory authority marketplace question raise ongoing safety include modify prescribe information communication surveillance postmarkete study governmental agency physicians healthcare provider restriction product thirdpartie analyse publicly available clinical trial result prescribingavailability help assure safe use carry clinical trial certain case appropriate stop clinical group currently defendant number product liability lawsuit trial withdraw medicine market group global include class action involve significant claim damage relate safety board gsb comprise senior physician representative product litigation particularly inherently unpredictable support function integral component system gsb class action seek sweep person prescribe include subsidiary board dedicate consumer healthcare product product increase potential liability claim pain suffer vaccine review safety investigational market product punitive damage frequently assert product liability action group authority stop clinical trial deem allow represent potentially openende exposure possibly harmful human volunteer materially adversely affect group financial result addition medical governance framework group mitigating activity describe group use mechanism foster early construct system medical governance help ensure evaluation mitigation resolution dispute arise potential safety efficacy pharmaceutical vaccine consumer claim arise goal programme create healthcare product group produce culture early identification evaluation risk claim actual potential order minimise liability litigation gsk annual report intellectual property strategic priority deliver product value grow diversified global company risk definition depend certain key product significant portion sale failure appropriately secure protect intellectual property right timing impact entry usa major markets europe followon product seretideadvair uncertain patent risk impact composition contain combination active substance seretideadvair expire patent loss patent protection include reduce scope patent right component advair diskus device continue august compulsory licensing government force manufacturer able predict generic competitor seretideadvair license patent specific product competitor materially enter market adversely affect financial result market absence adequate patent datum exclusivity protection limit opportunity generic drug manufacturer exhibit readiness market rely market future sale growth product generic version important product prior materially adversely affect financial result expiration patent effort involve challenge validity enforceability patent assertion generic product context infringe patent result continue involve legal proceeding involve patent challenge materially innovative pharmaceutical vaccine consumer healthcare adversely affect financial result usa product company seek obtain appropriate intellectual property increasingly common patent infringement action prompt claim protection product ability obtain enforce patent antitrust law violate prosecution patent proprietary right regard product critical litigation involve defence patent claim direct business strategy success pharmaceutical vaccine product indirect purchaser payer typically file class action usually protect copied generic manufacturer relief seek include treble damage restitution claim period exclusivity provide issue patent relate intellectual similarly antitrust claim bring government entity property right regulatory data protection orphan drug private party follow settlement patent litigation allege status follow expiration certain intellectual property right generic settlement anticompetitive violation antitrust law manufacturer lawfully produce generic version product successful antitrust claim private party government entity face technological regulatory barrier marketing materially adversely affect financial result operate market intellectual property law patent office expiration date patent major product affect develop government unwilling grant date generic version product introduced set enforce intellectual property right fashion similar developed page legal proceeding involve patent challenge region japan usa develop country set note financial statement legal proceeding reduce threaten reduce effective patent protection pharmaceutical product generally particular therapeutic area facilitate early competition market generic manufacturer mitigate activity global patent group focus secure protect patent face competition manufacturer proprietary generic right global group maintain internal process design help pharmaceutical product major market introduction generic ensure successful procurement enforcement defence patent product particularly usa high turnover goal maintain exclusive right market product margin typically lead dramatic loss sale reduce revenue margin proprietary product global patent group monitor new development international pharmaceutical vaccine product million annual patent law help ensure appropriate protection asset global sale certain product generic competition act trade association work local government seek usa markets europe experience secure effective balanced intellectual property protection design impact sale product expiry loss patent meet need patient payer support longterm protection product market competitor similar product class investment innovation treatment similar disease condition gsk annual report investor information principal risk uncertainties product quality strategic priority deliver product value grow diversified global company risk definition adopt single quality management system qms failure ensure product quality manufacturing define quality standard system business associate distribution process result noncompliance good pharmaceutical vaccine consumer healthcare product manufacturing practice gmp regulation investigational material qms broad scope cover endtoend supply chain start material distribute product risk impact applicable complete lifecycle product mature commercial supply failure ensure product quality far reach implication term health patient customer product recall qms periodically update base experience evolve potential damage reputation regulatory legal regulatory agency expectation requirement improve scientific financial consequence materially adversely affect understanding help ensure operation comply gmp financial result requirement globally support delivery consistent reliable product large network quality compliance professional context align business unit provide oversight assist delivery quality performance operational compliance management patient consumer healthcare professional trust quality oversight activity accomplish hierarchy quality product point use failure ensure product quality council meeting staff train help ensure standard enterprise risk applicable business activity expect behaviour base value follow product quality influence factor include product process understand consistency manufacturing component implement riskbase approach assess manage compliance gmp accuracy labelling reliability security thirdparty supplier provide material finished product supply chain embodiment overarching quality culture contract manufacturer make product expect comply internal external environment continue evolve new standard identify group audit help provide product new market new legislation introduce particularly assurance expect standard meet security supply good distribution practice product chief product quality officer oversee activity gsk standard quality council serve forum escalate emerge risk share experience handle quality issue business mitigate activity help ensure lesson learn assess deploy globally medicine development scientist adopt principle quality preparation implementation new legislation regularly design new product devise control strategy deploy review gsk quality council advocacy communication product lifecycle help ensure consistency reliability programme maintain awareness external environment performance supply convey consistent message group emphasis quality performance metric culture right time gsk annual report supply chain continuity strategic priority simplify operating model deliver product value risk definition failure small number singlesource thirdparty supplier failure deliver continuous supply compliant finished product service provider fulfil contractual obligation timely manner result regulatory noncompliance physical disruption risk impact logistic manufacturing site result delay service interruption interruption supply exclusion healthcare programme impact patient access product expose litigation regulatory mitigating activity action materially adversely affect financial result particular incur fine disgorgement result noncompliance supply chain model design help ensure supply quality manufacturing practice regulation materially adversely security product globally closely monitor delivery affect group financial result result reputational damage product help ensure customer medicine vaccine product need safety stock backup supply context arrangement high revenue medicallycritical product place practical help mitigate risk addition supply chain operation subject review approval standing manufacture external supplier routinely monitor regulatory agency effectively provide licence operate order identify manage supply base risk failure manufacture distribution facility supplier key service material lead litigation regulatory action practical dependency single source critical item product recall seizure interruption supply delay remove reliance single source component approval new product revocation licence operate reduce key product qualification alternative pende resolution manufacture logistic issue material help improve supply chain robustness material service provide thirdparty supplier necessary supply chain operating model modify commercial production product include active strengthen link commercial forecasting manufacturing pharmaceutical ingredient api antigen intermediate commodity action time decrease risk associate demand component necessary manufacture package fluctuation impact ability supply writeoff associate pharmaceutical vaccine consumer healthcare product product exceed expiry date new model node thirdparty service procure service provide supply chain optimise help ensure adequate safety clinical research organisation support development key product stock balance work capital associate endtoend important continuous operation business supply chain undertake business continuity planning single source certain component bulk api finish product service create risk failure supply event regulatory noncompliance physical disruption manufacturing site logistic financial reporting disclosure strategic priority simplify operating model risk definition mitigate activity failure report accurate financial information compliance group maintain control environment design identify material accounting standard applicable legislation error financial reporting disclosure design operating effectiveness key financial reporting control periodically test risk impact provide assurance control key financial noncompliance exist new financial reporting disclosure report disclosure process operate effectively requirement change recognition income expense uptodate late development financial reporting expose litigation regulatory action materially requirement work external auditor advisor adversely affect financial result help ensure adherence relevant reporting disclosure requirement context share accountability financial result new revise accounting standard rule interpretation issue business financial result review approve regional time time international accounting standard board management review financial controller result change recognition income expense chief financial officer cfo allow financial controller materially adversely affect financial result cfo assess evolution business time group require law jurisdiction evaluate performance plan significant judgment review publicly disclose financial result regulator routinely review confirm senior management financial statement list company compliance account regulatory requirement group believe complie appropriate regulatory requirement concern financial statement disclosure subject investigation potential noncompliance accounting disclosure requirement potential restatement previously report result subject significant penalty gsk annual report investor information principal risk uncertaintie tax treasury strategic priority simplify operating model risk definition liquidity risk manage diversify liquidity source failure comply tax law significant loss treasury range facility maintain broad access funding market activity order meet anticipate future funding requirement hold significant amount cash investment invest line risk impact strict investment guideline change tax law application respect matter interest rate risk manage limiting float rate transfer pricing foreign dividend control company interest payment prescribe percentage operate profit tax credit taxation intellectual property restriction tax relief mix debt fix float interest rate monitor regularly allow interest intragroup debt impact effective tmg tax rate significant loss arise treasury activity foreign currency transaction risk arise internal external trade inconsistent application treasury policy deal settlement flow generally hedge internal trading transaction error counterparty default change tax law match centrally manage intercompany payment term application failure comply tax law significant loss reduce foreign currency risk foreign currency cash flow treasury activity materially adversely affect financial hedge selectively management treasury result tmg possible manage cash surplus borrowing requirement subsidiary company centrally order reduce context foreign currency translation exposure seek denominate group treasury group deal high value transaction borrowing currency principal asset cash flow foreign exchange cash management transaction daily basis tmg review ratio borrowing asset major currency monthly group effective tax rate drive rate tax jurisdiction higher low addition counterparty risk manage set global counterparty limit jurisdiction currently offer regime encourage innovation banking investment counterpartie base long investment science provide tax incentive term credit rating moodys standard poor treasury tax credit low tax rate income derive patent usage limit monitor daily corporate compliance furthermore international business face risk associate officer cco operate independently corporate treasury intragroup transfer pricing cco monitor credit rating counterpartie change rating occur notifie treasury change tax charge include financial statement good estimate investment level authority limit appropriate tax liability pende audits tax authority submit tax return accord statutory time limit engage tax authority help monitor government debate tax policy key jurisdiction ensure tax affair current exceptional case matter deal proactively potential future change tax law tax settle agreement tax authority risk manage set policy procedure help ensure resolve dispute formal appeal proceeding consistency compliance tax legislation engage advisor international business subject range duty legal counsel review tax legislation applicability taxis carry similar type risk business increase focus tax position multinational attempt mitigate risk aggressive tax authority audit business consequence challenge economic date possible tax affair working environment priority place address proactively tax authority possible move allegation tax avoidance see increase audits centralise simplify intellectual property ownership government seek raise revenue corporate taxis trading model model centralises pharmaceutical intellectual line taxis custom duty property reduce complexity intercompany arrangement enable drive bilateral advance pricing mitigate activity agreement apa jurisdiction treasury operate profit centre enter operate apa great certainty application transfer financial derivative transaction speculative purpose price direct tax affair reduce risk internal transaction financial instrument undertake manage structure enhance centralised team risk arise underlie business activity treasury activity dedicate specialist responsible manage transactional tax govern policy approve board director report compliance compliance regularly review treasury management group tmg chair cfo gsk annual report antibribery corruption strategic priority grow diversified global company risk definition mitigate activity failure foster culture group bribery code conduct value behaviour commitment zero corruption unacceptable adopt measure embed procedure tolerance integral mitigate risk group prevent bribery corruption employee complementary enterprisewide abac programme design respond threat worker party interaction investigate allegation risk bribery corruption build group value bribery corruption remediate issue identify comply exist standard form comprehensive practical approach applicable antibribery corruption abac legislation compliance complex risk area abac programme support toplevel commitment risk impact global policy proportionate procedure include speak failure comply applicable local international abac procedure ongoing training communication include legislation expose group associate person confidential reporting line ongoing risk assessment monitor governmental investigation regulatory action civil criminal investigation party diligence include contracting liability damage group reputation shareholder value requirement monitor oversight addition programme licence operate materially adversely mandate enhance control interaction government official affect financial result undertake business development transaction programme governance provide group abac oversight committee context include representation key functional area like large organisation group face risk fraud additionally dedicated abac team responsible driving member staff nature scale geography international implementation evolution programme response business activity increase possibility bribery corruption development internal external environment capability risk additionally healthcare industry highly regulate include abac investigation team empower review bribery overseas market operation emerge market corruption allegation recommendation remedial action susceptible bribery corruption risk improvement support network functional expert legal compliance audit assurance group continually benchmark abac programme use external expertise review help improve element programme gsk annual report investor information principal risk uncertainties commercial practice scientific engagement strategic priority deliver product value grow diversified global company risk definition mitigate activity failure engage commercial andor scientific activity commit legitimate scientific engagement ethical consistent letter spirit legal industry group responsible commercialisation medicine support mission requirement relate marketing communication improve quality human life enable people medicine associate therapeutic area appropriate interaction feel well live long accomplish mission engage healthcare professional hcp patient legitimate healthcare community way advance scientific transparent transfer value knowledge provide important information medicine risk impact obligation learn scientific engagement interaction failure comply applicable law rule regulation result provide accurate complete information appropriate governmental investigation regulatory action legal proceeding channel careful correct nonpromotional manner researcher bring group governmental private plaintiff hcp healthcare organisation hco external expert failure provide accurate complete information relate engage fairly compensate service expertise product result incomplete awareness benefitrisk profile provide payment excessive medicine possibly suboptimal treatment patient perceive inducement reward prescribing consequence materially adversely affect financial product result practice find misaligned value promotion approve medicine helps ensure hcp globally result reputational damage dilute trust establish access information need patient access key stakeholder medicine need medicine prescribe manner provide maximum healthcare benefit patient context committed communicate information relate approve group disseminate information product product responsible legal ethical manner promotion nonpromotional scientific engagement interaction exchange information group take action level group enhance improve partner external community order advance scientific standard procedure scientific engagement promotional medical understanding include appropriate development interaction base value transparency respect integrity use product management disease patient care patient focus policy standard govern promotional distinct promotional activity place activity scientific engagement undertaken group authorisation new product indication conduct behalf activity conduct worldwide conform strictly accordance promotional law code group high ethical medical scientific standard local standard policy differ global standard stringent apply legal regulatory financial reputational risk group promotional material activity review approve activity perceive exceed proper accord group standard conduct accordance boundary inappropriately influence hcp pay local law regulation help ensure material billion resolve government investigation usa focus activity fairly represent product service group large promotional practice necessary discipline include termination employee engage misconduct broaden ability claw remuneration senior management event misconduct recent year take step feel industry lead area commercial practice scientific engagement example group stance recognise industryleade include remove prescriptionvolume incentive compensation sale representative global standard scientific engagement gsk annual report research practice strategic priority deliver product value grow diversified global company risk definition commit reporting result human subject failure protect inform patient involve human clinical trial research evaluate product regardless research conduct objective ethical preclinical clinical trial outcome perceive positive negative believe sound scientific principle guarantee integrity discovery preclinical fundamental advancement medical science help clinical development datum manage human biological sample inform prescriber patient product accord establish ethical standard regulatory expectation commit make datum publicly available enable valid scientific treat animal ethically practice good animal welfare appropriately research respect human biological sample commit disclose human subject research medicinal product ensure manage sample manner respect right integrity regulatory filing datum publish research clinical participant meet applicable legal regulatory ethical obligation risk impact implement control help ensure trial conduct impact risk include harm patient reputational damage accordance good clinical practice gcp guideline failure obtain necessary regulatory approval product develop international conference harmonisation governmental investigation legal proceeding product liability suit base principle contain world medical association claim damages regulatory action fine penalty declaration helsinki ethical principle medical research loss product authorisation materially adversely involve human subject affect financial result establish office animal welfare ethic strategy oawes lead chief animal welfare ethic strategy help context ensure humane responsible care animal increase research relate animal human raise ethical concern knowledge application nonanimal alternative group attempt proactively address animal study remain oawes embed framework animal welfare governance explore vital research case method opportunitie crossindustry datum sharing create consistency investigate effect potential new medicine metric replacement refinement reduction animal live body test human generally mandate research conduct quality assessment regulator ethically imperative animal research provide report result human subject research medicine critical information cause disease develop vaccine publicly accessible clinical study register website country require additional animal testing medicine governmentrequire repository submit human research approve use result manuscript publication peer review scientific clinical trial healthy volunteer patient assess journal commit expand register include demonstrate investigational product efficacy safety clinical study report system introduce allow evaluate product approve marketing researcher request access anonymise patientlevel datum work human biological sample sample fundamental group clinical trial subject review scientific validity discovery development safety monitoring product independent panel certain condition integrity datum essential success stage global human biological sample management hbsm research datum lifecycle design generation record management governance framework place oversee ethical lawful analysis report storage retrieval research datum acquisition management human biological sample govern legislation regulatory requirement global hbsm network champion hbsm activity provide experienced group support internal sample custodian good research datum support document core component practice stage pipeline progression decisionmake form content regulatory submission poor datum integrity continue enhance datum integrity control remain important compromise research effort priority scientific datum misrepresentation discover relation nature medicine publication take immediate innate complexity interdependency require action retract publication analysis incident regulatory filing particularly give global research scientific datum misrepresentation discover undertaken development footprint currently rapid change submission base analysis improve control implement requirement develop country increase complexity meeting regulatory requirement chief regulatory officer oversee activity regulatory mitigating activity governance board include promote compliance proactively address ethical concern raise research relate regulatory requirement groupwide standard make regulatory animal human transparent practice service efficient agile align regulatory regularly engage academic scientist regulator policymaker capabilitie international business need enterprise industry colleague stakeholder request advice help local level ensure good practice commit act ethically provide animal health wellbee reduce number animal find alternative use animal gsk annual report investor information principal risk uncertaintie environment health safety sustainability strategic priority grow diversified global company risk definition mitigate activity failure ethically manage environment health safety management ehss risk fundamental performance sustainability ehss consistent group objective policy reputation commit appropriately manage ehss risk relevant law regulation embed importance mission improve quality human life enable people feel well live long risk impact operate rigorous procedure help eliminate hazard failure manage ehss risk lead significant harm people practicable protect employee health wellbee right environment community operate fine failure culture essential starting point employment practice meet stakeholder expectation regulatory requirement litigation design create work place culture employee feel regulatory action materially adversely affect value respected empower inspire achieve goal financial result continue effort improve environmental sustainability reduce water consumption hazardous waste energy context consumption actively manage environmental remediation group subject health safety environmental law obligation help ensure practice environmentally sustainable jurisdiction law impose actual potential compliant obligation remediate contaminate site identify potentially responsible party ehss performance result share public year comprehensive environmental response compensation liability corporate responsibility report act number site remediation cost relate use ownership site failure manage environmental risk properly result litigation regulatory action additional remedial cost materially adversely affect financial result note financial statement legal proceeding discussion environmental relate proceeding involve routinely accrue amount relate liability matter information protection strategic priority simplify operating model risk definition mitigate activity risk group business activity critical sensitive computer group global information protection policy support system information available need access dedicated programme activity increase focus authorise deliberately change corrupted information security group establish office chief information security officer provide strategy direction oversight risk impact enhance global information security capability failure adequately protect critical sensitive system assess change information protection risk environment information result inability maintain patent right loss briefing government agency subscription commercial commercial strategic advantage damage reputation threat intelligence service knowledge sharing business disruption include litigation regulatory sanction fine pharmaceutical crossindustry company materially adversely affect financial result aim use industry good practice information security policy process technology invest strategy context commensurate change nature security threat rely critical sensitive system datum corporate landscape strategic plan sensitive personally identifiable information intellectual subject law govern processing property manufacturing system trade secret personally identifiable information pll help ensure compliance potential malicious careless action expose computer crossborder pii transfer requirement group bind system information misuse unauthorised disclosure corporate rule bcrs approve information commissioner office human resource research activity datum bcrs possible transfer pii internationally group entity individual privacy agreement european union country gsk annual report crisis continuity management strategic priority deliver product value grow diversified global company risk definition mitigate activity inability recover sustain critical operation follow disruption group place crisis management business continuity respond crisis incident timely manner regardless cause plan critical business operation plan include authorise response recovery strategy key area responsibility risk impact clear communication plan establish ccm failure manage crisis continuity management ccm effectively governance board representative group lead prolong business disruption great damage provide vital information ccm programme team new group asset risk medicine supply disruption patient threat acquisition significant business organisational change materially adversely affect financial result delay dedicated team ccm expert support business activity delivery product consumer responsibility include coordinate crisis management business patient rely expose litigation regulatory continuity training facilitate exercise monitor provide action materially adversely affect financial result lead global consistency alignment centrally store monitor reputational damage plan update crisis management plan business continuity plan support critical business process help ensure context appropriate level readiness response capability maintain patient consumer healthcare professional rely product develop maintain partnership external body like readily available need event crisis business continuity institute international strategy international operation partner maintain disaster risk reduction help improve business continuity vast global footprint expose people facility operation initiative disaster prone area information technology potential disruption result natural continually improve training programme tool base event storm earthquake manmade event civil unrest learning plan activation example indepth video case study terrorism global emergency global public health emergency create share lesson learn respond japan earthquake superstorm sandy regularly evaluate introduce new tool improve ccm practice gsk annual report investor information shareholder information shareholder information share capital control share buyback programme board authorise issue allot ordinary share detail issue share capital number share hold article company article association power treasury december find note article authority company purchase financial statement share capital share premium account share subject shareholder authority share list london stock exchange seek annual basis annual general meeting agm quote new york stock exchange nyse form share purchase company cancel hold american depositary share ad ad represent treasury share ordinary share detail list debt list refer continue longterm buyback programme note financial statement net debt million share purchase total cost million holder ordinary share entitle receive dividend share purchase period january february declare company annual report attend speak period february february million general meeting company appoint proxy exercise share purchase cost million voting right programme cover purchase share cancellation restriction transfer limitation hold hold treasury share accordance authority renew ordinary share requirement obtain approval prior shareholder agm company transfer ordinary share carry special right regard authorise purchase maximum million share control company restriction vote detail share purchase cancel hold right major shareholder voting right share treasury share disclose note financial statement shareholder share capital share premium account know arrangement financial right exact time future purchase extent hold person holder share know repurchased share hold treasury share agreement restriction share transfer voting right cancel determine company dependent market condition factor share acquire share scheme plan rank equally share issue special right trustee market capitalisation employee share ownership plan trust waive market capitalisation base share issue exclude right dividend share hold trust treasury share gsk december billion exchange control limitation date gsk fifth large company market capitalisation ftse index affect security holder certain economic sanction force share price time time currently applicable law decree regulation restrict import export capital affect remittance dividend payment holder company january share nonresident similarly certain december economic sanction force time time increasedecrease limitation relate nonresident english law company article association right holder high year vote respect company share low year table set middle market closing price interest voting right company share price increase compare state far aware increase ftse index year person significant direct indirect holding company share price february information provide company pursuant financial conduct authoritys fca disclosure transparency rule dtrs publish regulatory information service company website february company receive notification accordance fca dtrs follow notifiable interest voting right company issue share capital percentage issue share capital blackrock inc invesco asset management legal general group plc ercentage ordinary share issue exclude treasury share acquire disposed interest share period review connection share price ad price share buyback programme gsk annual report analysis shareholding december number total total number account account share share hold share hold nominee company investment trust company insurance company individual corporate body bny nominee limit hold treasury share glaxosmithkline bny mellon depositary company adss list nyse ordinary share represent company adr programme manage depositary register bny nominees limited february bny nominees limit hold ordinary share represent issue share capital exclude treasury share date february number holders shares usa holdings share number register holder ad holding ad certain share ad hold broker nominee result number holder record register holder usa representative number beneficial holder residence beneficial holder nature trading market follow table set period indicate high low middle market closing quotation pence share london stock exchange high low closing price dollar ad nyse penny share dollar ad ordinary share high low ad high low february february january january december december november november october october september september quarter end december quarter end december quarter end september quarter end september quarter end june quarter end june quarter end march quarter end march quarter end december quarter end december quarter end september quarter end september quarter end june quarter end june quarter end march quarter end march year end december year end december year end december year end december year end december year end december february gsk annual report investor information shareholder information dividend shareholder summary apply resident shareholder hold company pay dividend quarterly continue return cash share capital asset shareholder dividend policy ongoing longterm share buyback programme dividend remain essential component taxation dividend total shareholder return company commit increase resident shareholder generally subject income tax dividend long term detail dividend declare dividend pay gross amount payment date give note financial tax credit tax credit set individual income statement dividend tax liability respect gross dividend repayable shareholder tax liability associate tax credit dividend share tax year subsequent tax year additional rate table set dividend share ad income tax dividend impose taxpayer income year dividend ad translate dollar resident shareholder corporation applicable exchange rate taxpayer note dividend generally entitle exemption corporation tax year dividend pence taxation capital gain shareholder liable tax gain disposal share adr disposal individual subject supplemental availability exemption relief annual exempt taxable capital gain accrue disposal share adr tax allowable deduction shareholder taxable income tax year exceed basic rate supplemental dividend relate disposal certain income tax limit case taxable capital gain accrue noncore otc brand north america pay fourth disposal share adr tax quarter ordinary dividend combination rate corporation taxpayer entitle dividend calendar indexation allowance apply reduce capital gain extent gain arise inflation indexation allowance quarter exdividend date record date payment date reduce chargeable gain create allowable loss february february april inheritance tax july individual shareholder liable inheritance tax transfer august august october share adr tax charge november november january value shareholders estate reduce result transfer way gift disposal market value tax information shareholder gift disposal subject inheritance tax estate gift tax estate gift tax convention generally summary certain tax federal income tax provide tax pay usa credit tax payable consequence holder share adr citizen usa set complete analysis possible tax consequence purchase ownership stamp duty sale security intend general guide stamp duty stamp duty reserve tax sdrt subject holder advise consult adviser respect tax certain exemption payable transfer share rate consequence purchase ownership sale share consideration transfer adr consequence state local tax law usa implications current ukus tax convention holder adr generally treat owner underlie share purpose current usauk double taxation convention relate income gain income tax convention estate gift taxis estate gift tax convention purpose internal revenue code amend code gsk annual report shareholder stamp duty summary apply shareholder citizen stamp duty sdrt subject certain exemption resident usa domestic corporation person payable transfer share adr custodian depository subject federal income tax net income basis rate consideration provide respect share adr hold share adr capital transfer sale value transfer consideration asset resident tax purpose sdrt payable transfer agreement hold share purpose trade profession vocation transfer adr stamp duty payable carry branch agency transfer adr provide instrument transfer summary address tax treatment holder execute remain time outside stamp duty subject special tax rule bank taxexempt entity transfer adr payable rate insurance company dealer security currency person consideration transfer sale underlie share hold share adr integrate investment subject certain exception result liability stamp include straddle comprise share adr duty case sdrt rate position person directly indirectly vote stock company annual general meeting taxation dividend wednesday queen elizabeth conference centre broad sanctuary gross dividend receive treat foreign source westminster london swp dividend income tax purpose eligible dividend receive deduction allow corporation dividend adr agm company principal forum communication payable dollar dividend share payable pound private shareholder addition formal business sterling dividend pay pound sterling include income presentation ceo performance group dollar calculate reference exchange rate future development opportunity question day dividend receive holder subject ask board chairman board committee certain exception shortterm hedge position individual question relate committee eligible holder subject taxation maximum rate respect qualified dividend investor hold share nominee service arrange nominee service appoint proxy respect taxation capital gain shareholding order attend vote meeting generally holder subject capital gain tax adr holder wish attend meeting obtain proxy subject tax capital gain realise sale bny mellon enable attend vote business disposal share adr gain longterm capital gain transact adr holder instruct bny mellon subject reduce rate taxation individual holder way share represent adr vote share adr hold year complete return voting card provide bank information report backup withholding document display dividend payment proceed sale share articles association company document adr pay usa certain usrelated financial refer annual report available inspection intermediary subject information reporting company register office website subject backup withholding holder corporation available inspection agm exempt recipient provide taxpayer identification number certifie loss exemption occur nonus holder generally subject information report backup withholding require provide certification nonus status connection payment receive amount withhold allow refund credit holder federal income tax liability provide require information furnish internal revenue service estate gift taxis estate gift tax convention shareholder generally subject inheritance tax gsk annual report investor information shareholder information financial reporting calendar definition political donation political expenditure political organisation legislation wide publication date particular definition political organisation extend body concern policy review law reform result announcement representation business community special interest group quarter april concern environment company quarter july subsidiary wish support result definition quarter october cover legitimate business activity ordinary sense preliminaryquarter february consider political donation political expenditure annual reportsummary februarymarch activity design support political party result announcement independent election candidate authority board seek annually precautionary measure ensure company result announcement issue london stock exchange subsidiary inadvertently breach legislation available news service send securities exchange commission nyse issue director medium available website director power determine legislation financial report article association available website article amend special resolution member company publish annual report shareholder director exercise company power provide need detail annual report summary article applicable legislation stipulate document available website date power exercise member publication summary send shareholder shareholder rule appointment replacement director elect receive annual report contact registrar contain article provide director alternatively shareholder elect receive notification appoint ordinary resolution member resolution email publication financial report register director provide instance director appoint wwwshareviewcouk way retire agm follow appointment copy previous financial report available website article provide director normally subject print copy obtain registrar reelection agm interval year annually gsk response center usa page hold office continuous period year contact detail board agree director wish donation political organisation continue member board seek reelection annually accordance corporate governance code member political expenditure remove director pass ordinary resolution special notice give pass special resolution effect january ensure consistent approach political contribution group introduce global director automatically cease director policy stop voluntarily corporate political contribution bankrupt compound period january december group creditor generally political donation noneu organisation cease director virtue company notwithstanding introduction policy accordance act article federal election campaign act usa continue support suffer mental physical ill health employeeoperate political action committee pac facilitate board resolve shall cease director voluntary political donation eligible gsk employee miss director meeting continuous pac control gsk decision amount period month permission board recipient contribution participate employee resolve shall cease director exercise legal right pool resource political contribution subject strict limitation total prohibit director law donate political resign organisation gsk employee pac offer resign board accept offer agm shareholder authorise company director number require donation political organisation incur resign political expenditure provision political party election referendum act year authority renew annually company act require company continue obtain shareholder approval donation political organisation incur political expenditure intend donation political party independent election candidate donation political organisation incur political expenditure gsk annual report director conflict interest law regulation director duty company act avoid number provision law regulation apply situation direct indirect conflict company share quote new york stock interest possible conflict company duty apply exchange nyse form ad particular exploitation property information opportunity company advantage article nyse rule provide general power board authorise conflict general nyse rules permit company follow nominations committee authorise board corporate governance practice instead apply usa grant periodically event annually review provide explain significant variation explanation potential actual conflict authorisation director count contain form filing access quorum authorisation actual potential security exchange commission sec edgar database conflict authorisation grant record company website nyse rule come effect require secretary register note board meeting file annual interim write affirmation concern audit ongoing basis director responsible inform risk committee statement significant difference company secretary new actual potential conflict corporate governance arise change circumstance affect sarbanesoxley act authorisation previously give provide authorisation director absolve statutory duty follow number corporate accounting scandal promote success company actual conflict arise usa congress pass sarbanesoxley act sarbane postauthorisation board choose exclude director oxley wideranging piece legislation concern largely receipt relevant information participation financial report corporate governance debate suspend director board resort recommend sec company establish require director resign disclosure committee committee report ceo cfo nominations committee review register potential audit risk committee chair company conflict authorisation october report board secretary member consist senior manager finance conflict appropriately authorise legal corporate communication investor relation process authorisation continue operate effectively external legal counsel external auditor internal expert describe note financial statement relate party invite attend meeting periodically responsibility transaction end financial year director consider materiality information timely basis connect person material interest contract determine disclosure information responsibility significance group company timely filing report sec formal review annual report form committee meet time independent advice sarbanesoxley require annual report contain board recognise occasion statement member audit risk committee director feel necessary independent legal arc audit committee financial expert define sarbane andor financial advice company expense agree oxley statement relevant member arc procedure set website enable stacey cartwright judy lewent tom swaan include indemnification director audit risk committee report additional disclosure requirement arise section section sarbane qualify party indemnity provision define oxley respect disclosure control procedure internal company act force benefit director control financial report director hold office sign annual report change control essential contract contract arrangement individually fundamental ability business operate effectively company party material agreement effect altered terminate change control follow takeover bid agreement director provide compensation loss office employment result takeover provision company share plan cause option award grant plan vest takeover detail termination provision company framework contract executive director give page gsk annual report investor information shareholder information section corporate responsibility financial report section management annual report internal control sarbanesoxley introduce requirement ceo financial reporting cfo complete formal certification confirm accordance requirement section sarbane oxley follow report provide management respect review annual report form companys internal control financial reporting define base knowledge annual report form rules securities exchange contain material misstatement omission act base knowledge financial statement management responsible establish maintain financial information fairly present material respect adequate internal control financial reporting group financial condition result operation cash flow internal control financial reporting design provide date period present annual report reasonable assurance reliability financial reporting form preparation financial statement external purpose responsible establish maintain disclosure accordance ifrs control procedure ensure material information management conduct evaluation effectiveness internal known evaluated effectiveness control financial reporting base framework internal control procedure yearend result control integrate framework issue committee evaluation contain annual report sponsor organisation treadway commission form change group internal control responsible establish maintain internal financial reporting materially affect control financial reporting provide reasonable assurance reasonably likely affect materially group internal control reliability financial reporting preparation financial report financial statement external purpose accordance management assess effectiveness internal control generally accept accounting principle financial reporting december disclose annual report form conclusion file group form change internal control financial reporting pricewaterhousecooper llp audit consolidated period cover annual report form financial statement group year end december materially affect reasonably likely affect materially assess effectiveness group internal company internal control financial reporting control financial reporting auditing standard disclose base recent evaluation internal control public company accounting oversight board united states financial report external auditor arc audit report file group form significant deficiency material weakness design operation internal control financial reporting section securities exchange act reasonably likely affect adversely company ability record section securities exchange act amend process summarise report financial information fraud require issuer specific disclosure annual report regardless materiality involve person significant certain type dealing iran include transaction dealing role company internal control financial reporting governmentowne entity dealing entities group carry evaluation supervision sanction activity relate terrorism proliferation weapon participation management include ceo mass destruction activity prohibit cfo effectiveness design operation law involve person group group disclosure control procedure legal entity base iran export certain pharmaceutical december vaccine product pharmaceutical vaccine business iran sale nonus entity privately hold iranian inherent limitation effectiveness system distributor distributor uae group disclosure control procedure include possibility business nonus entity jurisdiction target human error circumvention override control sanction law include cuba syria sudan believe procedure accordingly effective disclosure control group direct dealing iran require specific procedure provide reasonable assurance achieve disclosure requirement group policy limit control objective sale iran product high medicalpublic health need ceo cfo expect complete certification determine criterion set world health organization report conclusion effectiveness disclosure control group direct knowledge identity distributor procedure february follow certificate downstream customer possible customer include file sec group form entity governmentowne hospital pharmacy own control directly indirectly iranian government person entity sanction connection terrorism proliferation activity group direct knowledge distributor customer establish proportion gross revenue sale potentially attributable entity affiliate iranian government party sanction disclosable activity result group report entire gross revenue million net profit million group sale iran gsk annual report shareholder service contact registrar company registrar equiniti limited aspect house spencer road lance tel wwwshareviewcouk tel outside equiniti provide range service shareholder service offer participate shareview service enable create free online portfolio view register share balance movement update address wwwshareviewcouk dividend payment instruction register vote agm corporate sponsor nominee account convenient way manage share application form download require share certificate service provide facility hold share nominee company sponsor wwwshareviewcouk company continue receive dividend payment request telephone equiniti annual report attend vote company general meeting shareholder name appear publicly available share register service free join dividend payment direct bank currently receive dividend cheque dividend bank mandate form account post instead pay directly bank download building society account quick secure wwwshareviewcouk avoid risk cheque go astray request telephone equiniti dividend payment direct instead wait sterling cheque arrive post details service bank account overseas shareholder equiniti convert dividend local currency cost involve contact equiniti send direct local bank account service available country worldwide dividend reinvestment plan alternative receive cash dividend choose drip election form drip reinv dividend buy gsk share download wwwshareviewcouk request telephone equiniti duplicate publication mailing receive duplicate copy report mailing contact equiniti contact equiniti arrange account merge convenience avoid waste unnecessary cost share deal service shareholder trade share hold certificate form internet transaction log note market trading hour hold corporate sponsor nominee internet wwwshareviewcoukdealing telephone postal dealing service provide equiniti monday friday exclude financial service limited telephone transaction public holiday outside postal transaction request deal form individual saving account isas company arrange equiniti financial service detail available limited provide gsk corporate isa hold gsk wwwshareviewcouk ordinary share request telephone equiniti line open monday friday public holiday call number charge minute plus network extras provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser gsk annual report investor information shareholder information adr depositary share scam alert receive unsolicited telephone offering sell buy adr programme administer share extra care caller highly bny mellon shareowner services organise financial scam box shareholder contact financial conduct college station authority information similar activity overnight correspondence send consumer helpline bny mellon shareowner services tel quality circle suite line open time college station monday friday public holiday wwwbnymelloncomshareowner corporate responsibility report tel toll free tel outside usa publish corporate responsibility report online email shrrelationsbnymelloncom outline gsk approach performance key corporate responsibility area health behaviour depositary provide global buydirect direct ad people planet purchasesale dividend reinvestment plan adr holder detail enrol visit wwwmbnymdrcom internet helpline number obtain enrolment pack information company include share price available website wwwgskcom information available glaxo wellcome smithkline beecham website constitute annual report corporate pep share centre limited contact oxford house oxford road aylesbury buck gsk response center tel tel toll free donating share save child investor relation gsk embark ambitious global partnership investor relation contact follow save child share expertise resource aim help save live million child gsk save child partnership focus particular great west road brentford develop childfriendly medicine reduce child mortality middlesex newborn death widen vaccination coverage reduce number child tel death hard reach community usa research new affordable nutritional product help alleviate crescent drive malnutrition child philadelphia increase investment training reach scope health tel toll free worker poor community help reduce child mortality tel outside usa shareholders small number share value make uneconomical sell wish consider donate save child donate share aggregate sell save child use fund raise help reach goal obtain share donation form contact registrar equiniti manage donation sale share save child free charge provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser gsk annual report glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation american depositary receipt adr receipt evidencing title ad glaxosmithkline adr represent ordinary share american depositary share ad list new york stock exchange represent ordinary share basic earning share basic income share call share capital ordinary share issue fully pay cer growth growth constant exchange rate company glaxosmithkline plc corporate integrity agreement cia company enter settlement federal government relate past sale marketing practice settlement company enter corporate integrity agreement department health human service improvement build exist compliance programme currency swap exchange currency couple subsequent reexchange currency agree exchange rate date define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy sharebase employee incentive plan equity shareholder fund shareholder equity finance lease capital lease freehold ownership absolute right perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement make offset commitment intangible fix asset asset physical substance computer software brand licence patent knowhow marketing right purchase outside party profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay share option stock option share premium account additional paidup capital paidin surplus distributable share issue number share outstanding subsidiary entity glaxosmithkline exercise control treasury share treasury stock turnover revenue corporate governance code require list authority company disclose annual report apply good practice corporate governance provision financial reporting council corporate governance code gsk annual report investor information index index accounting principle policy investor relation acquisition disposal key accounting judgement estimate adjustment reconcile profit tax operate key performance indicator cash flow latestage pipeline summary annual general meeting legal proceeding asset hold sale longterm incentive plan associate joint venture major restructuring cost board movement equity cash cash equivalent net debt chairman statement new accounting requirement chief executive review nonexecutive director fee commitment note financial statement committee report operate profit competition intangible asset consolidate balance sheet investment consolidate cash flow statement noncurrent asset consolidate income statement noncurrent liability consolidated statement change equity operating income consolidate statement comprehensive income provision consumer healthcare product competition outlook contingent liability pension postemployment benefit corporate executive team pharmaceutical product competition corporate governance intellectual property critical accounting policy pipeline director senior management presentation financial statement director interest share principal group company director statement responsibilitie property plant equipment dividend quarterly trend donation political organisation reconciliation net cash flow movement net debt political expenditure registrar earning share relate party transaction employee cost relation shareholder employee share scheme remuneration policy report employee remuneration report exchange rate research development executive director remuneration responsible business finance expense risk factor finance income segment information financial instrument relate disclosure segment review financial position resource share capital control financial review share capital share premium account financial statement glaxosmithkline plc prepare share price gaap shareholder information year record strategy glossary term taxation goodwill taxation information shareholder independent auditor report remuneration committee intellectual property trademark trade payable inventory trade receivables investment associate joint venture law regulation gsk annual report gsk glaxosmithkline plc incorporate notice limitation director liability english law english public limited company december company act safe harbour limit liability director respect statement omission form merger director report strategic report page remuneration report glaxo wellcome plc smithkline beecham page english law director liable company party plc gsk acquire english company report contain error result recklessness know misstatement dishonest concealment material december merger fact liable arrangement website glaxosmithkline website wwwgskcom give additional information group notwithstanding reference annual report glaxosmithkline website share list london stock information available website constitute annual report shall deem exchange new york stock exchange incorporate reference cautionary statement forwardlooke statement read wwwgskcom group report file furnish securities exchange commission sec include document write information release oral statement public future behalf group contain forwardlooke statement forwardlooke statement group current expectation forecast future event investor identify statement fact relate strictly historical current fact use word anticipate estimate expect intend project plan believe word term similar meaning connection discussion future operate financial performance particular include statement relate future action prospective product product approval future performance result current anticipate product sale effort expense outcome contingency legal proceeding financial result group undertake obligation update forwardlooke statement result new information future event forwardlooke statement involve inherent risk uncertainty group caution investor number important factor include document cause actual result differ materially contain forwardlooke statement factor include limit discuss risk factor page annual report number adjust measure report performance business measure define brand name brand name appear italic report trademark own andor license glaxosmithkline associate company exception nicoderm trademark johnson johnson novartis sanofi glaxosmithkline potiga trademark valeant prolia xgeva trademarks amgen axentri trademark emcure pharmaceutical volibris trademark gilead xyzal trademark ucb glaxosmithkline zyrtec trademark ucb glaxosmithkline certain country licence group printing print pureprint group iso fsc certify carbonneutral paper annual report print amadeus silk recycle paper fsc certification pulp deinked postconsumer waste elemental chlorine free manufacturing mill hold iso ecolabel certificate environmental managementwwwgskcom find downloadable pdfs annual report annual summary form corporate responsibility report head office register office glaxosmithkline plc great west road brentford middlesex search united kingdom tel register number